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ABSTRACT
This thesis explores aspects of Streptococcus pneumoniae (pneumococcus) epidemiology and
control, in view of the possible widespread introduction of conjugate vaccines in England and
Wales.
A review and analysis of a range of different epidemiological data sources showed that the
burden of pneumococcal disease in England and Wales is high and remains mostly a
condition of the very young and the elderly. A meta-analysis demonstrated the effectiveness
of the polysaccharide vaccine against invasive pneumococcal disease among healthy elderly,
to whom vaccination was not recommended at the start of this work. Using this result, a cost-
effectiveness analysis assessed the economic acceptability of such a programme, from the
public health perspective.
A better understanding of pneumococcal carriage and transmission is required to assess the
effectiveness and cost-effectiveness of mass vaccination strategies with the pneumococcal
conjugate vaccine. A novel model framework was developed and fitted to a longitudinal
dataset of carriage in UK families. The results demonstrated an inverse relationship between
duration of carriage and age and highlighted the importance of both family size and
composition for persistence in a household. Great dissimilarities were estimated among the
specific serotypes in terms of transmissibility, duration of carriage and level of competition.
Realistic age-structured dynamic models were developed and used to investigate the impact of
a range of vaccine strategies. The importance of serotype replacement, as a consequence of
vaccination, was demonstrated. The economic acceptability of alternative interventions with
the conjugate vaccine depended on the magnitude of its indirect effects. Herd immunity had a
considerable impact on the overall cost-effectiveness of the programmes since it may
substantially reduce the burden of disease in older age groups. However, serotype
replacement may counterbalance this reduction and lead to a non cost-effective result.
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CHAPTER 1 - INTRODUCTION
Pneumococcal disease is an important public health problem, caused by Streptococcus
pneumoniae, with the highest incidence of disease observed in the very young and in the
elderly. It causes a range of diseases, from mild respiratory tract infection (i.e. sinusitis, otitis
media) to more serious invasive or non-invasive conditions (i.e. pneumonia, septicaemia,
meningitis). Asymptomatic carriage of S.pneumoniae is relatively common, especially in
children, with prevalence of carriage decreasing from 50-60% in the first two years of life to
10% in adulthood. Whether these lower carriage rates among adults are the result of
acquisition of immunity, lower contact or transmission rates among these age groups, or the
two effects combined, is still a matter of debate. These interactions are complicated further by
the large diversity of the organism (over 90 different serotypes have been isolated) and the
different immunogenic and pathogenic properties of these serotypes (Kalin, 1998).
A 23-valent pneumococcal polysaccharide vaccine has been available for decades and has
been recommended for use in the UK since 1992 for people with medical conditions for
whom pneumococcal infection is likely to be more common or serious (at-risk groups)
(Salisbury & Begg, 1996). Although the 23 serotypes contained in the vaccine account for
over 90% of the pneumococcal isolates causing serious infection in England and Wales
(George & Melegaro, 2001), uncertainty about the level of protection conferred by the
vaccine among individuals at the extremes of age as well as among at-risk groups has limited
its widespread use. Moreover the vaccine is generally unsuitable for use within a routine mass
vaccination programme because of its poor immunogenicity in young children and short
period of protection (3-5 years) (Konradsen, 1995;Sankilampi et al., 1997). Similar problems
had earlier limited the use of a polysaccharide vaccine against Haemophilus influenza type b
14
(Hib) disease and later on Neisseria meningitidis serogroup C (MenC) disease, but these
difficulties were overcome by conjugating respectively the Hib and MenC capsular
polysaccharide to an immunogenic protein such as diphtheria or tetanus toxoid. Using a
similar manufacturing technology, a pneumococcal conjugate vaccine, which contains
polysaccharide from seven common capsular types, became available in 2002 and was
recommended for immunisation of at-risk groups under the age of two years and very recently
(2004) extended to at-risk children below five years. Moreover, the UK recommendation that
was introduced in 2000 that all elderly (65+) should receive the influenza vaccine provided an
opportunity for the 23-valent pneumococcal vaccine for all elderly, since both vaccines may
be given at the same time. The recommendation for the polysaccharide vaccine was thus
modified in 2003, including healthy elderly 65+ years of age in the at-risk categories.
While discussions are ongoing on whether or not to include the pneumococcal conjugate
vaccination programme in the infant immunisation schedule, a number of questions on the
long-term effects of the vaccine remain still unanswered (Pelton et al., 2003;O'Brien &
Dagan, 2003;Peltola et al., 2004). Moreover, in contrast to the plain polysaccharide vaccine,
the conjugate vaccine also seems to have an impact on S.pneumoniae colonisation rates,
inducing not only a reduction in the prevalence of carriage of vaccine serotypes among
vaccinated individuals (and also among their siblings), but also an increase in the prevalence
of non-vaccine serotypes. These can now occupy the ecological niche that was previously
almost fully occupied by the vaccine types. Whether this effect will have repercussions on the
overall incidence rates of pneumococcal disease is not straightforward as it depends on the
properties of the serotypes that are taking over; their relative invasiveness as well as the host
response to their presence. Some evidence is already available on an increase of
pneumococcal disease caused by serotypes not contained in the vaccine, both non-invasive
clinical manifestations, such as otitis media (Eskola et al., 2001), as well as more serious
invasive disease (Kaplan et al., 2004). These indirect effects have to be taken into account
when considering the impact of vaccination programmes and when performing economic
evaluations of public health interventions.
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The role of mathematical modelling has become progressively more important in guiding
vaccine policy decisions (Salisbury et al., 2002) and, together with economic analysis
(Edmunds et al., 1999), provides additional information to policy decision makers regarding
the potential impact and its economic acceptability. Through models we can gain a better
understanding of the transmission dynamics of infectious organisms, we can investigate the
observed pattern of disease and its epidemiology and we can predict the potential impact of
alternative public health interventions, such as vaccination. However, models are necessarily
simplifications of the real world, and thus their applicability is restricted by the availability of
sound parameter estimates and realistic model assumptions. For extremely diverse organisms,
such as Sipneumoniae, for which a comprehensive understanding of the biology is far from
achieved, realistic model parameterisations are not always easy to formulate and still
represent a challenge.
The broad research aims of this PhD project were:
1. To describe the epidemiology of pneumococcal invasive and non-invasive disease in
England and Wales;
2. To further the understanding of pneumococcal carriage, to estimate pneumococcal
transmission parameters and to investigate serotype specific differences;
3. To use models to predict the impact of the UK vaccination programme and to
investigate a range of alternative vaccination schedules;
4. To evaluate the cost-effectiveness of the vaccination programme with the 23-valent
polysaccharide vaccine;
5. To evaluate the cost-effectiveness of universal infant vaccination with the 7-valent
conjugate vaccine taking into account herd immunity effects and potential serotype
replacement.
The thesis structure is as follows. Chapter 2 provides an overview of S.pneumoniae and
highlights the essential features of carriage, disease, epidemiology and control. In particular,
an overview of the pathogenesis of S.pneumoniae is presented at the beginning of the chapter,
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from its microbiological composition to the way in which this interacts with human host. This
is followed by a description of the clinical manifestations and the development of
pneumococcal vaccines. The available national surveillance systems on pneumococcal disease
conclude the chapter. In Chapter 3 the epidemiology of pneumococcal disease is investigated
and estimates of the current burden of disease in England and Wales are provided. Both
invasive and non-invasive conditions are considered and comparisons between laboratory
reports, hospitalisations and consultations to the general practitioner (GP) are made. Chapter 4
is the first of two chapters examining the effectiveness and cost-effectiveness of the 23-valent
polysaccharide pneumococcal vaccines among the elderly. Here a systematic literature review
of published randomised controlled trials on the pneumococcal polysaccharide vaccine
efficacy is performed. Meta-analysis techniques are applied in order to estimate the overall
pooled efficacy level among elderly at high and low-risk of pneumococcal infection. These
results inform the cost-effectiveness analysis of the next chapter. Chapter 5 determines the
costs associated with treatment of pneumococcal disease in the elderly and performs an
economic evaluation of what was, at the time of the analysis, the pneumococcal vaccination
programme with the plain polysaccharide vaccine among high-risk elderly. Possible
extensions of the programme, which were under discussion at the Department of Health when
this PhD project started, are also considered (indeed the results of this work helped inform the
national policy debate). Chapter 6 moves the focus away from pneumococcal disease, towards
pneumococcal carriage. Here, longitudinal data for pneumococcal carriage in UK households
are for the first time analysed with a statistical model that takes into account the family effect
on the transmission dynamics of pneumococci. This chapter and the following one, which
extends the model to include serotype-specific information, lay the foundations for further
modelling work and parameterisation of Chapter 8. Chapter 7 takes forward the modelling
framework developed in Chapter 6 to include serotype specific data as well as individual risk
factors for pneumococcal carriage that were available for the study population. Here,
serotype-specific differences in pneumococcal transmission dynamics are investigated, and
estimates of the duration of carriage for the most prevalent types are produced. In Chapter 8 a
realistic age-structured transmission dynamic model is developed using parameter estimates
obtained in the previous chapters. The model is used to investigate the impact of vaccination
17
on pneumococcal carriage and, in particular, the dynamics of vaccine vs. non-vaccine
serotypes. In Chapter 9 a static cohort model is used to generate estimates of the cost per life
year saved by a routine infant vaccination with the pneumococcal conjugate vaccine from the
perspective of the health care provider (the NHS). The effects of the indirect effects of
vaccination (herd immunity and serotype replacement) are considered in the model. Finally,
in Chapter 10, the implications of this work and future directions for research are discussed.
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CHAPTER2-BACKGROUND
2.1 Introduction
Streptococcus pneumoniae is one of the most important bacterial pathogens in respiratory
tract infections, affecting children and adults worldwide (Booy & Kroll, 1994;Booy et al.,
1995;Fedson et al., 1999a;Robinson et al., 2001;Cartwright, 2002). It is a common
component of the nasopharyngeal flora in healthy individuals although it is also responsible
for causing a variety of infections ranging from upper respiratory tract infections, ear
infections and sinusitis, to more serious diseases such as pneumonia, septicaemia and
meningitis (Miller et al., 2000;Kaltoft et al., 2000;Spanjaard et al., 2000;Eriksson et al.,
2000;Syriopoulou et al., 2000;Kyaw et al., 2002).
Asymptomatic carriage of S.pneumoniae is common, especially among children, and the
existence of almost 90 different pneumococcal serotypes whose prevalence varies in different
geographical regions adds complexity to the already diverse epidemiology of pneumococcal
disease around the world (Bruyn et al., 1992).
A number of different data sources are available for England and Wales to monitor disease
incidence rates over time and to assess whether any change will occur as a result of new
vaccination programmes in both the incidence of invasive and non-invasive disease. Ongoing
surveillance is necessary to better ascertain the effectiveness of the programme and to detect
any potential harmful indirect effect, such as serotype replacement, that vaccination may
produce and that may also increase disease severity.
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The aim of this chapter is to provide an overview of the pneumococcus and to highlight the
essential features of carriage, disease, epidemiology and control. The literature review related
to the modelling and economics of pneumococcal infection and vaccination is not included in
the current chapter but will be provided in the relevant parts of the thesis. The current chapter
is divided into four components. First, an overview of the pathogenesis of Sipneumoniae will
be presented, from its microbiological composition to the way in which this interacts with the
human host. This is followed by a description of the clinical manifestations of pneumococcal
infection and the risk factors associated with disease. Thirdly, the development of vaccines
and the roles of vaccines in the control of pneumococcal carriage and disease are reviewed.
The chapter ends with a description of the national surveillance systems.
2.2 The organism
Isolated first in 1880 from carriers of the organism in the United States (Stenberg, 1881) and
in France (Pasteur, 1881) (Watson & Musher, 1999), Streptococcus pneumoniae, or the
pneumococcus, is one of the most important bacterial pathogens in respiratory tract infections,
still affecting children and adults worldwide despite the use of antibiotics and the
development of vaccines (Fedson et al., 1999a;Robinson et al., 2001). The main reservoir is
the nasopharynx and the possible outcomes, once colonisation has taken place, may be
clearance of the organism, the asymptomatic persistence for several weeks (the carrier state),
or the progression to disease (Cundell et al., 1995;Schaechter et aI., 1998). When this occurs,
the bacteria can either spread to adjacent mucosal tissues, causing mucosal infection (otitis,
sinusitis and pneumonia) (Block, 1997;Brown & Lerner, 1998;Marrie et al., 2002), or else
invade the bloodstream, or other sterile sites, producing an invasive disease condition (sepsis
or bacteraemia, meningitis) (Miller et aI., 2000;Shackley et al., 2000).
2.2.1 Cell surface structure
The pneumococcal cell surface structure is the part of the organism that primarily interacts
with host factors, immune cells, and epithelial surfaces. The majority of pneumococci are
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encapsulated, and although many of the interactions between host factors and the bacteria
involve the capsular polysaccharide that coats the outermost surface of pneumococci, other
components of the cell surface, located under the capsule, have a role in the interaction
between host and bacteria.
The pneumococcal outer surface consists of three parts: the capsule, the cell wall and the
plasma membrane (Figure 2.1).
Figure 2.1- Schematic illustration of pneumococcal outer surface
:-+--- Capsular polysaccharide
Cell wall constituents:~~~~~r:==outer}Inn Layer of C-polysaccharide
The capsular polysaccharide (CPS). The capsule of the pneumococcus represents the most
important virulence factor of the organism because it protects the bacterium from
phagocytosis (Magee & Yother, 2001;Bogaert et al., 2004a). Non-capsulated variants are
incapable of causing progressive disease unless injected in overwhelmingly large numbers
(Austrian, 1984). To date, almost 90 different capsular serotypes have been described (Bruyn
et aI., 1992), six of them quite recently (Henrichsen, 1995). The serotypes differ in the
chemical structure of their CPS and in the capability of the immune system to recognise these
structural differences and to respond with specific antibodies (Tomasz, 2000). The virulence
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of each capsular type is associated with both the quantity of capsular polysaccharide produced
and, most importantly, the chemical structure of the capsule, which is known for most of the
serotypes (Kamerling, 2000). The frequency of the capsular types varies by time, geographic
areas and age group and it may be linked to both evolutionary patterns of the organism and to
the level of serotype-specific immunity of individuals.
Two different systems of nomenclature exist to define the capsular types: the Danish system
and the American system. The Danish system is based on cross-reaction between types, so
that antigenically related serotypes are assigned to a common serogroups, with individual
serotypes within each group distinguished by the trailing letter (e.g. 6A and 6B, 9A, 9L, 9N
and 9V). Types without a close antigenic relationship to other types are given numbers only
(i.e, 1, 2, 3, 4, 5). The American system assigns number sequentially (in order of discovery)
to the individual serotypes, without taking into account cross-reactions between types. As the
Danish nomenclature is now generally employed, we will be using this throughout this thesis.
The cell wall. The layer underneath the capsule, the cell wall, is responsible for the intense
inflammatory reaction that accompanies pneumococcal infection (Bruyn et al., 1992) and
serves as an anchor for cell-wall associated surface proteins such as pneumococcal surface
adhesin A (PsaA) (Bogaert et al., 2004a). Its major component is the C-polysaccharide
antigen, which is located on both the outer and the inner surfaces of the cell wall (Figure 2.1)
and includes the teichoic acid constituent of the cell wall, and is common to all pneumococci
(Tomasz, 1981). Antibodies to the C-polysaccharide, common to most of the 90 different
serotypes, start developing in children after the age of 5 months and increase steadily
thereafter as a consequence of exposure to pneumococcus through carriage or infection.
Nearly all children develop some antibody by the age of 4 years (Gray et al., 1983).
The plasma membrane. The plasma membrane is situated on the inner inside of the cell wall
and is composed of lipoteichoic acid, lipid and protein (Bruyn et al., 1992). It also contains
the Forssman antigen (F-antigen), which is common to all pneumococci and functions as a
powerful and highly specific inhibitor of pneumococcal autolysin (Tomasz, 1981).
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2.2.2 Colonisation and pathogenesis
Colonisation. The bacterium gains entry into the host by colonising the nasopharyngeal
mucosal epithelium. Attachment is thought to be mediated through a specific bacterium-
derived adhesin molecule that forms a bridge between bacterial surface components and
epithelial cell receptors (Ghaffar et al., 1999). The outcome of colonization is determined by
the intrinsic virulence of the colonizing serotype and the efficiency of the host defence
mechanism. Some serotypes are more virulent and more likely to cause severe disease; others
are less virulent and are usually only isolated from the nasopharynx of asymptomatic persons.
Only a small proportion of colonisations progresses to disease (~15%)(Gray et al., 1980). The
interval between colonization and onset of disease, though variable, is usually short (Gray et
al., 1980;Schaechter et al., 1998;Ghaffar et al., 1999). One individual may become colonized
many times, usually with different serotypes. Moreover, simultaneous carriage of two, or
more, S.pneumoniae serotypes has been demonstrated (Gratten et al., 1989;Huebner et al.,
2000). More on this will be presented in section 2.2.4.
Progression to disease. After colonising the nasopharynx, S.pneumoniae may spread locally,
either upward into the Eustachian tube and the middle-ear cavity to produce otitis media, or
downward into the alveoli of the lower respiratory tract to cause lobar pneumonia (Cundell et
al., 1995). At this point, if the host defence mechanism is not able to confine the
pneumococcus to the lungs or middle ear, it may spread causing a bacteraemic infection or
invade the cerebrospinal fluid (CSF) leading to meningeal inflammation (Austrian, 1984).
Transmission. Transmission from a sick person or, more commonly, from an asymptomatic
carrier, is via droplets of respiratory secretions that may remain air-borne over a distance of
up to one meter. The infecting organism may also be carried on hands contaminated with
secretions. Transmission occurs mainly within the family and closed institutions such as day-
care centres (Givon-Lavi et al., 2002). Because there are many more asymptomatic carriers
than diseased people, most of the links in the chains of transmission are unobserved.
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2.2.3 Virulence
Although the pneumococcal polysaccharide capsule is still considered the primary virulence
factor for S.pneumoniae (Kalin, 1998), recent studies have suggested that certain proteins
displayed on the surface of gram-positive organisms significantly contribute to its
pathogenesis. These, as summarised in Table 2.1, are involved in the disease process caused
by these pathogens interacting with the host cells and in facilitating the invasion and spread of
the organism in the host environment (Jedrzejas, 2001).
Table 2.1 - Outer membrane proteins
Protein Function
Pneumococcal surface protein A (PspA) Interferes with host complement system reducing
the complement mediated clearance and
phagocytosis of pneumococci
Hyaluronate lyase (Hyl) It enhances the host membrane cleavage facilitating
bacterial invasion
Pneumolysin (Ply) Cytoplasmatic enzymes. Released upon autolysis.
Facilitates the spread ofPnc infection, suppressing
the host inflammatory and immune response
Autolysin (LytA) Involved in cell wall degradation which facilitates
the release of the components of the cell wall shown
to be highly inflammatory
Pneumococcal surface antigen A (psaA) It stabilises cell wall structure and it also modulates
the transport of metals inside cytoplasm of
pneumococci, possibly causing toxic effects on host
cells.
Choline binding protein A (CbpA) Interacts with immune mediated host cells
preventing them to be effective. This process might
be involved in advancing pneumococcal disease
from colonisation to invasion.
Neuraminidase Enhances colonisation and adherence damaging
host cells membrane
The information on the table were abstractedfrom Jedrzejas MJ (2001)
2.2.4 Laboratory diagnosis
The isolation of S.pneumoniae from blood, CSF or other normally sterile body sites is the
requirement that is needed in order to confirm the aetiological diagnosis of a clinical
manifestation that may be related to a pneumococcal infection. Bacterial culture still remains
the most frequently used method to detect pneumococcus from a variety of clinical specimens
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(Lankinen, 2003). It is routinely used in clinical diagnosis of suspected invasive infections
although the low levels of sensitivity that have been found, partly as a result of prior
administration of antibiotics, seriously limit its utility. The value of culture methods in
diagnosing pneumococcal pneumonia is still very much debated, with 48% to 94% of
confirmed bacteraemic pneumococcal pneumonia patients having the organism isolated from
sputum samples (Drew, 1977) and extremely low sensitivity levels (27%) for culture of
nasopharyngeal swabs in adult patients with community-acquired pneumonia (CAP)
(Hedlund et al., 1990).
Traditional non-cultural techniques include microscopic examination of Gram stained
specimens (i.e. urine, blood or CSF) and antigen detection with a range of immunoassays (e.g.
by latex agglutination). The former provides a visual assessment of the presence of
pneumococci in the specimen, evaluating the reaction to the Gram staining (i.e pneumococcus
is a Gram-positive bacterium and stains purple) which correlates to differences in the cell wall
structure of the organism. Antigen detection methods, on the other hand, are procedures that
measure the presence of specific microbial antigens. Although these tests give results within
minutes of receipt of the specimen, their sensitivity is not significantly greater than the Gram
stain and false positive results may occur due to cross reactive antigen (Mims et al., 1995). A
rapid immunochromatographic membrane assay (Binax NOW S.pneumoniae Urinary Antigen
Test, Binax, Portland ME, USA) has been approved for the diagnosis of pneumococcal
pneumonia in adults (Henney, 1999). Differently from other antigen tests, that detect capsular
antigens, this test detects C-polysaccharide cell wall antigen common to all S.pneumoniae
serotypes. Various studies have demonstrated high levels of both sensitivity and specificity
among adults with bacteraemic pneumococcal pneumonia (~80% sensitivity and ~90%
specificity) (Murdoch et al., 2001;Dominguez et al., 2001;Smith et al., 2003) although
sensitivity in children remains low (11-50%) (Dowell et al., 2001;Hamer et al., 2002). The
NOW test appeared to be very sensitive and specific in detecting pneumococcal antigen in the
CSF of patients with pneumococcal meningitis (Marcos et al., 2001;Samra et al., 2003).
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Serological diagnosis by enzyme linked immunoabsorbent assay (ELISA) is used to diagnose
infections measuring any antibody response, regardless of immunoglobulin class, or to detect
class specific antibody. The major disadvantages of diagnoses based on serology are that it
requires both acute and convalescent sera and it is retrospective, as 2-4 weeks must elapse
before IgG antibodies, produced in response to infection, are detectable in the serum (Mims et
al., 1995). However, serological diagnosis is of great value when the organism is difficult to
culture or when the individual has to be screened for several different infections
simultaneously. Moreover, it provides information not only for the diagnosis of a clinical
manifestation but also for the evaluation of exposure, and consequent asymptomatic carriage
of a specific pathogen.
Advances in molecular biology have resulted in new techniques for the genotypic
identification and characterisation of microorganisms. Nucleic acid amplification using the
polymerase chain reaction (PCR) is considered a very sensitive and specific non-culture
diagnostic technique for the detection of pathogens in a clinical specimen. In these techniques
genomic sequences specific for infectious agents, such as the pneumococcus, are selected,
cloned, synthesised and used as probes. These probes can bind with high specificity to
complementary sequences of target nucleid acid of the pathogen. PCR techniques can be
applied to different clinical specimens such as blood, CSF, urine and sputum although due to
the high levels of sensitivity of this test (Dagan et al., 1998), cross contamination resulting in
false positives may occur and, thus, appropriate treatment of biological materials is one of the
most important steps carried out in molecular microbiology.
Detecting carriage. Pneumococcal carriage is detected by isolating the organism from the
human nasopharynx. The isolation rate may change according to variations in sampling
methods, delays prior to culturing and differences in culture techniques (Rapola et al., 1997).
Several studies (Gray et al., 1980;Capeding et al., 1995;Rapola et al., 1997) have shown that
nasopharyngeal sampling is better than oropharyngeal sampling for detecting S.pneumoniae,
and that although nasopharyngeal aspirates (NPA) are superior for the detection of
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pneumococci, nasopharyngeal swab specimens are adequate when the NPA is not available
(i.e. healthy children or children with no obtainable secretions) (Rapola et al., 1997).
Serotyping. Serotyping of pneumococcal isolates is usually performed with the Quellung
reaction method, in which cultured isolates are blended with group or type-specific antisera,
and the capsular swelling reaction is observed under a microscope (Henrichsen, 1999). Other
typing methods include: capillary precipitin typing (Russell et al., 1978),
counterimmunoelectrophoresis (Leinonen, 1980), latex agglutination (Arai et al., 2001) and
coagglutination (Lalitha et al., 1996).
Most carriage studies select only one colony from a plate for further serotyping and so are
unable to detect simultaneous carriage of multiple strains. Studies that perform "multiple
picks" are laborious and expensive. However, Huebner and colleagues (2000) detected
simultaneous carriage of 2 serogroups in only 1.3% and 2.4% of the specimens examined in,
respectively, South Africa and Israel. A similar percentage (1.2%) was found when up to 5
colonies were examined. A much higher rate of simultaneous colonisation was found by
Gratten and colleagues (1989) who found that 29.5% of 156 children in Papua New Guinea
were colonised by multiple pneumococcal serotypes. In the FinOM cohort study, the
proportion of carriers with two or more serotypes found in the (healthy) nasopharyngeal
samples of 649 children was 3.7% (Syrjanen et al., 2001).
2.3 Pneumococcal disease
2.3.1 Clinical conditions
A very diverse spectrum of clinical manifestations may result from infection with the
pneumococcus, from relatively benign infections, which mayor may not have long-term
consequences (i.e, conjunctivitis, ear infections, sinusitis), to more serious invasive disease,
which may result in the death of the patient (i.e. septicaemia, meningitis). A comprehensive
review of the unusual manifestations of invasive pneumococcal infection can be found in
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Taylor and Sanders (1999). Moreover, antimicrobial resistance in pneumococci has also been
associated with rare or particularly severe disease forms (Saenz et al., 1998;Go et aI., 1998)
and, also, with nosocomial infections (Cimolai et al., 1999;de Galan et al., 1999;Weiss et al.,
2001).
Acute otitis media (AOM). Acute otitis media, or middle ear infection, is predominantly a
disease of infancy and early childhood, which can progress from a number of different
bacterial and viral infections, the most important of which are: S.pneumoniae, H.injluenza,
Moraxella catarhalis, respiratory syncytial virus, influenza virus and rhinovirus (Faden et al.,
1997;Rovers et al., 2004). Streptococcus pneumoniae has been implicated, in particular, with
recurrent AOM (Black et al., 2000). Although it is not a life-threatening condition in itself, it
can cause serious chronic complications (i.e, recurrent AOM episodes before the age of 3
years can have adverse long-term consequences in school performance (Luotonen et al.,
1998» and is a major public health problem worldwide (Klein, 2000). Symptoms of AOM
may include some or all the following: irritability, crying, ear pain, fever, feeding problems,
vomiting and hearing impairment. These symptoms are frequently associated with signs of
respiratory infection, such as runny nose or cough. Severe ear infections can also cause the
rupture of the eardrum, which will then lead to pus draining out of the middle ear into the ear
canal. The eardrum rupture usually heals after medical treatment. Infants and young children
are very susceptible to pneumococcal acute otitis. The flow of bacteria and viruses from the
throat to the middle ear is also facilitated by the shape of the tube connecting the throat to the
middle ear (Eustachian tube) which, in children, appears to be shorter, wider and more
horizontal (Rovers et al., 2004). Diagnosis of AOM is usually clinical and treatment with
antibiotics for a week to 10 days is usually effective, although improvement has been seen in
around 80% of the children with AOM within 2-14 days without any medical interventions
(Rovers et al., 2004).
Community-acquired pneumonia (CAP). Pneumonia is an inflammation of the lungs
caused by infection with bacteria, viruses and other organisms. It is usually triggered when
the host defence system is weakened, which most often occurs as a consequence of viral
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upper respiratory infection. Streptococcus pneumoniae is one of the most frequent causes of
bacterial pneumonia with 20-60% of all episodes of CAP requiring hospitalisation and 9-20%
of outpatients visits being related to pneumococcal infection (Bartlett & Mundy, 1995).
Further insights on this will be presented in Chapter 3. Symptoms generally include a sudden
onset with a single shaking chill that is usually followed by fever with cough, sputum
production, and chest pain. Extra-pulmonary symptoms such as nausea, vomiting or diarrhoea
and headache are reported in 10-30% of patients with CAP (Brown & Lerner, 1998;Marrie,
2000). Serious and potentially lethal complications of pneumococcal pneumonia include
progressive pneumonia, sometimes associated with the adult respiratory distress syndrome
and/or septic shock, empyema (infection of the pleural space), pericarditis (inflammation of
the sac around the heart) and endobronchial obstruction. Some patients develop pulmonary
super-infections, which consists of a temporary improvement during treatment followed by
deterioration, with recurrence of fever and worsening pulmonary infiltrates.
The most important diagnostic test for CAP is the chest radiograph. X-ray examinations help
distinguish pneumonia from other conditions and can provide information on the severity of
illness and the presence of other coexisting conditions such as bronchial obstruction or pleural
effusion.
Bacteraemia. When the host immune mechanism fails to confine the pneumococcus to the
lung, the organism may spread via the pulmonary lymphatics to the hilar lymph nodes and via
the thoracic duct to the systemic circulation, causing a bacteraemic infection (Austrian, 1984).
It may also arise as a consequence of pneumococcal meningitis (Austrian, 1964) and from
organisms colonising the respiratory mucosa of the nasopharynx, entering the lymphatic
vessels and, finally, gaining access to the blood. Non-specific symptoms occur such as fever
and irritability.
Meningitis. Pneumococcal meningitis is an inflammation or infection of the membranes
covering the brain and spinal cord which may arise in a variety of ways (Austrian, 1984),
progressing from pneumonia and bacteraernia or else as an extension of a middle ear infection
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or paranasal sinuses that involve the bony structure of the skull and ultimately the meninges.
Direct migration of organisms colonising the upper respiratory tract to the subarchnoid space
may also occur following the fracture of the skull. High fever, headache and stiff neck are the
common symptoms of meningitis in anyone over the age of 2 years. Other symptoms may
include nausea, vomiting, discomfort looking into bright lights, confusion and sleepiness. In
newborns symptoms may be less specific (i.e, fever, irritability, inability to feed and
drowsiness), and may be more difficult to detect. Unlike meningococcal disease,
pneumococcal meningitis is not usually associated with any skin rash. Once meningitis is
diagnosed, antibiotic treatment should be started, even before hospitalisation (Booy & Kroll,
1994).
2.3.2 Outcome (mortality rate and sequelae)
Despite the advent of antibiotic therapies, mortality associated with invasive pneumococcal
infection has remained high, ranging from 6% to 19% in uncomplicated hospitalised cases of
pneumococcal pneumonia (Mufson, 1981) and three to four times higher levels for
pneumococcal pneumonia patients with a bacteraemic infection (Laurichesse et al., 1998)
(See also Chapter 3). The clinical outcome of bacterial meningitis varies according to
socioeconomic aspects (developed or developing countries), age and causative pathogen
(Baraff et al., 1993;Koedel et al., 2002). Mortality rates for meningitis due to S.pneumoniae
infection is higher than for any other bacterial aetiology, with reported case-fatality ratio
(CFR) in the range of 15.3% (Baraff et al., 1993) to 30% (Mufson, 1981), with higher case-
fatality rates in the very young and in the elderly (Laurichesse et al., 1998;Berezin et al.,
2002) and in those infected with antibiotic resistant pneumococci (Berezin et al., 2002). Of
the survivors, up to 30% develop long-term sequelae (Koedel et al., 2002), including mental
retardation, sensorineural hearing loss, motor deficit and seizure disorder (Baraff et al.,
1993;Pikis et al., 1996;Arditi et al., 1998;Bedford et al., 2001). Language difficulties and
school learning impairment have been reported also following chronic and recurrent middle-
ear disease, especially when occurring under the age of3 years (Luotonen et al., 1998).
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2.3.3 Antimicrobial resistance
The increasing incidence of antimicrobial resistant S.pneumoniae isolates is becoming a
problem worldwide (Campbell & Silberman, 1998;Saha et al., 1999;Rudolph et al.,
2000;Hyde et al., 2001;Aspa et al., 2004) with penicillin non-sensitive rates as high as 50% in
France and Spain (Fenoll et al., 1998;Felmingham & Gruneberg, 2000) and 16%-25% in the
USA (Hofmann et al., 1995;CampbeU & Silberman, 1998) and up to 20% in other European
countries (Reacher et al., 2000;Jacobs et al., 2003). Previous use of ~-lactam antibiotics,
alcoholism, and non-invasive disease have been associated with penicillin resistant strains
(Clave-Sanchez et al., 1997;Nasrin et al., 2002), whereas the extremes of age «5 and 65+
years) and the previous use of ~-lactam antibiotics in non-invasive disease cases were found
to be risk factors for multidrug resistant pneumococci (Clave-Sanchez et al., 1997). In
addition, chronic pulmonary disease, HIV infection, and previous hospital admission have all
been associated with penicillin-resistant pneumococcal pneumonia (Aspa et al., 2004).
There is evidence of serotype-specific differences in antibiotic susceptibility patterns, with
serotypes 14, 6B and 23F accounting for most of the resistant strains (Munoz et al.,
1991;Fenoll et al., 1998;Saha et al., 1999;Rudolph et al., 2000;Hyde et al., 2001).
2.3.4 Risk factors associated with disease
The risk of developing pneumococcal disease is influenced by a number of factors, which are
related to the characteristics of the invading organism, the host defence mechanisms (carrier)
as well as to the environmental conditions to which the carrier is exposed. It is usually the
combination of all these factors that determine the severity and invasiveness of the clinical
manifestation.
Agent factors. The encounter of the organism is clearly the first step that is needed in order
for the individual to then progress to disease. Colonisation and asymptomatic carriage in
healthy individuals depend on a number of factors associated with the bacteria and its
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relationship with the host immune system. A number of carriage studies have shown that
carriage is inversely related to the age of individuals, with carriage rates as high as 60%-70%
in children less than 2 years of age (Gray et al., 1980;Coles et al., 2001) and a steady and
consistent decline thereafter (Leino et al., 2001) (Table 2.2). This can be the result of both the
poorer immunity defences of young children and the close contacts they experience during
childhood (Ghaffar et al., 1999).
In addition, several studies have shown significant serotype specific differences in relation to
acquisition rates, duration of carriage and invasiveness (Smith et al., 1993;Kalin,
1998;Hausdorff et al., 2000a;Hausdorff et al., 2000b;Brueggemann et al., 2003), with some
serotypes (i.e, 1, 4, 14, 7) being found more often among invasive pneumococcal disease
patients than among asymptomatic carriers (Brueggemann et al., 2003). More on the
relationship between pneumococcal carriage and disease will be covered in Chapter 6.
Host factors. Several host factors are associated with an increased risk of pneumococcal
disease given carriage: the extremes of age, non-immunological defects and immunological
ones, both inherited and acquired (Gillespie, 1989).
Individuals at the extremes of age (<2 years and 65+) are generally considered at high-risk of
pneumococcal infection, experiencing the highest rates of both invasive and non-invasive
pneumococcal conditions (George & Melegaro, 2001). Although in infants this is thought to
be associated with an immature immune system and a lack of acquired immunity, the high
incidence among the elderly is not completely understood and may be related to increasing
rates of immunocompromising conditions, such as congestive heart failure, diabetes mellitus
and haematological malignancies (Obaro et al., 1996b).
A number of non-immunological and immunological defects increase individual susceptibility
to pneumococcal infection (Obaro et al., 1996b). Whereas the former (e.g. skull fracture,
damage to bronchial epithelium as occurs with influenza viral infection) disrupt the natural
barriers of the host facilitating the entrance of the organism and leading to recurrent and
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severe pneumococcal infection (Johnston, Jr., 1991), the latter increase the risk of invasion
through an inadequate production of antibodies (Siber et al., 1980;Douglas et al., 1983).
Persons with human immunodeficiency virus (HIV) infection have an increased incidence
rate of pneumococcal disease (Nuorti et al., 2000b). McEllistrem and colleagues (2002) found
that recurrent pneumococcal infection is 6 times more common in HIV-positive persons than
in persons without HIV infection. Asplenia is associated with increased susceptibility to
pneumococcal infection being the organism responsible for 50% of the cases of bacterial
septicaemia in asplenic patients (Wara, 1981).
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Socio-economic and environmental factors. Independent determinants of nasopharyngeal
colonisation are environmental features and socio-economic factors such as crowding, family
size (i.e. number of siblings), income, smoking (active and passive) and recent antibiotic use.
Crowding, as occurs in hospital, day-care centres and prisons, increases horizontal spread of
pneumococcal strains and is, thus, a major risk factor in nasopharyngeal colonisation (Bogaert
et al., 2004a). Several studies have demonstrated a strong association between day-care
attendance and higher risk of colonisation by S.pneumoniae (Givon-Lavi et al., 1999;Principi
et al., 1999;Raymond et al., 2000;Neto et al., 2003;Regev-Yochay et aI., 2004), and, in
particular, with antibiotic resistant strains (Henderson et al., 1988;Steele et al., 1996;Dagan et
al., 1996b). Evidence of genetic clustering among pneumococcal isolates in both day care
centres (Bogaert et al., 2001) and prisons (Hoge et al., 1994), have been shown and support
the idea of horizontal transmission of specific pneumococcal strains.
Family size, and specifically the number of older siblings, has been associated with
nasopharyngeal carriage of S.pneumoniae in children (Dagan et al., 1996b;Petrosillo et al.,
2002). Moreover, the exposure to other family members colonised with a particular
pneumococcal strain was found to be associated with colonisation of that particular type in
infants 7-24 months of age (Leino et al., 2001). Shimada and colleagues (2002) gave evidence
of household transmission of genetically similar strains of S.pneumoniae between siblings
with concurrent or closely related episodes of AOM. More generally, a case-control study
looking at risk factors for invasive pneumococcal disease (Nuorti et aI., 2000a) indicated that
patients (especially 18-49 years of age) were three times as likely as control subjects to live in
a household with children under the age of six who were in day care. Nuorti and colleagues,
in the same study (2000a), showed also an association between low socioeconomic status
(low educational level and low income, lack of health insurance) and pneumococcal disease.
The relationship between family size as well as composition (number of children and adults in
the family) and pneumococcal infection will be further investigated in Chapter 6 where the
rate of infection by family size will be estimated using data from a longitudinal study of
pneumococcal carriage in UK families.
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Recent antibiotic treatment is also indicated as one of the causes of the increase in
pneumococcal colonisation (Petrosillo et al., 2002;Ghaffar et al., 2002). This occurs through
the generation of antibiotic resistant strains that survive the natural selection in the
nasopharynx of colonised individuals and that are then likely to spread throughout the
community.
Both active and passive smoking increase the risk of pneumococcal disease (Sung et al.,
1995;Nuorti et al., 2000a;Iles et al., 2001), as for other respiratory tract infections (Bogardus
et al., 2003). Nuorti and colleagues (2000a) found that the odds of invasive infection are four
times higher for current smoker and that non-smokers, who were exposed to second hand
smoke, experienced 2.5 times the odds of disease of non-smokers without such exposure. A
clear dose-response relation with respect to the amount of smoking, the duration of passive
exposure and the length of time since the cessation of smoking was also indicated in the
study.
2.3.5 Immunity to Streptococcus pneumoniae
Although the nasopharynx is colonised frequently with pneumococci, the normal human
respiratory tract opposes strong resistance to the development of symptomatic infection. Such
resistance is not type specific and depends on anatomic and physiological characteristics of
the host defence mechanisms (Austrian, 1984). Moreover, the activity of the spleen is known
to prevent and limit the severity of S.pneumoniae infection, contributing in both the early
stages of infection and also when the infection progresses enhancing the production of
serotype-specific antibodies (Gillespie, 1989).
In contrast to this general resistance of the host, immunity to pneumococcal infection depends
on both the natural (innate) and adaptive (acquired) immune mechanisms (Casal & Tarrago,
2003), which recognises elements of the surface structure of pneumococci and produces
antibodies that may vary by the age of the host and by the invading serotype (Gillespie, 1989).
Although historically studies of immunity to S.pneumoniae have focused on antibody to
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pneumococcal capsular polysaccharide (CPS) as an essential element for the individual
defence against a pneumococcal infection (MacLeod et al., 1945;Heidelberger et al.,
1946;Zysk et al., 2003), more recent works have shown that a variety of other antibodies are
elicited by infection with encapsulated bacteria such as pneumococci (Bruyn et al.,
1992;Rapola et al., 2000;Musher et al., 2001;Rapola et al., 2001a;Rapola et al., 2001b).
These antibodies are generated from encounters of the host defence mechanism with some of
the most important virulence factors of the organism (section 2.2.3) such as pneumococcal
surface protein A (PspA), pneumococcal surface adhesin A (PsaA), and pneumolysis (Ply).
Unlike antibody to pneumococcal CPS, which are type-specific (Gillespie, 1989), antibody to
surface proteins are common to all serotypes (Casal & Tarrago, 2003).
Naturally acquired immunity. Naturally acquired immunity to one or more pneumococcal
types can be acquired passively from mother to child if the mother possessed such immunity
in the form of immunoglobulin able to traverse the placenta (Austrian, 1984). This naturally
acquired protection is serotype specific (Carvalho et al., 1999) and wanes following birth,
disappearing by the age of 7 months (Munoz FM et al., 2002).
In older children and adults immunity is generated following episodes of pneumococcal
carriage and is generally type specific although some evidence of cross-reaction between
types have been shown (Coughlin et at., 1998;Soininen et al., 2001). Soininen and colleagues
(2001) followed up 329 children prospectively during the first 2 years of life and found a
significant increase in antibody production in children aged 12-18 months, when
pneumococcal carriage and AOM rates are highest. Of these children, those who encountered
types llA or 14 pneumococci had significantly higher serum antibody titre of the
homologous type than did children who had contact with heterologous serotypes. In contrast,
antibodies to CPS 1, 19F and 23F correlated strongly with each other. Rapola and colleagues
(2000) explored the relationship between the levels of IgG antibody to surface proteins and
previous exposure to pneumococcal carriage in children and found that children who were
exposed to pneumococci had a higher rise in antibody titres to PspA, PsaA and Ply. Anti-Ply,
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in particular, was also found to be associated with the level of exposure (Le. higher anti-Ply
among children who had Pnc AOM than in healthy children colonised with Pnc).
The role of antibodies in protection against disease. Evidence of an inverse relationship
between antibody levels (to both CPS and pneumolysin) and invasive pneumococcal disease
is available (Musher et al., 2001;Zysk et al., 2003). Musher and colleagues (2001) explored in
a cross sectional sample of middle aged adults (50-64 years old) the effect of antibody to
pneumolysin on the development of pneumococcal disease and interestingly found that
patients with bacteraemic pneumococcal pneumonia had significantly lower mean anti-
pneumolysin IgG levels than patients with a non-bacteraemic condition. Furthermore, Musher
and colleagues (1997) conducted a study in a military camp during an epidemic of
pneumococcal pneumonia serotype 1 and found that 27.8% of those who were present at the
camp at the time of the epidemic but who didn't develop the infection had IgG antibody to
that specific type, whereas only 3.6% of controls had this antibody. A similar inverse
relationship between antibody levels against CPS and incidence of invasive pneumococcal
disease was observed by Zysk and colleagues (2003) who also investigated the antibody
levels against some of the pneumococcal surface proteins and found no clear association with
invasive pneumococcal disease. A number of studies have been performed (Virolainen et al.,
1996;Rapola et al., 1997;Virolainen et al., 2000;Rapola et al., 2000;Rapola et al.,
2001a;Rapola et al., 2001b;Rapola et al., 2003) to investigate the relationship between
antibody titres against pneumococcal surface proteins and exposure to pneumococci, but this
relationship is still under discussion and no unanimous finding is available for the different
proteins and the various pneumococcal related clinical conditions. An association between
anti-PsaA antibodies and reduced involvement of S.pneumoniae in AOM was found by
Rapola and colleagues (2001b) although only in infants older than 8 months of age. Similar
findings have been found in mice, where vaccination with PsaA elicited protection against
nasopharyngeal carriage of the pneumococcus and, in combination with PspA, also against
Pnc bacteraemia and pulmonary Pnc infection (Briles et al., 2000). However, more recent
investigations (Rapola et al., 2003) looked at whether anti-PsaA antibody would reduce the
overall risk of pneumococcal AOM and/or of pneumococcal carriage and found a much more
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complex interrelationship. A higher anti-PsaA concentration was found to predict a higher
risk of pneumococcal carriage and of pneumococcal AOM (RR=1.51), whereas a higher anti-
PsaA concentration at 12 and 18 months seemed to slightly decrease the risk of pneumococcal
AOM (RR=0.94 and 0.88 respectively).
2.4 Pneumococcalvaccines
2.4.1 Polysaccharide vaccines (23-valent)
The currently available 23-valent polysaccharide pneumococcal vaccines (PPV),
manufactured by both Aventis Pasteur MSD (Pneumovax@ II) and Wyeth-Lederle Pediatrics
and Vaccines (Pnu-Immune@), include 23 purified capsular polysaccharide antigens of
S.pneumoniae (serotypes 1,2,3,4,5, 6B, 7F, 8, 9N, 9V, IDA, IIA, 12F, 14, I5B, I7F, 18C,
19A, 19F, 20, 22F, 23F and 33F) which account for around 96% of pneumococcal isolates
causing serious infections in England and Wales (George & Melegaro, 2001). These vaccines
were licensed in the United States in 1983, and later marketed in Europe, replacing an earlier
14-valent formulation that was licensed in 1977 (ACIP, 1997). Pneumococcal capsular
antigens induce a type-specific antibody response normally within 2-3 weeks in healthy
young adults whereas the antibody response to most capsular types is generally poor or
inconsistent in children aged <2 years (Douglas et al., 1986;Koskela, 1986;Leinonen et al.,
1986). Therefore, these vaccines are licensed for immunization only of persons over the age
of 2 years for whom the risk of contracting the pneumococcus is unusually high or dangerous
(Figure 2.2) (Salisbury & Begg, 1996). Since July 2003 a pneumococcal immunisation
programme for older healthy adults has also been introduced, partly as a result of the work
performed in this thesis (Figure 2.2).
Re-immunisation with polysaccharide vaccine is not currently recommended in the UK
except for people whose antibody levels are likely to have declined more rapidly (i.e. those
with no spleen, with splenic dysfunction or with nephrotic syndrome). In these circumstances,
another dose is recommended at 5-year intervals.
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Figure 2.2 - Current PPV immunisation policy
Current PPV immunisation policy - at risk groups (Green Book)
Pneumococcal vaccine is already recommended for all those in whom pneumococcal
infection is likely to be more common and/or serious. The at-risk groups, defined in
paragraph 25.3 of the new pneumococcal chapter of Immunisation Against Infectious
Disease 2003 (The Green Book available at www.doh.gov.uk/greenbook) are people
with:
i. Asplenia or severe dysfunction ofthe spleen, including homozygous sickle cell
disease and coeliac syndrome
ii. Chronic renal disease or nephrotic syndrome
iii. Chronic heart disease
iv. Chronic lung disease
v. Chronic liver disease including cirrhosis
vi. Diabetes mellitus
vii. Immunodeficiency or immunosuppression due to disease or treatment
viii. HlY infection at all stages.
ix. Cochlear implants
New immunisation policy - older adults
The new pneumococcal immunisation policy includes all adults aged 65 years and over who
have not previously been immunised.
This policy is being introduced in England over the next 3 years, introducing younger
cohorts each year. All people aged 80 years and over will be offered pneumococcal
polysaccharide vaccine from 21st July 2003. They will be followed by all those 75 years
and over from l" April 2004 and all those 65 years and over from I" April 2005.
The effectiveness of 23-valent polysaccharide vaccines has been assessed in various studies
and the result seems to depend strongly on the study design used. On one hand case-control
and retrospective cohort studies have indicated variable, but sometime considerable benefits
in terms of vaccine efficacy against invasive disease among the elderly (Shapiro & Clemens,
1984;Sims et al., 1988;Shapiro et al., 1991;Butler et al., 1993). On the other hand, meta-
analyses based on randomised control trials show variable but sometimes very little protection
of the vaccine against invasive pneumococcal disease in high or moderately high risk
categories (Fine et al., 1994;Hutchinson et al., 1999;Moore et al., 2000). Furthermore, the
results appear to be strongly dependent on whether or not the studies included in the analysis
are restricted to truly randomised trials or include quasi-randomised ones. Further insights on
the efficacy of PPV will be, presented in Chapter 4.
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2.4.2 Conjugate vaccines
A heptavalent pneumococcal conjugate vaccine (PCV) has been registered in the USA and
recommended by the American Academy of Paediatrics and the Advisory Committee on
Immunisation Practices for universal use in children less than 24 months of age and also for
high-risk children aged 2-5 years old (ACIP, 2000). In the latter setting, conjugate vaccination
is followed by a polysaccharide booster in order to improve pneumococcal antibody titres in
this age group. In the UK, the vaccine was licensed in 2001 and is now recommended to
infants aged between 2 months and 5 years who are at increased risk.
Several studies have shown evidence of the direct effect of different formulations of the
conjugate vaccines on the incidence of disease (invasive pneumococcal disease, pneumonia
and acute otitis media) among vaccinated individuals (Table 2.3). Moreover, the vaccine
reduces nasopharyngeal carriage of vaccine-type (VT) pneumococci (Table 2.4). In addition
to individual protection against further development of pneumococcal disease, reduced
colonisation of vaccinated individuals elicits protection against both pneumococcal
colonisation and disease also among unvaccinated people (herd immunity). Some evidence of
these indirect effects has already been presented for both pneumococcal carriage and disease
(Table 2.5 and Table 2.6). In particular, Whitney and colleagues (2003) showed a decrease in
the number of reported invasive pneumococcal disease cases (8%-32% in 20+ years of age)
two years after the introduction of the conjugate vaccine. Whether this reduction is truly a
consequence of the introduction of the conjugate vaccine, or if it simply follows the
prevailing downward trend of invasive pneumococcal disease, is still under discussion and
more post-vaccine surveillance data is necessary in the US and elsewhere in order to assess
this.
Depending on the formulation, the conjugate vaccine covers 7 to a maximum of 11
pneumococcal serotypes. The proportion of disease caused by the serotypes contained in the
7-valent vaccine (the only one currently licensed) varies across different geographical areas,
from 85% in the USA, to 60-70% in Europe and around 55% in Asia (Pelton et al., 2003). As
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a consequence of vaccination, the remaining non-vaccine types (NVT) may benefit from this
selective immunological pressure. Replacement ofVT with NVT in the nasopharyngeal niche
of colonised individuals may thus occur causing a shift in the serotypes circulating in the
population and, potentially, in disease. Serotype replacement has been observed in vaccinated
as well as unvaccinated individuals colonised with pneumococci (Table 2.4 and Table 2.5). A
switch in serotypes causing acute otitis media has been shown in the Finnish and Dutch trials
(Eskola et al., 2001;Veenhoven et al., 2003), where AOM caused by non-vaccine types
increased following the introduction of the conjugate vaccine (Table 2.3). So far, the effect of
this mechanism on invasive disease remains unclear, although, recently, Kaplan and
colleagues (2004) noted an increase of non-vaccine serotypes (i.e. 3, 15, 33) causing invasive
disease in American children 2 years of age or less. Also, Brueggemann and colleagues
(2003) confirmed the results found in the early 1990s by Smith and colleagues (1993) who
derived the invasiveness of the different serotypes comparing carriage data to disease data.
Both the studies showed that certain NVT (i.e. 1, 7) have a high invasive capacity, although
most do not. This suggests the potential for serotype replacement to lead to replacement in
invasive disease as well, alleast for some serotypes.
Bacterial replacement as a consequence of vaccination might also include other species,
which, similarly to NVT dynamics, can invade the colonisation space that was occupied by
VT in the pre-vaccination period. Veenhoven and colleagues (2003) showed a significant
increase in Staphylococcus aureus-related acute otitis media after vaccination, though the
numbers of middle-ear fluid cultures of untypable Hiinfluenzae, Mcatarralis, group A
streptococci and P.aeruginosa did not differ between vaccine and control groups. Moreover, a
negative correlation has been detected for co-colonisation of S.aureus and vaccine-type
pneumococci (OR 0.68,0.48-0.94), but not for S.aureus and non-vaccine serotypes (Bogaert
et al., 2004b). These findings suggest that a natural competition between colonisation with
vaccine-type pneumococci and S.aureus may well exist, and that this might explain the
increase in S.aureus-related otitis media after vaccination shown in Vennhoven's study.
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Direct and indirect effects of vaccines are both crucial elements to considering the changes to
national immunisation policies. The direct effects (i.e, reduction in carriage and, thus, disease
in vaccinated individuals) are usually available as a result of properly designed studies and
surveillance data in time with the launch of the vaccine. Indirect effects are usually only
visible after the introduction of the vaccine when, in fact, the policy has already been
implemented. Nevertheless, their impact can be substantial when evaluating a vaccination
policy, both in terms of health gains as well as in terms of costs. In the following work we
will use modelling techniques in order to take these effects into account.
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2.5 Surveillance of pneumococcal disease in England and Wales
The uncertainties with regards to the long-term effect of the introduction of new formulations
of pneumococcal vaccines makes the availability of surveillance data even more crucial than
in normal circumstances. A number of data sources are available and, although none of them
can be considered complete and exhaustive, they all facilitate the monitoring and assessment
of potential changes in pneumococcal disease trends. However, whereas for invasive
pneumococcal disease the surveillance system in place is based on aetiologically confirmed
pneumococcal diseased patients, the monitoring of less severe non-invasive pneumococcal
cases usually relies upon clinical diagnosis. For instance, the Royal College of General
Practitioners (RCGP) sentinel surveillance system reports the clinical manifestation for which
the visit is required (i.e, pneumonia and acute otitis media) but not the related organism.
Hospital admissions are also available for the different pneumococcal related condition and
can be used also to ascertain the costs related to the most severe conditions. Again, discharge
diagnoses are often clinical rather than microbiologically based.
Although the management and use of each specific data source will be fully described in
Chapter 3, the following paragraphs aim to give a brief introduction on the data that are
available to gain insights into the epidemiology of pneumococcal disease.
2.5.1 Laboratory reports
The Health Protection Agency Communicable Disease Surveillance Centre's (CDSC)
national laboratory reporting scheme is the main data source for the ascertainment of invasive
pneumococcal disease in England and Wales (Miller et al., 2000). This is based on voluntary
weekly reports to CDSC of all clinically significant bacterial isolates from blood,
cerebrospinal fluid (CSF) and other sterile sites from public health and non-public health
laboratories around England and Wales. Each record corresponds to an individual episode of
illness and contains information such as: patient's date of birth, sex, age, reporting laboratory,
and nature of specimen or specimens from which the organism was isolated. When the
47
bacterium is isolated from the CSF, the patient is recorded as a meningitis case. Sometimes
additional information on associated clinical features, during and at the end of the episode,
and on antibiotic susceptibility is also included.
A second data source consists of fPD isolates referred for serotyping to the Respiratory and
Systemic Infection Laboratory (RSfL) at the Specialist and Reference Microbiology Division
of the Health Protection Agency. From 1996 all laboratories reporting an invasive
pneumococcal infection in children less than 6 years of age to the national surveillance system
were asked to send to RSIL the isolate from that patient for serotyping, if they had not already
done so. As not all the isolates sent to RSIL for serotyping are reported also to CDSC, and
vice versa the two databases were therefore reconciled in 1996, matching on date of birth,
date of specimen taken, sex, source of laboratory, name of patient or Soundex code when the
name was not available. Moreover, the Antibiotic Reference Unit (ARU) at the Specialist and
Reference Microbiology Division routinely performs antibiotic sensitivity testing on the
isolates referred to RSIL.
2.5.2 Notifications
Clinicians have been required by statute to notify the proper officer of the local authority
(usually the Consultant in Communicable Disease Control) cases of pneumococcal meningitis
since 1968 (McCormick, 1993). Clinically diagnosed cases of pneumococcal meningitis are
reported on a weekly basis to regional health authorities and data are collated at CDSC and
published in the Communicable Disease Report.
2.5.3 Consultation to General Practice
The Royal College of General Practitioners (RCGP) set up a sentinel surveillance programme
using a representative sample (currently 69 practices) of the practitioners throughout England
and Wales in 1967 (Fleming, 1999). The system, which evolved from the Epidemic
Observation Unit of the College of General Practitioners set up in 1953, provides weekly data
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on diagnosis (now recorded with the ICD-9 coding system), age, and sex of the patient who
consults the GP. Each report is based on a new episode of illness although ongoing
consultations are also reported.
2.5.4 Hospital Episode Statistics
A further source of information for pneumococcal disease, which also includes more
information on co-morbidities, is the Hospital Episode Statistics (HES)
(http://www.dh.gov.uk/Home/fs/en).This is a computerised hospital discharge database that
collates output from all National Health Service hospitals in England. It contains information
on individual episodes of illness, together with patient's details (age, date of birth, postcode,
sex), clinical conditions, number of days spent in the hospital and admissions to Intensive
Care Unit (ICU). For each record, seven diagnostic fields are available, allowing co-
morbidities to be recorded. Since April 1995 the tenth revision of the International
Classification of Disease (ICD-10) has been adopted for coding discharge diagnosis. Before
that time the ICD-9 version of the code was used.
2.5.5 Deaths
Doctors have been required to certify the cause of death for patients under their care since the
early 1840s (Rooney & Devis, 1996). The certifying doctor is required to explicitly state the
condition that led directly to death in Part I of the certificate, whereas the disease or condition,
which started the sequence, is reported in the lowest line (what is defined the underlying
cause of death). All certified deaths are notified to the Office for National Statistics (ONS),
and coded according to ICD codes 9th revision (ICD-9) until 1999 and 10th revision for 2000
data and onward.
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2.6 Discussion
This chapter presented an overview of the pneumococcus, the pneumococcal vaccines and the
surveillance systems that are available to monitor the incidence of pneumococcal disease in
the UK. These aspects represent the necessary background that is needed in order to
investigate the epidemiology of the bacterium, the characteristics of its transmission dynamics
in the population and the potential effects of different vaccination policies. Using the
surveillance systems that are available for the UK, in the following chapter (Chapter 3) the
epidemiology of S.pneumoniae infection in England and Wales will be described and the
current burden of pneumococcal disease will be estimated.
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CHAPTER 3 - THE EPIDEMIOLOGY OF
PNEUMOCOCCAL DISEASE IN ENGLAND AND
WALES
3.1 Aims
• To describe and compare available surveillance systems for pneumococcal disease;
• To describe the epidemiology of pneumococcal disease in children and in the elderly;
• To describe changes in the serotypes distribution of pneumococcal disease;
• To investigate the antibiotic susceptibility patterns of pneumococcal disease cases
over the years;
• To estimate the overall burden of pneumococcal disease in England and Wales.
3.2 Introduction
In this chapter the epidemiology of pneumococcal disease is described and the current burden
of disease in England and Wales is estimated. Reliable surveillance systems are required in
order to monitor incidence and trends in infectious diseases. Surveillance systems are used to
inform policy decision makers about possible control measures and also to ascertain the
impact of specific interventions, such as vaccination, once they have been put in place. As
described in the previous chapter, two pneumococcal vaccines are currently available and
recommended in the UK although a number of open questions are still threatening the overall
effectiveness of the vaccination programmes. In particular, uncertainties related to the indirect
and long-term effects of new formulations of pneumococcal conjugate vaccines (i.e. herd
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immunity and serotype replacement) - discussed in section 2.4.2 - require a comprehensive
and well planned surveillance system which would enable the ascertainment of changes in the
overall morbidity and mortality due to S.pneumoniae from the pre to the post vaccination era.
A number of data sources are available and taken together they facilitate the monitoring and
assessment of potential changes in pneumococcal disease trends. Whereas for invasive
pneumococcal disease the surveillance system in place is based on laboratory reports of
microbiologically confirmed cases of pneumococcal disease, less severe non-invasive
pneumococcal conditions (i.e, pneumonia and acute otitis media) are monitored using a
surveillance system (RCGP) that is based on vague clinical definitions that are unlikely to be
investigated microbiologically. However, hospital admissions (HES) are also available for
different pneumococcal related conditions and can also be used to ascertain the overall burden
of disease and the associated costs.
3.3 Method
3.3.1 Sources of data
The sources of data for pneumococcal diseases have been presented in Chapter 2 (section
2.5). In the following paragraphs, the management of the data will be described.
Laboratory reports. Line listings of cases of laboratory confirmed invasive pneumococcal
disease reported from laboratories in England and Wales from January 1990 to December
2000 was extracted. Since 1996 the data were downloaded from the newly reconciled
enhanced surveillance system of invasive pneumococcal disease (CDSCIRSIL) which is the
most complete dataset for IPD in England and Wales containing information on serotype as
well as antimicrobial susceptibility information for around 50% of the cases (George &
Melegaro, 2001). IPD cases were those for which pneumococci were isolated in the blood,
CSF or other normally sterile body fluids. Only strictly invasive infections were extracted
though some non-invasive cases are also recorded in the system. Pneumococcal meningitis
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cases were defined where the organism was isolated from the CSF or when the diagnosis of
"pneumococcal meningitis" was specifically reported in the patient's record. The extracted
data included age, sex, earliest specimen date, serotype (when available), antimicrobial
susceptibility information (penicillin and erythromycin), region and method of confirmation.
Hospital Episode Statistics (HES). From HES all hospital admissions reporting one of the
pneumococcal related ICD-I0 codes (Table 3.1) in any of the seven diagnostic fields were
extracted. This included strictly IPD codes (pneumococcal meningitis and septicaemia),
pneumococcal pneumonia (under which both IPD and non-IPD can be recorded) as well as
non-invasive codes such as otitis media and lobar or unspecified pneumonia. Admissions due
to lobar pneumonia, organism unspecified (JI81), were extracted as pneumococcus is
considered one of the major cause of lobar pneumonia, especially in children (Djuretic et al.,
1998). In the former ICD-9 coding system a unique code (481) was used for both lobar
pneumonia, organism unspecified, and pneumococcal pneumonia (Djuretic et al., 1998;Miller
et al., 2000).
Table 3.1 - International classification of diseases codes for pneumococcal disease
Definition ICD-9 code lCD-tO code
Pneumococcal meningitis 3201 GOOI
Pneumococcal septicaemia 0382 A403
Pneumococcal pneumonia 481 JI3X
Lobar pneumonia, organism unspecified 481 JI81
S.pneumoniae as the cause of the disease 410 B953
Non-Suppurative otitis media 3810-3814 H650-H659
Suppurative and unspecified otitis media 3820-3829 H660-H669
Otitis media in diseases classified elsewhere n.a. H670-H678
n.a. = no equivalent ICD-9 code was available
The period between April 1995 and March 2000 was considered (HES financial year goes
from April to March). As in HES each episode of patient care under a consultant is recorded,
and as a patient may have several different episodes during a single hospital stay (i.e. change
of consultants, unit, etc.), the records were linked together through the personal identifiers
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(date of birth, sex and district health authority of the hospital (DllAtreat) and the admission
date, which should remain the same, and the last episode of each patient hospitalisation was
retained. When it was not possible to link different episodes of the same patient's admission,
due to inappropriate date coding, further investigations were required. Moreover, as there may
also be duplicates in the data, the following criteria were followed in order to minimise the
number of episodes from the same patients:
a) A duplicate record was deleted when patient date of birth, sex, postcode, admission date
and date episode began and ended were the same;
b) Any multiple episodes were identified ("epiorder"> 1) and when the patient date of birth,
sex, DHAtreat and admission date were the same only the record with the latest episode
end date was retained;
c) Matching on date of birth, sex, date of admission, and DHAtreat identified any multiple
episodes that had not been linked. All matching records were ordered by date of episode.
If the dates of the episodes overlapped the record with the latest episode end was retained,
and other records were deleted.
Once the data were cleaned, each hospitalisation was recorded according to the reported
pneumococcal code and to whether this code appeared in the first diagnostic field, in the first
three or in the last three fields. We assumed that more important clinical conditions were
recorded in the first diagnostic field. In case more than one pneumococcal code was present
for a patient, the most severe code was considered first. The following order of importance
was thus followed: GOOI, A403, J13, B953, JI81. Otitis media hospitalisations were treated
separately and were available only for the period 1999-2000.
GP Consultations. The weekly number of consultations to general practitioners for a
diagnosis of either pneumonia/pneumonitis or acute otitis media and population at risk was
obtained from the Royal College of General Practitioners (RCGP) Weekly Returns System.
The bi-weekly number of pneumonia and AOM was calculated for the period 1996-2000 and
used as an outcome variable in a multivariate regression analysis with the aim of investigating
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the underlying aetiologies of GP consultations for pneumonia and AOM and, thus, the
proportion of these attributable to S.pneumoniae. The details of the analysis are reported
below (Section 3.3.2.1).
Moreover, additional and more detailed information on patients attending the GP practices
was available from the Morbidity Survey of General Practices Fourth Edition (MSGP4),
which is a one-year prospective survey of around 500,000 patients attending GP practices
(McCormick et al., 1995). This database contains information on people attending the
practices in the survey, such as socio-economic status, details on family composition,
individual characteristics (i.e, smoking status) and the history of the patient's health status
during the year of the survey.
Notifications. The total number of pneumococcal meningitis cases diagnosed and notified by
clinicians and reported to CDSC was extracted for the period 1995-2000. Figures were
compared to the overall numbers reported by laboratories around England and Wales to
CDSCIRSIL enhanced surveillance system.
3.3.2 Data analysis
3.3.2.1 Comparison of data sources
The total number of pneumococcal confirmed cases identified by laboratory reports,
notifications and HES for the period 1995-2000 (the last year that was available at the time of
the analysis) was derived and comparisons were made between the data sources. The seasonal
patterns were investigated from both laboratory reports and hospitalisations data.
Multiple linear regression analysis was used, following the technique developed by Ryan and
colleagues (1996), to ascertain the underlying aetiologies of pneumonia and acute otitis media
GP consultations and to estimate the proportion attributable to Sipneumoniae infection. The
observed seasonality in agents that could potentially cause pneumonia and AOM was
compared to the number of consultations reported for the two clinical outcomes over the same
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time period. The weekly number of consultations (RCGP) for the period 1996-2000 was used
as the dependent variable of the regression. The independent variables were the weekly
number of national laboratory reports for the following agents: Streptococcus pneumoniae,
Haemophilus influenzae, Adenovirus, Influenza A (Flu A), Influenza B (Flu B), Klebsiella
pneumonia, Legionella pneumophila, Moraxella catarrahlis. Mycoplasma pneumonia,
Parainfluenza, Pneumocistis carin ii, Rhinovirus, RSV, Chlamydia pneumonia and Chlamydia
pisittaci.
The formula for calculating the expected number of GP consultation for pneumonia (and
similarly AOM) Yj in a 2-week period j is:
3.1
Where Lij is the number of laboratory reports for pathogen i in the 2-week period j, (lj is the
regression coefficient for organism i used to estimate the number of GP consultations
associated with each organism, and C is a constant representing the background number of
GP consultations for pneumonia associated with other infectious or non-infectious causes of
clinically suspected pneumococcal disease.
As the age-specific weekly number of GP consultations was not available, patients of all ages
were combined, as well as laboratory reports. A backward stepwise regression was performed
using STATA 6.0. This technique is based on a variable selection procedure in which all
variables are entered into the equation and then sequentially removed if non significant (p-
vaJue>0.05). The importance of two-way interaction terms for the explanation of the
dependent variables was also investigated, assessing the significance (p<O.Ol) of each
interaction term between the organisms in the final model. The validity of the model was
assessed (R2) and the impact of changes in the model specification was investigated.
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3.3.2.2. Analysis of epidemiological data
Age-specific incidences of laboratory confirmed IPD was calculated using ONS population
estimates for the appropriate years and age groups. Similarly, hospitalisation rates were
derived separately for each pneumococcal related ICD-I0 code and, also, for any
pneumococcal confirmed hospitalisations, using ONS population estimates for England.
The serotype distribution of IPD cases was derived for each year from 1996 to 2000
examining the isolate characteristics and identifying the most common 15 serotypes in the
following age groups: <5 years, 5-64 years and 65+. Less common serotypes were grouped
together. The proportions of invasive infections that are caused by the serotypes contained in
the different formulations of pneumococcal conjugate and polysaccharide vaccines were
estimated for different age groups and for each year. Moreover, for each isolate, information
on the susceptibility to penicillin and erythromycin was also derived and resistance patterns
were examined for the most prevalent types and for the different age groups.
The number of patients that died during their hospital admission was derived. Case-fatality
ratios (CFR) from 1995/96 to 1999/2000 were estimated by dividing the number of deaths by
the number of pneumococcal disease cases admitted to the hospital. Due to the presence of
other serious co-morbidities conditions in many patients (especially the elderly) hospitalised
with pneumococcal codes, it was not possible to ascertain with confidence from the data
whether the patient had died because of the pneumococcal infection or, simply, with a
pneumococcal infection. For this reason we estimated CFR for patients reporting a
pneumococcal code in the first diagnostic code, in the first three or in any of the seven
diagnostic fields. Considering that the first diagnosis is more likely to report the underlying
cause of the hospitalisation, we assumed that CFR calculated on the first diagnosis only were
more likely to be related to Spneumoniae infection. From ONS, the number of pneumococcal
related deaths (Le. pneumococcal code as the underlying cause of death) were also obtained
and CFR were estimated dividing these figures by the number of laboratory reports.
Although, in fact, vital status information is available for some of the IPD cases reported from
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the laboratories, these data are far from being complete (3% in 2000 data) and hence could
not be used for deriving pneumococcal specific mortality.
Average age-specific episode and consultation rates for community-acquired pneumonia and
acute otitis media were estimated using MSGP4 data and compared to the rates provided by
RCGP. Moreover, from MSGP4 data, episode rates of both CAP and AOM due to
pneumococcal infection were also derived for high and low-risk individuals, stratifying the
patients according to whether their clinical record reported one of the following chronic
medical conditions: diabetes mellitus, chronic renal, hepatic, or pulmonary disease,
alcoholism, or neoplastic disease, chronic immunosuppression. These represent the high-risk
group for which the polysaccharide pneumococcal vaccine has been in the past and is
currently recommended (Chapter 2).
3.4 Results
3.4.1 Comparisons of data sources
From CDSCIRSIL the number of laboratory reports for each year since 1990 was obtained
and showed an increase in the annual figure in 1996 when the enhanced surveillance system
was implemented (Figure 3.1). Since then, an annual average of around 4700 IPD cases had
been reported. Of these, an average of 343 were identified as cases of pneumococcal
meningitis (pneumococci isolated from the CSF) whereas the remaining isolates were
obtained from bacteraemic patients with pneumococcus isolated from the blood or other
sterile body fluids.
More cases of pneumococcal meningitis were identified in HES than in the laboratory reports
and notification system each year (Table 3.2). This suggests that the latter systems may
underestimate the true incidence of pneumococcal meningitis. Similarly, the overall number
of invasive pneumococcal isolates reported from the laboratories around England and Wales
was lower than the number of hospital admissions due to confirmed pneumococcal infection
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(ICD-IO codes: G001, A403, Jl3, B953) for the same years. Although this may again suggest
that laboratories are underreporting the number of IPD cases to the national surveillance
system, it may also highlight the non-invasive nature of codes Jl3 and B953 which,
differently from the other codes (G001, A403), do not necessarily imply that pneumococci
have been isolated from a sterile body fluids (which represents the criterion for extraction of
invasive pneumococcal isolates from laboratory reports).
Figure 3.1 - Cases of pneumococcal meningitis and other IPD in England and Wales (1990-
2000).
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Source: National enhanced surveillance of pneumococcal disease (CDSCIRSIL).
The presence of an epidemic cycle was assessed using weekly laboratory reports of IPD and
hospitalisations for confirmed pneumococcal infection. A marked seasonal pattern in the
presentation of IPD with preponderance in the winter months was observed. Figure 3.2 notes
the number of cases reported from laboratories around England and Wales by week of earliest
specimen date over the period 1995-2000. Reported IPD cases reach a low during August and
peak in December and January when reporting rates are 3-5 times higher. Although these
reports regard most severe cases of pneumococcal infection (the invasive ones), they probably
represent just a small proportion of the true burden of pneumococcal disease present both in
the community and in the hospital. The seasonal changes in disease presentation observed
here, however, may be correlated to the more intense circulation of respiratory viruses during
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the same period of the year, and also appear to be reflected in non-IPD admissions to
hospitals and consultations in Primary Care. Figure 3.3 shows a comparison between
laboratory weekly reports of IPD and hospitalisations due to all pneumococcal confirmed
infection and also admissions with a diagnosis of lobar pneumonia, organism unspecified. The
almost overlapping seasonal pattern observed when considering all confirmed pneumococcus-
related patients suggests that hospital episodes with an ICD-I0 code mentioning
S.pneumoniae are an accurate reflection of IPD incidence as reported in the national enhanced
surveillance system (CDSC/RSIL). Moreover, a similar seasonal pattern characterises also
lobar pneumonia admissions though the numbers are much higher.
Previous studies looked at the aetiological cause of lobar pneumonia (Djuretic et al., 1998)
and, more generally, community-acquired pneumonia (CAP) requiring hospitalisation (Lim et
al., 2001) and showed that the proportion caused by pneumococcal infection is high, going
from 46% of lobar (pneumococcal) pneumonia (ICD-9 code: 481) in children to 48% of CAP
in adult. Muller-Pebody and colleagues (2002), following the technique developed by Ryan
and colleagues (1996), investigated the aetiological cause of lower respiratory tract infections
(LRTI) (including lobar pneumonia) among hospitalised children «5 yrs) (Muller-Pebody et
al., 2002) and elderly patients (65+ yrs) (Muller-Pebody personal communication) and found
that, respectively, 42% and 19.8% of unspecified hospitalisations for LRTI were attributable
to S.pneumoniae.
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Figure 3.2 - Weekly number of invasive S.pneumoniae isolates in England and Wales
reported to the national laboratory surveillance system (1995-2000)
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Figure 3.3 - Comparison of weekly reports of pneumococcal disease from the national
laboratory surveillance system and from hospital admissions (1995-2000).
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Pnc confirmed hospitalisations include the following ICD-10 codes: GOal, A403, J13, B953 reported
in any of the seven diagnostic fields. ICD-10 code for lobar pneumonia: J181.
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3.4.2 Multiple regression analysis of GP consultations
A multivariate regression analysis was performed to assess the proportion of cases of CAP
and AOM that are likely to be pneumococcal in origin.
Three models were estimated for both CAP and AOM. We found no biologically plausible
statistically significant interaction terms. Table 3.3 and Table 3.4 provide estimates of the
proportion of CAP and AOM attributable to each of the different agents. The variables
laboratory reports for S.pneumoniae, Adenovirus, M'pneumoniae, RSV and Flu A stayed in
the model for unspecified pneumonia cases (Model CAP1). The adjusted R2 indicates that
67% of the variation in the weekly number of unspecified cases was explained by the model.
Using this model, it was estimated that 31% of unspecified pneumonia could be attributed to
S. pneumoniae, 38% to Adenovirus, 17% to Mqmeumoniae, 6% to RSV and 8% to Flu A. A
slightly more adequate fit (R2=68%) was achieved by model CAP2, where the variable
Adenovirus was dropped from the model and "other organism" was added to consider all the
other possible infectious and non infectious causes of pneumonia that were not included in the
analysis. Using CAP2, the proportion of unspecified pneumonia attributed to S. pneumoniae
was 26%, 14% to Mqmeumoniae, 8% to RSV, 11% to Hiinfluenzae, 10% to Flu A and 31% to
"other organism". Hiinfluenzae was kept in the model, though the p-value was less
significant, but still within the acceptable range (p-value=O.019). The sensitivity of model
results to the variable Hiinfleunzae was assessed in CAP3. Using this model, it was estimated
that the proportion of pneumonia cases attributable to Sipneumoniae was 29%, 12% to
Mipneumoniae, 6% to RSV, 8% to Flu A and 44% to "other organism". Similarly to the
previous models, the latter explained 67% f the data variability. For the unspecified acute
otitis media episodes, the variables Sipneumoniae, Flu B, Mpneumoniae, RSV, Rhinovirus
and Adenovirus stayed in the model, explaining 68% of the data variability. From this model,
S.pneumoniae was estimated to cause 23% of AOM episodes, 4% were due to Flu B, 12% to
Mipneumoniae, 8% to RSV, 18% to Rhinovirus and 36% to Adenovirus. Dropping
Adenovirus from the model reduced the fit to 63% and 58% when the variable "other
organism" was, respectively, included and excluded from the model specification.
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In summary, from the six models just described, S.pneumoniae was estimated to cause from
26% [95%CI: 10-37%] to 31% [95%CJ: 21-39%] of pneumonia consultations, whereas from
23% [95%CI: 14-29%] to 42% [95%CI: 36-47%] of AOM consultations. Figure 3.4 and
Figure 3.5 show the observed and estimated seasonal patterns and the contribution of each
pathogen.
Although not much variation was found in the proportion of CAP attributable to
pneumococcal infection in the three models, CAP2 was the one that showed the best fit
(highest adjusted R-square) and, consequently, was chosen as our final model. The proportion
of OP consultations for CAP attributable to Sipneumoniae was thus assumed to be 26%.
Similarly, the proportion of AOM attributable to pneumococcus was assumed to be 23%
according to model AOM1, being this the model with the best fit (adjusted R-square equal to
70%). These results will be used in section 3.4.3.5 to derive the pneumococcal age-specific
consultation rates to the general practitioner.
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Table 3.3 - Estimation of the proportion of unspecified CAP attributable to specific
pathogens.
ModeICAP2-
Pathogen Model CAPl* Final model ModelCAP3
S.pneumoniae 31% 26% 29%
Adenovirus 38%
Mipneumoniae 17% 14% 12%
RSV 6% 8% 6%
H injluenzae 11%
FluA 8% 10% 8%
Other organism 31% 44%
Adjusted R2 67% 68% 67%
* Regression through the origin (no-intercept model)
Table 3.4 - Estimation of the proportion of AOM attributable to specific pathogens.
Model AOMI * Model Model
Pathogen - Final model AOM2 AOM3*
S.Pneumoniae 23% 27% 42%
FluB 4% 4% 3%
MPneumoniae 12% 10% 15%
RSV 8% 7% 5%
Rhinovirus 18% 25% 35%
Adenovirus 36%
Intercept 27%
Adjusted R2 68% 63% 58%
* Regression through the origin (no-intercept model);
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Figure 3.4 - Comparison of observed biweekly number of CAP episodes with estimated
number derived from final best fitting model.
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The best-fitting model estimated that the proportion ojCAP due to S.pneumoniae is 26% (Fable 3.3).
Figure 3.5 - Comparison of observed biweekly number of AOM episodes with estimated
number derived from final best fitting model.
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The best-fitting model estimated that the proportion of AOM due to S.pneumoniae is 23% (Fable 3.4).
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3.4.3 Pneumococcal disease epidemiology
3.4.3.1 Disease incidence
Age-specific incidence rates of pneumococcal meningitis and other invasive pneumococcal
disease were calculated using the overall number of isolates reported over the period 1996-
2000 and the annual population figures for England and Wales, produced by the Office of
National Statistics (ONS). Number and incidence rates are reported in Table 3.5 and show, as
reported in previous studies (Laurichesse et al., 1998;Smith et al., 1998), IPD rates peaking in
infants and among the elderly. Incidence rates for pneumococcal meningitis are highest in
infants (15 per 100,000 population) and remain low in all other age groups.
Table 3.5 - Number and incidence rates ofIPD cases by age in England and Wales (1996-
2000).
Pne Mentnzttts Other IPD AIIIPD
Age group Cases Rate Cases Rate Cases Rate
<1 month 41 15.6 157 59.7 198 75.3
1-11 months 442 15.3 677 23.4 1119 38.6
1-4 years 221 1.7 1294 9.9 1515 11.6
5-9 years 32 0.2 316 1.8 349 2.0
10-14 years 32 0.2 138 0.8 170 1.0
15-44 years 256 0.2 3104 2.8 3360 3.1
45-64 years 361 0.6 4035 6.7 4396 7.3
65-74 years 197 0.9 4259 19.3 4456 20.2
75+ years 136 0.7 8441 43.6 8577 44.3
Total 1719 0.7 22421 8.5 24140 9.2
Source: National enhanced surveillance of pneumacoccal disease (CDSCIRSIL). Rates are per 100,000
population per year.
Overall, HES data show a similar incidence of admission due to confirmed pneumococcal
infection (10.84 per 100,000) as laboratory reports of invasive disease (9.2 per 100,0000)
(Table 3.6).
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Admissions for lobar pneumonia show a similar age distribution as laboratory-confirmed
invasive infection, suggesting that these may be attributable to infection with S.pneumoniae.
The number and rates of otitis media hospitalisations are shown in Table 3.7 for the different
age groups and also according to whether the otitis media diagnosis was reported in the first
RES diagnostic field or in any of the seven available fields. A peak in the incidence rate is
seen in the 1-4 years of age, although the incidence remains high in all age groups for children
less than 10 years old. Almost twice as many hospitalisations are reported in children when
considering any diagnostic field. This may suggest that otitis media represents a co-morbidity
condition rather than the actual cause of the hospitalisation.
Table 3.7 - Otitis media number of cases and hospitalisation rates by age (1999-2000).
Aoy dlaznosis First dlaanosts
Age group Cases Rates Cases Rates
<1 month 15 30.2 7 14.1
1-11 months 1883 345.0 1024 187.6
1-4 years 9937 406.8 4964 203.2
5-9 years 7705 236.2 4040 123.9
10-14 years 1665 52.1 1096 34.3
15-44 years 2765 13.2 1979 9.5
45-64 years 1845 16.0 1355 11.7
65-74 years 650 15.9 452 11.0
75+ years 499 13.5 278 7.5
Total 26964 54.2 15195 30.5..Rates are per 100,000 population per year. Otitis media ICD-lO codes (H65-H67) either in thefirst or
in any diagnostic fields (HES).
3.4.3.2 Serotype distribution
The enhanced surveillance of pneumococcal disease has identified that the proportion of
invasive isolates with serotype information has increased since 1996, going from 36% in 1996
to 50% in 2000 (Table 3.8). An average of31 different serotypes were detected annually, with
the 15 most prevalent types counting for 93% of the overall number.
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Table 3.8- Proportion ofIPD isolates with serotype information (1996-2000)
Non-typed Typed % Typed
1996
1997
1998
1999
2000
3071
3238
2843
2776
2393
1696
1921
1938
1906
2351
36%
37%
41%
41%
50%
Source: National enhanced surveillance of pneumococcal disease (CDSCIRSIL)
Though some changes occurred over the 5-year period in terms of the serotypes causing IPD
in England and Wales, the most frequent groups remained 14, 9, 19, 6, 23 and 1 (63% of
IPD). Since 1996 a significant reduction of infections caused by types 1 and 4 has been
observed (p<O.OOOI)as well as an increase of types 6 (p<0.0005), 23 (p:::::0.3019)and 8
(p<O.OOOI).Age specific differences in the serotypes causing IPD have been observed in the
past (Scott et al., 1996;Hausdorff et al., 2000a) and are confirmed here (Figure 3.6). Type 14
is more common in children « 5 years) than in older age groups, though still remains the
most frequent type in recent years and across all ages. Types 19 and 6 cause a higher
proportion of infections in children, whereas type 1 (though it is decreasing in all age groups)
is relatively more likely to be the cause of infection in 5-64 years old than in younger children
or in the elderly.
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Source: National enhanced surveillance of pneumococcal disease (CDSCIRSIL).
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The proportions of IPD in England and Wales that are caused by the serotypes contained in
the available formulations of vaccines (7, 9, 11, 23-valent) are, respectively, 64%, 72%, 80%
and 97% if we assumed that cross protection within serogroups occurs (i.e, vaccine containing
serotype 6B also confers protection against serotype 6A). 82% of IPD cases occurring in
children 0-5 years of age are caused by serotypes contained in the 7-valent pneumococcal
conjugate vaccine. Table 3.9 gives the proportions in different age groups.
Table 3.9 - Number and % ofIPD cases caused by the 7, 9, 11 or 23 serotypes contained in
the available vaccines (1996-2000).
7-valent 9-valent ll-valent 23-valent
Age group Cases % Cases % Cases 0/0 Cases %
<1 month 59 47% 81 64% 96 76% 117 93%
1-11 months 587 81% 606 84% 647 89% 708 98%
1-4 years 845 88% 892 93% 908 94% 944 98%
5-9 years 88 53% 126 76% 137 83% 160 96%
10-14 years 29 43% 44 66% 47 70% 66 99%
15-44 years 601 47% 863 67% 977 76% 1249 98%
45-64 years 884 55% 1026 64% 1177 74% 1544 97%
65-74 years 960 62% 1043 68% 1204 78% 1495 97%
75+ years 2008 68% 2134 72% 2364 80% 2855 97%
Unknown 250 62% 277 69% 311 77% 386 96%
Total 6311 64% 7092 72% 7868 80% 9524 97%
3.4.3.3 Antimicrobial susceptibility
Antibiotic susceptibility information was available for laboratory reports of invasive
pneumococcal infection and, in particular, susceptibility to penicillin and erythromycin was
present for, respectively, 73% and 63% of the 24133 isolates reported over the period 1996-
2000 to CDSC/RSIL. The overall proportion of penicillin resistant isolates increased over the
5-year period, ranging from 5% in 1996 to 7% in 2000. Age-specific proportions are shown in
Figure 3.7 and highlight a similar pattern across all ages. Similarly, the proportion of isolates
resistant to erythromycin increased over the period, going from 11% in 1996 to 15% in 2000,
with significantly higher proportions (20%-25%) in children « 5 years) than in older age
groups (Figure 3.8).
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Figure 3,7 - Proportion of invasive isolates resistant to penicillin by age group (1996-2000)
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Figure 3,8 - Proportion of invasive isolates resistant to erythromycin by age group (1996-
2000)
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3.4.3.4 Co-morbidities of hospitalised patients
The condition of hospitalised patients was assessed, checking for the presence of co-
morbidities within the seven diagnostic fields available in HES. Eighty one percent of the
patients were recorded with more than one diagnostic code, 54% with more than two, and
38% had more than three diagnoses. Co-morbidities were clearly directly associated with the
age of the patients, being much higher for older age groups (Figure 3.9).
S.pneumoniae was present in the first diagnosis in 72% of the patients, and the remaining
28% was distributed among neoplasm cases (11%), disease of the circulatory system (23%),
disease of the respiratory system (20%), and various other conditions (46%). In Figure 3.10
the age-specific proportions are shown. In the second and further diagnoses the proportion of
pneumococcus related codes were of course lower, being 15% in the second diagnosis, and
7% in the third (co-morbidities respectively: 60% and 46%, the remaining being blank fields).
Figure 3.9 - Proportion of hospitalisations reporting 1, 2-4 and 5+ diagnoses during their
hospital stay (HES 1995-2000)
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Figure 3.10 - Proportion of hospitalisations that reported a non-pneumococcal diagnosis in
their first diagnostic fields by age (HES 1995-2000).
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3.4.3.5 GP consultation and episode rates
Age-specific episode and consultation rates for both CAP and AOM derived from MSGP4
data (McCormick et al., 1995) are higher than those routinely produced by the RCGP system
(Fleming, 1999) (Table 3.10).
Table 3.10 - Consultation and episode rates for CAP and AOM (MSGP4 vs. RCGP)
Consultation rates Episode rates
Age RCGP MSGP4 RCGP MSGP4
group CAP AOM CAP AOM CAP AOM CAP AOM
<1 467 23636 717 52841 276 18332 417 36283
1-4 272 24857 582 55894 165 18121 333 40888
5-14 62 7699 310 18840 27 5249 161 13936
15-24 51 2250 146 4140 30 1448 71 2719
25-44 152 1742 301 3912 66 1169 104 2383
45-64 268 1175 610 2958 110 753 206 1663
65-74 508 -994 1347 2495 229 602 539 1282
75+ 1161 520 3826 1478 630 344 1681 754
Overall 266 3612 679 8900 128 2507 282 6138
Rates are per 100,000 population per year
Higher episode rates were found in patients with high-risk conditions. In Figure 3.11
pneumococcal pneumonia and AOM age-specific episode rates per 100,000 populations per
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year, calculated using MSGP4 data, are reported for high and low risk individuals. For otitis
media, higher rates were observed in children less than 10 years old, and almost twice as
many episodes were reported for children <5 years of age when they also have other high-risk
conditions. A similar pattern is observed also for pneumonia episodes although, in this case,
higher rates were reported at a much later age (60+).
Figure 3.11 - Pneumococcal pneumonia and otitis media episode rates by age in high and low
risk individuals.
Age groups
Source: MSGP4 data. It is assumed that 26% and 23% of respectively, CAP and AOM GP
consultation are attributable to pneumococcal infection (see section 3.4.2).
3.4.3.6 Deaths
The total number of deaths for the period April 1995 to March 2000 was derived from both
ONS and HES data, extracting those records for which one of the pneumococcal codes was
either specified as the underlying cause of death (ONS) or recorded as the primary diagnosis
of the patient (HES). Deaths reporting a pneumococcal related ICD-I0 code in any of the
seven diagnostic fields were also extracted from HES. The number of ONS registered deaths
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from invasive pneumococcal diseases (Pnc meningitis and septicaemia) ranged between 72
and 117 per year in the period 1995 to 2000. The number of deaths from lobar
(pneumococcal) pneumonia was in the range of 1807 to 2064 (Table 3.11). These figures
represent around 70% of the total number of deaths reported in HES for patients admitted
with a pneumococcal meningitis or septicaemia code in the first diagnostic field though only
around 40% of cases that died in the hospital and for which the pneumococcal related
diagnosis was extracted from any of the seven diagnostic fields. The apparent under-reporting
of deaths in ONS may represent cases that die with a pneumococcal related condition but for
which the underlying cause of death (as reported in the death certificate) was non-
pneumococcal specific. In Figure 3.12 the number of reported pneumococcal meningitis and
septicaemia deaths from both ONS and HES is shown for the different age groups and
highlights that the major discrepancies occur in the elderly (75+) where the presence of co-
morbidities makes more difficult the assessment of the underlying cause of death. In 15+
years of age the CFR derived from HES data (deaths/admissions) was considerably higher
than the one obtained dividing the ONS reported number of deaths by the laboratory reports
ofIPD cases (Figure 3.6).
Case-fatality ratios were calculated also for hospitalised patients reporting a pneumococcal
code in the first three or in any diagnostic fields and little variation was shown in the
proportion of individuals who died during the hospital admission (all ages: 13%; in 65+: 21%-
28%).
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Table 3.11 - Number of deaths from pneumococcal disease
ONSa RES - first diag_nosisb RES - an_y_diag_nosisb
Lobar (pnc) Lobar (pnc) Lobar (pnc)
Year pneumonia IPD pneumonia IPD .pneumonia IPD
95/96 1907 94 2468 133 4553 219
96/97 2064 117 2841 140 5286 268
97/98 1807 99 2738 132 5323 223
98/99 1991 104 3471 114 6357 229
99/00 2059 72 3696 127 6853 234
"The ICD-9 coding system was used for ONS records until 2000 data (lobar, pneumococcal pneumonia
code = 481, IPD = 0382 (pnc septicaemia) + 3201 (pnc meningitis); b The ICD-10 coding system was
used in HES since 1995 (lobar, pneumococcal pneumonia code = J181 (lobar pneumonia organism
unspecified) + 113 (pneumococcal pneumonia), IPD = A403 (pnc septicaemia) + GOOI (pnc
meningitis).
Figure 3.12 - Number ofPnc meningitis and septicaemia deaths reported to ONS and to RES
and CFR by age.
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Deaths reporting the following ICD-9(10) codes as the underlying cause of death (ONS) and the as the
primary diagnosis (HES): pneumococcal meningitis: 3201 (G001); pneumococcal septicaemia:
0382 (A403).
3.4.3.7 Burden of disease
The burden of pneumococcal disease was derived from incidence, hospitalisation and
consultation rates provided in this chapter and is summarised in Table 3.12. The proportion of
consultations to the general practitioner for CAP and AOM attributable to the pneumococcus
were estimated using the results of the multivariate regression analysis (3.4.2) where we
found that 26% of CAP and 23% of AOM GP consultations may be attributable to
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S.pneumoniae infection. Otitis media represents a major component of the overall burden of
disease with over 650,000 consultations to the general practitioner per year. Of these, around
60% occurs in children less than 10 years of age. Similarly 70% of OM hospitalisation occurs
in children as well as around 40% of pneumococcal meningitis cases. The burden of
pneumococcal disease in the elderly is represented mostly by episodes of pneumococcal
pneumonia and septicaemia. Fifty-three and 60% of hospitalisations for, respectively, Pnc
confirmed disease and lobar pneumonia occurs in 65+ year of age.
Table 3.12 - Burden of pneumococcal disease in England and Wales.
Laboratory reportsB Hesnitaltsatlens" GP consultanons"
Pnc Other Pne Lobar Pne
Age group meningitis IPD confirmed pneumonia OM pneumonia PneOM
<1 year 93 161 488 1,500 1,055 937 53588
1-4 years 43 253 418 3,371 5,200 2839 237629
5-9 years 6 63 125 1,355 4,227 1654 104156
10-14 years 7 28 69 589 1,174 875 25160
15-44 years 52 626 783 4,228 2,102 13093 144547
45-64 years 74 826 1,069 5,680 1,455 14157 58930
65-74 years 39 841 1,004 6,382 480 10504 17476
75+ years 28 1723 1,771 15,996 298 25626 9082
Total 342 4522 5,240 37,602 14,937 69686 650568
aCDSCIRSIL; bICD-10 codes - Pnc confirmed: G001, A403, J13, B953; Lobar pneumonia: J181; OM:
H65-H67; "Average MSGP4 and RCGP rates (from the multivariate regression, reported in section
3.4.2 of this thesis, 26% and 23% of, respectively, CAP and AOM consultations are considered to be
due to S.pneumoniae). Rates are applied to ONS England and Wales 2000 population estimates.
3.5 Discussion
The aims of this chapter were to explore and compare the available data sources for
pneumococcal disease, to describe the epidemiology of S.pneumoniae infection and to
investigate whether any change occurred in the last few years in the incidence of invasive and
non-invasive disease. From the public health perspective, this information is necessary in
order to monitor the short and long term impacts of pneumococcal vaccination strategies
(discussed in section 2.4) and to provide economic evaluations analyses for the proposed
vaccination schedules.
A number of surveillance systems are in place for England and Wales and contribute to the
understanding of the burden of pneumococcal disease. However, whereas IPD cases are
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generally diagnosed through laboratory-based methods, the aetiological responsibility of less
severe pneumococcal-related clinical conditions, such as CAP and OM, is generally left
unspecified. This generates a gap in the knowledge about the real burden of pneumococcal
disease and, in particular, on its contribution to all those clinical diagnoses that mayor may
not be due to pneumococcal infection. A number of studies have attempted to estimate the
real burden of pneumococcal disease, either increasing the number of reported cases applying
the sensitivity of alternative laboratory diagnostic methods (i.e. PCR, latex agglutination) to
unspecified clinical conditions (McIntosh & Booy, 2002), or reviewing hospital admissions to
estimate the proportion likely to be attributable to S.pneumoniae infection (Djuretic et al.,
1998). Moreover, capture-recapture analysis has been utilised to improve estimates of disease
incidence and deaths from pneumococcal meningitis among adults in England (Gjini et al.,
2004). The authors estimated a sensitivity of 40% (95% CI 37% to 44%) of the CDSCIRSIL
enhanced surveillance system and 46% for HES (95% CI 42% to 50%). These estimates will
be used in Chapter 9, where the cost-effectiveness of the conjugate vaccination programme
will be evaluated taking into account possible underestimates of the burden of disease from
the national surveillance systems.
In this chapter, we tried to quantify the amount of pneumococcal disease, invasive and non-
invasive, that is present in England and Wales, using both national surveillance databases and
multivariate regression techniques (thanks to the clear seasonality of pneumococci) to
estimate the proportion of GP consultations for both pneumonia and OM that is attributable to
S.pneumoniae infection. The strength of this modelling technique has been shown in the past
when similar questions were addressed for rotavirus (Ryan et al., 1996) and hospital
admissions for RSV (Muller-Pebody et al., 2002).
As shown in previous studies (Smith et al., 1998;Miller et al., 2000;Sleeman et al.,
2001;Kyaw et al., 2002) the estimated burden of pneumococcal disease in England and Wales
is considerable, with incidence rates of both IPD and non-IPD peaking in children «5 years)
and in the elderly (75+ years). Morbidity appears to be related to the presence of high-risk
conditions, with over 80% of hospitalised patients presenting with more than one diagnosis.
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In particular, neoplasm and diseases of the respiratory and circulatory systems are common
co-morbidity conditions.
The potential threat of serotype replacement occurring as a consequence of vaccination
requires the monitoring of the changes in the serotype distribution of pneumococcal disease
patients and, ideally, asymptomatic carriers. Though some changes were observed in the
serotypes causing IPO in England and Wales over the S-year period 1996-2000, no new
serotypes emerged. However, a significant reduction was observed for some of the types (i.e.
1, 4) as well as a significant increase for others (i.e. 6, 23, 8). Moreover, age specific
differences in the prevalence of pneumococcal types have been shown with some types
causing IPO more frequently in children than in adults (i.e, 14, 19,6).
IPO patients were found to be less susceptible to antibiotic (penicillin and erythromycin) in
more recent years than in 1996. Penicillin non-susceptibility levels increased similarly over
the S-year period in all age groups. Children less than five years of age were found to be
erythromycin resistant in much higher percentages compared to older age groups.
Morbidity and mortality data presented in this Chapter will be used in Chapters 5 and 9 of this
work, where economic evaluations will be performed. Moreover, in Chapter 6, the dynamics
of pneumococcal carriage and transmission will be investigated and comparisons will be
produced between serotypes asymptomatically carried and those causing severe disease.
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CHAPTER 4 - THE EFFECTIVENESS OF THE 23-
VALENT PNEUMOCOCCAL POLYSACCHARIDE
VACCINE
4.1 Aims
• To determine the level of protection that the pneumococcal polysaccharide vaccine (PPV)
confers to high and low risk elderly in order to then inform the cost-effectiveness analysis
of Chapter 5. This will be achieved by the following:
o Systematic literature review of published randomised and quasi-randomised
controlled trials (RCT and QRCT) looking at vaccine efficacy (VE) ofPPV;
o Meta-analysis to estimate overall pooled efficacy level among individuals at high
and low-risk of pneumococcal infection;
• To compare the pooled estimates to results of other published meta-analyses and case-
control studies (CCS).
4.2 Introduction
The current and the following chapter are intended to investigate, respectively, the
effectiveness of the currently available 23-valent PPV, and to determine the economic
acceptability of alternative vaccination programmes with PPV in England and Wales. The
work presented in these two chapters was used to inform the UK Joint Committee on
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Vaccination and Immunisation (JCVI) (which advices the Departments of Health on National
Vaccine Policy) on the effectiveness and cost-effectiveness of the current (at the time, May
2002) and alternative programmes. The content of these two chapters has been published
(Melegaro & Edmunds, 2004a;Melegaro & Edmunds, 2004b).
At the time of the analysis the 23-valent PPV was recommended only to individuals older
than 2 years of age with a high risk of pneumococcal infection (section 2.4.1) (Salisbury &
Begg, 1996). However, discussions were ongoing on the degree of protection afforded by
PPV in these categories and, in addition, questions on whether it would have been appropriate
to extend the vaccination programme to the healthy elderly (i.e, without high-risk conditions)
were also under consideration by the JCVI. This subgroup of the population has always
experienced high incidence rate of pneumococcal disease (Laurichesse et al., 1998;Smith et
al., 1998;Sleeman et al., 2001;Kyaw et al., 2002) and had recently been recommended to
receive the influenza vaccine (www.dh.gov.uk.lastaccessedSeptember2004).This provided
an opportunity for the introduction of the 23-valent-pneumococcal vaccines for all the elderly
since both vaccines may be given at the same time (Fedson, 1998;Ament et aI., 2000).
However, the level of protection afforded by PPV in the general elderly population and
among specific at-risk categories has been highly debated (Jefferson & Demicheli,
2002; French, 2003). Several randomised (or quasi-randomised) clinical trials, case-control
and indirect cohort studies investigated the vaccine efficacy (VE) against pneumococcal
pneumonia and/or IPD, but none of the clinical trials had sufficient power to detect a
significant effect of the vaccine. Meta-analyses were thus applied to obtain an overall pooled
estimate of VE but none of these focused exclusively on elderly patients and, in particular,
none differentiated between the general elderly and elderly at a higher risk of infection. The
level of protection of the vaccine in these groups represented a crucial aspect in the debate on
whether or not to extend the vaccination programme to all the elderly.
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4.3 Methods
4.3.1 Inclusion criteria
A PubMed literature search (without any year or language restriction) was used to identify
published studies on PPV efficacy. The following keywords were used to identify relevant
articles: "pneumococc*", "vaccination", "pneumococcal vaccine", "immunisation" and
"clinical trial". Papers that included words such as "children", "infants", "conjugate",
"carriage" and "otitis media" in the title, were excluded from the list of selected papers.
Previous meta-analysis and reviews were also extracted and checks were made in order to
have a complete list of studies. References of the retrieved papers were also examined. The
inclusion criteria that were adopted to select the papers to be part of the analysis were:
1. All randomised and quasi-randomised controlled trials with a well-defined
randomisation or quasi-randomisation process and with a PPV and a control group
(placebo or a control vaccine). A trial is defined quasi-randomised when the method
of allocating participants to different forms of care is not truly random (i.e. allocation
by date of birth, day of the week, medical record number, month of the year, or the
order in which participants are included in the study);
2. Studies which targeted immunocompetent and immunocompromised individuals (50+
years of age);
3. Studies that assessed at least one of the following endpoints: pneumococcal
pneumonia and/or invasive pneumococcal disease.
The definition of pneumococcal pneumonia that was used consisted of a clinically and
radiographically confirmed diagnosis of pneumonia, with Sipneumoniae cultured from
sputum or a nasal swab. Diagnoses made on the basis of a twofold rise in pneumolysin
antibody level in paired serum samples were also accepted, due to the high sensitivity (97.8%)
and specificity (83.4%) that was shown by Leinonen and colleagues (1990) for these tests,
using standard procedures (i.e. blood or culture of sputum) as reference methods (see section
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2.2.4 for discussion on sensitivity of different laboratory tests). Similarly, the technique of
pneumococcal antigen detection by electrophoresis of urine specimen was also accepted as a
diagnostic method. Invasive pneumococcal disease patients were defined as bacteraemic cases
with Sqmeumoniae isolated from blood or any other usually sterile body fluid (e.g. peritoneal,
pleural, cerebrospinal, or joint). Although the two endpoints were not consistently assessed
throughout the studies (with some studies that included bacteraemic cases within the
pneumococcal pneumonia group and some others that considered the two groups
distinctively) the following analysis considers them separately. However, estimates of vaccine
efficacy for pneumococcal disease (invasive and non invasive) are given in the sensitivity
analysis where the number of cases of pneumococcal pneumonia and IPD are summed up for
each trial and a unique level of protection is produced.
4.3.2 Information collected from the eligible trials
WJ Edmunds (HPA, CDSC, Modelling and Economics Unit) and myself independently read
the selected papers and extracted information on study design (type of interventions, number
of serotypes included in the vaccine (valency), follow-up time) and on the participants
(demographic characteristics and background health conditions) of each trial. Similarly, the
number of pneumococcal pneumonia and bacteraemic cases was assessed for each study and
compared to that published in previous meta-analyses.
The Jadad's system (Jadad, 1996) was used to score each report according to whether or not
randomisation, blinding and description of withdrawals were part of the study. One point was
given for each of these, and one additional point was added or subtracted when either methods
of randomisation or blinding were, respectively, well described by the authors or inadequately
performed. The maximum possible score was five. When discrepancies in the quality
evaluation existed, we met and discussed to resolve them. All the studies that were not
reporting clear information about the age of the participants, about the randomisation process
or the diagnostic procedures that were used were excluded from the analysis.
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Information about the health conditions of all the study populations was collected and the
proportion of high-risk individuals in each trial was assessed (where high-risk was defined as
those categories to which the vaccine was recommended in the UK (Salisbury & Begg,
1996». As most of the studies included in their analysis at least a proportion of
institutionalised patients or elderly with some chronic condition, we decided to consider as
'high-risk' those study populations that had at least 50% of the individuals with some chronic
condition or immunodeficiency. When the proportion was below this threshold, then the trial
was considered to be a study of the general elderly population. This criterion was widened in
the sensitivity analysis so that all the trials in which more than 20% of the study population
were at high-risk were included when calculating vaccine efficacy in high-risk groups.
4.3.3 Statistical Methods
Several statistical techniques are available to estimate summaries of the effect size (i.e. OR) in
different trials. One of the most crucial differences among them is whether or not they
incorporate between-study variation (heterogeneity) and, consequently, whether the model
used is a fixed or a random effect model. This latter type of model, which is appropriate when
significant heterogeneity is present between studies, produces a more conservative estimate
(i.e, wider confidence intervals) of the pooled effect size.
Here we assumed that the trials considered were a random sample from a hypothetical
population of studies, and thus the DerSimonian & Laird (DerSimonian & Laird, 1986)
random effect model Odds Ratio (OR) was adopted in the base-case. This computes a
weighted average of individual studies' OR, taking into account both sampling variation and
between study heterogeneity.
All analyses were performed using Stata 6.0 and the results are presented using funnel plots
with single and overall OR and related 95%CIs. The results obtained were compared with
previous meta-analyses. The definition of vaccine efficacy used was VE=(l-OR)*lOO(%)
(Orenstein et al., 1988;Giesecke, 1994), with confidence intervals of the pooled estimate
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obtained, similarly, as a function of those derived for overall OR. Odds ratios are good
approximation of relative risks when outcomes are comparatively rare, as in the studies
included in this analysis, and have desirable properties when combining results across studies
(Oxman et al., 1994). Conventional levels of statistical significance (i.e. 5%) were used
throughout the analysis.
4.3.4 Sensitivity analysis
Sensitivity analyses were performed to assess whether different model assumptions would
have changed the results. The Mantel-Haenszel fixed effect method was adopted under the
assumption that the differences among the results of the studies were due to chance alone.
Further sensitivity tests were performed by modifying the inclusion criteria in the analysis and
considering only randomised controlled trials.
Moreover, case-control and indirect cohort studies were also included in the sensitivity
analysis to assess whether their results are consistent with findings from randomised
controlled trials. We evaluated the effects their inclusion had on the overall pooled estimates
for VE against IPD in high and low risk elderly, and compared this to the results produced
using randomised and quasi-randomised trials.
4.4 Results
4.4.1 Literature review
Of all the studies retrieved from the literature search, six randomised and three quasi-
randomised clinical trials were selected that satisfied the inclusion criteria (Table 4.1),
although three of them (Kaufinan, 1947;Gaillat et al., 1985;Honkanen et al., 1999) were
methodologically weak according to the Jadad scores assigned by the two reviewers. Of the
nine studies, five were European studies (Gaillat et al., 1985;Klastersky et al., 1986;Koivula
et al., 1997;Ortqvist et al., 1998;Honkanen et al., 1999), three American (Kaufinan,
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1947;Simberkoff et al., 1986;Davis et aI., 1987), and one Canadian (Leech et al., 1987). The
study by Kaufman and colleagues (1947), although it is one of the largest trials, and has the
largest mean effect (both for pneumonia and IPD) (Table 4.1), was not included in our base
case pooled estimates due to the methodological weaknesses that were present in the design
and implementation of the study. It was an open trial, performed over a period of six years
during which the participants were recruited using different randomisation procedures.
Indeed, the first cohort recruited into the trial was not randomised and patients volunteered for
the injection. Furthermore, it used 2 and 3-valent vaccines, and 21% of the participants were
under 60 years of age. Three studies that were included in previous meta-analyses were
excluded from ours due to the presence of healthy young adults in their study population
(Austrian et al., 1976;Smit et al., 1977;Riley et al., 1977) (Table 4.2). The mean age of the
study population was available for all the trials used in our analysis (range: 61-74 yrs.), as
well as the proportion of chronically ill elderly (range: 27%-100%). Four studies that were
undertaken among elderly with respectively, chronic obstructive pulmonary disease (COPD),
bronchogenic carcinoma, or various chronic conditions, as defined in the recommendations,
were defined as studies of high-risk groups (HRG) (Klastersky et al., 1986;Simberkoff et al.,
1986;Davis et al., 1987;Leech et al., 1987). In addition, a Swedish study (Ortqvist et al.,
1998) was included in the HRG on the basis of the history of community-acquired pneumonia
that the study participants had experienced, and due to the high proportion of HR individuals
(58%) that were present in the trial. Three studies were undertaken among elderly patients not
experiencing, in high percentages, specific chronic conditions (GaiJlat et al., 1985;Koivula et
al., 1997;Honkanen et al., 1999). Their study participants were considered representative of
the general elderly population, although they all reported a proportion of high-risk individuals
in the range of 27-34% (Table 4.1). In the sensitivity analysis the high-risk threshold was
reduced to 20% and these studies were included in the HRG.
In accordance with previous meta-analyses (Hutchinson et al., 1999;Moore et al., 2000;Cornu
et al., 2001), the study by Davis and colleagues (1987) was excluded from the analysis for our
base case estimate of VE against IPD. Although, in fact, a case of pneumococcal bacteraemia
was reported among the participants, this occurred during a terminal episode of pneumonia in
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a severely ill patient who had been hospitalised on a long-term basis for respiratory
insufficiency, repeated urinary tract infections, cardiac failure and acute pancreatitis. The
effect of this case on the estimate of VE against IPD in HRG was explored in the sensitivity
analysis.
4.4.2 Statistical analysis
The individual trials and summarised OR [95% CI] are shown in Figures 4.1-4.2, for the two
study outcomes, according to the different level of risk of the study participants. The overall
results obtained when RCT and case-control studies were considered together are presented in
the sensitivity analysis and shown in Figure 4.3.
4.4.2.1 Vaccine efficacy against pneumococcal pneumonia
A low level of protection of the polysaccharide vaccine against pneumococcal pneumonia
among elderly individuals has already been shown (Simberkoff et al., 1986;Koivula et al.,
1997;Ortqvist et al., 1998;Honkanen et aI., 1999). Among the randomised controlled trials
included in the analysis, seven studies had pneumococcal pneumonia diagnosed with one of
the methods outlined in the inclusion criteria. All of them showed a negative or non-
significant effect against pneumococcal pneumonia in the elderly, with VE ranging from
-28% [-153% to 35%] (Simberkoff et al., 1986) to 76% [-150% to 98%] (Klastersky et al.,
1986).
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Overall pooled estimates of the odds ratio were produced in order to assess the significance of
previous findings and, most importantly, to determine the level of protection by risk group. A
non-significant and very low level of protection of the vaccine was found; VE 16% [-50% to
53%] using a random effects model including the three trials (Gaillat et al., 1985;Koivula et
al., 1997;Honkanen et al., 1999) representative of the general elderly population (Figure
4.1a). Bacteraemic cases were excluded from the calculation. The estimated mean protective
effect of vaccination was actually negative (though not significant) when considering the
studies that were performed among high-risk elderly (Klastersky et al., 1986;Simberkoff et
al., 1986;Davis et al., 1987;Ortqvist et al., 1998), VE=-20% [-92% to 25%] (Figure 4.1b).
Comparing to previous meta-analyses (Table 4.2), a level of protection of 60% [44% to 71%]
and 2% [-89% to 49%] in, respectively, low and high risk adults was shown by Fine and
colleagues (1994). Their estimates of VE, which are higher than those reported here, were
influenced by the inclusion of trials that were performed among healthy young adults
(Austrian et al., 1976;Smit et al., 1977;Riley et al., 1977). Similarly, another two meta-
analyses (Hutchinson et al., 1999;Cornu et al., 2001) found a positive level of protection
against pneumonia, but these estimates might still be a consequence of the inclusion of studies
performed in healthier individuals. For HRG, Cornu and colleagues (2001) found a negative
and non-significant vaccine protection, in accordance with this analysis. Moore and
colleagues (2000) found a higher estimate of VE although the populations they allowed for in
their analysis were, exclusively, young healthy adults.
4.4.2.2 Vaccine efficacy against invasive pneumococcal disease
The level of protection against invasive pneumococcal disease was assessed in six out of the
eight studies that were considered in the analysis. Two trials studied the protective effect of
the vaccine against IPD in the general elderly population (Gaillat et al., 1985;Honkanen et al.,
1999). Both of them suggested that the vaccine was protective, though none of them obtained
a statistically significant result (Figure 4.2a). The pooled estimate showed an unsignificant
reduction in the incidence of pneumococcal bacteraemia, VE=65% [-49% to 92%].
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Four trials were performed among the elderly at a higher risk (Klastersky et al.,
1986;Simberkoff et al., 1986;Leech et al., 1987;Ortqvist et al., 1998). The results of these
were scattered around a zero effect and all had a lack of statistical power. The pooled estimate
of efficacy was weakly positive, VE=20% [-187% to 78%] (Figure 4.2b). A further two trials
(both quasi-randomised) were performed on elderly populations which had between 20% and
50% of high-risk individuals (Gaillat et al., 1985;Honkanen et al., 1999). The inclusion of
these two trials improved our mean estimate of vaccine efficacy in the high-risk elderly,
though this remained non-significant, VE=44% [-45% to 79%].
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Figure 4.1- Published odds ratios and associated 95%CI for pneumococcal pneumonia.
Study Odds ratio
(95% CI)
[Figure 4.la - General elderly]
Gaillat,QRCT (1985) 0.26 (0.07,0.98)
Koivula,RCT (1997) 0.85 (0.50,1.43)
Honkanen,QRCT (1999) 1.20 (0.80,1.82)
Overall (95% CI) 0.84 (0.47,1.50)
Odds ratio
[Fig. 4.1b - High risk elderly]
Klastersky,RCT (1986)
Odds ratio
(95% CI)
----1-- ----- 3.24 (0.l3,81.47)
Study
Davis,RCT (1987)
0.24 (0.02,2.50)
Simberkoff,RCT (1986) 1.28 (0.65,2.53)
Ortqvist,RCT (1998) 1.25 (0.63,2.47)
Overall (95% CI) 1.20 (0.75,1.92)
Odds ratio 1
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Figure 4.2- Published odds ratios and associated 95%CI for invasive pneumococcal disease.
[Fig. 4.2a - General elderly]
Odds ratio
(95% CI)Study
Gaillat,QRCT (1985)
0.35 (0.08,1.49)
---+---- 0.27 (0.01,6.54)
Honkanen,QRCT (1999) 0.37 (0.07,1.91)
Overall (95% CI)
Odds ratio
[Figure 4.2b - High-risk elderly]
Study
Leech,RCT (1987)
Klastersky,RCT (1986)
Simberkoff,RCT (1986)
Ortqvist,RCT (1998)
Overall (95% CI)
Odds ratio
Odds ratio
(95% CI)
3.20 (0.13,79.47)
0.80 (0.05,13.60)
2.01 (0.18,22.20)
0.21 (0.02,1.77)
0.80 (0.22,2.88)
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The level of protection against IPD among the general elderly population (65%) was similar
to that reported in previous meta-analyses (Hutchinson et al., 1999;Moore et aI., 2000;Cornu
et aI., 2001) , i.e. previous estimates ranged between 66% [52% to 76%] and 82% [66% to
91%] (Table 4.2). Previous meta-analyses of VE in high-risk groups also appeared to
confirm the findings presented here, i.e. estimates of vaccine efficacy are low and non-
significant (Fine et aI., 1994;Moore et al., 2000;Cornu et aI., 2001). Fine and colleagues
(1994) failed to demonstrate a protective effect against IPD in high-risk elderly, VE=-23% [-
449% to 72%], whereas Moore and colleagues (2000) showed a slightly higher, although
non-significant, level of protection against IPD, 47% [-94% to 86%]. The latter included in
their analysis three fully randomised clinical trials performed among the elderly with
underlying chronic conditions or with a history of community-acquired pneumonia but did
not consider the randomised clinical trial that was performed among US veterans in 1987
and that did not demonstrate any efficacy, VE=-28% [-153% to 35%]. Cornu and colleagues
(2001) found similar estimates of vaccine efficacy to Moore and colleagues (2000) when
considering a subgroup of patients over 55 years old, VE=42% [0% to 82%].
4.4.3 Sensitivity analysis
A sensitivity analysis on the level of protection of the PPV was performed using, initially, a
less conservative type of model and then different inclusion criteria with regards to the
randomisation process and the study design. Estimates of vaccine efficacy against
pneumococcal diseases, which consisted of both pneumococcal pneumonia and IPD cases, in
high and low risk elderly were also derived.
For the effect sizes that were produced here, there was no evidence of significant between-
study variation, and the two methods produced almost overlapping results (Table 4.3). If
only randomised controlled trials were considered, the power to detect an effect was
significantly reduced as the largest trial used a quasi-randomisation technique (Honkanen et
al., 1999). For the general elderly this left only one and zero trials respectively for
pneumococcal pneumonia and IPD. For mixed elderly populations, the removal of the
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QRCT had little impact on estimates of vaccine efficacy, though it further reduced the
precision of the results (Table 4.3).
Table 4.3 - Sensitivity analysis of the results
OR, random
No. of effects model OR, fixed effects Chi-square
studies 195% CIs] model 195% CIs) !d.f'~i P-value
All RCT & QRCT
Pneumococcal pneumonia
- Low risk group (LRG) 3 0.84 [0.47-1.50] 0.96 [0.70-1.30] 5.11(2); 0.078
- Mixed risk group (MRG) 6 1.04 [0.68-1.59] 1.09 [0.81-1.46] 7.12(5); 0.212
- High risk group (HRG) 4 1.20 [0.75-1.92] 1.19 [0.75-1.89] 2.22(3); 0.527
Invasive pneumococcal disease
- Low risk group (LRG) 2 0.35 [0.08-1.49] 0.34 [0.08-1.48] 0.03(1); 0.857
- Mixed risk group (MRG) 6 0.56 [0.21-1.45] 0.54 [0.23-1.30] 3.57(5); 0.613
- High risk group (HRG) 4 0.80 [0.22-2.88] 0.73 [0.24-2.20] 2.84(3); 0.418
OnlyRCT
Pneumococcal pneumonia
- Low risk group (LRG) 1 0.85 [0.50-1.43] 0.85 [0.50-1.43]
- Mixed risk group (MRG) 4 1.20 [0.75-1.92] 1.19 [0.75-1.89] 2.22(3); 0.527
Invasive pneumococcal disease
- Low risk group (LRG) 0 n.a. n.a.
- Mixed risk group (MRG) 4 0.80 [0.22-2.88] 0.73 [0.24-2.20] 2.84(3); 0.418
Inclusion of Kaufman study (1947)
Pneumococcal pneumonia (LRG) 4 0.58 [0.27-1.26] 0.60 [0.48-0.76] 24.63(3); <0.01
Invasive pneumococcal disease (LRG) 3 0.23 [0.12-0.46] 0.23 [0.12-0.46] 0.39(2); 0.825
Inclusion of Davis study (1987)
Invasive pneumococcal disease (HRG) 5 0.97 [0.29-3.18] 0.88 [0.32-2.43] 3.47(4); 0.483
Inclusion of CCS
Invasive pneumococcal disease (LRG) 7 0.53 [0.40-0.70] 0.55 [0.45-0.67] 6.57(6); 0.363
Invasive pneumococcal disease (HRG) 6 0.48 [0.29-0.80] 0.50 [0.39-0.65] 5.61(5); 0.346
Two endpoints together
- Low risk group (LRG) 3 0.79 [0.45-1.42] 0.91 [0.67-1.23] 5.19(2); 0.074
- Hi~h risk ~rouE 1HRG~ 5 1.10 [0.72-1.70J 1.11 [0.72-1.70J 2.78!4l; 0.595
RCT=randomised controlled trials; QRCT=quasi-randomised controlled trials; df=degree of
freedom; n.a. = not available; CCS = case-control studies
Although the study by Kaufman and colleagues (1947) appeared methodologically weak, its
effect on the pooled estimates was assessed. Including this study in our analysis results in an
estimated vaccine efficacy of 42% [-26% to 73%] against pneumococcal pneumonia (i.e
higher but still not significant) and 77% [54% to 88%] for IPD (i.e, slightly higher with
significant 95%Cls). Moreover, the single bacteraemic terminally ill patient reported by
Davis and colleagues, was also included in the overall calculation of VE against IPD in
HRG, and the final estimate dropped to a very low level with extremely wide confidence
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intervals 3% [-218% to 71%]. Similarly, the level of protection of the vaccine fell
considerably when the two final endpoints were analysed together, VE= 21% [-42% to 55%]
in healthy elderly and a VE=-l 0% [-70% to 28%] in high-risk elderly.
Vaccine efficacy estimates from case-control and indirect cohort studies (Shapiro &
Clemens, 1984;Bolan G et al., 1986;Forrester et al., 1987;Sims et al., 1988;Shapiro et al.,
1991;ButIer et al., 1993;Farr et al., 1995), also including elderly, have generally ranged
around 50-80% for invasive pneumococcal disease (Table 4.4). Only one study showed no
effect when looking at healthy or high-risk adults (30+), and elderly patients (55+) (Forrester
et al., 1987). When looking at the impact that all case-control studies had on our estimate of
VE against invasive pneumococcal disease, a decrease on the level of protection of PPV is
observed in the low risk elderly, VE=47% [30% to 60%], whereas a significant and higher
estimate of VE is produced in the high-risk group VE=52% [20% to 71%]. Indeed,
examining the funnel plots (Figure 4.3), it seems that there may be evidence of bias in
studies of high-risk elderly, as the case-control studies tend to give higher estimates of
vaccine efficacy (lower Odds Ratios) than the randomised controlled trials.
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Figure 4.3 - Published odds ratios (RCT, QRCT, CCT) and associated 95%CI for invasive
pneumococcal disease.
[Fig. 4.3a - General elderly] Odds ratio
(95% CI)
Study
0.27 (0.01,6.54)
0.37 (0.07,1.91)
0.35 (0.12,1.05)
1.44 (0.44,4.70)
0.37 (0.15,0.93)
0.34 (0.17,0.69)
0.60 (0.47,0.75)
Gaillat, QRCT (1985)
Honkanen, QRCT (1999)
Shapiro 55+, CCS (1984)
Forrester 55+, CCS (1987)
Farr 65+, CCS (1995)
Sims 55+, CCS (1988)
Shapiro 18+, CCS (1991)
--.~:-
-at•
Overall (95% CI) 0.53 (0.40,0.70)
-~----~~------'---
Odds ratio
[Fig. 4.3b - High risk elderly]
Klastersky, RCT (1986)
Simberkoff, RCT (1986)
Leech, RCT (1987)
Ortqvist, RCT (1998)
Shapiro, CCS (1984)
Shapiro, CCS (1991)
Odds ratio
(95% CI)
Study
0.80 (0.05,13.60)
2.01 (0.18,22.20)
____+--+-_. 3.20 (0.13,79.47)
0.21 (0.02,1.77)
0.18 (0.05,0.68)
0.51 (0.39,0.67)
-~~-----.-+--+--
•
Overall (95% CI)
•
<> 0.48 (0.29,0.80)
Odds ratio
RCT=randomised controlled trial; QRCT=quasi-randomised controlled trial; CCS=case-control
studies
100
4.5 Discussion
The purpose of this chapter was to review the published estimates on VE of the
polysaccharide pneumococcal vaccine and to perform a meta-analysis in order to predict the
level of protection among the general elderly population and elderly at a higher risk of
infection because of the presence of other diseases. These two groups of individuals were at
the centre of the debate on whether to extend the vaccination programme to include healthy
elderly, as has been done in the UK for the influenza vaccine. Randomised and quasi-
randomised clinical trials were taken into consideration and previous meta-analyses were
presented and discussed in order to understand the different results. Due to the small sample
size of most of the trials, very wide confidence intervals were estimated for individual studies
as well as for the overall pooled estimate.
The results of the meta-analysis, when taken with the findings of other meta-analyses and
observational studies, showed that PPV offers a reasonable degree of protection in the general
elderly population against invasive disease and a moderate effect in the high-risk elderly. The
vaccine appeared to have little or no effect against pneumonia.
In the process of selecting the studies and extracting the data, a number of difficulties have
arisen, first of which is related to the small number of methodologically strong (Jadad
score>3) studies that satisfied the inclusion criteria and, secondly, their lack of power in
detecting any effect of the vaccine. For these reasons, and also because of the wish to obtain
comparable results to previous meta-analyses, it was decided to include all the studies that
satisfied the inclusion criteria, whatever their Jadad score was, and to use meta-analysis so
that the final estimate of vaccine efficacy would have more power. Furthermore, as diagnostic
methods were not consistent throughout the papers, as well as the separate counting of the
number of pneumococcal pneumonia and IPD cases, it was crucial that the two reviewers
extrapolated the data separately and then cross-checked them with previous studies and
reviews. The different inclusion criteria adopted for each study population and the variable
definition of high-risk patients, represent another limitation of the analysis. We tried to take
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this into account by selecting those studies that were most similar in term of place (all studies
are in developed countries), age of the participants and their risk conditions.
Further studies would clearly help clarify whether the vaccine has any effect in these risk
groups, and/or on non-invasive pneumonia. It is debateable, however, whether the additional
expense of performing these studies would be cost-effective, particularly as the conjugate
vaccine may be effective even in immunocompromised patients. A lack of efficacy against
pneumonia does not necessarily preclude the use of the vaccine in the general elderly
population. Recent economic evaluations have suggested that the vaccine may be cost-
effective in these groups even though its efficacy is limited to invasive disease (Sisk et al.,
1997;Ament et al., 2000). The following chapter (Chapter 5) will aim to evaluate the
economic acceptability of the alternative vaccination programmes with PPV in the UK. This
will be informed by the overall estimates of vaccine efficacy that have been derived in this
chapter, and the estimates of the burden of disease gained in Chapter 3.
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CHAPTER 5 - COST -EFFECTIVENESS ANALYSIS OF
THE PNEUMOCOCCAL POLYSACCHARIDE VACCINE
AGAINST INVASIVE PNEUMOCOCCAL DISEASE
AMONG THE ELDERLY IN ENGLAND WALES
5.1 Aims
• To determine the costs associated with treatment of pneumococcal disease in the elderly;
• To develop a cohort model to estimate the reduction in the burden of disease attributable
to the PPV vaccination programme;
• To investigate whether extending the vaccination strategy to include the healthy elderly
would be a cost-effective policy from the health payer perspective.
5.2 Introduction
The resources available to the health care system are limited and so choices must be made
concerning how to best allocate them among possible alternatives. Economic evaluation is a
tool that can be used by decision makers to help allocate scarce resources. New medical
interventions must be shown to be safe and effective (Black et al., 2000) to justify their
introduction. Increasingly, they also have to be shown cost-effective (Salisbury et al., 2002).
In particular, the introduction and the implementation of a new vaccination programme is
usually a long process, that requires a pre-licensing evaluation of the vaccine (Phase I-III), the
definition of a vaccination programme - aims, strategy and coverage targets - as well as a post
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licensing evaluation phase which should monitor the short and long term effects of the
vaccine in the population (Begg & Miller, 1990). In addition, economic analysis and
mathematical modelling should be carried out to deal with both direct and indirect costs and
consequences of activities and, thus, to ensure optimal vaccine delivery (Drummond et al.,
1997;Salisbury et al., 2002).
As discussed in Chapters 2 (section 2.4.1) and 4, PPV has been available for a number of
years and, at the time of this analysis, was recommended to individuals at higher risk of
pneumococcal infection. Although a number of economic evaluations had been performed for
other European countries (Ament et al., 2000;Postma et al., 2001) as well as for the US
(Gable et al., 1990;Rose et al., 1993;Sisk et al., 1997;Nichol et al., 1999;Weaver et al.,
2001;Pepper & Owens, 2002) and generally found that pneumococcal vaccination of the
elderly population is relatively cost-effective and potentially cost-saving to the health care
sector and to society, no such analysis had been performed for England and Wales when
possible changes to the PPV programme were being discussed.
The aim of this chapter is thus to assess the costs and the health effects of vaccination with the
23-valent polysaccharide pneumococcal vaccines in England and Wales and to determine
whether the current (at the time of the analysis) UK recommendation is a cost-effective
programme from the public health perspective. As the vaccine does not confer protection
against pneumococcal carriage (Chapter 2), the indirect effects of the vaccination programme
are negligible and are not included in this analysis. The content of this chapter has been
published (Melegaro & Edmunds, 2004b).
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5.3 Background
5.3.1 Conducting an economic analysis
The establishment of the economic evaluation as one of the tools for decision-making in
healthcare has lead to the development of standardised procedures and guidelines which have
been published and that are now considered an essential requirement for sound and applicable
analysis (Drummond et al., 1997;Sculpher et al., 2001;Claxton et al., 2002;Spier, 2002). In
particular, in conducting an economic analysis, the following steps should be considered:
define the question, decide which type of analysis to use, establish the perspective (viewpoint)
that will be adopted and, finally, compare methods and results to other published works.
These aspects are described in detail below.
5.3.1.1 Defining the question
The definition of the question(s) to be addressed is clearly the first step. For example, which
alternatives are being compared? In this case, the general question was: 'What are the costs
and consequences of vaccinating the elderly at high risk of pneumococcal infection compared
to the alternative of treating cases as they arise?' and 'What if the at-risk group is extended to
include also healthy elderly?' .
5.3.1.2 Type of analysis
Three major economic techniques are available to perform economic evaluation, which differ
in the measurement of the consequences of a course of action. These techniques, well
described in Drummond (1997) and in a previous work by Torrance (1986) are: cost-
effectiveness analysis, cost-utility analysis, and cost-benefit analysis. Which one to choose,
generally depends on the question(s) that is asked. Cost-effectiveness analysis (CEA)
measures the outcomes of a programme in terms of natural units (cases or death averted, life-
years gained, etc.) and compares it to the cost of the intervention to determine the cost-
effectiveness ratio (cost per case averted, cost per life year gained). Cost-utility analysis
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(CVA) is a special form ofCEA in which the measure of the effect takes account of morbidity
as well as mortality. Such measures include the disability-adjusted life years (DALYs) or,
more commonly, quality-adjusted life years (QALYs) gained. The advantage of CVA over
CEA is that each year of life gained is weighted by its utility or health related quality of life
measure (on a scale 0-1), so that different conditions and interventions can be compared.
Cost-benefit analysis (CBA) determines the net societal benefit of the programme by placing
a monetary value on the outcome and subtracting the monetary costs from the monetary
benefits.
Cost-effectiveness analysis is the most widely used method and this may reflect the
difficulties and extra effort in assigning health related quality of life weights or monetary
values to health outcomes. The economic evaluation analysis of PPV described in this chapter
uses cost-effectiveness analysis for this reason, i.e. the lack of high quality data on the impact
of invasive pneumococcal disease on health related quality of life in the elderly and
individuals' willingness to pay to avoid it. In any case, due to the high CFR for IPD (see
chapter 3), most QALYs lost due to this condition will arise from the reduction in life
expectancy. Thus QALYs and life-years lost are likely to be similar.
5.3.1.3 Viewpoint
Possible viewpoints include that of the patient and family, the hospital, the health care sector,
and the global or societal viewpoint (Torrance, 1986). Although the latter include a much
wider range of indirect consequences and would be, in theory, the appropriate one for public
policy decision-making (Torrance, 1986), policy makers are generally more concerned with
the direct cost of an intervention to their department and, moreover, reliable estimates of the
societal costs may be difficult to obtain and time-consuming. Therefore, the analysis in this
chapter took the viewpoint of health care provider (NHS).
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5.3.1.4 Measuring costs and consequences
The collection or estimate of all the costs and outcomes related to the intervention requires the
use of a wide range of data sources and the assessment of the level of reliability for each of
these. The level of uncertainty of both costs and consequences is a crucial aspect to be
considered when performing an economic evaluation and sensitivity analysis should be
conducted to assess the effect of changes in the parameters and assumptions (Briggs & Gray,
1999;Briggs, 1999). Sensitivity analysis may be conducted using the following three
approaches: one-way sensitivity analysis, extreme scenario analysis, and probabilistic
sensitivity analysis (Figure 5.1). Univariate and multivariate sensitivity analysis were
performed here.
Moreover, the impact of an intervention is generally measured over a predefined time span,
and models are frequently used to assess the impact of the interventions on the burden of
disease. Two different types of model may be used when evaluating vaccination programmes:
cohort (or static) models and transmission dynamic models (Edmunds et al., 1999). Cohort
models assume that the risk of disease (which may be age-specific) in the unimmunised is
unchanged by the intervention. Changes in future disease incidence only result from direct
vaccine protection, which results from the assumed levels of vaccine coverage and efficacy.
However, some vaccination programmes may interfere with the transmission of the infection
in the population and, thus, have indirect effects among unimmunised individuals. These
would normally be expected to be beneficial to public health but can also be detrimental. A
shift in the age distribution of infection after vaccination may lead to an increase in disease
severity for some infections, or a replacement effect may occur with an increase in the
prevalence of non-vaccine types as a consequence of vaccination. These indirect effects of
vaccination can be estimated using a transmission dynamic model (Brisson et al., 2002).
Since PPV only protects against disease (i.e, no herd immunity effects are produced by
vaccination), the cost-effectiveness analysis presented in this chapter is based on a static
model.
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Figure 5.1 - Sensitivity analysis
Alternative forms of sensitivity analysis - Definitions
One-way sensitivity analysis systematically examines the impact of each variable in the study
by varying it across all plausible range of values while holding all other variables in the
analysis constant at their "best estimate" or baseline value.
Extreme scenario analysis involves setting each variable to simultaneously take the most
optimistic (pessimistic) value from the point of view of the intervention under evaluation in
order to generate a best (worst) case scenario.
Of course in real life the components of an evaluation do not vary in isolation nor are they
perfectly correlated, hence it is likely that one way sensitivity analysis will underestimate, and
extreme scenario analysis overestimate, the uncertainty associated with the results of economic
evaluation.
Probabilistic sensitivity analysis, which is based on a large number of Monte Carlo
simulations, examines the effect on the results of an evaluation when the underlying variables
are allowed to vary simultaneously across a plausible range according to predefined
distributions. These probabilistic analyses are likely to produce results that lie between the
ranges implied by one-way sensitivity analysis and extreme scenario analysis, and therefore
may produce a more realistic estimate of uncertainty.
Information abstracted from Briggs & Gray (J 999)
5.3.1.5 Comparison with other studies
It is important to compare the methods and results of studies that have asked the same or
similar question. A number of studies have been performed to assess the economic
acceptability of the PPY in the US and in various European countries (Table 5.1). Of these
studies, most concentrated on Pnc bacteraemia or IPD as an outcome of interest and showed
that the vaccination was a cost-effective policy from health care payer and societal
perspective. Assuming, (probably erroneously, Chapter 4), that PPY is as protective against
pneumococcal pneumonia as it is against IPD, Ament and colleagues (2000) suggested that
the programme would be cost saving from the societal perspective. Two studies (Patrick &
Woolley, 1981;Sisk et al., 2003) looked at high-risk groups in their analysis though
considered different outcomes (pneumococcal pneumonia and IPD) and different study
populations (18+ and 50-64 years of age ) to those being addressed here. Neither of them
considered the different levels of protection of the PPY in the high-risk group. The section
below provides details of the method used and on the measurement of specific parameters.
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5.4 Methods
5.4.1 Analytical approach
A cost-effectiveness analysis was performed to determine the economic acceptability of PPV
among the elderly at 65 years old. In particular, this analysis assessed the impact of
widespread vaccination among high-risk elderly (which was the UK policy at the time of the
analysis) as well as on the health benefits and costs that would derive from widening the PPV
recommendations to include healthy elderly individuals in the at-risk categories. In the base-
case the alternative programs were either one-off vaccination at 65 or treatment of invasive
pneumococcal disease as cases occur. The perspective adopted was the one of the health care
provider (NHS) hence the costs were limited to expenditures and savings within this sector,
leaving the costs to society and the wider economy out of the analysis. Health outcomes were
measured in terms of life-years gained (LYO) from vaccination. The Net Benefit of the
program was also calculated by multiplying these LYO by their shadow price (Drummond et
al., 1997) (which was varied in the analysis) and then subtracting from this the costs of the
program.
As discussed in section 5.3.1.4, the model did not take into account population dynamics as
herd immunity effects derived from vaccination of the elderly, with a vaccine that does not
appear to prevent carriage (Herva et aI., 1980), would be negligible.
Moreover, estimates of the optimum age to vaccinate were produced using incremental
analysis (Drummond et al., 1997), which calculates the incremental cost-effectiveness ratios
(additional costs that one programme imposes over another divided by the additional benefits,
i.e, life-years gained) for each successive alternative (one-off vaccination at different ages),
from the least costly to the most. With the same technique, we looked at the incremental costs
and benefits of introducing regular booster doses at specific intervals (5 and 10 years) and
assessed what is the optimum interval for revaccination.
110
5.4.1.1 Cohort model
Two hypothetical cohorts - vaccinated and unvaccinated - were followed throughout their
lives, and morbidity, mortality and discounted costs of eventual treatment were compared.
Due to the differences between elderly with or without underlying risk conditions (in terms of
incidence rate, responsiveness to the vaccine, duration of protection and background mortality
rate) (Fine et al., 1994;Rubins et al., 1999;French et al., 2000), the hypothetical cohorts were
each divided into two distinct sub-groups: high-risk group (HRG) and non high-risk group
(NHRG) (see below). Results for the overall general population were derived within the
model, weighting outcomes and costs with the prevalence of high-risk people in the
community.
Prevalence and life expectancy of HRG vs. NHRG. The Morbidity Statistics from General
Practices (MSGP4) survey (see Chapter 3, section 3.3.1.3 for details) provided the prevalence
and background life expectancy of the two risk groups. Patients in the survey were divided
according to whether or not they consulted for one of the high-risk codes that were included
in the PPV recommendation (Salisbury & Begg, 1996) (Table 5.2) and from this the
proportion of high-risk individuals was estimated. Background mortality rates were calculated
for the two groups and for the general elderly population from deaths recorded in MSGP4.
Checks were made to compare the background mortality rate obtained from this survey to
those derived from the 1991 Census.
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Table 5.2- ICD-I0 codes that were considered in the definition ofHRG among hospitalised
patients
Code description ICD-9Code ICD-IOCode
Asplenia or severe dysfunction of the spleen (inc!. 282.5-282.6,289.4-289.5,
sickle cell disease and coelic syndrome) 7590 D57; D73; Q89.0
Chronic renal disease or nephrotic syndrome 581,582,584,585
Immunodeficiency or immunosuppression due to
disease or treatment, including HIV infection at all
stages 0420-0449, 140-208,279
N04; N18
B20-B24; COO-C97;
D80-D89
Chronic heart disease 393-398,414,416 105-109; 125; 127
Chronic lung disease 490-496 141-147
Chronic liver disease including cirrhosis 571-573
Diabetes mellitus 250
K70; K73-K74
EIO-EI4
5.4.1.2 Costs and discounting
All future benefits and costs were discounted at a constant rate (3% per annum for both in the
base case as recommended in the US Panel on Cost-effectiveness (Weinstein et al., 1996).
Discount rates were varied in the sensitivity analysis to allow for the UK recommendation
levels (6% per annum for costs and 1.5% for health benefits (Department of Health, 1995)).
5.4.1.3 Sensitivity analysis
Due to the uncertainty that surrounds many of the key parameters included in the model,
univariate (one-way) and multivariate (probabilistic) sensitivity analyses were performed. For
the multivariate analysis, the model was run 1000 times and on each occasion a random set of
input parameter values were chosen by means of Latin Hypercube Sampling using the
software @Risk 4.0 (Palisade Corporation, New York). In this wayan outcome distribution
was produced that gave the proportion of simulations in which the programme is cost-
effective (Net Benefit>O) for different values of the maximum willingness to pay for a life-
year gained. Uniform, triangular and normal distributions were assumed for input
distributions (Table 5.4).
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5.4.2 Estimating model parameters
5.4.2.1 Disease incidence
Age-specific incidence rates of IPD obtained from the national laboratory enhanced
surveillance system (CDSCIRSIL) and from HES (any pneumococcal confirmed code) were
very similar, especially in the elderly (section 3.4.3.1). Since it was possible to determine the
risk status of patients from the latter database, where seven diagnostic fields are available to
record possible co-morbidities, this data-source was used (rather than CDSCIRSIL) to
generate base-case incidence estimates of IPD. Only HES data for the period 1995-1998 were
available at the time of the analysis.
Data were extracted and cleaned as explained in section 3.3.1.2 of this thesis and then records
were divided into two groups according to whether or not any of the high-risk lCD-to codes
presented in Table 5.2 were reported in any of the seven diagnostic fields. The presence of at
least one of these codes categorised the patient as being at high-risk (the remainder being
assumed to be non-high risk patients). Age-specific incidence rates were calculated using
HES data and population estimates for England published by the Office of National Statistics
for the same years and are shown in Table 5.3. The following age categories were considered:
65-69, 70-74, 75-79, 80-84, and 85+ years old. A uniform distribution for incidence was used
in the multivariate analysis; lower and upper bounds were set at, respectively, the minimum
and maximum values that were observed over the three years period in each age group (Table
5.4).
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Table 5.3 - Base case parameters values and sources
Age Groups
Parameters 65-69 70-74 75-79 80-84 85+ Data source
Health outcomes
Admission rate - HRGa 83 126 124 157 250 HES
Admission rate - NHRGa II 17 21 33 82 HES
LOS per admission - HRG (days) 16 15 16 18 18 HES
LOS per admission - NHRG (days) 13 15 16 18 14 HES
High CFR - HRG 16% 18% 21% 24% 28% HES
High CFR - NHRG 15% 18% 17% 24% 16% HES
LowCFR-HRG 9% 8% 13% 20% 17% HES
Low CFR - NHRG 9% 9% 11% 20% 10% HES
Direct cost"
Cost per GP consultation (£) 19 19 19 19 19 (Netten A & Curtis L, 2002)
Cost ofinitiaI treatment (£) 8 8 8 8 8 (British Medical Association, 2002)
Cost of inpatient day (£) 242 242 242 242 242 (Netten A & Curtis L, 2002)
Cost of intensive care (£) 1,103 1,103 1,103 1,103 1,103 (Department of HeaIth, 2002)
Vaccine parameters"
Cost of vaccine & delivery (£) 11.4 11.4 11.4 11.4 11.4 (British Medical Association, 2002)
Vaccine efficacy - HRG (%) 20 20 20 20 20 Chapter 4
Vaccine efficacy - NHRG (%) 65 65 65 6S 65 Chapter 4
Duration of protection - HRG (yrs) 5 5 5 S S
Duration of protection - NHRG (yrs) 6.5 6.5 6.5 6.5 6.5
Analysis
Prevalence ofHRG (%) 9.6 9.7 10.2 9.7 7.7 (McCormick A et al., 1995)
Admitted to lCU (%)h 5 5 5 5 5
Discount rate outcomes (%)h 3 3 3 3 3
Discount rate costs (%)h 3 3 3 3 3
Cover~e ~%t 60 60 60 60 60
"All rates are per 100,000 populations per year; bThese parameters are not age dependent
Average lengths of inpatient stay were derived also from HES for the specified age groups.
Although clear dissimilarities were not observed between high and low risk patients, specific
levels were assigned to the two groups. Minimum and maximum levels that were observed
during the analysed period (1995-1998) were used as lower and upper bounds in the
multivariate analysis.
We assumed that each case of IPD would visit the GP and receive antibiotic treatment before
hospitalisation. A proportion of the hospitalisations (5%) were admitted in the Intensive Care
Unit (ICU) of the hospital. This percentage was varied in the univariate analysis.
5.4.2.2 Case fatality ratio
Due to the difficulty in determining whether a patient who dies with IPD died ofIPD, age and
risk specific case-fatality ratios (CFR) for IPD were calculated in two ways. First, all deaths
among patients that were admitted to hospital who had a discharge diagnosis including any
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IPO codes were assumed to have died of IPO (Scenario 1). This gives an upper estimate, as in
many instances pneumococcal infection would not be the underlying cause of death as many
of these patients also have other codes recorded (Chapter 3). A low estimate is produced when
considering hospitalised patients that had only IPO codes recorded (Scenario 2). For these,
IPO was the only reported clinical condition and, thus, the number of deaths among them was
more likely the result of the pneumococcal infection they contracted. Risk-specific CFR were
produced dividing the number of deaths by the number of admissions and adjusting by the
proportion of deaths among high-risk individuals that was observed in Scenario 1. Lower and
upper bounds were estimated looking at, respectively, the minimum and maximum level
observed over the three years period for the two scenarios.
5.4.2.3 Vaccine parameters
Estimates of vaccine efficacy in high and non-high risk groups were derived as described in
Chapter 4. Overall levels of protection of 65% and 20% were used for, respectively, non-high
and high-risk group, although the confidence intervals were very wide. A range of 5-10 years
of protection was found in the literature (Shapiro et al., 1991;Ortqvist, 2001), although some
evidence of a lower vaccine-induced immunity was detected in certain high-risk groups
(Obaro et aI., 1996b;Rubins et aI., 1998). In our analysis, base case values of 6.5 and 5 years
for, respectively non-high and high-risk individuals were adopted. Probability distributions
were assigned to vaccine efficacy and duration of protection (Table 5.4). We assumed that
adverse events following immunisation would be negligible (Fedson et aI., 1999b), and were
therefore ignored.
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Table 5.4 - Input distribution for the multivariate analysis
NHRG HRG
Input name Distribution Minimum Maximum Minimum Maximum
Admission rate - 65-69 yrs" Uniform 9.2 13.6 52.1 99.4
Admission rate - 70-74 yrs' Uniform 14.2 19.4 78.6 153.6
Admission rate - 75-79 yrs' Uniform 16.4 26.6 73.9 160.1
Admission rate - 80-84 yrs' Uniform 25.9 40.0 86.3 209.0
Admission rate - 85+ yrs" Uniform 49.3 112.7 109.4 348.9
CFR - 65-69 yrs (Scenario 1) Uniform 13% 17% 15% 17%
CFR -70-74 yrs (Scenario 1) Uniform 14% 22% 15% 18%
CFR - 75-79 yrs (Scenario 1) Uniform 15% 19% 20% 23%
CFR - 80-84 yrs (Scenario 1) Uniform 22% 26% 17% 26%
CFR - 85+ yrs (Scenario 1) Uniform 13% 22% 25% 31%
CFR - 65-69 yrs (Scenario 2) Uniform 6% 11% 6% 12%
CFR - 70-74 yrs (Scenario 2) Uniform 3% 12% 3% 11%
CFR - 75-79 yrs (Scenario 2) Uniform 8% 12% 10% 15%
CFR - 80-84 yrs (Scenario 2) Uniform 19% 24% 19% 24%
CFR - 85+ yrs (Scenario 2) Uniform 8% 17% 14% 29%
LOS per admission - 65-69 yrs Uniform 13.0 13.4 14.5 16.7
LOS per admission - 70-74 yrs Uniform 13.6 15.4 14.1 14.8
LOS per admission - 75-79 yrs Uniform 15.9 16.1 15.1 16.3
LOS per admission - 80-84 yrs Uniform 17.7 18.3 17.0 18.7
LOS per admission - 85+ yrs Uniform 12.4 17.3 16.9 19.6
Vaccine efficacy" Normal -49% 92% -188% 78%
Duration oferotection !~rsl Trianiularc 4 9 3 7
"All rates are per 100,000 populations per year; 695% CIs are displayed; C symmetric triangular
distribution (mode 0/6.5 and 5 years in, respectively, NHRG and HRG)
5.4.2.4 Cost estimates
The costs included were the ones of the primary health care (OP consultation and first blind
treatment) and the hospitalisation costs. All costs are given in pounds sterling at year 2000
prices.
The unit cost of a typical OP consultation (£19) was taken from the Unit Costs of Health and
Social Care (Netten & Curtis, 2002). The average initial treatment cost per case was estimated
from the standard recommendations given in the British National Formulary (BNF) for
antibacterial therapy (British Medical Association, 2002). The Formulary recommends
erythromycin for the treatment of atypical pneumonia (7 days course, £9.26) whereas
erythromycin plus cefuroxime (7 days course, £18.71) is recommended for severe
community-acquired pneumonia of unknown aetiology. The initial blind therapy for a
possible meningitis or septicaemia case was assumed to be respectively a single dose of
benzylpenicillin (OP pack = £1.90), or aminoglycoside (£1.51) together with broad-spectrum
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penicillin (£2.01). The mean cost of the treatment becomes £8.35. In the univariate sensitivity
analysis initial blind treatment with ceftriaxone was also considered (£21.89, 2-g vial), which
gave a mean cost of the initial OP treatment of £16.62.
The unit cost per inpatient day was taken from the same standard source (Netten & Curtis,
2002), using the price of a generic ward (£ 242) that is the average cost of a variety of
specialties. The inpatient cost for the infectious disease and geriatric wards (£348 and £144)
were used in the sensitivity analysis as the upper and lower limit. All these costs take into
account the average nursing costs, cost of the bed, cost for investigations to ascertain a
diagnosis and treatment costs. The average cost of a bed per day in the ICU was taken from
NHS Reference Cost (£1,103) (Department of Health, 2002). Due to a lack of data, we
ignored long-term care for sequelae of IPD. Thus cost-estimates are likely to be somewhat
higher than is reported here, and our cost-effectiveness estimates will be conservative.
The cost of the vaccine (Pnu-Immune) was taken from the BNF (£9.94), whereas the delivery
cost was set at £1.5, similarly to that used by Ament and colleagues (2000) in their base case
analysis (3.00 ecu) (i.e. in the base case it was assumed that the vaccine would be given
opportunistically, possibly with influenza vaccine). The overall cost of the vaccine for the
base case was thus set at £11.44 and varied in the univariate sensitivity analysis. These unit
costs were applied to the estimated outcome predicted by the model.
5.5 Results
5.5.1 Life-expectancy
From MSGP4 data,different background life expectancies were estimated for low and high-
risk patients, with a probability of survival much lower in the latter case (Figure 5.2). Almost
10% of individuals over the age of 65 were found to have an underlying high-risk condition.
The age specific percentages that were used in the model are reported in Table 5.3.
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Figure 5.2 - Survival curves for elderly at different risk of infection.
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5.5.2 Burden of invasive pneumococcal disease
From the base case analysis, around 3,000 invasive pneumococcal infections were estimated
annually for England and Wales in 65+ years of age, and 34% have a discharge diagnosis
indicative of being at high risk. From the MSGP4 survey around 10% of the elderly are high-
risk, thus the incidence of IPD is roughly 3-4 times higher in HRG compared to NHRG. The
overall average length of inpatient stay was estimated to be 11 and 13 inpatient days for non-
and high-risk patients, respectively. Age specific figures are shown in Table 5.2. The
estimated number of deaths attributable to IPD in 65+ years of age goes from an annual
average of only around 50, if the low estimate of CFR is assumed (Scenario 2), to an annual
average of roughly 500 deaths per year if the higher CFR is used (Scenario 1).
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5.5.3 Cost-effectiveness results
5.5.3.1 Base Case Scenario
Vaccinating the HRG (Le. elderly at increased risk of disease due to underlying morbidity
conditions) was estimated to have a net discounted cost to the health service of £215,002 (cost
of vaccination was estimated to be £302,291 and the discounted medical care savings was
£87,289). Vaccinating all elderly individuals (65 years of age) was estimated to cost the
health service £2,485,65 (cost of vaccinating the cohort is estimated to be £3,163,165
resulting in discounted medical care savings of £677,510 over their lifetime).
Under Scenario 1 and holding all other parameters at their base case values, the past UK
recommendations, which consisted of vaccinating all HR elderly with PPV, gave a cost per
life year gained of £9,477. Vaccinating all 65 years old, with or without high-risk conditions,
is a dominating strategy (i.e, more effective and less costly) with a lower cost per life year
gained of (£8,504) under base case assumptions. Higher estimates of cost per life year gained
were reached when using the lower CFR (Scenario 2): £17,065 and £15,052 for, respectively,
HRG and all 65 years old.
The optimum age at vaccination was determined ranking the different options, from the least
costly to the most, and calculating the incremental expenditure and the additional life years
that were gained switching from one option to the following (Table 5.5).
Table 5.5 - Incremental cost-effectiveness ratios for one-off vaccination policies at different
ages.
Age at LowCFR HighCFR
vaccination NHRG HRG NHRG HRG
85 £3,362 £5,418 £2,077 £3,350
80 £5,140 £8,493 £7,110 £12,102
75 £27,911 £33,202 £11,633 £11,629
70 dominated dominated £13,168 £4,101
65 dominated dominated dominated dominated
Alternatives that give/ewer LYG with an increased expenditure are considered dominated options.
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Assuming a maximum willingness to pay for an extra LYG of approximately £30,000, then
the optimum age at vaccination, when higher values of CFR were considered, was 70 years
old for both NHRG and HRG. Seventy-five years appeared to be the best option under the
low CFR Scenario, although both incremental cost-effectiveness ratios were very close to
what could be considered the maximum willingness to pay for an extra LYG. In Table 5.6
incremental cost-effectiveness ratios are shown comparing one-off vaccination at specific
ages (65, 70, 75) to vaccination policies with booster doses every 10 years, and the latter with
the option of revaccinating at shorter intervals (5 years). Incremental cost-effectiveness ratios
below the level of £17,000 were estimated for both groups of elderly when revaccinating
every 10 years and under the high CFR option. This value increased to £26,000 when
considering the lower estimates of CFR. Much higher levels of incremental cost-effectiveness
ratios were produced when looking at a revaccination policy every 5 years (£23,000-£61,000).
Table 5.6 - Comparisons of different vaccination policies. Incremental cost-effectiveness
ratios.
NHRG HRG
AGeat vaccination: 65 ~ears 70 ~ears 75 ~ears 65 ~ears 70~ears 75 ~ears
Scenario 1 - High CFR
Vaccinationone off £8,422 £6,143 £5,239 £9,477 £7,088 £7,584
Revaccinationevery 10yrs £14,602 £11,787 £10,438 £16,746 £13,897 £10,344
Revaccinationevery 5 yrs £37,380 £35,328 £26,309 £29,085 £28,771 £23,680
Scenario 2 - Low CFR
Vaccinationone off £14,886 £11,048 £7,589 £17,065 £13,930 £11,564
Revaccinationevery 10yrs £21,811 £15,473 £16,892 £25,663 £17,216 £16,714
Revaccinationeve!l 5 ~rs £61,310 £57,120 £32,188 £55,332 £46,459 £28,196
5.5.3.2 Univariate sensitivity analysis
In Table 5.7 the results of a univariate sensitivity analysis are reported under the two different
scenarios. Apart from the CFR, the most influential parameter is the estimated incidence of
IPD. Basing incidence on the primary discharge diagnosis only resulted in vaccination being
unlikely to be deemed cost effective, regardless of mortality assumptions (£20,000-£54,000
per LYG). It is also apparent from Table 5.7 that if an extra GP consultation is necessary to
vaccinate the elderly (instead of vaccinating opportunistically, presumably with influenza
vaccine) then vaccination appears much less cost-effective (range £23,000-£52,000 per LYG).
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Slightly higher levels of cost per life-year gained (range £10,000-£22,700) were also reached
when the vaccine was assumed to prevent only the additional inpatient days caused by the
bacteraemic episode (the average length of stay is from 2 to 3 days longer when looking at
IPD compared to other non-invasive pneumococcal disease). Other important parameters
include the discount rate: adopting the UK Treasury recommended discount rates means that
vaccination becomes slightly more economically attractive than was shown in the base-case
analysis (range £8,000-£16,800 per LYG).
Table 5.7 - Univariate sensitivity analysis. Cost per life-year gained of vaccinating elderly (65
years of age) with PPV
Scenario 1 ~HiGhCFR2 Scenario 2 !Low CFR2
NHRG HRG ALL NHRG HRG ALL
Base case values £8,422 £9,477 £8,504 £14,886 £17,065 £15,052
Admission rate
Only first diagnosis admissions £19,616 £30,000 £20,277 £34,770 £53,999 £35,977
All diagnoses (SP codes + JI81) C.s. C.s. c.s. C.s. C.s. c.s.
Intensive Care Unit
Proportion to ICU = 20% £7,437 £7,744 £7,461 £13,144 £13,945 £13,205
Proportion to ICU = 40% £6,123 £5,434 £6,070 £10,822 £9,785 £10,743
Vaccine parameters
Only protective against invasive part £10,354 £12,604 £10,528 £18,300 £22,695 £18,635
Protection in HRG=3, NHRG=4 yrs £12,522 £13,420 £12,596 £22,444 £24,007 £22,572
Protection in HRG=7, NHRG=9 yrs £6,589 £7,725 £6,674 £11,504 £13,917 £11,679
Costs
Costs per course of vaccination
Only vaccine cost (£9.94) £7,031 £7,730 £7,085 £12,427 £13,919 £12,540
Vaccine cost + GP consultation £23,782 £28,764 £24,169 £42,034 £51,795 £42,779
Costs per inpatient day
Infectious disease ward (£348) £7,654 £8,126 £7,690 £13,528 £14,632 £13,612
Geriatric ward (£144) £9,132 £10,726 £9,256 £16,141 £19,313 £16,383
Cost per GP cons & treat
-25% of the base case £8,426 £9,483 £8,508 £14,892 £17,075 £15,059
+25% of the base case £8,418 £9,471 £8,500 £14,879 £17,054 £15,045
Average cost of GP treat =£16.62 £8,418 £9,470 £8,499 £14,878 £17,052 £15,044
Discount rate
Benefits 6%, costs 6% £14,786 £13,738 £14,690 £26,449 £24,658 £26,286
Benefits 0%, costs 3% £5,215 £6,976 £5,333 £9,143 £12,568 £9,368
Benefits 1.5%, costs 6% £8,264 £9,342 £8,347 £14,688 £16,808 £14,849
C.s. = cost saving
Figure 5.3 shows the sensitivity of the results to the different levels of protection of the
vaccine in high and low risk elderly. Taking a maximum willingness to pay for a life-year
gained of £30,000 (which has been suggested to be the National Institute for Clinical
Excellence's upper limit (Devlin & Parkin, 2003», for instance, then the model predicts that
121
provided vaccine efficacy is at least 10-15% then vaccination of the high risk would be cost-
effective and 25-40% for vaccination of the non-high risk elderly to be cost-effective
(holding other parameters at their base-case level).
Figure 5.3 - Cost per life-year gained by vaccine efficacy for high and low risk elderly.
£50,000
£40,000...,
(I)
.S
Cd £30,000OI)
t:a
(I)
>.
I £20,000c2
:.:::l
!U
0.. £10,000.....
00
0
U
£0
o 0
-£10,000
- NHRG(Low CFR)
-8- NHRG (High CFR)
- HRG(Low CFR)
~ HRG (High CFR)
20% 40% 60% 80% 100%
Vaccine efficacy
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5.5.3.3 Multivariate sensitivity analysis
The results of the sensitivity analysis, in which all parameters except the discount rate (fixed
at 3%) were varied probabilistically, are shown in Figure 5.4.
The figure shows the proportion of simulations that would be deemed cost-effective (positive
net benefit) for different upper limits of society's willingness to pay for an additional life-year
gained. Vaccination of high-risk groups leads to a relatively low proportion (no more than
about 60%) of simulations being cost-effective regardless of which CFR is assumed and
regardless of the society's willingness to pay for a life-year gained. This is because the
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programme has a relatively low probability of being effective. On the other hand, when
considering low-risk elderly, a higher proportion of simulations were cost-effective compared
to HRG, unless the upper value that society places on a LYG is unrealistically low. The two
different scenarios of CFRs are, nevertheless, influencing the rise of the curve and have a
strong impact on the probability of having a positive Net Benefit in NHRG when the value of
a LYG is around £15,000.
Figure 5.4 - Results of the multivariate analysis.
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All the parameters are varied within their predefined distribution and the proportion of cost-effective
simulations is shown for different values of a life year gained and for high and non high risk groups
(respectively HRG and NHRG). CFR estimates are set to the lower or higher values.
5.6 Discussion
Invasive pneumococcal disease burden is high among the elderly and, in particular, among
those considered to be at high-risk of pneumococcal infection. These individuals experience
the highest incidence rates, and are those to whom the vaccine was recommended at the time
of the analysis. In this chapter, an economic evaluation of the current 23-valent-
polysaccharide vaccine against invasive pneumococcal disease was presented, looking at
high-risk elderly and at the general elderly population. Although other analyses have been
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published for other European countries (Ament et al., 2000;Postma et al., 2001;Ament et al.,
2001) as well as for the US (Gable et al., 1990;Rose et al., 1993;Sisk et al., 1997;Nichol et
al., 1999;Weaver et al., 2001;Pepper & Owens, 2002;Sisk et al., 2003), this is the first study
for England and Wales.
The previous UK recommendation is not likely to be the most cost-effective strategy, due to
the low level of protection of the vaccine in these risk groups and the shorter life expectancy
of elderly patients with chronic diseases. Routine vaccination of all elderly individuals
appears to be more cost-effective. Although the relative ranking of these alternatives are
unlikely to change, exact quantification of the cost-effectiveness of either of the programmes
is hampered by considerable uncertainties in the degree of protection afforded by the vaccine
(Chapter 4) and the number of hospitalisations and deaths that are attributable to invasive
pneumococcal disease (Chapter 3). Although many hospitalised patients have invasive
pneumococcal disease and a sizeable proportion of them die, their underlying cause of death
was not necessarily IPO, nor could this necessarily be prevented by vaccination. This analysis
attempted to account for some of these problems in estimating the number of preventable life-
years being lost by IPO by taking average life expectancy by risk group (rather than for the
population as a whole), and by testing the robustness of the findings to very different
assumptions regarding CFR. Clearly further work could be performed in this area; the most
valid and relevant information would be derived from a properly designed and implemented
randomised clinical trial that was appropriately powered to investigate the effect of
vaccination on mortality. This is unlikely to happen in the foreseeable future. Therefore, is
there enough information currently available to make a reasonably sound judgement on the
cost-effectiveness of vaccination of the elderly with PPV? Provided the vaccine is given
opportunistically (at the same time as influenza vaccination, for instance) then it seems likely
that vaccination of the non-high risk elderly population would be cost-effective by most
criteria, simply because the vaccine is cheap, and the burden of disease is high. Vaccination of
high-risk groups does not have a high probability of being deemed cost-effective, because the
vaccine may not be effective in these individuals. It seems unlikely, however, that vaccination
would be withdrawn from this group.
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The incremental analysis suggests that the optimal age to vaccinate is 70-75 years depending
on whether the, respectively, high or low CFR assumptions are adopted. This produces a
lower gain in life expectancy as opposed to vaccinating at earlier ages (i.e. 65 years), but, at
the same time, keeps at a lower level the costs associated with the programme. Our analysis
also suggests that giving a booster dose of the vaccine every ten years could be an
economically sensible policy to adopt as its additional cost per life-year gained still lies within
the acceptable range.
The results of this and the previous chapter were presented at the JCVI, and partly contributed
to the decision of recommending vaccination to all elderly individuals regardless of risk group
(July 2003) (Chapter 2).
This chapter concludes a section that focused exclusively on the elderly population and that
intended to investigate the effectiveness and cost-effectiveness of the pneumococcal
polysaccharide vaccine. The PPV has been on the market and recommended to some at-risk
categories for a number of years, although the levels of protections it confers and its economic
acceptability had been frequently debated. The current availability of the pneumococcal
conjugate vaccine, which appears to confer protection against both carriage and disease, even
in the very young children, brings up new public health related questions on its direct and
indirect effects and, as for the PPV, on the cost-effectiveness of alternative vaccination
programmes. The following chapters will thus focus on these topics. Modelling as well as
economic techniques will be used in order to gain insights into the pneumococcal conjugate
vaccine and its effects at the population level.
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CHAPTER 6 - PNEUMOCOCCAL TRANSMISSION IN
HOUSEHOLDS: PARAMETER ESTIMATION AND
MODELLING
6.1 Aims
• To gain insights into Pnc transmission dynamics in the pre-vaccination era;
• To estimate the duration of carriage and acquisition rate from the community and from
infected family members in different age groups;
• To assess the importance of household vs. community transmission;
• To estimate the Secondary Attack Rate and Reproduction Number in households of
different size and composition;
• To assess the importance of age and day care attendance as risk factors for pneumococcal
carriage.
6.2 Introduction
As the majority of infected individuals remain asymptomatic, carriage data are needed in
order to gain an indepth understanding of the transmission dynamics in the pre-vaccination
era. Longitudinal studies have been performed to gather insights into the pathogen's
mechanism of carriage and transmission within hosts (Gray et al., 1980;Aniansson G et ai.,
1992;Ekdahl et al., 1997;Syrjanen et al., 2001;Coles et al., 2001). In this type of study
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individuals are swabbed at regular intervals, their carriage status is assessed and inference on
their rate of acquisition and on the duration of carriage can be obtained.
One of the most extensive studies on the duration of pneumococcal carriage was carried out
by Ekdahl and colleagues (1997) who found an inverse relationship between duration of
carriage and age among Swedish patients with clinical infections (diagnosed as pneumonia
and acute otitis media) carrying penicillin-resistant pneumococci. Confirming previous work
by Smith and colleagues (1993) who found great dissimilarities among the serotypes both in
terms of acquisition and clearance rates, the study by Ekdahl and colleagues (1997) found
serotype-specific durations of carriage. The authors, however, argued that this association was
only due to age-specificity in the serotype distribution (i.e the types which showed longer
duration were the ones that appeared to be more common in children, who typically carry the
organism for longer). Similar results were found by Auranen and colleagues (2000), who
fitted a transmission model to longitudinal data on pneumococcal carriage in Finnish families
(FinOM Family study) taking into consideration transmission within the family and from the
community and estimating acquisition rates and duration of carriage for children and adults.
Prospective longitudinal studies are, thus, particularly informative by following individuals
for a period of time and recording their history of, for example, carriage acquisition as well as
other personal information which may well be associated with the carriage episode (i.e. health
status, living condition, day-care attendance). In the context of familial studies, such design
might be of particular interest to assess the proportion of the data variability explained by
within-individual variation or other sources of variation (Briollais et al., 2003). However, the
data arising from a longitudinal familial study have a complex correlation structure that
cannot be modelled using classic methods for analysis of familial data at a single time point.
The key feature of these correlated (or clustered) data is that items under study are bound
together in sets (or clusters) that are known to the data analyst. For example, children in a
day-care tend to cluster together (that is, respond alike), as do family members, and multiple
measures on a single subject over time. This complexity of the data, however, can be an
advantage, permitting more interesting, insightful analysis. Specifically, as Begg and Parides
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(Begg & Parides, 2003) point out, 'in addition to studying how individual-level factors impact
individual-level responses, clustered data allow us to study the effect of cluster-level factors
on individual-level responses. Fuller, more thoughtful modelling of individual-level and
cluster-level effects might enable us to exploit the data more completely, thereby leading us to
better understand the sets of relationships that underlie important questions in medicine,
public health and other domains'.
Longitudinal data are commonly analysed using one of three methods: marginal models,
conditional models or transition models (Diggle et al., 1994). Unlike marginal models and
conditional (i.e.random-effects) models, which are focused on the correlation among response
variables, a transition (Markov) model explicitly expresses the influence of past outcomes on
the present outcome by modelling the conditional expectation of the response variable as a
function of past outcomes and explanatory variables.
In this chapter a longitudinal dataset on pneumococcal carriage in UK families will be
analysed and a first-order Markov model will be used to estimate pneumococcal transmission
parameters. The approach that will be presented in this chapter represents a novel
mathematical framework, whereby families (rather than individuals) are the unit of
observation and the risk of infection is defined as a function of the number of other household
members carrying the organism at a specific time point. Also, the model will account for
possible unobserved events that may have occurred in between swabbing intervals.
Although serotype information was also collected in the study, the model that will be
presented in this chapter will only consider pneumococcal carriage in general. An extension
of this model will be provided in Chapter 7, where serotype-specific pneumococcal
transmission parameters will be estimated. The chapter is divided into three parts. The first
one provides a description of the available data, followed by a qualitative analysis on the age-
related pattern of acquisition and carriage. In the second part of the chapter the model
structure will be presented and results will be discussed. The third part will cover an extension
of the model. In particular, the age specification of the model will be improved and possible
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risk factors for pneumococcal carriage will be considered. The presentation of the
longitudinal study and the descriptive analysis of the data can be found in Hussain and
colleagues (2004a). The modelling work can be found in Melegaro and colleagues (2004).
6.3 Methods - The data
6.3.1 Description of the data
Data from a 10-month longitudinal follow-up study of pneumococcal carriage conducted in
UK families were used. The study, which started on the l" of October 2001 and ended in July
2002, was part of a EU funded project on pneumococcal disease (PncEuro) (Hussain et al.,
2004a;Hussain et al., 2004b). The data consisted of follow-up measurements of Pnc carriage
of pre-school children «3 yrs.) and their families, which were enrolled through primary
health care child registers of four general practices in Hertfordshire.
Following recruitment of a family, a study nurse administered a pre-tested structured, detailed
questionnaire at the initial visit to each family member. Both household and individual data
were gathered on potential risk factors or confounders including age, gender, education, day-
care attendance, smoking, health status, population mixing in and out the house, any
medication including antibiotics and household socio-demographic factors (type of house,
number of rooms, parental occupation). A shorter questionnaire was administered at each
monthly visit to each family member to gather information on any changes in individual and
household details.
From each family member, a nasopharyngeal (NP) swab was obtained at initial home visit
and followed by 9 further swabs at 4-week intervals. Sampling of absent members or
members with illness was performed at a later date but within a 14-day period. Swabs were
taken by a study nurse and transported to the Respiratory and Systemic Laboratory (RSIL) at
the Specialist and Reference Microbiology Division (SRMD), HPA Colindale London within
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24 hours. All NP samples were handled according to the Standard Operating Procedures of
the WHO-Pnc trialists' network (O'Brien & Nohynek, 2003).
Data were collected on a standard case report form, which were doubled entered onto the
database housed in CDSC. Laboratory data was entered on a laboratory form at RSIL and
entered into a common database.
6.3.2 Data analysis
Descriptive data analyses were performed in Microsoft Excel. Confidence intervals on risk
ratios were calculated using Taylor series in Epilnfo Version 6. The number of times a new
serotype was introduced in the family was derived for different age groups. A new
introduction was defined as the situation in which one family member was found to be
carrying a serotype that was not present in that family at the previous test point.
6.3.3 Descriptive results of the PncEuro longitudinal study
6.3.3.1 Household
A total of 151 children in 132 families, representing 534 persons gave informed consent to
take part in the study. Household relationship to the children included 132 mothers (24.7%),
125 fathers (23.4%), 101 siblings (18.9%) and 25 others including 3 grandparents.
Of the 132 initial families, 11 withdrew before the first visit and completion of the
questionnaire. Of the remaining 121 families, more detailed household data indicated 21
families (17.4%) living in local authority-owned rental accommodation and 98 (81%) in
owner occupied houses. Household size ranged from two to seven persons per house (mean
and median of 4.0 persons/house). One hundred and six of these 121 families remained until
the completion of the study (dropout rate 20%).
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Of the 26 families that failed to complete the entire study, three immediately withdrew before
completing the household questionnaire, four withdrew due to discomfort of nasopharyngeal
swabbing, three had social reasons (i.e. family break-up) and the remaining 16 withdrew
either due to inconvenience related to time involved or because they emigrated.
6.3.3.2 Individual
Demographic and health. In total 121 families (with 140 index cases) were visited at least
once by the study nurse (representing a total of 489 individuals). The age and gender
distribution of these children, their siblings and adult household members are summarised in
Table 6.1 together with smoking, medication and vaccination history.
Table 6.1 Demographics of individuals in 121 'swabbed' households.
Index cases
(N=140)
Siblings «18 yrs) Adults (>18yrs)
(N=109) (N=239)
Age in years (mean & range) 1.5 (0.3-3) 7.0 (3-18) 34.3 (18-72)
% female
% male
55.8
44.2
49.1
50.9
52.3
47.7
% at day-care
% at primary school
% at secondary school
55.1
o
o
24.6
58.8
14
% antibiotics past 12 mths
% smoking
37.7
o
23.7
0.9
24.3
23.7
n=488, 1individual without age information
% pnc vaccinated 0 o o
Prevalence of Pnc carriage. Nasopharyngeal swabbing was performed at least once in these
489 individuals with a total of 3767 swabs taken, representing 77% of the possible maximum.
Overall 932 (25%) samples revealed pneumococcal carriage. At least one episode of
pneumococcal carriage was noted amongst 112 of the 121 families swabbed (93%) over the
study period. There were no significant seasonal differences in the prevalence of carriage by
age group over the to-month period (Figure 6.t) (t-test trend >0.05 for all age groups).
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Figure 6.1 Pneumococcal carriage rates by age and swabbing month.
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Rates are reported by age of the study participants at the start of the study and by month of swabbing
(October 2001- July 2002).
Mean prevalence by age group over the entire study period ranged from 52% for 0-2 yr. olds,
to 45% for 3-4 yr. olds, 21% for 5-17 yr. olds and 8% for those 18+ yrs. Children less than 5
years of age were significantly more likely than the older age groups (5+ years) to carry Pnc
(RR=4.84, 95%CI: 4.25-5.51, p<O.OOOOOI).
Among all study participants, 282/489 (58%) individuals were found to be Pnc carriers at
least once throughout the study period (Table 6.2). When stratified by age the proportion
carrying Pnc at least once ranged from 86% in 0-2 year olds to 36% in those 18+ years of age.
Indeed, among the 0-2 years old, 47% were found to carry Pnc at least 5 times during the
study follow up time compared to 1% of those 18+ years of age.
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Table 6.2 Number (%) of positive swabs per person and by age group.
Number ofPnc positive
swabs eer eerson 0-2 Irs 3-4 Irs 5-t7 Irs t8+Irs Overall
0 19(14) 10(25) 26 (38) 152(64) 207 (42)
17 (12) 7 (18) 19(28) 51 (21) 94 (19)
2 14 (10) 7 (18) 10(14) 22 (9) 53 (11)
3 13(9) 3 (8) 6 (9) 9 (4) 31 (6)
4 12(9) 4 (10) 3 (4) 1 (0) 20 (4)
5 II (8) 3 (8) 3 (4) 1 (0) 18(4)
6 19(14) 5 (13) 2 (3) 3 (1) 29 (6)
7 10(7) I (3) 0(0) 0(0) 11(2)
8 12(9) 0(0) 0(0) 0(0) 12(2)
9 9 (6) 0(0) 0(0) 0(0) 9 (2)
10 4P} o {O} o {O} o {O} 4 {ll
Total 140POOl 40 {tOO} 69 {tOO} 239 {tOO} 488 {tOO}
1 individual with no age specification is not included in the table
Distribution of serogroups/types. In total 9011932 (97%) pneumococcal isolates were
serotyped (the remainder being non-capsulate). 34 distinct serotypes were found in the
isolates. The 10 most prevalent serotypes comprised 90% of all isolates in the 0-5 years olds
(Figure 6.2). The five most prevalent serotypes in this group were 6B (27%) followed by 19F,
23F, 6A and 14, accounting for 51% of the samples. Among the 5+ years old, serotypes 14,
6A, 19F and 23F were again the most frequent isolates with 6B less frequently found
compared to <5 year olds (Figure 6.2)
Simultaneous carriage of more than one serotype in an individual at a particular time-point
was only detected on six (0.16%) occasions. Five of these individuals were ~5 years of age.
Antibiotic resistance. The proportion of isolates with any erythromycin resistance (alone or
in combination) was 10% and the proportion with any degree of penicillin resistance (alone or
in combination) was 3.7%. Cefotaxime resistance was noted in only 0.3%. The most common
serotypes showing resistance to any of the three antibiotics were: serotypes 14 (45%, n=92),
19F (11%, n=128), 6B (14%, n=214) and 9V (17%, n=23). All of these serotypes are included
in the 7-valent PCV.
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Figure 6.2 Serotype frequency distribution among pneumococcal carriers.
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Comparison with invasive isolates. Comparison of the distribution of carriage serotypes
with the distribution of invasive Pnc isolates in those under-5 year olds in England and Wales
in year 2000 demonstrated large differences between serotypes (Figure 6.3). Serotypes 14,
18C, 9V, 4, 1,8, 7F and 3 in particular seemed to be more likely to be invasive than carried.
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The latter four serotypes (1,8,7F and 3) are not covered by the 7-valent conjugate vaccine.
The same non-vaccine serotypes appear to be more common among invasive isolates than
among Pnc carriers in 5+ years of age.
Role of the household. The effect of within family exposure on pneumococcal carriage was
assessed examining the number of changes in individual status over the observation intervals
once stratified by age-class and background carriage in other family members (Table 6.3).
Individual pneumococcal carriage was found to be associated with carriage in the other family
members with risk ratios of 1.42 (95%CI: 1.26-1.61), 1.25 (95%CI: 0.95-1.64) and 2.25
(95%CI: 1.65-3.08) for the age groups 0-2 years, 3-4 and 5+ respectively.
The relative importance of intra- and extra-household exposure to infection by age group was
initially evaluated by examining introductions of new serotypes into the household (Table
6.4). Young children (0-5 years old) were found to be significantly associated with the
introduction of a new serotype in the household (p<0.005). Of the 931 positive tests, 353
(38%) were new introductions. Of these, 264 (75%) occurred in children less than 5 years of
age compared to 45 (13%) in 5-17 and only 44 (12%) in 18+. Though providing some insights
on first occurances within the household, the validity of these results is, however, limited by
the fact that first introductions by adults are less likely to be detected, as their duration of
carriage is shorter. Modelling techniques will be utilised, in the second part of this chapter, to
further explore this topic.
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Figure 6.3 Serotype frequency distribution: comparing IPD isolates with carriage study
results.
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Table 6.4 Number of Eositive, negative, and tested samEles b~ age.
Positive test
First introd. Ongoing/ All Number of
Age grouE {%} Concurrent All ne~ative tests (%~
a.<ly 89 (25) 174 263 209 472 (13)
b. ly 69 (20) 119 188 180 368 (10)
c.2y 68 (19) 69 137 150 287 (8)
d.3-4y 38 (11) 60 98 159 257 (7)
e.5-17y 45 (13) 51 96 359 455 (12)
f. >l8~ 44 {12} 105 149 1779 1928 {51}
Total 353 {l00} 578 931 2836 3767 {lOO}
Positive tests are stratified also according to whether it was a new introduction or if it was an ongoing
or concurrent episode of carriage of a specific serotype (ongoing = the type was carried at the
previous test point by either the same individual in the family or other family members; concurrent =
someone else in the family is carrying the same type at the same time).
6.3.4 From individual level data to family data
The 121 families that were visited at least once by the study nurse and which comprised 489
individuals were considered in the following analysis, to estimate pneumococcal transmission
parameters within the household (section 6.4). Although serotyping was performed when Pnc
carriage was detected, this initial analysis considered pneumococcal carriage in general and,
thus, only looked at whether or not the individual was carrying the bacteria. Moreover, as
there were only six circumstances in which two serotypes were found in the same individual
at the same time, the model was based on the assumption that simultaneous carriage of
different serotypes is rare enough to ignore initially.
For each individual that took part in the study, the carriage status at each monthly visit was
obtained from the data and then recoded as 0, if non-carrier, 1 if carrier and 9 when either the
swab was not taken or the lab result was not reported. The household state at each visit was
derived combining the carriage status of all the family members and resulted in a sequence of
Os and 1s if their information was complete. Missing information on at least one family
member resulted in incomplete information at the household level and, thus, a missing value
code. Family sequences were organised so that the last number represented the status of the
youngest member of the family. Due to the strong association that has been shown in other
studies (Ekdahl et al., 1997;Auranen et al., 2000) between pneumococcal carriage and age,
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with younger children having a much higher prevalence and longer duration of carriage, a cut-
off at 5 years of age was set and households were stratified by family size and composition
(number of individuals <5 and 5+ years of age in the family). Strings of household results
were derived, which were then converted into a table showing the number of transitions
between each pair of household states over a 28-day period for each family size and structure
(Table 6.5).
Table 6.5 -Example of a count of family transitions over a 28-day period.
Family Family status at time t+1
status at
time t 000 100 010 110 001 101 011 111
000 85 0 2 0 23 1 0 0
100 0 0 0 0 0 0 0 0
010 3 0 1 0 2 0 0 0
110 0 0 0 0 0 0 0 1
001 22 0 3 1 51 2 4 1
101 2 0 0 0 4 3 I 0
011 1 0 0 0 6 1 2 0
111 2 0 0 0 1 1 0 0
Data extracted from from the Pnc-Euro study, families of 3 individuals with one child < 5years of age.
Two households of 2 individuals and one of 7 were excluded from the analysis as their
sequences were non informative. Ten distinct tables Nz•u were derived for the available
combinations of, respectively, household size (z) and number of adults (u) in the family: (3,1),
(3,2), (4,2), (4,3), (5,2), (5,3), (5,4), (6,3), (6,4), (6,5). Only complete family transitions,
where the infection state of all household members was known on two consecutive
observations, were used in the following analysis.
As a previous study (Ekdahl et al., 1997) suggested that duration of carriage might be less
than 28 days, especially in adults, it was possible that not all episodes of carriage were
observed from the data. This aspect was considered in the structure of the following model.
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6.4 Methods - The model
Following the work by Auranen and colleagues on both Hib and Pnc infection (1996;2000)
the model considered pneumococcal transmission within the household. Each individual is
assumed to be either in a non-infected state, i.e. susceptible to infection (S), or already
infected (carriers) (C) and, as a consequence, able to spread the infection to uninfected
individuals in their household. No pneumococcal specific disease was observed so this
possibility was not included. As in Auranen and colleagues (2000) the transition from C->S
was set to be dependent on a age-dependent recovery rate, and the transition from S->C to be
a function of the potential exposure to the infective agent both within the family (within-
family acquisition rate) and outside the family (community acquisition rate).
The probabilities of transition from an infected to an uninfected state and vice versa in a short
time interval ot were then defined for an individual in the age class i=1,2 (where 1=child «5
years) and 2:::::adult(5+ years»
[6.1]
[6.2]
where Ili and k, are, respectively, the clearance and the community acquisition rates for age
class i and z is the family size. 11(t)and h(t) are the number of, respectively, infected children
and infected adults in the family. ~ij is the transmission rate from an infected to an uninfected
individual and it reflects both the infectiousness of an individual in the age class j and the
susceptibility of an individual in the age class i. Thus the within household probability of
being infected in ot is a function of the number and age class of the other family members that
are carrying the bacteria at that particular time. Community acquisition rates and recovery
rates are similarly defined in vectors: [kl' k2] and [Ill. 1l2]. The term (z-l r in equation [6.2]
represents a density correction factor; (z-I) being the number of other family members in
families of size z and w the factor that controls the extent of density dependence. When w=O
the model reflects density independent transmission: the probability of contracting infection
140
from another specific individual in the family does not change with family size and, thus, the
average number of contacts increases linearly with family size. When w= 1 the probability of
getting in contact with the same individual decreases in bigger families although the average
number of contacts remain constant. If w> 1 the average number of contacts decreases with
family size. In total nine parameters define the model.
Equations [6.1] and [6.2] were used to derive the probability Prs of transition between two
different family states r and s in a short time interval 8t. These probabilities were calculated
for each household size and composition. It is assumed that in a short time interval St, here
chosen as 1 day, only one member of the household will change status (either through
infection or recovery). The probability of transitions where more than one individual changes
status is therefore set to zero. For example, in a family of size three composed of two adults
and one child, the probabilities of going from state 001 (two susceptible adults and one carrier
child) to states 000, 101 and 011 in one time step, are derived using respectively equation
[6.1] to become a fully susceptible household and equation [6.2] to reach states 101 or OIl.
The Tl(3,2) matrix, (equation [6.3] below), contains all the probabilities of transitions from
the initial family status at the top of the matrix to the consecutive status given on the left hand
side of the matrix when 8t is 1 day.
The sensitivity of the model to changes in the definition of St (112 day, 2 days) was checked.
The daily probability that the family does not change state is given by qrr= l-:E_prs. Similar
formulations of the transition matrix Tl are expressed for families with 3 to 6 members and
different age structures.
The families transition probabilities for a 28-day interval were then derived as
T28(3,2)=TI28(3,2).This allowed handling transitions in which more than one individual in the
family changes status. Moreover, not having specified the pathway from one state to the next,
unobserved events were implicitly included.
141
,......,
('r')
C'l1.0
"""........ .....
'" '" 000 0 0 :;j_ 0 :;j_ :;j_ 00..... <::r-.....
'"""C
+
N
.....
'" ::::
~..... 0 0 :;j_ 0 :;j_ 0 +0 <::r-
i:l
~._,
~
I
~
'"""C
+
N
'" s
~.....
0 0 0 0~ :;j_ :;j_ <::r- +
i:l
~._,
~
I
~
,......, ,......,
'" '"""C ""C
+ +
8 '" N:;j_ 0 0 0 '" '" 0<::r- ~~
~ ~
I I
~ N'-'
""C
+
~ 0 '" '" ; 0 0 0 :::l ~..... :;j_ :;j_ <::r- ~ "1::!:..i: ~,.!.
~ ~t:!
'" ~""C ~ ~
+ + :::::
0 '" 0 '" '" 0 0 :::l 0 ~0 :;j_ '" '"<::r-~ ~ t~ ~
I I .......
N N II'-' '-' ~
'" ~ ~""C
~+ +
~ '" i:l 0 '" 0 '" 0 0 .~:;j_ '" ~ ,t;<::r- ~ t:!~ " i::I I
N ~ I::'-' ·9.1::
§ '" '" 0 ~ 0 0 0 ~<::r- ""C ""C
~
~
<:> 8 <:> <:> ...... ...... ...... ...... ~<:> ...... ...... <:> <:> ...... ......<:> ...... <:> ...... <:> ...... <:> ...... ·s...
--- t:!~ ~
('r') ~'-"
~f-4
6.4.1 Parameter estimation
Maximum likelihood techniques (Brown & Rothery, 1993;Williams & Dye,
1994;Hilborn & Mangel, 1997) were adopted to estimate the nine model parameters.
This technique is broadly applicable to problems of parameter estimation. The basic idea
of maximum likelihood is to find those values of the parameters for which the observed
data are most likely to have occurred (Brown & Rothery, 1993). These parameter
estimates are thus called maximum likelihood estimates (MLE). The log likelihood
L(z,u) and saturated log likelihood L'(z,u) functions were derived from each monthly
transition matrix TZ8(z,u) and from the observed number of family transitions between
states nrs(z,u). The deviance was then calculated for each family size and composition as
follows:
2Z 2Z
Dev Z,u= 2· (L· - L) = 2· LLnrJln{nrs)-ln{PrsNr)]
r=1 5=1
[6.4]
where nrs is the number of family transitions observed in the data from state r to state s
and N r = Lnrs . The Prs is the element rs of matrix T2S(z,u) or, in other words, is the
s
model probability that a family of size z and with u adults moves from state r to state s in
a 28 day interval. The upper limit of the summations represents the number of family
states that are possible for each family size.
The overall deviance [6] is obtained as the sum over all family sizes and compositions
6 z
Dev = LLDevz,u
z=3 u=1
[6.5]
Maximum likelihood estimates for the parameters are obtained by minimising the
deviance.
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The profile likelihood method (Armitage & Colton, 2004) was used to derive confidence
intervals for the model parameters. The model was set up first in Microsoft Excel and
then programmed in Matlab 6.5. The development of the programme in Matlab allowed
more flexibility in the model structure and the possibility to include further information
that was available in the dataset. More on this will be said in section 6.4.9 of this
chapter.
6.4.2 Model fit
The overall fit of the model could not be formally assessed using a chi-squared test on
the residual deviance and degrees of freedom. This was because the expected count for
each cell was too small and usually less than one.
However, after aggregating the states with the same number of carriers, it was possible
to assess the goodness of fit visually for each family size by plotting the number of
family transitions between states and comparing it to the number obtained from the
model after aggregating across cells. Chi-square tests comparing the observed and
estimated number of transitions on the aggregated data were performed. Using the chi-
squared test in this way only enables the detection of fairly large aberrations in the
model fit because the fit is only being tested after aggregation of data and estimates from
a more complex model.
6.4.3 Measures of transmissibility
Equation 6.2 gives the individual probability of being infected in the small time interval
ot taking into account the number of infectious carriers in the same household and the
age-specific transmission rates. Nevertheless, in order to assess the transmissibility of an
infection inside a household, more specific measures are needed that also take into
consideration each carrier's duration of infectiousness and, thus, give the number of new
infections produced during that period.
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The within household secondary attack rate (SAR) is one such measure. It gives the
proportion "attacked" (=infected) among individuals in contact with an infected case in a
household during their entire period of infectiousness. From the model parameters the
SAR for a carrier j and a susceptible i was derived
-PdSAR·= p..(S~C)d ==l-e IJ J
IJ lJ j [6.6]
where dj is the duration of carriage (=lI)..lj,with j=c,a) and ~ij is the transmission rate
from j to L Applying the age-specific acquisition rates to formula [6.6], allows the
estimates of SARs for the different age classes defined in the model. Moreover, the
number of secondary infections in group i caused by a carrier in group j is derived as a
function of the specific SARs and the household's composition, building a next
generation matrix (NOM) (Diekmann & Heesterbeek, 2000) for each family size and
structure
[
(Z - a -1)· SARcc
NOMij(z,a) = a .SARac
(z-a)·SARca ]
(a -1)· SARaa
[6.7]
The dominant eigenvalues of each NOMij(z,a) provide us with the average number of
secondary infections produced by the introduction of one carrier in households with
different sizes and structures (Basic Reproduction Number).
6.4.4 Prevalence of'Pnc infection by household size and composition
A steady-state vector v of dimension 2z was calculated from any of the family transition
matrix (i.e. T1(z,u» by solving the following system of equations
T1(z,u)·v(z,u) = v(z,u) [6.8]
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where v gives the proportion of households that are in each specific state at the
equilibrium (Chin Long Chiang, 1980). From this the expected prevalence of infection
in children and adults in a household of given size and structure can be calculated.
The proportion of community acquired Pnc infection was calculated using the steady-
state vector v and deriving the expected number of new infections produced exclusively
by household transmission (k=O) and comparing it to the expected number of those
acquired from the community «(3=0).
6.4.5 Model extensions (Matlab Individual Family Model)
To gain flexibility in the modelling framework that has just been explained and also to
allow the inclusion of additional available information (i.e, individual characteristics
such as better age stratification and day care attendance, and serotyping information) the
model was also programmed in Matlab (Matlab 6.5 @ The MathWorks).
A transition matrix, as the one presented in equation 6.3, was built for each family
(rather than for each group of famities of the same size and composition). The family
transition probabilities were generated taking into account the individual characteristics
of the family members and, in particular, age (0-1, 2-4, 5-17 and 18+ years) and number
of hours attending day-care (DC) per week. Though other important information was
contained in the dataset (smoking status, antibiotics prescription, socio-economic
indicators, etc.) it was decided to only consider, for the purpose of this work, the effects
of the two most important individual risk factors for pneumococcal carriage (age, day-
care attendance) (Givon-Lavi et al., 1999;Principi et al., 1999;Raymond et al.,
2000;Leino et al., 2001;Neto et al., 2003;Huang et al., 2004). Moreover, the more
flexible modelling framework that was developed allowed furthering the analysis and
estimating serotype-specific pneumococcal transmission parameter. More on this will be
said in Chapter 7.
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Recovery rates (and thus duration of carriage) were estimated for the following age
groups: 0-1, 2-4, 5-17 and 18+ years. The effect of day care attendance was explored
modifying the community acquisition rate k - which was constant in the Excel model in
each of the two age groups (section 6.4.5) - to take into account day care attendance
among children <5 years of age:
[6.9]
where kg represents the baseline community acquisition rate for children in the age
group g (0-1,2-4 years), kbris the acquisition rate per hour in the day care per week and
hr is the number of hours per week spent in the day care.
6.5 Model results
6.5.1 Excel model
In total 560 (51%) complete family transitions were available in the data (Table 6.6), the
majority of which were found in family size of 3 and 4. The overall deviance obtained
comparing the model log likelihood to the saturated log likelihood is 645, with 180
degrees of freedom (189 non-zero data points and 9 parameters to estimate). In Figure
6.4 the fit of the model is shown comparing the expected number of transitions estimated
by the model, for uninfected families and families with one carrier, to the number
observed from the data for the same transitions. The Chi-square tests of the model fit
(not shown) did not show evidence of any significant difference between the model and
the data.
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a e urn er 0 compi ete transitions )y amuy size an num er 0
Number of adults
Family Size 1 2 3 4 5 Total
3 8 226 - - - 234
4 - 146 54 - - 200
5 - 8 27 45 80
6 - - 14 1 31 46
Total 8 380 95 46 31 560
T bl 66 N b f
Figure 6.4 - Model fit.
No. of carriers in the family at t+28 days
(family size = 3)
No. of carriers in the family at t+28 days
(family size = 5)
b f ·1 d b fadults.
•
• Data (0 carrier in t)
-- Model (0 carrier in t)
• Data (1 carrier in t)
Model (1 carrier in t)
o 3 41 2
No. of carriers in the family at t+28 days
(family size = 4)
No. of carriers in the family at t+28 days
(family size = 6)
Transition probabilities obtained from the model for completely susceptible families (blue line)
and families with one carrier (red line), compared to proportions of transition observed from
carriage data (blue and red marks respectively).
Estimates of the 9 model parameters are shown in Table 6.7. In children less than 5
years of age the mean duration of pneumococcal carriage, derived using the inverse of
the estimated recovery rate, is 51 days (95%CI: 42-64). The estimated mean duration of
carriage in older family members is close to 19 days (95%CI: 14-24). The community
acquisition rate for children (0.012 per day) is more than three times higher than that for
adults (0.004 per day), showing that children <5 years of age are the most likely to
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introduce the infection into the household. On the other hand, estimates of the within
family acquisition rates show that the highest daily transmission rate is that from adults
to children, whereas the lowest is the one from children to adults. These results are
consistent with adults being more infectious but less susceptible to infection. A density
coefficient significantly greater than zero (w=1.2; 95%CI: 0.2-2.2) is estimated from the
model and suggests the importance of considering density dependent transmission.
However, due to the very wide confidence interval, no clear indication is given on the
strength of this effect (Figure 6.5). The sensitivity of the model to variation in the time
interval ot (ot=1I2 day, ot=2 days) was assessed and the parameters estimates were
found to be not significantly different from the base case results (0t=1 day).
Table 6.7 - Maximum likelihood parameter estimates
Rates (per
Descrietion of model earameters S~mbol used da~l 95%Cls
Community acq. rate (adult) k2 0.004 0.002-0.005
Community acq. rate (child) kl 0.012 0.008-0.016
Within family acq. rate (adult to adult) ~22 0.048 0.010-0.180
Within family acq. rate (adult to child) ~12 0.106 0.020-0.450
Within family acq. rate (child to adult) ~21 0.005 0.000-0.018
Within family acq. rate (child to child) ~ll 0.047 0.008-0.200
Recovery rate (adult) J.l2 0.053 0.041-0.070
Recovery rate (child) J.l1 0.020 0.016-0.024
Density factor w 1.184 0.200-2.200
Moreover, when looking at SAR measures that account for duration of infectiousness,
the proportion of children infected by a child or adult is considerably higher
(SARcc=0.40 and SARca=0.32) than the proportion of adults infected by a child or adult
(SARac=0.09 and SARaa=0.16).
149
Figure 6.5 - Profile likelihood for the density factor (w).
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In Table 6.8 estimates of the Reproduction Number are shown for the different family
sizes and composition. R increases with the number of children present in the family.
When 62% or over of the family members are aged less than 5 years, then the
Reproduction Number reaches its threshold level (R=l). When at least 2 children are in
the family, increasing the number of adults reduces R. This is the result of assuming
w=l; i.e. the number of contacts remains the same in families of different sizes and,
thus, the probability of getting in contact with other children in the family is smaller.
Table 6.8 Estimates of the Basic Reproduction Number for different household
compositions
Number of No. Adults
children 1 2 3 4 5
1 0.407 0.529 0.583 0.613 0.632
2 0.773 0.716 0.689 0.677 0.672
3 1.033 0.910 0.834 0.785 0.753
4 1.203 1.062 0.964 0.895 0.845
5 1.320 1.176 1.071 0.992 0.932
Children: 0-5 years; adults: 5+ years; w is assumed to be equal to 1.
The expected prevalence of Pnc infection at equilibrium in both adults and children is
given in Table 6.9. In order to have a baseline probability, the expected Pnc carriage in
adults is estimated also for families with no children although no such families exist in
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our data. The prevalence of Pnc carriage in adults does not vary much when bigger
families are considered or when more children are present in the family. The expected
prevalence in children increases with the number of children in the household. The
prevalence increases by 3%-10% for each additional child.
The proportion of household acquired Pnc infection increases in bigger families,
reaching 50% for both children and adults (Table 6.10). When only one child is in the
family the proportion in children (22%-38%) is lower than in adults (34%-50%).
Table 6.9 Expected equilibrium prevalence ofPnc carriage in household with different
compositions.
No. of children in the No. of adults in the household
Prevalence household 1 2 3 4 5
0 0.06 0.10 0.11 0.12 0.12
Adults 1 0.09 0.10 0.11 0.11 0.12
2 0.10 0.11 0.11 0.11 -
3 0.10 0.11 0.11 - -
1 0.44 0.47 0.48 0.49 0.50
Children 2 0.54 0.53 0.52 0.52 -
3 0.58 0.56 0.55 - -
Children: 0-5 years; adults: 5+years; W IS assumed to be equal to 1.
Table 6.10 Estimated proportion of within-family acquisition by household size and
composition.
No. of children in the No. of adults in the household
household 1 2 3 4 5
0 0% 40% 47% 50% 52%
Adult 1 34% 41% 45% 48% 50%
2 40% 42% 45% 47% -
3 42% 43% 45% - -
1 22% 29% 33% 36% 38%
Child 2 46% 43% 43% 43% -
3 54% 50% 49% - -
Children: 0-5 years; adults: 5+ years; W IS assumed to be equal to 1.
6.5.2 Matlab model
After checks were made to assess whether the Matlab model was producing the same
results as the Excel model initially developed (Figure 6.6), parameter estimates were
derived for the following age-groups: 0-1, 2-4, 5-17 and 18+ years.
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Figure 6.6 - Comparison of Matlab and Excel models results.
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Figure 6.7 and Figure 6.8 show, respectively, the estimated age specific community
acquisition rates and duration of carriage derived from the extended version of the
model. Confirming the findings of the previous section, community acquisition rates are
much lower in adults (18+ years of age) than among younger individuals. In particular
children 2-4 years of age experience the highest rates being probably highly susceptible
and exposed to pneumococci. Moreover, as shown in similar studies (Gray et al.,
1980;Ekdahl et al., 1997;Auranen et al., 2000), the duration of carriage decreases with
age, with infants 0-1 years of age carrying pneumococci on average for 72 days (95%CI:
51-105) as opposed to older individuals, 2-4, 5-17 and 18+ age groups, who carry the
organism for, respectively, 28, 18 and 17 days. These results will inform the modelling
work of Chapter 8.
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Figure 6.7 - Community acquisition rate by age and 95% CI (Matlab model).
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Figure 6.8 - Duration of carriage by age and 95%CI (Matlab model).
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The importance of day care attendance is shown in Figure 6.9, where the estimated
community acquisition rates in children <5 years of age are shown by age and day-care
attendance (Yes DC attendance VS. No DC attendance). The average and the maximum
number of hours attending the day-care per week and for the two age groups is used to
hours per week.
estimate the overall community acquisition rates. These were respectively 14 and 45
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Figure 6.9 - Community acquisition rates with 95%CI by age and day-care attendance
(Matlab mode!).
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6.6 Discussion
Data from a UK pneumococcal longitudinal carriage study in families were used in this
chapter and a transmission model fitted using maximum likelihood techniques to gain
some insights into pneumococcal transmission dynamics within the household, shedding
some light on its mechanism of acquisition and on the duration of carriage. These
estimates were used to derive the individual equilibrium prevalence of infection in
households of given size and structure and to assess the importance of household versus
community acquisition.
Interestingly, initial descriptive analysis of the dataset provided evidence of the absence
of any seasonality in the carriage rates as opposed to invasive disease rates, which are
much higher during the winter season (Chapter 3). This result, which is in contrast with
previous finding (Lakshman et al., 2003), suggest the importance of other factors (rather
than colonisation rates) that may influence the disease pattern. These may include: the
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circulation of other viruses in the population, climate changes, as well as the complex
relationship between pneumococcal serotypes involved in carriage and/or causing
disease. Moreover, the proportion of first introduction of a new serotype in the
household was significantly associated with younger ages, though first introduction by
adults were less likely to be detected, as their period of infection is generally shorter.
Modelling work was thus required to investigate this issue further.
Although the study was carefully designed and the swabbing interval was forced to its
minimum, the presence of unobserved events had to be considered in the setting up of
the model. In the past, Bayesian data augmentation methods have been adopted in order
to tackle this issue and MCMC simulation has been used to explore the joint posterior of
the model parameters and the augmented data (Auranen et al., 2000). Here, to deal with
unobserved events, the model was set up for a short time interval (1 day), during which
only one event could occur, and then the probabilities of transitions for longer (i.e. 28
days) intervals were derived. This enabled the description of the entire dataset with only
nine model parameters.
The model classified individuals as 'carrier' or 'non-carrier' and it did not consider
which serotype they were carrying. Acquisition and clearance rates were thus estimated
for carriage of any serotype. Serotype-specific differences in acquisition and clearance
rates were shown in the past (Smith et al., 1993;Ekdahl et al., 1997;Brueggemann et al.,
2003) and represent a very critical issue in terms of future disease burden and impact of
vaccination policies. Here some baseline information on transmission dynamics were
derived and, although the model allowed successive positive tests to be attributed to
recovery and reacquisition, it did not exploit the information provided by a change of the
serotype carried.
In agreement with previous findings, the model estimated that children carry the
organism for longer periods than adult family members (72 VS. 17 days). Smith and
colleagues (1993) estimated approximately two months of carriage in children for the
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most common serotypes (6,19,23) and for Auranen and colleagues (2000) the mean
duration of carriage for children aged under 2 years was 2.3 months (95%Cls: 1.5-3.3),
which is extremely close to the estimate derived in this chapter (2.4 months). The
estimated 1.5 months (95%CIs: 1.0-2.0) duration of carriage derived from the Finnish
study (Auranen et al., 2000) in 2 years of age and older is slightly higher than what was
found here, though within the confidence interval that was derived for the 2-4 years of
age. Slightly lower estimates of the duration of carriage were found in Ekdahl's study
(Ekdahl et al., 1997), where a significant relationship between carriage and age was
estimated: 30, 21, 12, 15, 14 days for individuals aged, respectively, <1, 1-4, 5-6, 7-18
and 18+ years.
Estimates of pneumococcal acquisition rates from the community showed a difference
between children and adults. The former were 3-4 times more likely to acquire the
infection from the community and introduce the bacteria in their household's
environment. Previous work by Auranen and colleagues (2000) showed a similar pattern
although the difference between children and adults was stronger in the Finnish data and
their rates were significantly lower than ours. This can probably be explained by the fact
that their model considered only three serotypes that account for 30-60% of infections.
The within family transmission rates incorporate infectiousness of the carrier,
susceptibility of the non-carrier and contact between them. Although various individual
factors, such as age and immunity levels, may contribute to this relationship, the model
used here is from the SIS class, and, thus, it does not explicitly account for immunity
after infection. Nevertheless, transmission rates within the family were derived
considering the age class to which both the carrier and the non-carrier belong, and
suggested a higher level of susceptibility in children and infectiousness in adults.
The importance of density dependence when looking at transmission dynamics of
infection has been discussed previously (McCallum et al., 2001 ;Finkenstadt et al.,
2002). A density dependent factor was included in the analysis and found to be an
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necessary element of the model to explain within-family transmission (w significantly
greater than 0). However, at this stage, no clear judgement can be made on whether the
transmission increases (w<l) or decreases (w> 1) as a consequence of being in bigger
families. More work could clarify this relationship and provide better estimates of
within-family transmission that takes into consideration changes in the contact patterns
in households of different sizes, environment and composition.
As expected, the prevalence of carriage for any family size and structure was higher for
children than for adults. Moreover, whereas the prevalence in adults did not vary much
for different family sizes and composition, the equilibrium prevalence in children
increased with the number of children and adults in the family. This may again reflect
the lower level of susceptibility in older individuals and the fact that they are less
sensitive to changes in the proportion of infectious contacts they may have within the
household.
Household-acquired infection made a major contribution to pneumococcal transmission
in families both for children and adults. The more siblings were present in the family the
more the infection could circulate among them and persist within the household.
However, even in large families approximately 50%-60% of children and adults'
infections were acquired outside the household.
The importance of age and day-care attendance as risk factors for pneumococcal
carriage was further investigated developing a similar, but more flexible, model
framework in Matlab. From this model, age-specific estimates of the community
acquisition rates and duration of carriage confirmed our previous finding, though a better
definition of the age strata was achieved with this version of the model. Age was
associated with both community acquisition rates and duration of carriage, with higher
levels among younger individuals. Moreover, day-care attendance was a risk factor for
pneumococcal carriage. Community acquisition rate of children attending day-care
centres were twice as high as the ones that did not attend day-care.
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Longitudinal data can be quite challenging to analyse and many critical aspects have to
be taken into account in doing so. Nevertheless they can provide a great contribution to
the understanding of a pathogen's dynamics within the human host and on the way
individual properties can affect transmission dynamics of the infectious agent. In this
chapter some conclusions have been drawn about pneumococcal transmission dynamics,
the contribution of community versus family transmission and the importance of family
structure when considering the prevalence of infection within the household. In the
following chapter further analysis will be provided which will focus on serotype specific
carriage. Potential links between serotypes and transmission in the pre-vaccination era
will be explored.
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CHAPTER 7 - MODELLING SEROTYPE-SPECIFIC
PNEUMOCOCCAL TRANSMISSION IN
HOUSEHOLDS
7.1 Aims
• To expand the modelling framework developed in the previous chapter to include
available data on serotype-specific pneumococcal carriage;
• To ascertain differences in within household acquisition rates as well as acquisition
rates from the community for the most commonly carried serotypes (ST) (68, 6A,
14, 23F, 19F);
• To estimate duration of carriage for the target ST and for different age groups;
• To investigate the existence of competition/interaction among the serotypes.
7.2 Introduction
In the previous chapter baseline estimates of transmission parameters have been derived
using the available UK longitudinal dataset of carriage in households. These estimates,
which are non serotype-specific, were derived using a modelling framework that enabled
us to incorporate the two levels of clustering that are typical of any longitudinal dataset
of individuals in households, schools, day-cares or any other social structure.
As seen in Chapter 3, however, Sipneumoniae is a very complicated and diverse
organism, which is present worldwide in more than 90 distinctive serotypes. Though
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only less than half of these appear to be circulating in the UK (Chapter 3) and some of
those circulating are not causing disease (Chapter 6), the dissimilarities of the remaining
types should be taken into account when investigating transmission dynamics.
This chapter aims to expand the previous modelling framework to enable potential
differences among the carried serotypes to be assessed from the serotype-specific
information that was available for the study population. As it was unfeasible to deal with
all the carried types distinctively, the five most prevalent types (6A, 6B, 14, 19F, 23F)
were investigated. The Matlab model (section 6.4.5) was used here and extended.
7.3 Method
7.3.1 Data
The longitudinal dataset on pneumococcal carriage in UK families, described in the
previous chapter (section 6.3), was used in this analysis. Differently from the data used
in Chapter 6, serotyping information, which was available for the study participants
when carriage was detected, was included in this chapter. An example of the data is
given in Figure 7.1 for a family of 4 individuals (2 adults and 2 children).
Figure 7.1- Example of carriage data for a family of 4 members.
Preliminary descriptive analyses on the serotypes being carried by the study participants
were performed. The number of serotypes carried by each individual throughout the
study period was extracted as well as the overall number of carriage episodes per carrier
and per serotype carried. Moreover, the number of consecutive carriage episodes for the
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most prevalent types was also derived and differences among the serotypes were
highlighted.
The Matlab programme that was described in Chapter 6 (section 6.4.5) and that was
used to improve the age stratification and to start exploring potential risk factors for
pneumococcal carriage was further developed to investigate serotype-specific
differences in both transmissibility and duration of carriage. The details of this analysis
are given below.
7.3.2 Model structure
Using a similar structure to the one developed for the 2-state model, where the
individual's state at each visit was coded as O=susceptible and I=pnc carrier, a 3-state
model was built where individuals can be susceptible (status code = 0), carrier of one of
the Target Serotypes TS (where TS: 6B, 6A, 14, 19F, 23F) (status code = 1) or carrier of
any Other Serotype as (status code = 2). In other words, due to the presence of 34
different serotypes in the dataset it was not possible to treat each of them separately and
thus the model's framework was set to look at one serotype per time vs. carriage of any
of the other 33 types. The household state at each visit was derived combining the
carriage status of all the family members and resulted in a sequence of Os, 1s and 2s if
their information was complete. For example, the 9 possible statuses of a family of two
individuals would be: 00, 01, 02, 10, 11, 12, 20, 21 and 22 (Le.I2 means that the first
individual in the family was carrying the target serotype TS at a specific test point and
the second person in the family was carrying one of the other 33 types). Five distinctive
datasets were thus derived, i.e. one for each of the TS considered. For example, in
Figure 7.1 the family status at the first swab is 0121 if TS=6A and 0212 if TS=6B.
As in Chapter 6 the individual probability of acquiring pneumococcus was defined as a
function of two components: a within family acquisition rate and the acquisition rate
from the community. Whereas community acquisition rates were age and serotype-
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specific (but constant in time and in different households), the within family acquisition
rate was time dependent being a function of the number of other household members
carrying that particular type at that time.
An SIS structure was assumed (Figure 7.2), and thus no immunity after a carriage
episode was considered in the current model. Thus, when individuals recovered from a
carriage episode (at an age and serotype-dependent rate f.l) they became susceptible
again to that specific type as well as to other types. Moreover, a new type can be
acquired although the host is already colonised by a different pnc serotype (C1->C2 and
C2->C1). The force of infection (FOI), however, for both these flows is adjusted by two
competition parameters (cs, where s= 1,2) that provide the relative risks of acquiring a
serotype if already colonised with the other, compared with a noncarrier. When cs=O,the
model assumes complete competition between the types, so that the presence of one type
fully protects against colonisation with the other types. When cs=l carriage of one type
does not affect the individual susceptibility to other types. Moreover, the model assumed
that individuals are co-colonised with more than one Pnc serotype for a very short
period, after which one type will out-compete the other. This allowed the model
structure to remain relatively simple (3 possible states to deal with) and close to our
original model. The addition of a fourth state (co-colonised individuals, i.e. Cd would
have required the use of alternative statistical techniques due to the impossibility of
dealing with 4 states within this modelling framework.
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Figure 7.2 - SIS model structure for estimating serotype-specific transmission
parameters.
S
Susceptible
C1
Carrier TS Carrier OS
TS=target serotype; OS=other serotypes
Due to the additional complication that generated from dealing with a 3-state (rather
than 2-state) model, it was decided to adopt the simpler age stratification «5, 5+ years)
rather than the 4 age groupings that were used in section 6.4.5. The probabilities of
transition from an infected to an uninfected state (Cs->S) and vice versa (S->Cs) in a
short time interval ot were thus defined for an individual in the age class i=a,c (where
c=child «5 years) and a=adult (5+ years». Differently from the previous model, these
probabilities now also depend on the serotype s (where s=I,2).
The following set of equations describes the model probabilities of transition between
the states:
Pi (C, ~ S)ot = f.tf . ot
Pi (S ~ Cs)ot = A.~.ot
Pi (C2 ~Cl)a ;::cl .Ali .bI:
Pi (Cl ~C2)a =c2 'A2i .bI:
[7.1]
[7.2]
[7.3]
[7.4]
The FOI of type s for an individual in the age group i(+-5 yrs) is defined as follows:
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[7.5]
where !-lis and kis are, respectively, the clearance and the community acquisition rates of
type s for age class i and z is the family size. 18S(t) and IcS(t) are the number of,
respectively, infected adults and infected children (type s) in the family. ~s. is the
1J
transmission rate of type s from an infected to an uninfected individual and it reflects
both the infectiousness of an individual in the age class j and the susceptibility of an
individual in the age class i. It was assumed w=l , given that the estimate derived in the
previous chapter was very close to one (w=l.184). A more detailed description of the
model parameters can be found in Chapter 6 and is summarised in Table 7.1.
Table 7.1- Description of model parameters/variables and symbols.
Description of model parameters/variables Symbol used
Community acquisition rate (child)
Community acquisition rate (adult)
Within family acquisition rate (adult to adult)
Within family acquisition rate (adult to child)
Within family acquisition rate (child to adult)
Within family acquisition rate (child to child)
Recovery rate (child)
Recovery rate (adult)
Density factor
Family size
Number of children in the HH carrying s at time t
Number of adults in the HH carrying s at time t
Relative risk of acquiring type 1 if already colonised with type 2
Relative risk of acquiring type 2 if already colonised with type 1
z
HH = household; s = 1,2
Different levels of model complexity (Table 7.2) were investigated comparing the
overall likelihood and calculating the change in the deviance and in the number of
parameters (d.f.). The following nested model structures were considered:
164
Model AO (Baseline model): different community acquisition rates (ki1:;t: k/)
Model AI: different community acquisition rates and recovery rates, i.e different
duration of carriage (kl1:;t: k? and f.ti1:;t:f.t?)
Model A2: different transmissibility (131/=0.13;/),community acquisition rates
and recovery rates (k/:;t: k? and f.t/:;t:f.t?)
Model A3: different transmissibility (f3i/:;t:f3/, 8 f3ij in the model), community
acquisition rates and recovery rates (~1:;t: k? and f.t/:;t:f.t/)
Model A 1 was compared to model AD and, if it resulted significantly different, A2 was
compared to A 1 and so on. When no statistically significant difference was detected the
model was no longer considered.
Table 7.2 - Description of the parameters of the four model structures
Model parameters
ST-specific ~ ST-specific f.t ST-specific k Number of
Model (B1 :;t:B2) (!! 1:;t:!!2) (kl:;t:k2) parameters
AO No No Yes 10
Al No Yes Yes 12
A2 a factor Yes Yes 13
A3 Yes Yes Yes 16
B'vbeta matrices; t1=recovery rate vectors; k=community acquisition rate vectors, where
s=1,2
Initially individuals already colonised by one type were assumed to be fully protected
against carriage of other types (Cl=C2=O). This assumption was then relaxed extending
the best-fit model for each of the serotypes to incorporate competition between the TS
and any other type (Model B).
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7.3.3 Parameter estimation
Maximum likelihood techniques were used as in Chapter 6 to estimate the model
parameters. Profile likelihood confidence intervals for predicted values were also
calculated numerically (Armitage & Colton, 2004).
7.4 Results
7.4.1 Data
The maximum number of serotypes carried throughout the study period and among all
study participants was 5. Two hundred and twenty two individuals (45%) carried 1 or 2
serotypes, 35 carried 3 (7%), and 20 (4%) carried 4 or 5 serotypes. In Figure 7.3 the
proportion of individuals carrying 0,1-2, 3 or 4+ serotypes is shown for different age
groups and highlights that children from 6 months to 4 years of age are the ones that
carried the maximum number of serotypes during the 10-month period.
Some serotypes (6B, 19F, 23F, 6A, 14) were detected 6 or more times in the same
individual though the majority of the types were found less than 3 times in the same
person (Figure 7.4).
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Figure 7.3 - Number of serotypes carried by each individual throughout the 10 months.
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Figure 7.4 - Number of carriage episode per carrier per serotype.
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In Figure 7.5 the proportions of consecutive carriage episode for the five most common
types are given and show that serotypes 6B, 19F and 23F were found in 6 or more
consecutive swabs, respectively, 8%,2% and 3% of the times they were carried.
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Figure 7.5- Number of consecutive positive swabs for the most prevalent serotypes.
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7.4.2 Model results
The parameter estimates for the different model structures and p-values are shown in
Table 7.3-Table 7.7. Parameter estimates from the non-ST specific model (Model AO)
are reported in each table so that comparisons can be made and the significance of the
ST-specific results can be assessed. Models reporting parameter estimates in bold
represent a significant improvement from the previous model structure. The significance
of competition parameters is assessed comparing the best-fit model (the last model on
the right in each table with results in bold) to the extended version of the same model
(Model B) that includes competition parameters (c, and C2).
Evidence of a significant improvement in the model fit was demonstrated when
comparing the non-ST specific model results to any of the ST-specific models. Estimates
of the recovery rates (and thus duration of carriage) for serotype 6B were significantly
different from the ones of the other types (X/=IO, p<O.OOI),with type 6B being carried
on average 67 days in children < 5 years of age and only 9 days in older family
members. Interestingly, serotype 6A appeared more transmissible than the other types
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(a=4.85), after adjusting for differences in the recovery rate (X12=16, p=O.OOll). For
serotype 14 significant serotype and age-related differences in transmissibility and
duration of carriage were detected (Xl=16, p=O.OOI),with the latter as short as 7 days in
children <5 years of age. The model derived different recovery rates also for type 19F
whereas no evidence of a statistically significant serotype-specific behaviour for type
23F was estimated.
In Figure 7.6 and Figure 7.7 community acquisition rates and duration of carriage (with
95%CJ) are shown for the different serotypes. For all the serotypes the community
acquisition rate was considerably higher in children than in older individuals, with type
14 being acquired mostly by children and at a very high rate (though the confidence
intervals are very wide). Differences in the duration of carriage were found both
between the two age categories and also among the model serotypes. Results for types
6B, 6A and 23F confirmed the previous finding (Chapter 6) that the duration of carriage
is longer at younger ages. On the other hand, the serotype specific model highlighted
that for some of the types (Le. 14 and 19F) this relationship may not be valid.
169
o~-
o....
or-.....
-r--
<""l
OO'<l'''''''''NN''!~9--.::t-M- --.::t"""'l.o
o
o.....
00
'O ...... \(")('f')M .......V;--V')f't"")M--d~<
o
o.....
In-ONM-OM
"'(':I "'<""l0-000000000000000000
<""l!::l88
80000000
00 <""l
-'<I"
o
Figure 7.6- Community acquisition rate from ST-model A3, 8 betas.
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Figure 7.7- Duration of carriage from ST-model A3, 8 betas.
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In the tables above the relative risks of acquiring the TS if already colonised by the other
serotype are given in Model B for the different serotype and using the best-fit model. It was
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assumed that CI may be different to C2, which implies that the reduction in the FOI of the
target serotype (when the individual is carrying some other type) is not equal to the one
observed in the other types when the individual is carrying the target serotype. Large variation
in the ability of TS to colonise individuals carrying other types were shown with the relative
risk of a carrier of another ST (compared with a non-carrier) acquiring the TS ranging from
60%-100% for ST 6A, 6B and 14, but only 13%-15% for ST 19F and 23F. The model
estimated that carriage of 6B significantly reduces the individual susceptibility to other types
(RR=33%).
7.5 Discussion
In the last two chapters a modelling framework has been presented for analysing longitudinal
family carriage studies. The model developed in Chapter 6 was here extended in order to
incorporate serotype-specific information at the individual level that was produced during the
study period when carriage was detected. This was an essential extension considering that
evidence of the diversity of Sipneumoniae serotypes had already been shown in the past
(Smith et al., 1993;Ekdahl et al., 1997;Brueggemann et al., 2003). To ignore these
dissimilarities would have been inappropriate, especially considering that one of the final
objectives of this thesis is to investigate pneumococcal transmission dynamics in the presence
of an intervention strategy such as vaccination. Differences in the characteristics of
pneumococcal serotypes as well as strain interaction (competition) may lead to serotype
replacement after the implementation of a vaccination policy (Lipsitch, 1997;Lipsitch,
1999;Lipsitch et al.,2000) (Chapter 8).
The model developed in this chapter estimated that pneumococcal serotypes may present
substantial differences in terms of both colonisation and clearance rates. Some serotypes (6A
and 14) appeared to be more transmissible and with higher clearance rates than the other
types, with children carrying serotype 6A for longer than adults and the other way around for
serotype 14. The duration of carriage for serotype 6B was considerably higher in children (67
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days) than in adults (9 days) as well as for serotype 23F, though, for the latter, the difference
was not as striking (31 VS. 20 days) and not statistically significant (p-value >0.1).
Interestingly, the overall community acquisition rate, obtained adding the 5 serotype-specific
rates derived here, is considerably higher than the one estimated for all the serotypes together
in the non serotype-specific model of Chapter 6 (0.018 vs. 0.012). This highlights the major
limitation of the non serotype-specific model, which consisted in not using the serotype
information and assuming that prolonged carriage episode occurred rather than clearance and
acquisition of a different serotype.
Allowing for partial competition between the serotypes (i.e individuals can be infected with
one serotype when already colonised by a different one) improved the model fit substantially.
Estimates of the competition parameters showed that carriage of some serotypes (i.e. 6B)
might significantly reduce the individual susceptibility to other types. Moreover, the relative
risk of a carrier (compared with a non-carrier) acquiring serotypes 6A, 6B and 14 was quite
high (69-100%) as opposed to the one for ST 19F and 23F, which was around 15%.
Great dissimilarities have been estimated between the five target serotypes, both in terms of
transmission parameters and of existing interactions that may influence their behaviours.
These represent important aspects in the analysis of host-pathogen interactions. Modelling
work on interference among viruses was addressed by the pioneering works of Dietz (Dietz,
1979) and Elveback and colleagues (1964;1968) who looked at competition of two virus
populations in a community and derived mathematical conditions for coexistence. Their work
has been greatly extended in recent years (Dietz, 1979;May & Nowak, 1994;Nowak & May,
1994;Gupta et al., 1994a;Gupta et al., 1994b;Gomes et al., 2002) when several models for
multi strain infections have started to appear in the literature addressing issues such as
intraspecific competition, replacement, cross immunity between strains and super-infection, in
which one strain replaces another within the host. Gupta and colleagues (l994a), in particular,
introduced the concept of parasite heterogeneity in the mathematical modelling field, and
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showed the effects of intraspecific parasite diversity (i.e. virulence and transmissibility) on the
transmission dynamics of Plasmodium Jalciparum.
To our knowledge, this is the first time that the level of competition/interaction between
different variants of the same organism in human population has been estimated. Lipsitch and
colleagues (2000) investigated competition among two pneumococcal serotypes in a mouse
model and found that carriage of the resident strain (6B) significantly inhibited acquisition of
the challenge strain (23F) at the lowest challenge dose. However, the inhibition did not appear
at higher doses of the challenge strain. The framework developed here has certainly taken
forward the understanding of pneumococcal transmission dynamics that was achieved in the
previous chapter. This is a highly diverse pathogen, and to consider all the different variants
that are circulating as if they were the same (as we did in Chapter 6) certainly represents a
major limitation. However, the model developed here does suffer from one significant
problem, which consist of being able to include only one serotype at a time. Ideally, a
multiple serotype model should have been used to investigate the diversity among the
serotypes and to establish a one-to-one relationship, at least, between the most common ones.
An individual based model would be necessary to incorporate the dissimilarities we have
found among the serotypes and the development of such a model is beyond the scope of this
thesis.
The following chapter presents a transmission dynamic model of carriage of vaccine and non-
vaccine serotypes. It was intended that the analysis presented here would inform the
competition parameters in the model. Unfortunately, the complex relationship between the
serotypes precludes a detailed parameterisation of this model. Nevertheless, the results
presented here certainly suggest that competition between serotypes may well exist. Hence,
serotype replacement must be considered in models of the effectiveness and cost-
effectiveness of pneumococcal conjugate vaccine. These are addressed in the following
chapters.
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CHAPTER 8 - DYNAMIC MODELS OF
PNEUMOCOCCAL CARRIAGE AND VACCINATION
8.1 Aims
• To develop and apply a transmission dynamic model to assess the effect of different
vaccination strategies on the age-specific prevalence of carriage of vaccine (VT) and non-
vaccine (NVT) serotypes.
8.2 Introduction
As reported in Chapter 2 of this thesis, evidence from various countries has started to build up
over the past few years on the direct and indirect effects of conjugate vaccines against
pneumococcal carriage and disease. Though most of the available literature highlights a
reduction in both carriage and disease among vaccinated and unvaccinated individuals, some
data are also available on an increase in the carriage prevalence of serotypes not contained in
the vaccine. Moreover, an increase in disease caused by non-vaccine serotypes has been
observed suggesting that replacement in carriage may also lead to replacement in disease
(Chapter 2). This phenomenon may not only have worrying implications on the outcome of
any vaccination programme but should also be considered when evaluating its economic
acceptability and the consequent allocation of public health resources.
Mathematical models have been used extensively to describe the dynamics of infectious
diseases (Anderson & May, 1991) and to predict the effects of vaccination against many
childhood infections, including rubella, measles (Anderson & May, 1983;Babad et al.,
1995;Gay, 2004) and varicella (Halloran et aI., 1994;Brisson et al., 2000). Through
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modelling, the direct and indirect effects of intervention programmes (such as herd immunity,
change in the age distribution of disease) have been investigated and policies have been
implemented on their findings. The effects of intervention programmes on multi-strain
bacteria, such as the pneumococcus, are, however, complex. Predicting them requires analysis
of the interaction (or interference) between the circulating serogroups as well as knowledge of
their characteristics, i.e. duration of carriage, transmissibility and pathogenicity/invasiveness.
The impact of vaccination on the coexistence of competing strains of the same pathogen was
addressed firstly by McLean (McLean, 1995) and a few years later by White and colleagues
(White LJ et al., 1998). White and colleagues (1998) conceptualised different forms of
interaction through the immunity developed by the hosts and noted that 'the disturbance of the
observed equilibrium by vaccination against the observed strain can allow other, out-
competed, strains to invade or increase in incidence/prevalence'. Over the past few years, a
few attempts to model S.pneumoniae infection have started to appear in the literature
(Lipsitch M., 1997;Lipsitch M., 1999;Auranen et al., 2000;Temime et al., 2003;Eerola et al.,
2003;Temime et al., 2004) and, although complete information on the biological and
immunological characteristics of the organism is still missing, some insights into its
transmission pattern have started to build up. Lipsitch (1997) developed a deterministic
transmission dynamic model to look at the impact of vaccination against H.injluenzae and
S.pneumoniae, both colonizing bacteria with multiple serotypes. This model differs from the
previously developed models (May & Nowak, 1994;Nowak & May, 1994;McLean, 1995) as
it assumes that hosts can be co-infected with multiple serotypes and that competition between
serotypes is mediated by reduced colonization probabilities in a host already colonized with
another serotype. Recently, the importance of these indirect effects on the dynamics of
resistant pneumococci has been investigated by Temine and colleagues (2003;2004) who
showed not only that an overall reduction of colonization may not occur (i.e. non-vaccine
serotypes may replace vaccine ones) but also that vaccination alone may not be successful in
controlling selection for resistance in S.pneumoniae.
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In the previous two chapters novel modelling techniques have been utilised to estimate
pneumococcal transmission parameters and duration of carriage episodes. The diversity of the
organism has been highlighted and knowledge of the serotype-specific differences in
transmissibility and duration of carriage has been taken forward. In this chapter a realistic
age-structured (RAS) transmission dynamic model (Schenzle, 1984) will be developed to look
at the medium and long-term effects of vaccination on carriage of vaccine and non-vaccine
serotypes. Parameter estimates will be drawn, where possible, from Chapter 6 where
pneumococcal carriage in general was looked at rather than serotype specific behaviours.
Parameter estimates obtained in Chapter 7, though they have deepened the understanding of
the diversity of pneumococci, will not be used here.
The three aspects that differentiate this model from previous works (Lips itch, 1997;Lipsitch,
1999) are: the inclusion of a realistic age structure, the use of parameters estimated from
population-based carriage data and the mixing assumptions. An age-structured model was
considered essential to assess the public health and economic impact of different vaccination
policies, since the risk of disease (IPD, pneumonia, otitis media) is highly correlated with age
(Chapter 3). Moreover, age-related vaccination programmes (such as addition of booster
doses, or age-based campaigns) are under consideration and to properly evaluate their impact,
the age-specific prevalence of VT and NVT post-vaccination needs to be derived. In the past,
transmission dynamic models of S.pneumoniae have all assumed homogenous mixing (i.e.
random mixing), which means that every individual is equally likely to come into contact
with every other individual regardless of age, sex, or other stratification. This is not a
reasonable assumption for pneumococcal disease, where transmissibility (and thus the force
of infection) is not age independent (Chapter 6). Alternative forms of mixing pattern will be
explored here and their impact on the outcome of the different vaccination strategies (in terms
of the overall and age-specific prevalence of carriage) will be assessed.
It is important to note that the analysis of this Chapter (which only considers pneumococcal
carriage), represents the first step in the investigation on the impact of vaccination
programmes and further work will be pursued to extend the current model to include
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pneumococcal disease (lPD, pneumonia, otitis media). This should provide estimates of the
changes from pre to post-vaccination in the disease incidence rates for England and Wales,
which could then be used to improve the economic evaluations presented in Chapter 9.
This chapter is structured as follows. Firstly, a section on the estimation of the force of
infection for VT and NVT from the longitudinal carriage dataset presented in Chapter 6 will
be provided. This is necessary information to parameterise any mathematical model of
pneumococcal carriage and transmission. Secondly the development of a RAS transmission
dynamic model for pneumococcal VT and NVT carriage will be presented. In the results
section the impact of different vaccination strategies will be investigated and sensitivity
analyses of the different model assumptions will be performed. A discussion section will
conclude the chapter.
8.3 Estimatingthe force of infection
As seen in Chapter 2, a number of factors may influence the individual propensity to carry an
organism such as the pneumococcus. From individual characteristics (such as age, health
status, etc) to other external factors related to the condition of the environment in which the
person is. Whereas more complicated modelling techniques are needed in order to factor in
the latter elements, individual characteristics, such as age, can be included in relatively simple
deterministic models by adopting age-dependent parameters. The force of infection, defined
as the 'per-capita rate at which susceptibles acquire infection' (Anderson & May, 1991) is, for
many pathogens, age-dependent, and is a function of the probability of effective contacts
between individuals, which may vary by age, and the age-dependent prevalence of infection.
Whereas the latter can be inferred from population based study, such as the longitudinal study
presented in Chapter 6, effective contact rates are much more difficult to estimate as they
depend on a number of factors difficult to measure, most importantly individual susceptibility
and infectiousness, and type of contacts. Estimating the force of infection is a crucial step for
any transmission dynamic model as it provides ways of estimating the effective contact rates,
which otherwise would be unknown.
182
8.3.1 Method
8.3.1.1 Model definition
The first stage in parameterising the force of infection is to choose an appropriate model
structure. As the analysis in Chapter 6 showed, individuals are likely to experience many
episodes of pneumococcal carriage in a lifetime, so a strict SIR model would be inappropriate.
The simplest structure is an SIS model. Alternatively, models including temporary or partial
immunity could be used (Gomes et al., 2004). Though models with immunity may be the
most appropriate to consider pneumococcal carriage and transmission, it would require a
complicated structure which could incorporate serotype specific immunity and also cross
protection between serotypes (i.e. carriage of one serotype may not provide equal protection
against all other serotypes), with a corresponding increase in the number of parameters
required to be estimated. However, due to the fact that VT and NVT were considered here and
that definitive information on the cross protection between serogroups is lacking, an SIS
model structure, similar to the one used in Chapter 7, appears to be adequate. This model
structure is the most parsimonious option, and will assist in further model development
(Figure 8.1).
Figure 8.1 SIS model structure for estimating the forces of infection for VT and NVT
S
Susceptible
VT carrier
BOTH
Co-colonised
NVT carrier
The model parameters are described in Table 8.1. Differently from the structure of Figure 7.2,
individuals of age i can be co-colonised by one serotype that belongs to the VT group and
another one that falls into the NVT category (i.e, 14 and 5). However, the rate at which co-
colonisation occurs depends on the age-dependent force of infection (see later section) and
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also on two competition parameters that determine the relative risk of acquiring a vaccine
serotype if already colonised by a non-vaccine serotype (cv) and vice versa (CN)' These
parameters are similar to the ones that were used in Chapter 7 to regulate the flows VT->NVT
and NVT->VT, although in the current chapter co-colonisation status is explicitly considered.
As the knowledge on the interactions between vaccine and non-vaccine serotypes is scarce,
the effects of three levels of competition are explored in the following analysis. These are
c=O.1 (strong competition: carriers of one type are less likely to acquire the other type than
individuals who are not carrying), c;:::;0.7(weak competition), c=I (no competition: VT and
NVT carriage prevalence are independent).
Table 8.1 - Description of model parameters/variables and symbols used.
Description of model parameters/variables Symbol used
Age-dependent recovery rate from VT carriage
Age-dependent recovery rate from NVT carriage
Age-dependent force of infection ofVT
Age-dependent force of infection ofNVT
Relative risk of acquiring VT if already colonised by a NVT
Relative risk of acquiring NVT if already colonised by a VT
The subscript i represents the age group
8.3.1.2 Model parameters
The recovery rate was assumed to be equal to the inverse of the duration of carriage,
estimated to be 72, 28, 18 and 17 days for, respectively the 0-1, 2-4, 5-17 and 18+ age groups
(Chapter 6). Recovery rates for VT and NVT were assumed to be the same (rVi=rNi).Though
this is a simplistic and, possibly, unrealistic assumption, the wide diversity of the serotypes in
terms of recovery rates (Chapter 7) does not allow an accurate estimate of the recovery rate
for vaccine and non-vaccine serotypes.
The forces of infection for, respectively, VT and NVT were assumed to be step functions, so
that a constant value was assumed within each of the following age groups: 0-1, 2-4, 5-9, 10-
19,20-29,30+ years.
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8.3.1.3 Fitting the model to the data
Maximum likelihood (Brown & Rothery, 1993;Williams & Dye, 1994;Hilborn & Mangel,
1997) was used to fit the model and function parameters to the carriage data (see Chapter 6,
section 6.4.1 for more details).
To fit the force of infection model parameters to the carriage data, where individuals can exist
in one of the 3 mutually exclusive compartments (S, VT, NVT) a multinomial model was
required. For simplicity, it was assumed that all co-colonised individuals were detected as
vaccine-serotype carrier and, thus, included in the VT compartment. This appeared a
reasonable assumption as the serotyping procedure in the laboratory favoured the detection of
vaccine serotypes (personal observation). The log likelihood of this model is:
[8.1]
Where i = age group, VT = observed number of VT carriers, vt=predicted prevalence of VT
carriers, NVT = observed number ofNVT carriers, nvt=predicted prevalence ofNVT carriers,
S = observed number of susceptibles, s=predicted prevalence of susceptibles.
The saturated log likelihood (i.e. the log likelihood that would be expected if the model
predicted the observed data perfectly) was derived and the deviance was calculated as twice
the difference between the saturated log likelihood (JogL') and the model log likelihood
(JogL): Deviance = 2*(logL· -logL). The combination of parameter values that minimised the
deviance were obtained using Excel's solver tool. The carriage data were split into 16 age
groups, which gave 20 degrees of freedom (16*2-12 parameters).
8.3.2 Results
The best fitting force of infection parameters for the SIS model are shown in Table 8.2 and
the resulting carriage prevalence curves are shown in Figure 8.2, where the model estimates
are compared to the observed data. The model appeared to fit well, except at age 0-5 months.
This results in a deviance of 37-39 (depending on which competition parameter was adopted)
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which, given the 20 degrees of freedom, indicated that it remained a fairly small amount of
unexplained variability in the data (p=0.006), mostly due to the lack of fit in the first five
months of life (which contributed 16 to the overall deviance) (Figure 8.2). Although in fact 3
children aged 0-5 months (n=16) were found to be carriers, for none of them serotype
information was available and thus these data were not included in the analysis.
Table 8.2 Estimated weekly force of infection for VT and NVT by age and competition
parameters.
c=O.l c=0.7 c=l
Age group VT NVT VT NVT VT NVT
0-1 0.1026 0.0438 0.0847 0.0438 0.0781 0.0439
2-4 0.0687 0.0418 0.0588 0.0415 0.0550 0.0415
5-9 0.0399 0.0355 0.0368 0.0354 0.0355 0.0354
10-19 0.0239 0.0295 0.0229 0.0294 0.0224 0.0295
20-29 0.0336 0.0107 0.0331 0.0107 0.0328 0.0107
30+ 0.0152 0.0156 0.0151 0.0156 0.0149 0.0156
Deviance 39.09 38.08 37.65
Figure 8.2 Estimated vs. observed carriage prevalence by age.
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The remaining part of this chapter will focus on the development of the transmission dynamic
model using the forces of infection and the steady state prevalences just derived.
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8.4 Transmissiondynamicmodel
8.4.1 Method
8.4.1.1 Population
In the model, the population of England and Wales is assumed to be stable (i.e. births equal
deaths) and no migration occurs. Individuals are born into age class 0 at the start of the year
and live to the age of75 years, at which point they die. Mortality is assumed to be zero up to
this point. The model has a realistic age structure (Schenzle, 1984) and consists of 75 cohorts
of individuals (0, 1, 2, 3, ... 74), which corresponds to each year of age. At the end of each
year individuals grow older: a person in the age group i moves into age group i+1 (3 years old
become 4, etc.) and newly born infants enter the age group O.
8.4.1.2 Model structure
A compartmental transmission dynamic model (Anderson & May, 1991) was developed to
examine the influence of competition and vaccination on the equilibrium prevalence of
serotypes contained and not contained in the 7-valent pneumococcal conjugate vaccine. The
model consists of a set of ordinary differential equations (Figure 8.3), which describes the
natural history of carriage with and without vaccination (Figure 8.4). An SIS-type of model
was chosen (i.e. no immunity after infection) (section 8.3.1). The possibility of co-infection
with both VT and NVT is incorporated in the model. Individuals in the age class i can exist in
one of the 8 following and mutually exclusive compartments (in case of no vaccination there
would be only 4 compartments and the model structure would reduce to that shown in Figure
8.1):
S = unvaccinated non-carriers
VT = unvaccinated Vaccine-Type carriers
NVT = unvaccinated Non- Vaccine-Type carriers
B = unvaccinated co-colonised individuals
Sv = vaccinated non-carriers
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VTv :::;:vaccinated Vaccine-Type carriers
NVTv :::;:vaccinated Non- Vaccine- Type carriers
Bv :::;:vaccinated co-colonised individuals
Individuals are born into the susceptible class at age 0 at the start of each year. Susceptible
unvaccinated (S) and vaccinated (Sv) individuals become infected (VT or NVT) according to
the age-specific force of infection of, respectively, vaccine-type (AVi)and non-vaccine-type
(ANi)pneumococci. These forces of infection are allowed to vary according to the number of
VT and NVT carriers that are present in the population and the age-specific contact rates l3ij,
which will be described in the next section. Individuals carrying VT become co-colonised (B)
according to the force of infection of NVT and the competition parameter (CN)described
earlier. The same goes for NVT carriers becoming also infected with VT at a rate cVTAvi.
Individuals recover naturally from carriage (VT, NVT, B) at an age-dependent rate ri (see
section 8.3.1.2 and 8.4.1.4 for details).
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Figure 8.3- Dynamic model structure in equations (see also figure 8.1)
dSJt) = rVj.V1j (t) +rNi .NV1j (t) -Si (t) .(AvJt) +ANi(t))-vjSj (t) +OJ·SVi(t)
dt
dV1j (t)
dt = Sj(t)· AVj(t) -cN .ANi(t)· V1j (t)-rVi .V1j (t)+rNi .B. (t)-Vj V1j (t)+OJ· VTVi(t)
dNV1j(t)
dt =Sj(t)·ANj(t)-cv ·AVj(t)·NV1j(t)-rNj ·NV1j(t)+rVj ·Bj (t)-vjNV1j (t)
+OJ·NVTvi (t)
dBi(t) ( )~=CN ·ANj(t)·V1j(t)+Cv ·AVi(t)·NV1j(t)-Bj(t)· rNj+rVj -vjBj(t)+OJ·BVj(t)
dSVj(t) (( ) )dt =rVj· VTVj(t)+rNi .NVTvi (t)-SVj (t)· 1-r ·AVj(t)+ANJt) +vjSj(t)-OJ·SVj(t)
dVTVj(t) ()
dt = SVj(t)· 1-r .AVi(t)-cN .ANi(t)· VTVi(t)-rVi .VTVj(t)+rNi .BVi(t)+ vi VTj(t)
-OJ· VTVj(t)
dNVTvi (t) ( )
dt =SVj(t)·ANj(t)-cv .AVj(t)· 1-r .NVTVj(t)-rNj ·NVTvi(t)+rVi ·BVj(t)+ViNV1j(t)
-OJ· NVTvi (t)
dBvJt) ( ) ()dt = cN ·ANJt)· VTVi(t)+Cv ·AvJt)· 1-r .NVTVj(t)-Bvi (t)· rNj+rVi +viBj(t)
-OJ·BVj(t)
AVi= LPVij· (VT/t) + VTVj(t) + Bj(t) + BVjCt))
j
ANi = LPNij .(NVTj(t)+NVTVj(t)+Bj(t)+BVj(t))
Where i is the age group, Vi represents the vaccine coverage in age group i, r, and r, are,
respectively, the recovery rates from VT and NVT infection, co is the rate of waning of vaccine-
induced protection, CNand cv represent the relative risk of acquiring, respectively, NVT and VT if
already a carrier of the other type (i.e. competition parameters), y is the vaccine efficacy against
VT carriage, "'Vi(t)and ANiCt)represent the age-specific force of infection for, respectively, VT and
NVT pneumococci at time t and PVij(PNij)is the effective contact rate for VT (NVT) between an
infected individual in the age group j and a susceptible in the group i.
Vaccination occurs at one point in age, such that in a routine vaccination programme all
infants are vaccinated at the same time, and in a catch-up campaign individuals in the targeted
age group are immunised according to the planned vaccination schedule. This assumes that
vaccination occurs as a discrete event at a specified time point, rather than at a constant rate.
Following vaccination a proportion (=vaccine coverage) of individuals moves into the
equivalent vaccinated compartment according to their status (S->Sv, VT->VTv, NVT-
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>NVTv, B->Bv) and gain partial protection against VT carriage acquisition. The force of
infection of VT pneumococci, among vaccinated individuals, is reduced by a factor (l-y)
where y is the vaccine efficacy. The force of infection of NVT among vaccinated individuals
remains the same as the one among unvaccinated individuals. Vaccinated individuals may
lose their protection and go back to the equivalent 'unvaccinated' compartment (Sv->S, VTv-
>VT, etc.). This occurs at a waning rate w (=1/duration of protection) that is constant
throughout all ages and all the compartments.
8.4.1.3 Model analysis
Numerical results were generated using ModelMaker version 4.0 software (ModeIKinetix,
Reading, UK). The system was solved using high order Runge-Kutta integration of ordinary
differential equations with fixed time steps. The model simulated 20 years (five years pre-
vaccination and 15 years after vaccination) and each run contained 1300 time steps (52 steps
each year, i.e. weekly. time steps). The effects of vaccination on both VT and NVT prevalence
of carriage was explored.
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8.4.1.4 Parameterisation
Initial conditions. The age-specific equilibrium carriage prevalences for VT and NVT,
estimated in the first part of this chapter, were used as initial conditions for the model.
Forces of infection. The forces of infection for VT and NVT were age and time dependent
(I"Ni(t)and "'Vi(t)),varying as a function of the number of vaccinated and unvaccinated vaccine
and non-vaccine serotype carriers (VT, VTv, NVT, NVTv) as well as co-colonised
individuals (B and Bv) in each age class i and the rate of effective contacts between
individuals in the age class i and those in the age class j (l3ij).
Recovery rates. The duration of carriage (1/recovery rate) was assumed to be age dependent
and the same for VT and NVT pneumococci (section 8.3.1). Vaccinated individuals were
assumed to recover from VT and NVT at the same rate as unvaccinated individuals. The
reduction in the prevalence of VT and NVT carriage in vaccinated compared to unvaccinated
individuals was therefore assumed to be only due to a reduced acquisition rate.
Mixing pattern. The effective contact rate (l3ij)represents a crucial element in transmission
dynamic models as it defines the mixing pattern of individuals in different age or activity
groups and thus directly influences the spread of the infection. The standard technique to
consider age-specific mixing pattern in the population is to use a Who-Acquired-Infection-
From-Whom (WAIFW) matrix (Anderson & May, 1991). The WAIFW matrix represents the
effective contact rate between age groups, i.e the rate at which an infected individual in the
age group j infects a susceptible in the age group i. Since the elements of the matrix cannot be
observed directly in the population, they must be estimated using the pre-vaccination force of
infection (assumed to be at time dependent equilibrium) and steady state values for carriage
prevalence. In doing this, alternative mixing patterns can be explored, which can go from
fully assortative (where individuals only mix with those in the same age group), to fully
disassortative where those of one age group do not contact individuals of the same age.
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Between these two extremes an infinite number of alternative mixing patterns are possible
(Garnett & Anderson, 1993).
The effective contact rates (!3vij and !3Nij)were calculated from the equilibrium values of AVi
and ANi (section 8.3) and the number of VT and NVT carriers in the population at steady state
(i.e, initial conditions) and for different values of the competition parameters (c=O.l, 0.7, 1).
Intially, proportional mixing was assumed in order to derive the values for the !3ij. This type of
mixing arises when individuals make contacts with other people in their own or other groups
in proportion to the number of contacts that are supplied from each group (Garnett et al.,
1992)
c·c·N·1 J J
C [8.2]
where Ci and Cj are the number of contacts provided by each individual in, respectively, group
i and j, Nj is the number of individuals in group j and C is the total number of contacts in the
population.
Effective contact rates were also estimated assuming a fully assortative mixing pattern
III .. ={~.Y'IJ _I
I·1
where i:;t:j
[8.3]
where i=]
where Ii is the number of infected (carrier) individuals. This allowed exploring intermediate
levels of mixing (i.e. in between a fully assortative and a proportionate mixing) using the
following formula
[8.4]
and E denotes the degree of assortative mixing (Garnett & Anderson, 1993). When E==I,
mixing is entirely assortative and when E==Omixing is proportionate.
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In Figure 8.5 the different estimates for the elements of the WAIFW matrices are shown, for
both VT and NVT and assuming different levels of assortati veness (&=0,0.5,1).
Figure 8.5 Values of Pij for VT and NVT assuming a different mixing patterns and strong
comnetition hetween serotvnes (c=G.l )
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The left (right) column corresponds to the effective contact rates for VT (NVT). Top graphs correspond
to fully assortative mixing (e=1), middle graphs to an intermediate level of mixing (&=0.5) and the
bottom graphs correspond to proportionate mixing (&=0).
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In the following analysis the proportionate mixing is chosen as the base case, as a fully
assortative mixing assumption would appear unrealistic. The effect of having intermediate
mixing patterns is, however, explored in the sensitivity analysis.
Vaccine associated parameters. In the base case, vaccine efficacy against VT carriage
acquisition (y) is assumed to be 68% (Dagan et al., 2002) although this level was varied in the
sensitivity analysis between 30% and 90% (Table 8.3). Direct protection from vaccination
was assumed to last for 5 years (Lakshman et al., 2003) (w=0.2) and again, w was varied in
the sensitivity analysis between 0.066 (15 years protection) and 0.5 (2 years protection).
Vaccinated VT carriers were assumed to be as infectious as unvaccinated VT carriers. This
assumption was tested in the sensitivity analysis where the infectiousness of vaccinated VT
carriers was reduced up to 70% compared to the one of VT unvaccinated carriers.
Table 8.3 Model parameters for the base case and ranges used in the sensitivity analyses.
Model parameters Range
Duration of carriage (days)":
0-1 yrs of age
2-4 yrs of age
5-17 yrs of age
18+ yrs of age
Base case
72
28
18
17
Initial prevalence of carriage
Initial force of infection
See figure 8.3
See table 8.1
Mixing pattern See figure 8.4 (top graphs) 8=0 and 8=0.5
0.5,0.06
(2 years, 15 years)
Waning immunity (w)
(llduration of protection)
Efficacy against VT carriage
acquisition (y)
Coverage (v)
Routine vaccination
Catch-up vaccination
Age (years): 1
2
3
4
0.2
(5 years)
0.68 0.3,0.9
0.6 0, 1
0.6
0.6
0.6
0.6
aEstimates of the duration of carriage are derived in Chapter 6
195
8.4.1.5 Alternative vaccination policies
The alternative vaccination strategies investigated were:
Strategy 1: routine vaccination at 3 months of age;
Strategy 2: routine vaccination at 3 months of age, plus a catch-up campaign targeting
all those under the age of 5;
Strategy 3: routine vaccination at 1 year of age;
Strategy 4: routine vaccination at 1 year of age, plus a catch-up campaign targeting all
those under the age of 5.
Strategy 1was assumed unless otherwise stated.
8.4.1.6 Sensitivity analysis
Many of the parameter estimates or model assumptions are uncertain. The effect of changing
these parameter values was assessed in a sensitivity analysis. The parameters that were varied
included the duration of protection, vaccine coverage and the vaccine efficacy against VT
carriage acquisition (Table 8.2). Moreover, alternative mixing patterns were also assumed and
the effect of these variations on pneumococcal carriage in different age groups was assessed.
8.4.2 Results
8.4.2.1 Impact a/vaccination on VT and NVT carriage prevalence
Figure 8.6 shows how vaccination might increase the carriage of non-target serotypes, while
reducing the carriage of vaccine serotypes. In the case of strong competition (Figure 8.6a),
non-vaccine serotypes completely replace vaccine ones slightly reducing the overall
proportion of non-carrier individuals (susceptible) in the population. On the other hand, when
weak or no competition between vaccine and non-vaccine serotypes is present (Figure 8.6b
and Figure 8.6c), the overall effect of vaccination is to reduce the proportion of carrier
through a reduction of vaccine serotypes together with a smaller increase of non-vaccine ones.
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Figure 8.6 Steady state values by vaccine coverage
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Moreover the existence of strong competition from non-target serotypes appears to be
beneficial as it reduces the fraction of hosts that must be vaccinated in order to eliminate the
target serotypes «40% instead of 80% under base case assumptions).
In Figure 8.7 the VT and NVT dynamics after vaccination and for different levels of vaccine
coverage are shown. Different levels of competition (strong and weak) have a substantial
impact on both the time to elimination for VT and on the rise ofNVT prevalence. VT carriage
prevalence goes to zero in 9-10 years assuming strong competition, whereas in 14 years when
a much lower level of competition is assumed. Routine vaccination of infants (Strategy 1)
produces a similar, though indirect, effect also among unvaccinated individuals of older ages
(herd immunity) (Figure 8.8). Also, the overall carriage prevalence of the organism may
increase in some age groups (5-9 and 30+ years of age) as a consequence of vaccination,
remaining stable among the 10-29 years of age (Figure 8.8c).
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Figure 8.7- The effects of vaccination on the prevalence ofVT and NVT, by levels of
coverage and competition.
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Figure 8.8- Direct and indirect effects of routine vaccination (Strategy 1).
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8.4.2.2 Alternative vaccination programmes
The impact of vaccination strategies 1 to 4 on carriage prevalence of vaccine serotypes is
shown in Figure 8.9. When VT and NVT are strongly competing (c=O.I) (Figure 8.9a), all the
strategies under consideration eliminate vaccine serotypes from the circulation. Routine infant
vaccination (2,3 and 4 months schedule) with a catch-up campaign targeting children less than
5 years of age (Strategy 2) appear to be the most effective strategy, reducing the prevalence of
carriage more quickly than the alternative policies. Vaccinating at 12 months of age (Strategy
3) is less effective than the routine infant schedule at 2,3 and 4 months (no catch-up) because,
even with a catch-up campaign (Strategy 4), in the medium term potentially preventable cases
occur in the under 1s. When the level of competition between VT and NVT is weaker (c=O.7)
(Figure 8.9b), vaccine serotypes manage to persist in the population, though the strategies that
focus on the very young infants (Strategy 1 and 2) achieve a bigger reduction in VT
prevalence.
Figure 8.9 Prevalence of VT carriage over 15 years following vaccination strategies 1 to 4
(c=O.I).
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8.4.2.4 Sensitivity analysis
It is important to conduct a sensitivity analysis to assess the effect of varying the uncertain
parameter estimates within their likely range (Table 8.3), especially considering that most of
the vaccine related parameters were unknown. In particular, vaccine efficacy, duration of
protection and mixing assumptions will be explored. Moreover, the effect of different levels
of infectiousness of VT and VTv carriers is also assessed. Unless otherwise stated, the
following model parameters are assumed: strong competition (c=O.l), waning rate =0.2 (5
years protection), vaccine efficacy=68% and proportional mixing (s=O).
Efficacy against VT carriage acquisition. The prevalence of VT carriage is highly sensitive
to changes in the assumption on vaccine efficacy against carriage acquisition. The higher the
protection conferred by the vaccine, the faster the decline in the prevalence of carriage. In the
case of low levels of vaccine efficacy (which could result from both vaccine failures and/or
low level of direct protection), the extinction of VT carriage, under a 60% level of coverage,
may not be achieved.
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Figure 8.10 Carriage prevalence under different levels of vaccine efficacy (Strategy 1).
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Waning immunity. The effect of changing the assumption on the waning rate (i.e. duration
of protection of the vaccine) was investigated. If the duration of protection is short, e.g. 2
years (w=0.5), then the initial impact of the vaccination programme is similar, but the
reduction in carriage prevalence is slower and VT persist for longer, though reaching
elimination in around 20 years. If the duration of protection is longer, e.g ~5 years, vaccine
serotypes should disappear from circulation quicker.
Figure 8.11 Carriage prevalence under different assumptions of waning immunity (Strategy
1).
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The above waning rates correspond to the following duration of protection: 15 (w=0.066), 10 (w=O.I),
5 (base case) (w=0.2) and 2 years (w=0.5).
203
Different mixing pattern. The mixing patterns of the population are perhaps one of the most
difficult sets of parameters to quantify. The sensitivity analysis of the mixing parameters is
therefore important. With the only exception of a fully assortative mixing, which is not
realistic, the differences in the estimated prevalence of VT carriage post vaccination are small
when the mixing assumption are changed (proportionate vs. assortative) (Figure 8.12a).
However, the differences in adopting alternative mixing patterns are slightly more evident
when looking at older age groups, which do not benefit from direct protection of the vaccine
and thus have to rely on herd immunity effects (Figure 8.12b). In Figure 8.13 the age
distribution of pneumococcal carriage (all serotypes) is shown under a range of different
mixing assumptions. The expected prevalence in the 0-4 years of age is reduced as a
consequence of vaccination. This results from the shift in the age at infection that is
postponed later on in life, after the vaccine protection has waned (5 years duration of
protection). This is confirmed by the slight increase in the 5-19 years old prevalence when
assuming a non-fully assortative mixing. The prevalence in this age group when assuming a
fully assortative pattern, however, remains at the pre vaccination levels and this may indicate
that mixing between age groups is necessary in order to have an increased overall prevalence.
The age group 20-29 years has a lower prevalence as opposed to the pre-vaccination era and
this is probably due to the fact that carriage prevalence of non-vaccine serotype is, in this age
group, lower than the one for the vaccine serotypes (Figure 8.2). Individuals aged 30+ years
experience an increased prevalence of carriage post vaccination unless mixing is fully
assortative. This may be the result of a higher level of effective contacts with children in the
5-9 years of age who have increased their overall prevalence.
204
Figure 8.12 Expected VT carriage prevalence under different mixing assumptions.
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Figure 8.13 Age distribution of the estimated pneumococcal carriage prevalence under
different mixing assumptions.
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Infectiousness of VTv carriers as opposed to VT carriers. The effect of changing the level
of infectiousness of vaccinated VT carriers as opposed to unvaccinated VT carriers was
explored to test the base case assumption that these two groups were equally infectious
(inf=IOO%). Reducing this level, the overall force of infection for VT decreases and this
generates a faster decline in VT carriage prevalence (Figure 8.14).
Figure 8.14 Expected VT carriage prevalence under different assumptions on the
infectiousness of vaccinated VT carriers
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8.5 Discussion
These models provide useful insights into the potential effects of pneumococcal conjugate
vaccination programmes at a population level. In particular, the work presented in this chapter
shows how VT and NVT medium to long-term carriage dynamics might be affected by the
introduction of the vaccine. Differently from previous modelling work on S.pneumoniae
infection (Lipsitch, 1997;Lipsitch, 1999), the models presented here are age structured, which
also allowed investigating the effects of vaccination on the age specific carriage estimates.
This is useful information considering that the risk of disease is highly correlated with age
(Chapter 3).
Data from the longitudinal study in UK families, presented in Chapter 6 and 7, were used here
to derive the initial prevalence of carriage, recovery rates and the forces of infection. These
allowed the estimation of the effective contact rates between different age groups and under
alternative mixing assumptions.
Several alternative vaccination strategies, that may be considered if/when widespread use of
the vaccine is introduced, were modelled. The predicted impact of these programmes varied
according to the number of people targeted (i.e. coverage level) and the level of
interaction/competition between vaccine and non-vaccine serotypes. When assuming
dependence between VT and NVT, a vaccine-induced reduction of VT carriage prevalence
produced an increase in carriage of NVT, though an overall reduction of the circulating
organism. However, the model showed that a slight increase in the overall pneumococcal
prevalence might occur when very strong competition between VT and NVT is present. In
this latter case, an increase in the prevalence of carriage among older age groups was shown.
Further modelling work is required, as relatively small effects on carriage prevalence, such as
this, may have enormous implications on the disease burden post vaccination, especially if
NVT are equally, or more, pathogenic.
Large herd immunity effects were seen when a catch-up campaign was implemented in
addition to routine vaccination. These indirect effects were much less marked when only
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routine vaccination was considered, although, in the short-medium term, routine vaccination
of very young infants provided a better effect than routinely vaccinating one year olds with a
catch-up campaign targeting children less than 5 years. Carriage prevalence rates are highest
among infants less than 1 year of age and directly targeting this age group has a
disproportionate effect on the overall prevalence. Although the strategies that were simulated
here are those that might be considered in the UK if the recommendation will be
implemented, these models are flexible and can be adapted to consider any vaccination
strategy for any country of interest. An optimal immunisation policy is based on the
epidemiology experienced in the country under consideration, which, in turn, is a result of the
intrinsic characteristics of the organism, pathogen-host relation and, most importantly, mixing
patterns.
The outputs of the model are certainly limited by the quality of the parameter estimates and
model assumptions. In this chapter some efforts have been made to fit the model parameters
to data from the longitudinal study and also to assess the sensitivity of the model to changes
in the parameter values. Model results were shown to be highly sensitive to changes in the
level of competition between VT and NVT. But the model simplistically assumes that
competition is perfectly symmetric (CV=CN), and as this clearly represents a crucial process in
the dynamics of pneumococci, this effect may well dominate the outcome of any vaccination
programme. More work should be done on investigating further different kinds of competition
rather than just considering a reduced susceptibility to infection when already colonised.
Zhang and colleagues (2004) using a transmission dynamic non age structured model
investigated different forms of competition (i.e, direct and indirect). The authors demonstrated
that direct (physical) competition between two serotypes only influences the prevalence of
carriers if the duration of naturally acquired immunity is small, whereas indirect (antibody
mediated) competition is only of influence if naturally acquired immunity is long lasting.
Whether there is any age related effects in these relationships still remains an open question
which deserves some attention, as both the duration of carriage and the risk of disease are
both highly age-dependent.
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Moreover, the reduction in the risk of being co-colonised may depend on the specific serotype
that is already present in the nasopharynx (rather than VT or NVT as was considered here).
Analysis of this issue was performed in Chapter 7 where diverse serotype-specific patterns
were shown. An individual based model should be considered if aiming to study this subject
further as only a model of this kind could incorporate the diversity that may be present.
Similarly, an individual based model could also improve other limiting aspects of the current
model, i.e forces of infection and recovery rates. Here serotypes included in the vaccine are
assumed to be completely identical in terms of transmissibility and, similarly, serotypes that
are not included have the same force of infection. It is well known, and has been shown in
Chapter 7, that serotypes are extremely diverse and that also transmissibility may be serotype-
specific. Also, recovery rates are assumed to be age dependent but the same for VT and NVT.
Again, this was a necessary simplification and alternative assumptions could be explored with
a different type of model.
Another major potential limiting factor is the assumptions made about the mixing pattern in
the population, as the true mixing patterns are unknown. This is a very critical point that
refers not only to the particular model developed here, but also to any model of this kind.
Edmunds and colleagues (1997) attempted to measure the contact patterns directly, through
questionnaire based methods. A larger study using similar method has recently been
conducted in both rural and urban settings, although these results are not yet available (Dr W.
John Edmunds, personal communication).
Assessing the effects of vaccination on pneumococcal disease is certainly the final outcome of
interest. More work will be done on including different forms of clinical conditions that may
derive from an episode of carriage. This will allow first validating the model assumptions
comparing results to data that will continue to be available from surveillance systems.
Secondly, incidence rates under alternative intervention programmes will be generated and
used in economic analyses to assess the cost-effectiveness of the vaccination programmes and
provide advice to policy decision makers.
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This type of analysis may be very useful for countries that are considering the introduction of
the conjugate vaccine. In addition, these models can be adapted to look at different
vaccination strategies for the UK and this will be extremely valuable as more information on
the observed effects of the UK campaign may improve the parameter estimates of the model.
The experience with the Hib and MencC vaccines (Trotter et al., 2003;McVernon et al.,
2004;Trotter et aI., 2004) showed that the post-vaccine era may be far from straightforward
and that continued monitoring of the effects of vaccination on carriage and on the duration of
vaccine efficacy may be critical to the success of the pneumococcal conjugate vaccine
programme.
In the following chapter, economic analysis of the conjugate vaccine will be performed. The
indirect effects of the vaccine, which have been shown to be so crucial in the long-term
dynamics of pneumococcal carriage post vaccination, will be included and their impact on the
cost-effectiveness of alternative vaccination programmes will be assessed.
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CHAPTER 9 - COST -EFFECTIVENESS ANALYSIS OF
PNEUMOCOCCAL CONJUGATE VACCINATION IN
ENGLAND AND WALES
9.1 Aims
• To assess the cost-effectiveness of PCV vaccination in England and Wales;
• To estimate the cost-effectiveness of a range of alternative strategies that may be
considered when a vaccination programme is introduced;
• To investigate the impacts that herd immunity effects and serotype replacement
mechanism may have on the overall cost-effectiveness of the programme.
9.2 Introduction
The importance of economic evaluation for the design of vaccination policies has already
been discussed in Chapter 5 where the then current UK vaccination programme with PPV was
evaluated and the cost-effectiveness of vaccinating all the elderly assessed. A separate
analysis, however, is necessary for the 7-valent pneumococcal conjugate vaccine (PCV)
which was licensed in the UK in 2001 and is currently only recommended to infants aged
between 2 months and 5 years who are at special risk (Salisbury & Begg, 1996). Although
evidence of the direct effect of the 7-valent vaccine on the incidence of Pnc disease (invasive
pneumococcal disease (JPD), pneumonia and AOM) among healthy children has been shown
(Chapter 2) as well as an indirect effect among unvaccinated individuals (Whitney et al.,
2003), changes in the prevalence of carriage of vaccine versus non-vaccine types has also
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been observed among vaccinated individuals (Dagan et al., 2002) and also among their
siblings (Givon-Lavi et al., 2003). A reduction of carriage of vaccine serotypes in the
population, as a consequence of the introduction of PCV, may induce other serotypes not
contained in the vaccine to occupy their ecological niche. Whether this change will have a
positive or negative overall effect at the population level is not straightforward as it depends
on the serotypes that are taking over (which may vary in different geographical regions), their
relative invasiveness as well as the host response to their presence. These indirect effects of
the vaccine are crucial aspects not only when considering the biology of S.pneumoniae
infection and the transmission dynamics in the population, but also when performing cost-
effectiveness analysis of the alternative vaccination programmes. However, as very little
information is available at the time of this analysis on these longer-term effects of the vaccine,
alternative potential scenarios have to be considered and their effects on the economic
analysis assessed.
This chapter addresses the issue of whether universal infant vaccination with the 7-valent
pneumococcal conjugate vaccine (PCV) would be a cost-effective policy under the health care
provider perspective (NHS). The analysis takes into consideration the various uncertainties
related to the burden of pneumococcal disease and the potential for indirect protection (herd
immunity) among unvaccinated individuals as well as serotype replacement effects in the
whole population. Different UK vaccination schedules are considered in the analysis as well
as the sensitivity of the model result to variations in the vaccine price. This work has been
published (Melegaro & Edmunds, 2004c).
9.3 Methods
9.3.1 Cohort model
A model was constructed to follow a vaccinated and an unvaccinated imaginary cohort of
individuals from birth until death. The number of life-years (LY) gained from the vaccination
programme was taken as the primary measure of the outcome of the programme, and this was
compared to its net cost (the net cost being the additional cost of vaccination minus the
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expected savings from the programme in terms of reduced use of health care resources).
Although pneumococcal infection can result in a wide range of outcomes such as invasive
disease, pneumonia, ear infections, sinusitis, bronchitis, arthritis, conjunctivitis, peritonitis,
etc., the model only considers the four major outcomes for which clinical trial data are
available regarding vaccine efficacy: pneumococcal meningitis, pneumococcal bacteraemia,
community-acquired pneumonia (CAP) and AOM. Future benefits and costs were discounted
according to the current recommendations in the UK (HM Treasury, 2003): 3.5% per annum
for costs and 1.5% per annum for health benefits. Herd immunity, i.e. changes in disease
incidence among unvaccinated individuals, is included as part of the scenario analyses
(section 8.3.6) as well as changes in carriage and serotype distribution that may be expected
to occur after the introduction of pneumococcal vaccination. These two scenarios are further
investigated in the multivariate (probabilistic) sensitivity analysis.
9.3.2 Epidemiological data
The epidemiological parameters used in the base case analysis, are shown in Table 9.1 and
Table 9.2. For the base case analysis the average annual incidence of both pneumococcal
bacteraemia and meningitis was derived extracting the number of invasive pneumococcal
disease cases that was reported to the reconciled CDSC/RSIL database (Miller et al.,
2000;George & Melegaro, 2001) (Chapter 3) for the period 1998-2000 and dividing it by the
ONS population estimates for England and Wales and for the same time period.
Age specific incidence rates were used in the model, using 5-year age bands except in those
under 1 year of age, which were grouped in one age category. In the univariate sensitivity
analysis (section 8.3.6) the effect of a further age stratification «6 mths, 6-11 mths) is
explored. The case-fatality ratio (CFR) and the average length of stay (LOS) in the hospital
for IPD cases were derived from Hospital Episodes Statistics (HES) (Department of Health,
2003), using number of deaths and length of stay of all pneumococcal septicaemia (ICD-IO
Code: A403) and pneumococcal meningitis (lCD-10 Code: G001) patients, as reported in the
first diagnostic field for the period April 1997 to March 2000 (Table 9.2).
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Table 9.1 - Estimated annual incidence of pneumococcal related diseases, hospitalisations,
and GP consultations in England and Wales.
Incidence rate" Hospitalisations rate" OP consultation rate"
Age Pnc Pnc Pneumonia
group bacteraemia meningitis with +fiIm AOM Pneumonia AOM
<1 27.3 14.6 221.2 173.2 467 23,636
1-4 10.6 1.6 131.2 203.2 272 24,856
5-9 1.9 0.2 41.7 123.9 62 7,698
10-14 0.7 0.2 17.2 34.3 62 7,698
15-19 1.2 0.1 16.3 13.1 51 2,250
20-24 1.8 0.2 18.1 7.5 51 2,250
25-44 3.1 0.3 26.0 9.1 152 1,741
45-64 6.5 0.5 55.4 11.7 268 1,175
65-74 18.7 0.9 193.6 11.0 508 994
75+ 42.5 0.6 697.7 7.5 1,161 520
OveraII 8.4 0.6 102.7 30.5 266 3,612
All rates are per 100,000 populations per year. aCDSCIRSIL; "Hospital Episode Statistics, first
diagnostic field (ICD-I0 codes for pneumonia: J13, J180, J181, J188, J189; any otitis media
codes used for OM hospitalisattons); "Royal College of General Practitioners (Fleming DM,
1999).
Table 9.2 - Estimated case fatality ratios and length of stay in the hospital.
Age Case-fatality ratio Length of stay (days)
group Pnc Pnc Pnc Pnc
(years) septicaemia meningitis Pneumonia septicaemia meningitis Pneumonia
<1 4% 4% 1% 5.4 10.5 4.4
1-4 1% 4% 0% 4.6 10.2 2.9
5-9 0% 3% 1% 13.1 9.4 3.2
10-14 0% 0% 2% 6.8 7.2 4.0
15-19 0% 11% 2% 11.0 8.9 4.9
20-24 8% 0% 3% 4.7 12.5 5.0
25-44 20% 11% 3% 12.3 14.3 6.0
45-64 26% 18% 14% 12.7 22.1 9.0
65-74 27% 29% 29% 11.3 20.9 11.8
75+ 40% 43% 46% 15.4 25.8 15.4
Overall 22% 12% 29% 11.5 16.9 8.1..Admitted patients reporting Pnc sepncaenua (ICD-IO code: A403), Pnc meningitis (G001) or
pneumonia (codes as in Table 1) in the first diagnostic field.
The number of hospitalisations for CAP was estimated from HES, extracting all records that
were reporting one of the following ICD-IO pneumonia codes in the first diagnostic field over
the period April 1995 to March 1998:
Pneumococcal pneumonia: J13 (ICD-9: 481)
Lobar pneumonia, organism unspecified: JI81 (ICD-9: 481)
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Bronchopneumonia, organism unspecified: J180 (ICD-9: 485)
Other pneumonia, organism unspecified: JI88 (ICD-9: 486)
Pneumonia, organism unspecified: JI89 (lCD-9: 486)
Based on a study by Djuretic and colleagues (1998), 79% of these admissions were assumed
to present with lobar/focal changes and thus were considered in this analysis in order to match
as closely as possible the case definition that was used in the Kaiser Permanente trial (Black
et al., 2002) to estimate the level of vaccine efficacy. Base case age specific hospitalisation
rates were thus derived dividing the number of hospital admissions (first diagnosis) by ONS
population estimates for England (Table 9.1). CFR and the average LOS in hospital for
patients with pneumonia were calculated from the extracted data. The annual GP consultation
rates for pneumonia were derived from the Royal College of General Practitioners (RCGP)
Weekly Returns Service (Fleming DM, 1999) (Chapter 2 and 3).
Acute otitis media hospitalisation rates were derived from HES extracting any hospitalisation
with AOM ICD-lO codes (H650-H678) in the first diagnostic field over the 1999-2000 HES
financial year and dividing it by the corresponding ONS population estimates for England.
RCGP data were used to derive GP consultation rates for AOM.
9.3.3 Vaccine efficacy
In the base case analysis the vaccine was assumed to give no protection against pneumococcal
carriage and, thus, no indirect effects such as herd immunity and serotype replacement were
considered. This scenario appears to be unrealistic, as some protection against carriage and
serotype replacement has been observed on pneumococcal carriage and disease (Chapter 2).
Quantifying the long-term impact of these processes is, however, difficult, hence in the base-
case these indirect effects of the vaccine will be ignored. Vaccine efficacy (VE) against
pneumococcal disease was based on intention to treat results of recent clinical trials and for
IPD this was adjusted to reflect the differing serotype distribution in the UK compared with
the population in Northern California at the time of the study (Black et al., 2000). The base
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case VB against IPD was therefore 63-87% in the first five years of life. VE against all cause
clinical pneumonia with a positive film was assumed to be 17.7% (95%CI: 4.8 to 28.9) (Black
et al., 2002); and VE against any confirmed otitis media was 7% (95%CI: -5% to 17%)
(Eskola et al., 2001). Note also that due to the lack of data on serotype distribution of otitis
media and pneumonia cases, we do not adjust the VE estimates for these conditions. It is
assumed, in the base case, that children who respond to the vaccine become protected at 4
months of age after 3 doses of vaccine have been given (accelerated infant schedule). Prior to
this age, they are unprotected. In addition, the following alternative schedules were also
considered: 3 doses with the protection starting at 6 months of age (non-accelerated infant
schedule); 2 doses with the protection effective from 6 months of age; and 1 dose at one year
of age. Note that in the trials three doses plus a booster were used whereas in the above
schedules one to three doses of vaccine are given, and it is assumed that the reduced dosage
does not reduce vaccine efficacy. Results of phase 2 trials with pneumococcal conjugate
vaccine in UK infants and toddlers demonstrated that 2 doses of PCV given at 2 and 4 months
of age provide satisfactory primary immunogenicity to the serotypes contained in Prevenar
(Goldblatt et al., 2004). Incremental cost-effectiveness ratios were calculated for each
successive alternative, from the least costly to the most, examining the additional costs that
one programme imposes over another, compared with the additional benefits it delivers
(Drummond et al., 1997). Clearly, if vaccine efficacy of the different schedules is the same,
and protection starts at the same age, then the schedule with the lower number of doses will
be preferred. Finally, in the base case we assume a to-year period of vaccine-induced
protection against disease although in the univariate sensitivity analysis the effect of changes
in the duration of protection on the model results were assessed.
9.3.4 Health outcomes
The primary outcome measure was discounted life-years gained. Pneumococcal specific case
fatality ratios were calculated from hospitalisation data (see above). Fatal cases were assumed
to lose the average life expectancy for individuals of that age. Life expectancy calculations
were derived from current all-cause mortality schedules, derived from ONS tables.
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The secondary outcome measure was discounted Quality Adjusted Life-Years (QALY)
gained which can simultaneously capture gains from reduced morbidity (quality gains) and
reduced mortality (quantity gains) and integrates these into a single measure (Drummond et
al., 1997). Reductions in health related quality of life due to pneumococcal disease (calculated
summarised in Table 9.3.
on a 0-1 scale where 1 is equivalent to perfect health) were derived from the literature and are
Outcomes from meningitis
Table 9.3 - Outcome from a meningitis episode and QALY lost of pneumococcal diseases
% Children Source
Severe bilateral hearing loss
Other sensorineural hearing loss
Conductive hearing loss
Seizures
14
16
19
16
(Hussain et al., 2003)
(Hussain et al., 2003)
(Hussain et al., 2003)
(Hussain et al., 2003)
Outcomes from PDC diseases QALYloss
Bacteraemia
Meningitis
- Bilateral hearing loss (first year)
- Bilateral hearing loss (subsequent years)
- Other hearing loss (all subsequent years)
Pneumonia
- Outpatient
- Inpatient
OM
0.0079b
0.0232 b
0.460·
0.200·
0.100·
(Bennett et aI., 2000)
(Bennett et aI., 2000)
(Cheng & Niparko, 1999)
(Cheng & Niparko, 1999)
(Oostenbrink et al., 2002)
0.004b
0.006b
O.005b
(Void & Owens, 2000)
(Void & Owens, 2000;Bennett et al., 2000)
(Oh et aI., 1996)
"peryear; per episode
A recent study (Prosser et aI., 2004) has suggested that the QALY's lost due to acute
pneumococcal disease are far greater than the values used here. These estimates were not used
in the current analysis as they are orders of magnitude greater than the other estimates
available in the literature. Note that due to the paucity of data, the proportion of IPD patients
developing sequelae and the QALY weights attached to these were assumed not age-
dependent. This is unlikely to be the case. However, it will only affect the results of the herd
immunity scenario (see below), as direct vaccine-induced protection is not assumed to be Iife-
long. As the elderly are more likely to have pre-existing morbid conditions, the QALY loss
from the herd-immunity scenario is likely to be overestimated. Other outcome measures
include GP consultations avoided, hospitalisations avoided and deaths avoided.
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9.3.5 Costs estimates
The perspective of the study was the health care provider (NHS). Costs to the patient and their
carers (i.e. absenteeism, travel to clinics etc) were ignored because of a lack of data on the
wider (societal) costs of pneumococcal disease in the UK. Average unit costs estimates of, for
instance, an inpatient day and GP consultation, were taken from standard sources and are
listed in Table 9.4. The cost per vaccine dose was set to £30, assuming a volume based
discount of approximately £9 (list price of the vaccine is £39.25 per dose (British Medical
Association, 2002). The cost per infant of vaccination was calculated multiplying the cost of a
vaccine dose by the number of doses and making an additional allowance of £ 10 per child per
dose (nurse consultation cost (Netten & Curtis, 2002» for the administration of the schedule.
All costs were measured in pounds sterling at 2002 prices. The average cost of a meningitis
case was derived from a case notes review of all meningitis cases <5 years age from 4 regions
reported to CDSCIRSIL between 1996 and 1999 (Hussain et al., 2003). This was calculated
considering the proportion of patients that experienced different types of sequelae (Table 9.3)
and estimating their related cost using standard sources (Netten & Curtis, 2002;Hussain et al.,
2003). Similarly, an additional annual cost to the health service was estimated for the
subsequent years considering the additional visits and therapies resulting from chronic
sequelae of pneumococcal meningitis. Hospitalisation cost for otitis media included the cost
of minor ear procedures (most would be tympanostomy) and one ENT outpatient visit. All
costs were varied in the sensitivity analysis between +1-25% of their base case values.
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Table 9.4 - Unit costs of care and treatment parameters.
Parameter Base Value (Ranze) Source
Cost per vaccine dose
(British Medical Association,
- Cost of vaccine (£) 30 (22-37) 2002)
- Administration cost (£) 10 (7-12) (Netten A & Curtis L, 2002)
- Number of doses 3
Cost per inpatient day
- Mean cost of inpatient day (general ward) (£) 273 (205-341) (Netten A & Curtis L, 2002)
- Mean cost of inpatient day (paediatrics) (£) 398 (298-497) (Netten A & Curtis L, 2002)
- Mean cost of intensive care bed/day (£) 1,232 (924-1540) (Department of Health, 2002)
- Mean cost of paediatric intensive care bed/day (£) 1,384 (1038-1730) (Department of Health, 2002)
Mean length of stay in hospital
- Bacteraemia (days) II (variable by age) RES
- Meningitis (days) 17 (variable by age) RES
- Pneumonia (days) 8 (variable by age) RES
Proportion of bed-days on intensive care (adult)
- Bacteraemia (%) 5 (3.7-6.2) RES
- Meningitis (%) 10 (7.5-12.5) RES
- Pneumonia (%) 1 (0.7-1.2) RES
Proportion of bed-days on intensive care (child)
- Bacteraemia (%) 3 (2.2-3.7) HES
- Meningitis (%) 6 (4.5-7.5) HES
- Pneumonia (%) 0 RES
Other costs (acute stay)
Bacteraemia & Pneumonia
- X-Ray (£) 16 (12-20) (Department of Health, 2002)
Meningitis
- CTscan (£) 89 (67-112) (Department of Health, 2002)
- Cranial ultra-sound (£) 51 (38-64) (Hussain et al., 2003)
- Follow-up (Exc. Sequelae) (£) 103 (77-129) (Department of Health, 2002)
- MRl (£) 270 (203-338) (Department of Health, 2002)
Otitis media
- Ear procedures (£) 517 (388-646) (Department of Health, 2002)
- Outpatient ENT consultant visit (£) 52 (39-65) (Department of Health, 2002)
Proportion undergoing different procedures
- CT scan (adult) (%) 100 (Hussain et al., 2003)
- CT scan (child) (%) 46 (Hussain et al., 2003)
- MRl (%) 9 (Hussain et al., 2003)
- Cranial ultrasound (child) (%) 30 (Hussain et al., 2003)
General practice consultation and treatment costs
- Cost per general practice consultation (£) 19 (14-24) (Netten A & Curtis L, 2002)
(British Medical Association,
- Mean cost of treatment per consultation - IPD (£) 8(6-10) 2002)
(British Medical Association,
- Mean cost of treatment per consultation - Pneumonia (£) 4 (3-5) 2002)
- Mean cost of treatment per consultation - OM (£) 2 (1.5-2.5)
(British Medical Association,
2002)
Average cost of a meningitis case
- First year (£) 4,703 (3,528-5,880) (Hussain et al., 2003)
- Subsequent years (£) 143 (113-189) (Hussain et al., 2003)
Discount Rates
- Discount Costs 3.5% (HM Treasury, 2003)
- Discount Benefits 1.5% (HMTreasury,2003)
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9.3.6 Sensitivity and scenario analysis
The most likely parameters values were used in the base case scenario. However, a univariate
sensitivity analysis was also performed looking at the effect of changing one parameter at a
time within its given range.
In addition to the sensitivity analyses and due to the high level of uncertainty that characterise
the current and future burden of pneumococcal disease, the following three scenarios were
also considered:
a) High incidence scenario. A capture-recapture study (Gjini et al., 2004), estimated
the sensitivity of CDSC/RSIL for the diagnosis of pneumococcal meningitis in adults
(mean age 55, range 16-97 years) to be 40% (95%CI: 37-44). Incidence rates were
thus inflated to take into account possible under ascertainment. For hospitalised
pneumonia, incidence rates were inflated by including the following additional codes
[ICD-I0: Jl58 (other bacterial pneumonia) and 1159 (bacterial pneumonia
unspecified)]; any code for pneumonia in any diagnostic field (i.e. not necessarily
primary diagnosis); and assuming that all admissions for pneumonia resulted in a
positive film (rather than the estimated 79%). For AOM hospitalisations, any AOM
codes in any diagnostic fields were considered. An upper estimate of both pneumonia
and AOM GP consultation rates was obtained using MSGP4 data (Chapter 3).
b) Inclusion of herd immunity effects. Whitney and colleagues (2003) recently
published estimates of the reduction in IPD incidence in the US in unvaccinated age
groups following the introduction of the pneumococcal conjugate vaccine in infants.
They estimated the following reduction in IPD incidence among unvaccinated
individuals: 32% (95%CI 23%-39%) in the 20-39 years old, 8% (95%CI 1%-15%) in
the 40-64 years and 18% (95%CI 11%-24%) in the 65+ roughly 1 year after the
introduction of infant vaccination. We allowed for these changes in invasive disease
incidence and assumed that a similar indirect effect occurs on the proportion of
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pneumonia and otitis media cases attributable to a pneumococcal infection (assumed,
respectively, 48% (Lim W.S. et al., 2001b) and 30% (Jacobs et al., 1998;Palmu et al.,
2004». The effect of changes in these proportions was considered in both the
univariate and multivariate sensitivity analyses. Since the period of protection against
carriage appears to be short (Lakshman et aI., 2003) we assumed that vaccination of
one infant cohort would reduce the carriage of pneumococci, and thus the incidence
of disease, in other age groups for one year.
c) Serotype replacement. Serotype replacement of vaccine types with non-vaccine
types has been observed in both pneumococcal carriage (Dagan et al., 2002;Dagan et
al., 2003) and disease (Eskola et al., 2001;Veenhoven et al., 2003;Kaplan et al.,
2004). The potential effect of a complete substitution of vaccine types with non-
vaccine ones on the cost-effectiveness of the programme is explored in this scenario
analysis reducing both the direct effect of the vaccine among vaccinated individuals
as well as the indirect effect (herd immunity as in scenario (b) produced among
unvaccinated ones (Whitney et al., 2003). The percentage substitution of vaccine
types with non-vaccine types, which in this scenario is set to 100% (i.e. complete
substitution), is referred to in the following text as the serotype replacement
coefficient (SRC). The severity of non-vaccine types in causing IPD is derived from
Brueggemenn and colleagues (2003) study, calculating the non-vaccine vs. vaccine
types odds ratio (OR) after adjusting by the serotype-specific duration of carriage
reported in Smith and colleagues (1993) (OR=0.16, 95%CI: 0.10-0.25). Non-vaccine
serotypes are assumed to be equally severe in causing CAP and AOM (OR=1).
Note that whereas scenario (a) still maintains the assumption that the vaccine does not
produce indirect effects, i.e. no protection against pneumococcal carriage, and simply
considers a change in the incidence rates of pneumococcal disease, scenarios (b) and (c) allow
the indirect effects of the vaccine at the population level to occur. In particular, scenario (b)
considers a reduction in pneumococcal disease among unvaccinated individuals as a
consequence of a reduction in carriage. Scenario (c) includes both the herd immunity effect as
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well as a change in the serotype distribution of pneumococcal carriage, which also produces
an effect on pneumococcal disease.
A multivariate sensitivity analysis was also performed using Monte Carlo simulation with
@Risk 4.0 (Palisade Corporation, NY, USA) and drawing input parameter values from
probability distributions using Latin Hypercube sampling. Uniform distributions were
assumed for age-specific incidence rates, case-fatality ratios and length of stay in the hospital
as well as for all the parameters related to the cost of care and treatment. For incidence
estimates the lower limit was set to be the base case and the upper limit was set to the high
incidence scenario (scenario a). CFRs and LOS were varied between +-25% of their base case
values. The SRC was assumed to follow a triangular distribution with a mode of I, and range
of 0-1. A normal distribution was assigned to the log OR estimated from the vaccine trials
(Black et al., 2000;Eskola et al., 2001;Black et al., 2002) and from which the levels of
protection were derived (VE=I-OR). The proportion of CAP and AOM cases caused by
Sipneumoniae (48% and 30% respectively in the base case) was assumed to follow a binomial
distribution with variance determined by the sample sizes of the original studies (Jacobs et al.,
1998;Lim W.S. et al., 2001a). The herd immunity effect was kept constant at 5% in three out
of the five scenarios explored in the multivariate analysis. The other two scenarios considered
were the base case, where no herd immunity and no serotype replacement effect were
included, and the Whitney scenario where age-specific indirect protection was assumed to
vary within the reported 95% confidence intervals (Whitney et al., 2003). A distribution of
outcome values was generated running the model 1000 times and the results are presented for
different levels of herd immunity and under different assumptions on the level of serotype
replacement.
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9.4 Results
9.4.1 Current burden of disease
Table 9.5 gives the estimated current burden of IPD, all-cause pneumonia and otitis media in
England and Wales. There are an estimated 2 million GP visits, almost 76 thousand hospital
admissions and over 17 thousand deaths per year (most of which are attributable to
pneumonia in the elderly). The health burden in children less than 15 years of age is large
with 46% and 75% of hospital admissions due to, respectively, meningitis and otitis media
falling in this age group as well as 62% of GP visits. The estimated cost to the health service
related to these outcomes is given in Table 9.6. In children an estimated 76% of the overall
cost is due to treating otitis media.
From these estimates and assuming that 48% and 30% are the proportions of, respectively,
pneumonia and AOM due to S.pneumoniae (Lim et al., 2001;Pelton, 2001), the burden of
pneumococcal specific disease consists of over 650,000 GP consultations, 36,000 hospital
admissions (lPD and non-IPD) and around 9,000 deaths in England and Wales per year.
Table 9.5 - Estimated current burden of IPD, pneumonia and otitis media in England and
Wales.
Current Burden
(England & Wales) All ages Under 15
GP visits 2,083,882 1,346,110
- Pneumonia 142,017 14,547
- OM 1,941,865 1,331,563
Admissions 75,720 19,989
- Bacteraemia 4,407 544
- Meningitis 324 148
- Pneumonia 54,373 6,904
- OM 16,616 12,394
Deaths 17,334 63
- Bacteraemia 1,225 11
- Meningitis 45 6
- Pneumonia 16,064 46
Pneumonia=all cause pneumonia with lobar/focal change; OM=all cause OM
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Table 9.6 - Estimated cost of the current burden of pneumococcal disease from the health care
payer perspective, England and Wales.
GP visits (total)
- Pneumonia
-OM
Acute admissions (total)
- Bacteraemia
- Meningitis
- Pneumonia
-OM
Sequelae for meningitis
All ages
£44,021,605
£3,223,027
£40,798,578
£212,275,776
£18,645,033
£3,873,214
£180,303,253
£9,454,276
£3,073,240
Under 15
£28,306,271
£330,142
£27,976,129
£16,552,586
£1,424,670
£1,415,882
£6,660,063
£7,051,971
£1,052,566
Total £45,911,423£259,370,621
9.4.2 Base case results
The estimated reduction in the burden of disease due to the vaccination programme is shown
in Table 9.7. The programme with base case parameters is estimated to prevent almost 63,000
OP consultations, 1890 hospital admissions and 14 deaths, resulting in a total of 1087
undiscounted life-years and 1824 undiscounted QALYs gained in the vaccinated cohort over
their life-span (at 1.5% discount rate these are 629 and 1188 respectively).
Table 9.7 - Undiscounted health outcomes and estimated reduction of disease burden in the
vaccinated cohort.
No vaccination With vaccination Difference
Deaths (total) 19,346 19,331 14
Deaths Bacteraemia 1,307 1,301 6
Deaths Meningitis 46 42 3
Deaths Pneumonia 17,993 17,988 5
Hospital's (total) 77,492 75,602 1,890
Hosp Bacteraemia 4,567 4,264 302
Hosp Meningitis 318 239 79
Hosp Pneumonia 57,527 56,632 894
HospOM 15,081 14,467 614
GP consult (total) 1,952,942 1,889,987 62,955
GP consult Pneumonia 141,952 140,211 1,741
GP consult OM 1 810,990 1,749,776 61,215
The base-case programme is estimated to have a net discounted cost to the health service of
£71m, i.e. cost of vaccinating the cohort is estimated to be £75m (£56m and £19m for,
respectively, administration and vaccine costs) resulting in discounted medical care savings of
£4m over their lifetime. The additional cost per life-year gained of vaccination is therefore
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estimated to be £113,231 under base case assumptions. The equivalent cost per QAL Y gained
is estimated to be £59,945.
9.4.3 Sensitivity and scenario analyses
Univariate sensitivity and scenario analyses were performed to assess the sensitivity of the
results to changes in the model parameters and assumptions (Table 9.8).
Table 9.8 - Univariate sensitivity analysis - Cost per LY/QAL Y gained of pneumococcal
conjugate vaccine programme.
Cost per LY Cost per QAL Y
2ained aatned
Base case £113,231 £59945
Higb incidence £48,257 £23,800
- High IPD incidence £54,066 £31,473
- High Pneumonia incidence £96,960 £54,757
- High AOM incidence £109,994 £41,186
- Incidence in <1 yr. stratified in 0-6 and 6-11 mths £111,491 £59,482
Higb Case-Fatality Ratio (CFR) £90,585 £52,938
- Among IPD cases £96,935 £55,046
- Among pneumonia hospitalisations £104,661 £57,454
Herd lmmunlty" £5,297 £5,013
- Proportion of pnc pneumonia = 24% £8,597 £7,899
- Proportion ofpnc AOM = 15% £5,297 £5,013
- HI effect only on IPD £22,795 £18,622
Herd immunity a & serotype renlacement" £30093 £26,683
Vaccine Parameters
Duration of protection (5 years) £123,916 £68,169
Duration of protection (15 years) £104,859 £54,043
Cost per dose (£20) £83,266 £44,081
Cost per dose (£40) £143,197 £75,809
Vaccine efficacy against AOM=O% £115,542 £83,639
Cost of a Menin2itis Case
Increased by 50% £112,523 £59,570
Increased by 100% £111 815 £59 195
Alternative Schedules
3 doses, protects from 6 months £130,071 £66,419
2 doses protects form 6 months £84,335 £43,065
1 dose protects from 1 year £70,699 £31,021
Discount Rate
Benefits 3%, costs 3% £174,665 £81,594
Benefits 6%, costs 6% £324,847 £120,938
Benefits 0%, costs 3% £65,154 £38,818
Benefits 1.5% costs 6% £113 608 £60,144
a ,bHerd tmmunity as In Whitney and colleagues (2003), complete serotype replacement (100%)
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This showed that the most striking changes in the cost per life year or QALY gained occurred
when the upper estimates of the incidence of IPO were used as well as when herd immunity
effects were included in the model. The vaccine price is also an influential variable. If the
vaccine were not reducing the incidence of acute otitis media (VE=O% rather than 7% as in
the base case analysis), then the cost per QALY gained would increase substantially (£83,639
vs. £59,945 of the base case), whereas the impact on the cost per life-year gained would be
negligible as the number of years gained from vaccination would be zero (no mortality is
assumed due to AOM).
Figure 9.1 shows the estimated cost per life-year and QALY gained for different costs of a
vaccine dose. At a maximum willingness to pay for a QALY gained of £30,000 (Devlin &
Parkin, 2003), the price of the vaccine would have to be reduced to a third of its current value
(under base-case assumptions). Under the high-incidence scenario, and with all other
parameters at their base case values, the cost per life year gained drops to £48,257 and cost
per QALY gained to £23,800.
The cost per life-year and QALYs gained decreased dramatically if indirect protection in
older age groups from the introduction of infant vaccination was included. Using the levels of
indirect protection reported by Whitney and colleagues (2003) for IPO and applying them to
all relevant outcomes, this indirect effect alone is estimated to result in a reduction of almost
46,000 GP visits, 4,800 hospital admissions and 1,551 deaths (204 bacteraemia, 6 meningitis,
1341 pneumonias), the majority of which falls in 65+ years of age (respectively 79%, 67%,
96%). This generates an additional 12,814 life-years gained (10,319 from pneumonia cases)
and 13,017 QALY gained, giving an overall cost per QALY gained of £5,013. In case herd
immunity effects were only applicable to IPO patients (i.e. different serotype distribution for
non-IPO cases), the cost per QALY gained is higher (£18,625) though remaining below what
is considered the acceptable range. Moreover, the inclusion of a complete serotype
replacement mechanism (i.e, carriage of non-vaccine serotypes completely substitutes
carriage of vaccine types) increases substantially the cost per LY and QALY gained though
remaining around £30,000. Note that this last scenario is significantly more cost-effective
than the base case (Table 9.8, Figure 9.4).
226
Figure 9.1 - Sensitivity analysis - Cost per LYIQALY gained for different cost per dose of the
vaccine.
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9.4.4 Alternative schedules
Figure 9.2 and Figure 9.3 show the effect of adopting different schedules on the cost per
QALY gained of the programme for different levels of, respectively, the cost of the vaccine
and the duration of vaccine-induced protection. Note that these results are for the base case
model and neither herd immunity nor serotype replacement mechanisms are included here.
At the base case cost of the vaccine (£30), a cost per QALY gained in the range of £31,000-
£66,000 is observed for different vaccination schedules (Figure 9.2); the lowest estimate
resulting from a 1 dose schedule at one year of age. Although more cost-effective, it should be
noted that such a strategy is expected to be less effective than the base-case resulting in 714
discounted QALYs gained in the cohort compared with 1188 in the base-case (Table 9.9). The
long-term effects of such a strategy should be carefully evaluated (Chapter 8). As expected, 3
doses and a non-accelerated schedule is the least cost-effective option, having the highest
vaccine related costs (3 doses) and since vaccine-induced protection is delayed to six months
of age, after the child has experienced high level of disease rates (30-55 per 100,000 per year
in 0-6 months of age, CDSC-RSIL 1996-2000). Results from the incremental analysis are
reported in Table 9.9, where the alternative strategies have been ranked according to their net
cost and the incremental cost-effectiveness ratios have been calculated.
A 10-year vaccine induced protection against disease was assumed in the base case analysis.
The cost per QALY gained becomes approximately £79,000 when the duration of protection
is reduced to 4 years and when three doses are considered in the schedule (Figure 9.3). For the
1 and 2 doses schedules the cost per QALY gained increases by, respectively, £10,500 and
£8,400 from their base case values (£41,585 and £51,466).
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Figure 9.2 - Cost per QALY gained for different vaccination schedules and varying the cost of
the vaccine.
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Figure 9.3 - Cost per QALY gained for different vaccination schedules and varying the
duration of vaccine-induced protection.
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9.4.5 Multivariate sensitivity analysis
In the multivariate analysis (Figure 9.4) the impact of different herd immunity and serotype
replacement scenarios is explored, keeping the discount rates fixed at their base case values
(3.5% and 1.5%) and allowing the other parameters of the model to change within their
specified ranges. In the base case (no herd immunity and no serotype replacement) 29% of the
model simulations resulted in a cost per QALY gained of less than £30,000. When assuming a
5% reduction ofPnc disease incidence among unvaccinated individuals (herd immunity) then
100% of the model simulations are below this level (Figure 9.4b, extreme left curve) unless
non-vaccine serotypes completely substitute vaccine types (serotype replacement), under
which circumstances almost all simulations result in a cost per QALY gained above £30,000.
If much higher levels of herd immunity were assumed, such as the ones estimated by Whitney
and colleagues (2003), the reduction in disease incidence would be so dramatic that even a
complete serotype replacement effect could unlikely change the cost-effectiveness of the
programme. When a less strong hypothesis is assumed for serotype replacement (i.e, the level
of serotype replacement is uncertain and thus is assumed to vary between 0 and 1) (see
Chapter 8) and the level of herd immunity is fixed at 5%, then around 90% of the simulations
are deemed to be cost-effective at an upper limit of £30,000 per LY/QAL Y gained. The
programme is not cost-effective when looking at the cost per LY gained under base case
assumptions and also when the hypothesis of complete serotype replacement is assumed (in
both cases the proportion of simulations that fall above £30,000 is 100%). However, when
serotype replacement varies between 0 and 1 or when herd immunity effects are as high as the
ones recently published (Whitney et al., 2003), then the cost per LY gained is below £30,000
in, respectively, 85% and 100% of the simulations.
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Figure 9.4 - Cost per LY/QAL Y gained estimated from multivariate sensitivity analysis.
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9.5 Discussion
This chapter considers the possible health effects and costs associated with a universal
childhood vaccination programme with the pneumococcal conjugate vaccine and establishes
baseline information on its cost-effectiveness under the public health perspective. Due to the
uncertainties that are related to the current burden of disease and the long-term effects of
vaccination on the epidemiology of pneumococcal disease, deriving a precise estimate of the
cost-effectiveness of the programme was not possible. However, sensitivity analyses were
performed looking at the range within which the cost per life-year gained lies for different
prices of a vaccine dose and for different levels of disease incidence rates. In addition, to take
into account the impact of conjugate vaccine not only in terms of life-years saved but also
considering the effect of morbidity on survivors, the cost per QALY gained was also
estimated. The possible impacts of herd immunity and serotype replacement were investigated
as scenario analyses and in the multivariate sensitivity analysis.
Ignoring potential herd-immunity effects, universal vaccination of children with the
pneumococcal conjugate vaccine is not likely to be deemed cost-effective from the NHS
perspective at the current price of the vaccine. The latter should be set at around £10-£ 15 per
dose in order to get a cost per QALY gained of approximately £30,000. On the other hand, if
the current burden of pneumococcal diseases was greatly under estimated by the national
surveillance systems, then the cost per QALY gained, at a £30 cost per vaccine dose, could
reach acceptable values.
A two-dose non-accelerated programme is estimated to be more cost-effective than a three
dose accelerated programme, assuming both result in similar vaccine efficacy. Nevertheless,
at the current price of the vaccine, this is still not within the generally accepted threshold
unless herd immunity effects occur without significant serotype replacement.
From the univariate sensitivity analysis the model estimated that the infant vaccination is
highly likely to be cost-effective if the levels of indirect protection observed by Whitney and
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colleagues (2003) are attributable to the vaccine and apply equally for each subsequent
vaccinated cohort. Rates of pneumococcal disease are very high in the elderly (Chapter 3) and
the consequent reduction of the number of cases in these age groups, without additional costs,
has a large effect on the overall cost-effectiveness of the programme. It should be stressed,
however, that these reductions are based on an ecological analysis of the reduction in reported
IPO incidence in the US just after the introduction of the vaccine compared with the period
just before (1998-99). These observed reductions should be set in the context that the
incidence of IPO was falling before the introduction of the vaccine in all of these age groups,
and so may partly or in whole be due to other factors. Finally, the reduction observed
immediately after the introduction of the vaccine may not reflect the long-term reduction in
incidence as a honeymoon period may occur (though this was not observed in the model
results presented in Chapter 8). Thus, taken together, the level of indirect protection reported
by Whitney and colleagues (2003) may well be an overestimate, hence in the multivariate
analysis the effect of having a lower indirect protection of the vaccine (5%) among
unvaccinated individuals is also investigated. However, even at this lower level of indirect
protection, infant vaccination is still highly likely to be cost-effectiveness unless there is
complete serotype replacement.
Serotype replacement has already been shown to occur in both pneumococcal carriage studies
(Obaro et aI., 1996a;Mbelle et al., 1999;Oagan et al., 2002) and disease (Eskola et al.,
2001;Veenhoven et al., 2003;Kaplan et al., 2004) following vaccine introduction. The effect
of a change in the serotype distribution on the economic analyses of pneumococcal
vaccination is to reduce the effectiveness of the programme over time and, consequently,
increase the cost per LY and QALY gained. Whether this increase will change conclusions on
the overall economic evaluation of the programme (making it not cost-effective) still remains
an open question, as little information is available on the magnitude of the herd immunity
effect and on the invasiveness of the non-vaccine serotypes. From this analysis, the overall
effect depends firstly on the level of indirect protection conferred to unvaccinated individuals
by the vaccination programme. Moreover, it also depends on whether the new types will
completely substitute those which have been eliminated by the introduction of the vaccine (in
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which case the programme is not likely to be cost-effective) or else if this substitution will
only be partial and, in other words, carriage of pneumococci (any serotype) will be reduced as
a consequence of the introduction of the vaccine. In this latter case, although serotype
replacement would increase the cost per LY/QALY gained in respect to the situation in which
only herd effects were present, infant vaccination would be deemed cost-effective under most
circumstances. Our conclusions on serotype replacement rely heavily on a two-strain model
by Lipstich (1997;1999) that is similar to the VT and NVT model presented in Chapter 8. The
models show that carriage of the non-vaccine type increases up to the level (but not beyond)
that of the original vaccine-type. However, it should be noted that Lipsitch also suggests that
with more than two strains it is possible to increase the prevalence of carriage over the pre-
vaccination level and in the model presented in Chapter 8 this was possible if strong
competition between VT and NVT was present. This possibility was not explored here and,
therefore, the estimates of the negative effect of serotype replacement may be somewhat
underestimated.
Currently a higher proportion of vaccine types have decreased susceptibility to antibiotics
than non-vaccine types. Hence widespread immunisation should lead to a reduction in the
circulation of resistant organisms (at least in the short term). If current trends continue, then
the future prevalence of non-susceptible types is likely to increase and therefore the average
costs of treating pneumococcal cases will also rise. This knock-on effect would render
pneumococcal vaccination more attractive economically than is apparent in this analysis.
In summary, the base-case analysis (excluding indirect effects) suggests that the use of the
pneumococcal conjugate vaccine in infants is not likely to be justified economically at current
vaccine prices. However, this conclusion is very sensitive to assumptions regarding the
current burden of pneumococcal disease and the future impact that vaccination will have in
the unvaccinated, and on the future serotype distribution. Herd immunity, even with a partial
serotype replacement, is likely to render infant vaccination cost-effective. This is the first
analysis to quantify the impact of these indirect effects on the cost-effectiveness of
pneumococcal conjugate vaccination.
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CHAPTER 10 - DISCUSSION
10.1 Introduction
This thesis develops a variety of methods to further the understanding of the epidemiology of
pneumococcal disease and carriage and to prepare the necessary ground for investigating the
impact of alternative vaccination strategies. These methods range from direct observation and
analysis of surveillance data, through more complicated statistical and mathematical models
to economic evaluation. Novel statistical techniques have provided parameter estimates and
deepened the understanding of basic biological concepts of pneumococcal carriage and
transmission. The short and long-term effects of vaccination on pneumococcal carriage have
been investigated through mathematical modelling. Moreover, economic evaluations have
been utilised to assess the cost-effectiveness of the alternative vaccination programmes with
the available pneumococcal vaccines.
10.2 Overview
Although polysaccharide pneumococcal vaccines have been available for decades and
recommended to certain at-risk groups, the level of protection that the vaccine confers to
these subgroups has been debated and, moreover, disease incidence rates in very young
children have not been affected due to the poor immunogenicity of these vaccines in the first
two years of life. Following the Hib and Mene experiences, pneumococcal conjugate
vaccines were developed and a 7-valent formulation of the vaccine (Prevenar@ Wyeth) has
been recommended since January 2002 in England and Wales for children less than 2
(recently extended to 5) years of age, who are at special risk of pneumococcal infection. The
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vaccine not only appears to offer some protection against invasive and non-invasive
pneumococcal disease (Eskola et al., 2001;Black et al., 2002;Black & Shinefield,
2002;Kaplan et al., 2004), but substantial evidence is now available on the protection it
confers against pneumococcal colonisation (Dagan et al., 1996a;MbeIle et al., 1999;Dagan et
al., 2002;Yeh et al., 2003). Though this has important positive public health implications as it
generates a reduction of pneumococci circulating in the population and, consequently, a
reduction of pneumococcal disease incidence rates also among unvaccinated individuals (herd
immunity), it also raises a number of questions on the long terms effects of the vaccine on
both pneumococcal carriage and disease (Chapter 2). Several studies have shown an increase
of carriage of non-vaccine serotypes among vaccinated and unvaccinated individuals
(serotype replacement) as well as an increase in otitis media and invasive disease caused by
these serotypes. Nevertheless, due to the considerable burden of pneumococcal disease, the
severity of some of its conditions and the risk of disabling sequelae in very young children
(Chapter 3), widespread vaccination with the pneumococcal conjugate vaccine is now under
consideration at the Department of Health and discussions are ongoing on whether to
incorporate PCV in the routine immunisation schedule.
10.3 Surveillance
The importance of surveillance systems to understand the epidemiology of pneumococcal
infection and to monitor trends in the pre widespread vaccination era was demonstrated.
Although a number of data sources are available for pneumococcal disease, surveillance has
particularly relied upon laboratory notifications, since this is the most specific source of
information on severe infections and reports on the serogroups and other characteristics of the
pathogenic serotype (i.e, antimicrobial resistance). This information is particularly important
when a vaccine programme does not target all the circulating types. While this provides a
solid base for disease surveillance, enabling trends to be detected in a timely manner, it is
clear that laboratory reports underestimate the real incidence of pneumococcal disease, as
they exclusively record invasive infections which only represent the tip of the iceberg of all
pneumococcal related conditions. It is important to assess the true burden of disease when
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considering the impact, particularly, the economic impact of public health intervention
programmes. Hospital admissions data (HES) and Royal College of General Practitioner data
(RCGP) were both shown to be valuable sources of information for retrospective analysis of
less severe pneumococcal conditions (pneumonia and otitis media). Moreover HES data also
provided interesting insights on co-morbidities related to pneumococcal hospitalisations, and
the assessment of the burden of disease among patients at high and low risk of infection
(Chapter 3). This information was used in the cost-effectiveness analysis of the
polysaccharide vaccine (Chapter 5).
10.4 Infection vs, Disease
Pneumococcal disease is, however, a rare outcome of infection with Spneumoniae and most
infected individuals will become asymptomatic carriers. Understanding the role of carriage in
pneumococcal transmission was therefore crucial in order to assess the impact of vaccination
programmes with the conjugate vaccine (which also protects against colonisation). Data from
a longitudinal study of pneumococcal carriage in UK households were analysed and a novel
modelling framework was developed in order to estimate age-specific transmission
parameters and the duration of carriage and hence evaluate the importance of household
versus community acquisition of the organism (Chapter 6). Longitudinal datasets can be very
useful in deepening the understanding of a pathogen's dynamics within the human host and in
highlighting the individual characteristics that can affect the transmission dynamics of the
infectious agent. However, different levels of complexities (clustered data and unobserved
events) are embedded in this type of data and, thus, non-straightforward techniques have to be
adopted to extrapolate some insights about the organism characteristics. In the past, complex
statistical methods have been utilised to address these difficulties and the challenges posed by
longitudinal studies (Auranen et aI., 2000). These methods consisted of data augmentation (to
deal with the unobserved events) and MCMC simulations to derive the posterior distributions
of the model parameters. Though this approach certainly represents a valuable technique,
being flexible and providing measures of the variability of the parameter estimates, on the
other hand it is much more complex and computationally intensive. Conversely, the model we
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developed here though has certainly some limitations in terms of flexibility and possibility to
add, for example, additional statuses (i.e. immunity), it provided parameter estimates which
fitted well the observed pattern and it allowed individual characteristics to be included in the
analysis and their relationship to carriage acquisition to be investigated.
10.5 Serotypediversity
The pneumococcus is a very diverse pathogen and more than 90 distinctive serotypes
circulate in the population. Though it is known that differences exist among them in terms of
duration of carriage and invasiveness (Smith et al., 1993;Brueggemann et al., 2003), precise
estimates of their transmission parameters have never been derived and neither have
inferences of their interfering transmission behaviours. The observed changes in the
circulating serotypes after the use of conjugate vaccines (serotype replacement) represent a
signal that serotypes are indeed competing to gain access within the available hosts, and that
disturbing this system by introducing widespread vaccination may have positive or negative
effects depending on the relative invasiveness of the new types and the immunological
response of the host. Serotype replacement and the analysis of the dynamics of competing
serotypes is certainly a central issue not only for S.pneumoniae infection, but also for a
number of other antigenically diverse pathogens (e.g Group A Streptococcus, Human
Papillomavirus) for which vaccines are under development (McMillan et al., 2004;Batzioff et
al., 2004;Ault et al., 2004). The use of vaccines designed to protect against certain variants of
these organisms may inadvertently lead to increases in the prevalence of non-targeted variants
of the same pathogen. This serotype replacement, a consequence of direct and indirect
competition between the variants, has the potential to result in adverse as well as beneficial
public health effects. To explore the differences and interaction between pneumococcal
serotypes, the model presented in Chapter 6 was further extended to include serotype specific
information that was available from the same longitudinal study in UK families (Chapter 7).
Five serotypes were considered and great dissimilarities were estimated among them in terms
of both transmissibility and duration of carriage. Whereas for some of the serotypes the
relationship decreasing duration of carriage with increasing age was still valid, for others the
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opposite was true. Interestingly, for each of the five serotypes the community acquisition rate
was significantly higher in children than in older family members, which shows that children
are more likely to be the source of infection in the household. The existence of competition
among the serotypes was also assessed, estimating the relative risk of acquiring one serotype
if already colonised by another one as opposed to a non-carrier. Though this is certainly a
crude simplification of the competing forces of the over 90 different circulating serotypes, it
allowed one to scratch the surface and to explore the diversity of the organism and the
distinctive behaviour of each of the target serotypes.
10.6 TransmissionDynamics
A transmission dynamic model was developed using parameter estimates from Chapter 6 to
investigate the impact of different vaccination programmes that may be implemented if the
vaccine will be introduced in England and Wales (Chapter 8). This allowed the transmission
dynamics of the organism as well as the long-term effects of vaccination on carriage of VT
and NVT pneumococci to be explored. This type of model has been extensively used in the
past to assess the transmission dynamics of infectious agents and the positive and negative
impacts any intervention programme may have on the endemic equilibrium of the organism in
the population (Babad et al., 1995;Brisson et al., 2002). Moreover, outcomes from these
models have provided potential post-vaccine disease incidence rates, on which to base cost-
effectiveness analysis of alternative intervention strategies. Chapter 8 of this thesis covered
only the initial stages of this task as it explored the effects of vaccination on the prevalence of
VT and NVT carriage rather than disease incidence rates. The results presented here,
however, provided further insights into the organism dynamics and on the uncertainty in
regards to certain parameter estimates. The contribution of various elements of vaccination
programmes was assessed and the effect of different levels of competition between vaccine
and non-vaccine serotypes on the outcome of the vaccination programme was shown. Future
work will clearly build on this model structure.
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10.7 Cost Effectiveness of Vaccination
Increasingly new medical interventions, including vaccination programmes, must be justified
by economic analyses. This provides public health professionals with summary measures that
should then influence policy decisions. Performing an economic analysis of a vaccination
programme, in particular, ideally requires the consideration of any short, middle and long-
term effect of the vaccine. Whereas short-term effects can be easily derived, given possible
coverage rates and the protection afforded by the vaccine, longer ones are much more difficult
to estimate and also to incorporate in the economic assessment. Moreover, we have seen in
this work (Chapter 5) that several possible analyses can be performed and that the decision of
which economic approach to use may also influence the outcome. Cost-effectiveness analyses
of pneumococcal vaccines (PPV and PCV) were performed in Chapters 5 and 9 of this thesis.
To assess the cost-effectiveness of PPV, estimates of the level of protection conferred by the
vaccine to high risk as well as healthy elderly were derived performing a meta-analysis of the
available randomised and quasi-randomised controlled trials (Chapter 4). The vaccine
appeared to offer no protection against pneumococcal pneumonia, little protection against IPD
among the high-risk elderly whereas some protection among the healthy elderly. Though
these estimates lacked of statistical significance and this analysis was limited by the paucity
of the data and the weaknesses of the studies included, they provided insights not only on the
difference between these two risk groups, but also on the levels of uncertainty that are present
for these estimates and that was then incorporated in the cost-effectiveness analysis of
Chapter 5. The latter was performed developing a cohort static model that showed that
vaccinating all elderly individuals (rather than only high-risk ones) would result in the most
cost-effective option with the cost per life-year gained well within what is currently
considered the acceptable range for the UK. A similar cohort model was developed to assess
the cost-effectiveness of the conjugate vaccine in children (Chapter 9) adopting the different
vaccination strategies that are currently under discussion at the Department of Health. Herd
immunity and serotype replacement, both key elements to consider if wanting to assess the
middle and longer-term effect of any vaccination programme (Chapter 8), were included in
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the model and showed that cost-effectiveness results were highly sensitive to their values.
Though serotype replacement may in fact partially counterbalance the positive effects of herd
immunity, the final outcome of any vaccine intervention is dependent on the real magnitude
of these indirect effects, the time it takes for them to occur in the population and, not least, the
characteristics of the non-target serotypes. As most of these are still unknown, different
scenarios were investigated in this thesis, which will be revised as soon as more information
becomes available and the results of the more comprehensive transmission dynamic model
will be generated.
10.8 Future work
There are two major issues that will be addressed in the future as continuation of this work.
The first one relates to the cost-effectiveness of the conjugate vaccine. The analysis presented
in Chapter 9, which was based on a static cohort model, did not adequately account for herd
immunity effects, since it assumed constant forces of infection, rather than varying them
according to the number of infectious individuals in the population. The transmission
dynamic model described in Chapter 8 will be further developed to include pneumococcal
disease (invasive and non invasive) and changes in disease incidence rates, as a consequence
of vaccination, will be estimated. The cost-effectiveness of PCV will be re-analysed using this
model as the basis for predicting the future incidence of disease under a range of vaccine
strategies.
Secondly, Chapters 6-8 are based on the assumption that pneumococcal transmission can be
described with an SIS model structure, i.e. no immunity after carriage. This was a necessary
simplification of the real host-pathogen interaction required to make progress, and it allowed
a deeper understanding of pneumococcal transmission and also some inference on the
competition between the most prevalent types. However, it remains to be seen to what extent
this assumption is true and the influence that immunity to reinfection has on transmission
dynamics. The considerable antigenic diversity presented by Spneumoniae suggests that
immunity is an important evolutionary force for the pathogen. On the other hand, the
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heterogeneity itself might mean that the SIS framework is adequate to describe the hosts'
experience. These issues can be explored using an individual based model including partial
and temporary immunity. The advantage of this approach is that models can be developed
which include personal characteristics (important for pneumococcal carriage), serotype
information (when carriage is detected) as well as family-related behaviours (i.e. day-care
attendance). This model could be fitted to the longitudinal carriage data and investigations on
the serotype-specific immunity and cross immunity after a carriage episode could be
performed.
10.9 Conclusion
s.pneumoniae causes a substantial burden of disease worldwide. Epidemiology, mathematical
modelling and economics are tools that together can help in gaining a better understanding of
the organism behaviour and on the host-pathogen interaction that is essential for evaluating
the impact of any vaccination policy. Though more work is clearly needed in order to proceed
in the understanding of these relationships, this thesis has posed the basis for the current
discussion and has furthered the understanding of the transmission patterns of the organism.
Moreover, the modelling framework developed in this work represents a robust method that
can be used for investigating any other longitudinal dataset of infectious diseases and to infer
intrinsic transmission characteristics of the organism. Also it could be adapted to look at other
antigenically diverse pathogens for which vaccines are currently under development. This
latter point represents a chaJlenge that ought to be addressed considering that public health
interventions should increasingly be based on solid ground and that longer terms effects will
necessarily have to be included in the economic evaluation.
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Abstract. A 23-valent polysaccharide pneumococcal
vaccine (PPV) has been available in the UK for more
than 20 years and is currently recommended for use
in high-risk groups (HRG) of 2+ years of age. The
degree of protection afforded by the PPV remains a
critical issue, although a number of randomised
clinical trials and case-control studies (CCS) have
been published. The aim of this work is to review the
estimates on the efficacy of PPV against pneumo-
coccal pneumonia and invasive pneumococcal disease
(lPD) in the elderly and to perform a meta-analysis in
order to obtain a pooled estimate of the level of
protection in high and low risk individuals. These two
groups of individuals are at the centre of the current
debate on whether or not to extend the vaccination
programme to all elderly individuals 65+. Only
randomised and quasi-randomised studies are in-
cluded in the analysis and results are compared with
previous meta-analyses. The effect of the inclusion of
observational studies is investigated in the sensitivity
analysis. When taken with the results of other meta-
analyses and observational studies, it appears that
PPV offers protection against IPD in the general el-
derly population (VE = 65%; 95% CI: -49-92%)
whereas it has a moderate effect in the high-risk el-
derly (VE = 20%; 95% CI: -188-78%). The vac-
cine has little or no effect against pneumonia
(VE = 16% in the general elderly and -20% in
HRG).
Key words: Elderly, High-risk, Meta-analysis, Polysaccharide pneumococcal vaccine (PPV), Vaccine efficacy
(VE)
Abbreviations: CCS = case-control studies; HRG = high-risk group; IPD = invasive pneumococcal disease;
OR = odds ratio; PPV = polysaccharide pneumococcal vaccine; RCT = randomised controlled trial; VE =
vaccine efficacy
Introduction
Streptococcus pneumoniae is an important bacterial
agent of the respiratory tract, which can cause serious
disease mainly in children and in the elderly. The
main reservoir is the nasopharynx and the possible
outcomes, once colonisation has taken place, are the
clearance of the organism, the asymptomatic persis-
tence for several months (carrier state), or the pro-
gression to disease. During. disease, the bacteria can
either spread to adjacent mucosal tissues, causing
mucosal infection (otitis, sinusitis, and pneumonia)
[1, 2], or else invade the bloodstream, or other sterile
sites, producing an invasive condition (bacteraemia,
septicaemia and meningitis) [3].
A 23-valent-polysaccharide pneumococcal vaccine
(PPV) has been available in the UK since the early
1980sand is currently recommended for use in high-
risk individuals of 2+ years of age [4]. These include
persons with asplenia or severe dysfunction of the
spleen, chronic renal disease, immunodeficiency,
chronic heart, lung, or liver diseases, and diabetes
mellitus. The degree of protection afforded by the
PPV remains an issue of some debate despite the
existence of a number of randomised (or quasi-
randomised) clinical trials, case-control and indirect
cohort studies. These studies have attempted to
investigate the vaccine efficacy (VE) against pneu-
mococcal pneumonia and/or invasive pneumococcal
disease (IPD). A number of meta-analyses have also
been used to obtain overall pooled estimates of VE,
because of the lack of power of the single trials to
detect a significant effect of the vaccine.
The purpose of this work is to review estimates on
the efficacy of the polysaccharide vaccine against
invasive and non-invasive pneumococcal disease, and
to perform a meta-analysis in order to obtain esti-
mates of protection for, respectively, the general el-
derly population and elderly at high-risk of disease.
Although, in fact, four other meta-analyses have been
published to assess the efficacy of PPV in adult
populations [5-8], none of these focused exclusively
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on elderly patients and, in particular, none differen-
tiated between the general elderly and elderly at a
higher risk of infection. The level of protection of the
vaccine in these groups represents a crucial aspect in
the current debate on whether or not to extend the
vaccination programme to all elderly individuals. For
these reasons and because the vaccine is not likely to
be recommended in healthy young adults, where the
incidence is low, the analysis will concentrate only on
randomised and quasi-randomised 1 clinical trials that
were performed among elderly populations. More-
over, there is evidence that the VE may be lower in
the elderly [9].
Methods
Inclusion criteria and information collected from the
eligible trials
A Medline and a PubMed literature search were used
to identify published studies on PPV efficacy, without
any year or language restriction and using the fol-
lowing keywords to identify relevant articles: 'Pneu-
mococc*', 'vaccination', 'pneumococcal vaccine',
'immunisation' and 'clinical trial'. Papers that were
including in the title words such as 'children', 'in-
fants', 'conjugate', 'carriage' and 'otitis media', were
excluded from the list of selected papers. Previous
meta-analysis and reviews were also extracted and
checks were made in order to have a complete list of
studies. References of the retrieved papers were also
examined. The inclusion criteria that were adopted to
select the papers to be part of the analysis were: (I)
All randomised and quasi-randomised controlled
trials with a well-defined randomisation or quasi-
randomisation process and with a PPV and a control
group (placebo or a control vaccine); (2) targeted
immunocompetent and immunocompromised elderly
individuals (50+ years of age) and (3) assessing at
least one of the following endpoints: Pneumococcal
pneumonia and/or IPD. The definition of pneumo-
coccal pneumonia that was used consisted of a clin-
ically and radiographically confirmed diagnosis of
pneumonia, with S. pneumoniae cultured from spu-
tum or a nasal swab. Diagnoses made on the basis of
a twofold rise in pneumolysin antibody level in paired
serum samples were also accepted, due to the high
sensitivity (97.8%) and specificity (83.4%) that was
shown by Leinonen et al. [10] for these tests, using
standard procedures (i.e. culture of blood or sputum)
as reference methods. Similarly, the technique of
pneumococcal antigen detection by electrophoresis of
1 A method of allocating participants to different forms of
care that is not truly random; for example, allocation by
date of birth, day of the week, medical record number,
month of the year, or the order in which participants are
included in the study (e.g. alternation).
urine specimen was also accepted as a diagnostic
method for pneumococcal pneumonia. IPD patients
had to be defined as bacteraemic cases with S. pneu-
moniae isolated from blood or any other usually
sterile body fluid (e.g. peritoneal, pleural, cerebro-
spinal, or joint). Although the two endpoints were
not consistently assessed throughout the studies (with
some studies that were including bacteraemic cases
within the pneumococcal pneumonia group and some
others that were considering the two groups distinc-
tively) we decided to consider them separately in the
base case analysis. Estimates ofVE for pneumococcal
disease (invasive and non-invasive) are given in the
sensitivity analysis where the number of cases of
pneumococcal pneumonia and IPD are summed up
for each trial and a unique level of protection is
produced.
The two authors independently read the selected
papers and extracted information on study design
(type of interventions, number of serotypes included
in the vaccine (valency), follow-up time) and on the
participants (demographic characteristics and back-
ground health conditions) of each trial. Similarly, the
number of pneumococcal pneumonia and bacterae-
mic cases was assessed for each study and compared
to that published in previous meta-analyses. The
Jadad's system [11] was used by the two reviewers to
score each report according to whether or not ran-
domisation, blinding and description of withdrawals
were part of the study. One point was given for each
of these, and one additional point was added or
subtracted when either methods of randomisation or
blinding were, respectively, well described by the
authors or inadequately performed. The maximum
possible score was five. When discrepancies in the
quality evaluation existed, the two authors met and
discussed to resolve them. All the studies that were
not reporting clear information about the age of the
participants, about the randomisation process or the
diagnostic procedures that were used were excluded
from the analysis.
Information about the health conditions of all the
study populations was collected and the proportion
of high-risk individuals in each trial was assessed
(where high-risk is defined as those categories to
which the vaccine is currently recommended in the
UK [4]). As most of the studies included in their
analysis at least a proportion of institutionalised pa-
tients or elderly with some chronic condition, we
decided to consider at high-risk those study popula-
tions that had at least 50% of the individuals with
some chronic condition or immunodeficiency. When
the proportion was below this threshold, then the
trial was considered to be a study of the general el-
derly population, This criterion was widened in the
sensitivity analysis where all the trials in which more
than 20% of the study population was at high-risk,
were included when calculating VE in high-risk
groups (HRG). Case-control and indirect cohort
studies were also included in the sensitivity analysis to
assess whether their results are coherent with findings
from RCT and to evaluate the effects they might have
on the overall pooled estimates that were produced
using randomised and quasi-randomised controlled
trials for VE against IPD in high and low-risk elderly.
Statistical methods
In order to estimate summaries of the effect size (i.e.
odds ratio (OR» in different trials, several statistical
techniques are available. One of the most crucial
differences among them is related to whether or not
they incorporate between-study variation (heteroge-
neity) and, consequently, to whether the model used
is a fixed or a random effectmodel. This latter type of
model, which is appropriate when significant
heterogeneity is present between studies, produces a
more conservative estimate (i.e. wider confidence
intervals) of the pooled effect size.
Here we assume that the trials considered are a
random sample from a hypothetical population of
studies, and thus the DerSimonian and Laird [12]
random effect model OR was adopted in the base-
case. This computes a weighted average of individual
studies' ORs taking into account both sampling
variation and between study heterogeneity. Sensitiv-
ity analysis was performed in order to assess whether
different model assumptions would have changed the
results. Therefore, the Mantel-Haenszel fixed effect
method was adopted under the assumption that the
differences among the results of the studies were due
to chance alone. Further sensitivity tests were per-
formed modifying the inclusion criteria in the analy-
sis and considering only RCT.
All analyses were performed using Stata 6.0 and
the results are presented using forest plots with sin-
gle and overall OR and related 95% CIs. The results
obtained are compared with previous meta-analy-
ses and the definition of VE that was used is
VE = (1 - OR) x 100 (%) [13], with confidence
intervals of the pooled estimate obtained, similarly,
as a function of those derived for overall OR. ORs
are good approximation of relative risks when out-
comes are comparatively rare, as in the studies in-
cluded in this analysis, and have desirable properties
when combining results across studies [14].
Results
Literature review
Of all the studies retrieved from the literature search,
six randomised and three quasi-randomised clinical
trials were selected that satisfied the inclusion criteria
(Table 1), although three of them [15-17] were
methodologically weak according to the Jadad scores
assigned by the two reviewers. Of the nine studies,
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five were European studies [16-20], three American
[15, 21, 22], and one Canadian [23]. The study by
Kaufman [15],although it is one of the largest trials,
and has the largest mean effect, both for pneumonia
and IPD (Table 1),was not included in our base case
pooled estimates due to the methodological weak-
nesses that were present in the design and imple-
mentation of the study (it was an open trial,
performed over a period of 6 years during which the
participants were recruited using different randomi-
sation procedures: indeed the first cohort recruited
into the trial were not randomised and patients vol-
unteered for the injection. Furthermore, it used 2 and
3-valent vaccines, and 21% of the participants were
under 60 years of age). Three studies that were in-
cluded in previous meta-analyses were excluded from
ours due to the presence of healthy young adults in
their study population [24-26] (Table 2). The mean
age of the study population was available for all the
trials used in our analysis (range: 61-74 years), as
well as the proportion of chronically illelderly (range:
27-100%). Four studies that were undertaken among
elderly with respectively, chronic obstructive pul-
monary disease (COPD), bronchogenic carcinoma, or
various chronic conditions, as defined in the recom-
mendations, were defined as studies of HRG [18, 21-
23]. In addition, a Swedish study [20]was included in
the HRG on the basis of the history of community-
acquired pneumonia (CAP) that the study partici-
pants had experienced, and due to the high propor-
tion of HR individuals (58%) that were present in the
trial. Three studies were undertaken among elderly
patients not experiencing, in high percentages, spe-
cific chronic conditions [16, 17, 19]. Their study
participants were considered representative of the
general elderly population, although they all reported
a proportion of high-risk individuals lower than 50%
but, nevertheless, in the range of 27-34% (Table 1).
These studies were included when the HR threshold
was lowered to 20%.
In accordance with previous meta-analyses [6-8],
we decided not to include the study by Davis et al.
[21] for our base case estimate of VE against IPD.
Although, in fact, a case of pneumococcal bactera-
emia was reported among the participants, this oc-
curred during a terminal episode of pneumonia in a
severely ill patient who had been hospitalised on a
long-term basis for respiratory insufficiency,repeated
urinary tract infections, cardiac failure and acute
pancreatitis. The effect of this case on the estimate of
VE against IPD in HRG was explored in the sensi-
tivity analysis.
Statistical analysis
The individual trials and summarised OR (95% CI)
are shown in Figures 1 and 2, for the two study
outcomes and according to the different level of risk
of the study participants. The overall results, when
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Study
Kolvula,RCT (1997)
Honkanen,QRCT (1999)
Overall (95% CI)
Odds ratio
(95%CI)
0.26 (0.07,0.98)
0.85 (0.50,1.43)
1.20 (0.80,1.82)
(a)
0.84 (0.47,1.50)
Study
Simberkoff,RCT (1986)
Klastersky,RCT (1986)
Davis,RCT (1987)
Ortqvist,RCT (1998)
Overall (95% CI)
(b)
Odds ratio
Odds ratio
(95%CI)
1.28 (0.65,2.53)
0.24 (0.02,2.50)
---I-i------- 3.24 (0.13,81.47)
1.25 (0.63,2.47)
1.20 (0.75,1.92)
Odds ratio
Figure 1. OR (dotted line) and associated 95% CI for pneumococcal pneumonia in (a) general elderly and (b) high-risk
elderly.
RCT and case-control studies (CCS) are considered
together, are presented in the sensitivity analysis.
VE against pneumococcal pneumonia
A low level of protection of the polysaccharide vac-
cine against pneumococcal pneumonia among elderly
individuals has already been shown [17, 19, 20, 22].
Among the RCT included in the analysis, seven
studies had pneumococcal pneumonia diagnosed
with one of the methods outlined in the inclusion
criteria. All of them showed a negative or non-sig-
nificant effect against pneumococcal pneumonia in
the elderly, with VE ranging from -28% (-153-35%)
[22] to 76% (-150-98%) [181.Overall pooled esti-
mates of the OR were produced in order to assess the
significance of previous findings and, most impor-
tantly, to determine the level of protection by risk
group. A non-significant and very low level of pro-
tection of the vaccinewas found, VE 16% (-50-53%)
using a random effects model and including in the
estimate the three trials [16, 17, 19]representative of
the general elderly population (Figure la). Bacterae-
mic cases were excluded from the calculation. The
estimated mean protective effect of vaccination is
actually negative (though not significant) when con-
sidering the studies that were performed among high-
risk elderly [18, 20-221, VE = -20% (-92-25%)
(Figure lb),
Comparing to previous meta-analyses, a level of
protection of 60% (44-71%) and 2% (-89-49%) in,
respectively, low and high-risk adults was shown by
Fine et al. [5]. Their estimates of VE, which are
higher than those reported here, are influenced by the
inclusion of trials that were performed among healthy
young adults [24-261. Similarly, another two meta-
analyses [7, 8] found a positive level of protection
against pneumonia, but these estimates might still be
a consequence of the inclusion of studies performed
in healthier individuals. For HRG, Cornu et al. [81
found a negative and non-significant vaccine protec-
tion, in accordance with this analysis. Moore et al. [61
found a higher estimate of VE although the popula-
tions they allowed for in their analysis were, exclu-
sively, young healthy adults (Table 2).
VE against IPD
The level of protection against IPD was assessed in
six out of the eight studies that were considered in the
analysis. Two trials studied the protective effectof the
vaccine against IPD in the general elderly population
Study
Honkanen,QReT (1999)
Gaillat,QReT (1985)
Overall (95% en
(a)
Study
Klastersky,ReT (1986)
Simberkoff,ReT (1986)
Leech,ReT (1987)
Ortqvlst,ReT (1998)
Overall (95% el)
(b)
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Odds ratio
(95%CI)
0.37 (0.07,1.91)
0.35 (0.08,1.49)
Odds ratio
Odds ratio
(95%CI)
0.80 (0.05,13.60)
2.01 (0.18,22.20)
---+i-_r---- 3.20(0.13,79.47)
0.21 (0.02,1.77)
0.80 (0.22,2.88)
Figure 2. OR (dotted line) and associated 95% CI for IPD in (a) general elderly and (b) high-risk elderly.
Odds ratio
[16, 17].Both of them suggested that the vaccine was
protective, though none of them obtained a signifi-
cant result (Figure 2a). The pooled estimate showed a
not significant reduction in the incidence of pneu-
mococcal bacteraemia, VE = 65% (-49-92%).
Four trials were performed among the elderly at a
higher risk [18, 20, 22, 23]. The results of these were
scattered around a zero effect and all had a lack of
statistical power. The pooled estimate of efficacywas
weakly positive, VE = 20% (-187-78%) (Figure 2b).
A further two trials (both quasi-randomised) were
performed on elderly populations which had between
20 and 50% of high-risk individuals [16, 17]. The
inclusion of these two trials improved our mean
estimate of VE in the high-risk elderly, though this
remained non-significant, VE = 44% (-45-79%).
The level of protection against IPD among the
general elderly population (65%) was similar to that
reported in previous meta-analyses [5-8], i.e. previous
estimates ranged between 66% (52-76%) and 82%
(66-91%) (Table 2). Previous meta-analyses ofVE in
HRG also appear to confirm our findings, i.e. esti-
mates of VE are low and non-significant [5, 6]. Fine
et al. [5] failed to demonstrate a protective effect
against IPD in high-risk elderly, VE = -23%
(-449-72%), whereas Moore et al. [6] showed a
slightly higher, although non-significant, level of
protection against IPD, 47% (-94-86%). The latter
included in their analysis three fully randomised
clinical trials performed among the elderly with
underlying chronic conditions or with a history of
community-acquired pneumonia but did not consider
the randomised clinical trial that was performed
among US veterans in 1987that did not demonstrate
any efficacy, VE = -28% (-153-35%). Cornu et al.
[8] found similar estimates of VE to Moore and col-
leagues when considering a subgroup of patients over
55 years old, VE = 42% (0-82%).
Sensitivity analysis
A sensitivity analysis on the level of protection of the
PPV was performed using, initially, a less conserva-
tive type of model and then different inclusion criteria
with regards to the randomisation process and the
study design. Estimates of VE against pneumococcal
diseases - which consisted of both pneumococcal
pneumonia and IPD cases - in high and low risk
elderly were also derived.
For the effect sizes that were produced here, there
was no evidence of significant between-study varia-
tion, and the two methods produced almost over-
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Table 3. Sensitivity analysis of the results
No. of
studies
OR, random
effects model
(95% CIs)
OR, fixed effects
model (95% CIs)
Chi-square
(d.f.); p-value
All RCT & QRCT
Pneumococcal pneumonia
Low risk group (LRG) 3 0.84 (0.47-1.50) 0.96 (0.70-1.30) 5.11(2); 0.078
Mixed risk group (MRG) 6 1.04 (0.68-1.59) 1.09 (0.81-1.46) 7.12(5); 0.212
High risk group (HRG) 4 1.20 (0.75-1.92) 1.19 (0.75-1.89) 2.22(3); 0.527
Invasive pneumococcal disease
Low risk group (LRG) 2 0.35 (0.08-1.49) 0.34 (0.08-1.48) 0.03(1); 0.857
Mixed risk group (MRG) 6 0.56 (0.21-1.45) 0.54 (0.23-1.30) 3.57(5); 0.613
High risk group (HRG) 4 0.80 (0.22-2.88) 0.73 (0.24-2.20) 2.84(3); 0.418
Only RCT
Pneumococcal pneumonia
Low risk group (LRG) I 0.85 (0.50-1.43) 0.85 (0.50-1.43)
Mixed risk group (MRG) 4 1.20 (0.75-1.92) 1.19 (0.75-1.89) 2.22(3); 0.527
Invasive pneumococcal disease
Low risk group (LRG) 0 n.a. n.a.
Mixed risk group (MRG) 4 0.80 (0.22-2.88) 0.73 (0.24-2.20) 2.84(3); 0.418
Inclusion of Kaufman study { 15}
Pneumococcal pneumonia (LRG) 4 0.58 (0.27-1.26) 0.60 (0.48-0.76) 24.63(3); <0.01
Invasive pneumococcal disease (LRG) 3 0.23 (0.12-0.46) 0.23 (0.12-0.46) 0.39(2); 0.825
Inclusion of Davis study[21}
Invasive pneumococcal disease (HRG) 5 0.97 (0.29-3.18) 0.88 (0.32-2.43) 3.47(4); 0.483
Inclusion of CCS
Invasive pneumococcal disease (LRG) 7 0.53 (0.40-0.70) 0.55 (0.45-0.67) 6.57(6); 0.363
Invasive pneumococcal disease (HRG) 6 0.48 (0.29-0.80) 0.50 (0.39-0.65) 5.61(5); 0.346
Two endpoints together
Low risk group (LRG) 3 0.79 (0.45-1.42) 0.91 (0.67-1.23) 5.19(2); 0.074
High risk group (HRG) 5 1.10 (0.72-1.70) 1.11 (0.72-1.70) 2.78(4); 0.595
RCT = randomised controlled trials; QRCT = quasi-randomised controlled trials; d.f. = degree of freedom; n.a. = not
available; CCS = case-control studies.
lapping results (Table 3). If only RCT were consid-
ered, the power to detect an effect is significantly re-
duced as the largest trial used a quasi-
randomisation technique [17].For the general elderly
this left only one and zero trials respectively for
pneumococcal pneumonia and IPD. For mixed el-
derly populations, the removal of the QRCT had
little impact on estimates of VE, though it further
reduced the precision of the results (Table 3).
Although the study by Kaufman et al. appeared
methodologically weak, its effect on the pooled esti-
mates was assessed. Including this study in our
analysis, results in VE being estimated to be 42%
(-26-73%) against pneumococcal pneumonia (i.e.
higher but still not significant) and 77% (54-88%) for
IPD (i.e. slightly higher with significant 95% CIs).
Moreover, the single bacteraemic terminally ill pa-
tient reported by Davis and colleagues, was also in-
cluded in the overall calculation of VE against IPD in
HRG, and the final estimate dropped to a very low
level with extremely wide confidence intervals 3%
(-218-71 %). Similarly, the level of protection of the
vaccine fell considerably when the two final endpoints
were analysed together, VE = 21% (-42-55%) in
healthy elderly and a VE = -10% (-70-28%) in
high-risk elderly.
VE estimates from case-control and indirect co-
hort studies [27-33], also including elderly, have
generally ranged around 50-80% for IPD (Table 4).
Only one study showed no effect when looking at
healthy or high-risk adults (30+), and elderly patients
(55+) [32].When looking at the impact that all CCS
have on our estimate of VE against IPD, a decrease
on the level of protection of PPV is observed in the
low risk elderly, VE = 47% (30-60%), whereas a
significant and higher estimate of VE is produced in
the HRG VE = 52% (20-71%). Indeed, examining
the funnel plots, it seems that there may be evidence
of bias in studies of high-risk elderly, as the CCS tend
to give higher estimates of VE (lower OR) than the
RCT.
Discussion
The purpose of this work was to review the published
estimates on VE of the PPV and to perform a meta-
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analysis in order to assess the level of protection
among the general elderly population and elderly at a
higher risk of infection because of the presence of
other diseases. These two groups of individuals are at
the centre of the current debate on whether or not to
extend the vaccination programme to include all el-
derly individuals, as has been done in the UK for the
influenza vaccine. Randomised and quasi-rando-
mised clinical trials have been taken into consider-
ation and previous meta-analyses have been
presented and discussed in order to understand the
different results. Due to the small sample size of most
of the trials, very wide confidence intervals were
estimated for individual studies as well as for the
overall pooled estimate.
The results of our meta-analysis when taken with
the findings of other meta-analyses and observational
studies show that PPV offers a reasonable degree of
protection in the general elderly population against
invasive disease and a moderate effect in the high-risk
elderly. The vaccine appears to have little or no effect
against pneumonia.
In the process of selecting the studies and extract-
ing the data, a number of difficultieshave arisen, first
of which is related to the small number of method-
ologically strong (Jadad score> 3) studies that sat-
isfied the inclusion criteria and, secondly, their lack of
power in detecting any effect of the vaccine. For these
reasons, and also because we wanted comparable
results with previous meta-analyses, we decided to
include all the studies that satisfied our inclusion
criteria, whatever their Jadad score was, and to use
meta-analysis technique ourselves so that the final
estimate of VE would have had more power. Fur-
thermore, as diagnostic methods were not consistent
throughout the papers, as well as the separate
counting of the number of pneumococcal pneumonia
and IPD cases, it was crucial that the two reviewers
extrapolated the data separately and then cross-
checked them also with previous studies and reviews.
The different inclusion criteria adopted for each study
population and the definition of high-risk patients
which varied across the studies, represent another
limitation of the analysis. We tried to take this into
account by selecting those studies that were most
similar in term of place (all studies are in developed
countries), age of the participants and their risk
conditions.
Further studies would clearly help clarify whether
the vaccine has any effect in these risk groups, and/or
on non-invasive pneumonia. It is debateable, how-
ever, whether the additional expense of performing
these studies would be worth it, particularly as the
conjugate vaccine may be effective even in immuno-
compromised patients. A lack of efficacy against
pneumonia does not necessarily preclude the use of
the vaccine in the general elderly population. Recent
economic evaluations have suggested that the vaccine
may be,cost-effective in these groups even though its
efficacy is limited to invasive disease [34, 35]. Fur-
thermore, it is unlikely that the vaccine would be
withdrawn from the currently recommended HRG,
even though it may have very little beneficial effect.
Bayesian value-of-information analysis [36] is the
most logical framework to assess whether more
information is required, and if so, how large any trial
should be. Meanwhile, trials of the conjugate vaccine
should be performed in the elderly.
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Abstract. The 23-valent pneumococcal polysaccha-
ride vaccine (PPV) has been available for a number of
years and is recommended for high-risk categories.
Relatively immunocompetent elderly people are not
included in this group, although their probability of
getting invasive pneumococcal infection is high. The
objective of this study was to assess whether vacci-
nating all elderly people over 65 years of age was a
cost-effective policy for England and Wales. The
analysis was performed comparing the cost and
health effects produced by vaccination, to what
would have been occurred if vaccination were not
introduced. A decision analysis model was used in
order to predict health outcomes under different
vaccination scenarios. Unit costs were applied to the
outcome and the cost per life-year gained was cal-
culated. Sensitivity analysis was performed to allow
for uncertain parameters to vary. The current UK
recommendation does not appear to be the most cost-
effective strategy due to the low level of efficacy of the
vaccine in high-risk groups (HRG) and their shorter
life expectancy. Routine vaccination of all elderly
appears to be more cost-effective. These results are,
nevertheless, very much dependent on the uncer-
tainties around vaccine efficacy estimates, which ap-
pear to be still present, especially in HRG, and on the
number of hospitalisations and deaths attributable to
invasive pneumococcal disease (IPD).
Key words: Cost-effectiveness, Elderly, High-risk, Polysaccharide pneumococcal vaccine
Abbreviations: CDSC/RSIL = Communicable Disease Surveillance Centre's/Respiratory and Systemic
Infection Laboratory; CFR = case-fatality ratio; GP = general practitioner; HES = Hospital Episode Sta-
tistics; HRG = high-risk group; ICD-1O = International Classification of Disease, tenth revision; ICU =
intensive care unit; IPD = invasive pneumococcal disease; LOS = length of stay; MSGP4 = Morbidity
Statistics from General Practices; NHRG = non-high risk group; PPV = polysaccharide pneumococcal
vaccine; SP = S. pneumoniae; VE = vaccine efficacy
Introduction
Streptococcus pneumoniae is one of the most impor-
tant bacterial respiratory tract infections. It is usually
found in the normal flora in the upper respiratory
tract and is considered responsible for causing 30-
50% of community acquired pneumonia [I, 2], 28-
55% of otitis media [3], 20-35% of sinusitis [4], plus a
wide variety of other more serious invasive pneu-
mococcal infections such as bacterial meningitis and
septicaemia [5].
Invasive pneumococcal diseases (IPD) account for
a large number of hospitalisations and deaths each
year in Western European countries [6]. In particular,
people aged 65+ years are considered at high risk of
acquiring an invasive pneumococcal infection and
usually experience higher morbidity and mortality
rates [7, 8].
The 23-valent-polysaccharide pneumococcal vac-
cine (PPV) is not currently recommended in the UK
for all elderly individuals. The vaccine is licensed for
immunisation only to persons over the age of 2 years
for whom the risk of contracting pneumococcal
pneumonia is unusually high or dangerous [9]. These
include persons with asplenia or severe dysfunction of
the spleen, chronic renal disease, immunodeficiency,
chronic heart, lung, or liver diseases, and diabetes
mellitus (in practice most of these are elderly). Al-
though they are recommended to receive the vaccine,
uptake rates have been low in this group [10], possi-
bly due to concerns regarding vaccine efficacy and the
consequent lack of initiatives for promoting the
programme. The recent recommendation in the UK
that all elderly individuals (65+) should receive the
influenza vaccine provides an opportunity for the
introduction of the 23-valent-pneumococcal vaccines
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for all the elderly since both vaccines may be given at
the same time [6, 11].
Although several economic evaluation analyses
have been performed for other European countries [6,
12]as well as for the US [13-18] and generally found
that pneumococcal vaccination of the elderly popu-
lation is relatively cost-effective and potentially cost-
saving to the health care sector and to society, no
such analysis has been performed for England and
Wales at the time of the writing.
This study is thus aiming to assess the costs and
the health effects of the introduction of the PPV
in England and Wales and to determine whether
extending the current UK recommendation to
include all elderly individuals, would be a cost-
effective programme from the public health perspec-
tive.
Methods
Model structure and perspective
A cost-effectiveness analysis was performed to
determine the net benefit gained from vaccinating all
elderly at 65 years old with the 23-valent polysac-
charide vaccines. Hypothetical cohorts - vaccinated
and unvaccinated - were followed throughout their
lives, and morbidity, mortality and discounted costs
of eventual treatment were compared. The perspec-
tive adopted was the one of the health care provider
(NHS) hence the costs were limited to expenditures
and savings within this sector, leaving the costs to
society and wider economy out of the analysis. Due
to the current recommendation on pneumococcal
vaccine in England and Wales [9] and to the differ-
ences between elderly with or without underlying risk
conditions (in terms of incidence rate, responsiveness
to the vaccine, duration of protection and back-
ground mortality rate) [19-21], the hypothetical co-
horts were each divided into two distinct sub-groups:
high-risk group (HRG) and non-high risk group
(NHRG). Results for the overall general population
were derived within the model, weighting outcomes
and costs with the prevalence of high-risk people in
the community.
The Morbidity Statistics from General Practices
(MSGP4) [22] is a l-year survey of general practices
in England and Wales covering over 500,000 indi-
viduals. This survey provided the prevalence and
background life expectancy of the two risk groups.
Patients were divided according to whether or not
they consulted for one of the high-risk codes (based
on the current recommendations [9];Table I) allow-
ing the proportion of high-risk individuals to be
estimated. Background mortality rates were calcu-
lated for the two groups and for the general elderly
population from deaths recorded in MSGP4. Checks
were made to compare the background mortality rate
obtained from this survey to those derived from the
1991Census.
Health outcomes were measured in terms of life-
years gained (LYG) from vaccination. The Net
Benefit of the program was calculated by multiplying
these LYG by their shadow price (which was varied
in the analysis) and then subtracting from this the
costs of the program. All future benefits and costs
were discounted at a constant rate (3% per annum
for both in the base case as recommended in the US
Panel on Cost-effectiveness [23]).Discount rates were
varied in the sensitivity analysis to allow for the UK
recommendation levels (6% per annum for costs and
1.5% for health benefits [24]).The model did not take
into account population dynamics as herd immunity
effectsderived from vaccination of the elderly, with a
vaccine that does not appear to prevent carriage [25],
would be negligible. As the current coverage of the
pneumococcal vaccine to the recommended catego-
ries remains low [10], the study also assesses the im-
pact of widespread vaccination among high-risk
elderly.
Furthermore, health benefits and costs that would
derive from widening the current recommendations
to include all elderly individuals are taken into
consideration as a different scenario. In the base-case
the alternative programs were either one-off vacci-
nation at 65 or treatment of IPD as cases occur.
Estimates of the optimum age to vaccinate are pro-
duced using incremental analysis technique [26J,
which calculates incremental cost-effectiveness ratios
(additional costs that one programme imposes over
another divided by the additional benefits, i.e. LYG)
for each successivealternative (one-off vaccination at
different ages), from the least cost-effective to the
most. With the same technique, we looked at the
incremental costs and benefits of introducing regular
booster doses at specificintervals (5 and 10years) and
assessed what is the optimum interval for revaccina-
tion.
Due to the uncertainty that surrounds many of the
key parameters included in the model, univariate and
multivariate sensitivity analyses were performed.
Univariate sensitivity analysis consists of varying one
parameter at a time, multivariate sensitivity analysis
allows for uncertain parameters to change simulta-
neously according to the probability distributions
that were assigned to them. The model was run 1000
times and on each occasion a random set of input
parameter values were chosen by means of Latin
Hypercube Sampling using the software @Risk 4.0
(Palisade Corporation, New York). In this wayan
outcome distribution is produced that gives the pro-
portion of simulations in which the programme is
cost-effective (net benefit >0). Uniform, triangular
and normal distributions were assumed for input
distributions (Table 3).
Epidemiological data sources and vaccine-related
parameters
Two data sources were used to estimate the incidence
of invasive pneumococcal infections: the HPA
Communicable Disease Surveillance Centre's/Respi-
ratory and Systemic Infection Laboratory (CDSCj
RSIL) reconciled database and the Hospital Episode
Statistics (HES) (http://www.doh.gov.uk/hes). The
CDSC/RSIL enhanced surveillance system is based
on weekly reports, from public health and non-public
health laboratories in England and Wales, of all
clinically significant bacterial isolates from blood,
cerebrospinal fluid (CSF) and other sterile sites [27].
HES records discharge diagnoses (using the Interna-
tional Classification of Disease tenth revision, ICD-
10) of all admissions to National Health Service
hospitals in England. It contains non-aggregate data
on personal, medical, and administrative details of all
patients admitted to and treated in NHS hospital. All
records with at least one S. pneumoniae related ICD-
10 code (GOOl, A403, J13X, B953) in any of the seven
available diagnostic fields were extracted from HES
downloads of individual patient data that are avail-
able to CDSC. The period considered was April 1995-
March 1998. Data were cleaned for possible dupli-
cates and the last episode of each hospitalisation was
kept. If more than one pneumococcal code was re-
ported for a single record, the following order of
importance was given: Pneumococcal meningitis
(GOOI), pneumococcal septicaemia (A403), pneumo-
coccal pneumonia (Jl3X), S. pneumoniae as the cause
of the disease (B953).
A list of high-risk ICD-I0 codes was produced
based on the current UK recommendations for PPV
(Table I). The presence of at least one of these high-
risk codes in any of the remaining diagnostic fields
was used to categorise patients at high risk (the
remainder being assumed to be non-high risk). Inci-
dence rates were calculated using 1995-1998 HES
data and population estimates for England published
by the Office of National Statistics and are shown in
Table 2. Age-specific incidence rates obtained from
CDSCjRSIL laboratory reports of IPD and HES
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(any S.pneumoniae diagnostic code) were very similar
(Figure I). Since it is possible to determine the risk
status of patients from the HES database, this data-
source was used (rather than CDSCjRSIL) to gen-
erate base-case incidence estimates. A uniform dis-
tribution was used in the multivariate analysis; lower
and upper bounds were set at, respectively, the min-
imum and maximum values that were observed over
the three years period in each age group (based on
HES data).
Average lengths of inpatient stay were derived also
from HES for the specified age groups. Although
clear dissimilarities were not observed between high
and low risk patients, specific levels were assigned to
the two groups. Minimum and maximum levels that
were observed during the analysed period (1995-
1998) were used as lower and upper bounds in the
multivariate analysis.
Due to the difficulty in determining whether a pa-
tient who dies with IPD died of IPD, age and risk
specific case-fatality ratios (CFR) for IPD were cal-
culated in two ways. First, all deaths among patients
that were admitted to hospital who had a discharge
diagnosis including any IPD codes were assumed to
have died of IPD (Scenario 1). This gives an upper
estimate, as in many instances pneumococcal infec-
tion would not be the underlying cause of death as
many of these patients also have other codes re-
corded. A low estimate is produced when considering
hospitalised patients that had only IPD codes re-
corded (Scenario 2). For these, IPD was the only
reported clinical condition and, thus, the number of
deaths among them was more likely the result of the
pneumococcal infection they contracted. Risk-spe-
cific CFRs were produced using the proportion of
deaths among high-risk individuals that was observed
when considering Scenario 1. HES data from April
1995 to March 1998 were analysed and lower and
upper bounds were estimated looking at, respectively,
the minimum and maximum level observed over the
3 years period for the two scenarios.
ONS 1998 data, reporting pneumococcal disease as
the underlying cause of death, were also analysed,
although the use of the ninth revision of the inter-
Code description
Table 1. ICD-IO codes that were considered in the definition of HRG among hospitalised patients
ICD-IO codeICD-9 code
Asplenia or severe dysfunction
of the spleen (incl. sickle cell disease and coelic syndrome)
Chronic renal disease or nephrotic syndrome
Immunodeficiency or immunosuppression
due to disease or treatment, including
HIV infection at all stages
Chronic heart disease
Chronic lung disease
Chronic liver disease including cirrhosis
Diabetes mellitus
282.5-282.6, 289.4-289.5,
7590
581, 582, 584, 585
0420-0449, 140-208, 279
D57; D73; Q89.0
N04; NI8
B20-B24; COO-C97; D80-D89
393-398,414, 416
490-496
571-573
250
105-109; 125; 127
J41-J47
K70; K73-K74
Elo-E14
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Table 2. Base case parameters values and sources
Age groups
Data
Parameters 65-69 70-74 75-79 80-84 85+ source
Health outcomes
Admission rate - HRGa 83 126 124 157 250 HES
Admission rate - NHRGa 11 17 21 33 82 HES
LOS per admission - HRG (days) 16 15 16 18 18 HES
LOS per admission - NHRG (days) 13 15 16 18 14 HES
High CFR - HRG 16% 18% 21% 24% 28% HES
High CFR - NHRG 15% 18% 17% 24% 16% HES
Low CFR-HRG 9% 8% 13% 20% 17% HES
Low CFR - NHRG 9% 9% 11% 20% 10% HES
Direct cost"
Cost per GP consultation (£) 19 19 19 19 19 {23}
Cost of initial treatment (£) 8 8 8 8 8 {24}
Cost of inpatient day (£) 242 242 242 242 242 {23}
Cost of intensive care (£) 1103 1103 1103 1103 1103 NHS
Vaccine parameters"
Cost of vaccine & delivery (£) 11.4 11.4 11.4 11.4 11.4 {24}
Vaccine efficacy- HRG (%) 20 20 20 20 20
Vaccine efficacy- NHRG (%) 65 65 65 65 65
Duration of protection - HRG (years) 5 5 5 5 5
Duration of protection - NHRG (years) 6.5 6.5 6.5 6.5 6.5
Analysis
Prevalence of HRG (%) 9.6 9.7 10.2 9.7 7.7 {15}
Admitted to ICU (%)b 5 5 5 5 5
Discount rate outcomes (%)b 3 3 3 3 3
Discount rate costs (%)b 3 3 3 3 3
Coverage (%)b 60 60 60 60 60
a All rates are per 100,000 populations per year.
bThese parameters are not age dependent.
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Figure 1. Comparison of admission rates calculated from HES with incidence rates of national laboratory reports of IPD
(CDSC 1999). Admission rates are calculated on 1997-1998 data for high and low risk elderly, and for all elderly 65 + .
national classification of disease (ICD-9) made it
difficult to compare HES figures to the number of
deaths reported by ONS. The ICD-9 pneumococcal
specific codes are: 0382 for pneumococcal septicae-
mia, 3201 for pneumococcal meningitis, and 481 for
pneumococcal pneumonia. Overall, and due to the
inclusion of lobar pneumonia (organism unspecified)
in the latter code, the number of deaths reported by
ONS was much higher (over 2000 deaths) than that
observed in hospitalisation data. Even when looking
at the upper estimate of IPD admissions (Scenario 1-
annual average of 692 deaths).
Vaccine efficacy and duration of protection (vac-
cine-induced immunity) were assessed reviewing
randomised and quasi-randomised clinical trials and
case-control studies. As the majority of these studies
were insufficiently powered to detect any effect of
PPV against IPD, a pooled estimate was performed
using a random effect model and having divided the
trials in relation to their study population: general
elderly population and elderly at high-risk. A detailed
description of the procedure used and of the studies
that were included for the overall estimate can be
found in a separate work [28].Overall levels of pro-
tection of 65% and 20% were used for, respectively,
low and high-risk group, although the confidence
intervals were very wide. Probability distributions
were assigned to vaccine efficacy and duration of
protection (Table 3). A range of 5-10 years of pro-
tection was found in the literature [29, 30], although
some evidence of a lower vaccine-induced immunity
was detected in certain high-risk groups [5, 31]. In our
analysis, base case values of 6.5 and 5 years for,
respectively low and high-risk individuals were
adopted. We assumed that adverse events following
immunisation would be negligible [32], and have
therefore been ignored.
We assumed that each case of IPD would visit the
General Practice and receive an antibiotic treatment
before hospitalisation. A proportion of the hospital-
Table 3. Input distribution for the multivariate analysis
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isations (5%) were admitted in the intensive care unit
(ICU) of the hospital. This percentage was varied in
the univariate analysis.
Cost estimates
The costs included were the ones of the primary
health care (GP consultation and first blind treat-
ment) and the hospitalisation costs. All costs are gi-
ven in pounds sterling at year 2000 prices.
The unit cost of a typical GP consultation (£19)
was taken from the Unit Costs of Health and Social
Care [33].The average initial treatment cost per case
was estimated from the standard recommendations
given in the BNF for antibacterial therapy [34].The
Formulary recommends erythromycin for the treat-
ment of atypical pneumonia (7 days course, £9.26)
whereas erythromycin plus cefuroxime (7 days
course, £18.71) for severe community-acquired
pneumonia of unknown aetiology. The initial blind
therapy for a possible meningitis or septicaemia case
was assumed to be respectively a single dose of ben-
zylpenicillin (GP pack = £1.90), or aminoglycoside
(£1.51) together with broad-spectrum penicillin
(£2.01). The mean cost of the treatment becomes
£8.35.
The unit cost per inpatient day was taken from the
same standard source [33],using the price of a generic
ward (£242) that is the average cost of a variety of
specialties. The inpatient cost for the infectious dis-
NHRG HRG
Input name Distribution Minimum Maximum Minimum Maximum
Admission rate - 65-69 years" Uniform 9.2 13.6 52.1 99.4
Admission rate - 70-74 years" Uniform 14.2 19.4 78.6 153.6
Admission rate - 75-79 years" Uniform 16.4 26.6 73.9 160.1
Admission rate - 80-84 years" Uniform 25.9 40.0 86.3 209.0
Admission rate - 85+ years" Uniform 49.3 112.7 109.4 348.9
CFR - 65-69 years (Scenario I) Uniform 13% 17% 15% 17%
CFR - 70-74 years (Scenario 1) Uniform 14% 22% 15% 18%
CFR - 75-79 years (Scenario 1) Uniform 15% 19% 20% 23%
CFR - 80-84 years (Scenario I) Uniform 22% 26% 17% 26%
CFR - 85+ years (Scenario I) Uniform 13% 22% 25% 31%
CFR - 65-69 years (Scenario 2) Uniform 6% 11% 6% 12%
CFR - 70-74 years (Scenario 2) Uniform 3% 12% 3% 11%
CFR - 75-79 years (Scenario 2) Uniform 8% 12% 10% 15%
CFR - 80-84 years (Scenario 2) Uniform 19% 24% 19% 24%
CFR - 85+ years (Scenario 2) Uniform 8% 17% 14% 29%
LOS per admission - 65-69 years Uniform 13.0 13.4 14.5 16.7
LOS per admission - 70-74 years Uniform 13.6 15.4 14.1 14.8
LOS per admission - 75-79 years Uniform 15.9 16.1 15.1 16.3
LOS per admission - 80-84 years Uniform 17.7 18.3 17.0 18.7
LOS per admission - 85+ years Uniform 12.4 17.3 16.9 19.6
Vaccine efficacy" Normal -49% 92% -188% 78%
Duration of protection (years) Triangular 4 9 3 7
aAll rates are per 100,000 populations per year.
b 95% CIs are displayed.
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ease and geriatric wards (£348 and £144) though,
were used in the sensitivity analysis as the upper and
lower limit. All these costs take into account the
average nursing costs, cost of the bed, cost for
investigations to ascertain a diagnosis and also
treatment costs. The average cost of a bed/day in the
ICU was taken from NHS Reference Cost (£1103).
Due to a lack of data, we ignored long-term care for
sequelae of IPD. Thus cost-estimates are likely to be
somewhat higher than is reported here, and our cost-
effectivenessestimates will be conservative.
The cost of the vaccine (Pnu-Immune) was taken
from the British National Formulary (£9.94),whereas
the delivery cost was set at £1.5, similarly to what
Ament and colleagues used in their base case analysis
(3.00 ecu) [6]. The overall cost of the vaccine for the
base-case was thus set at £11.44 and varied in the
sensitivity analysis. These unit costs were applied to
the estimated outcome predicted by the model.
Results
Life-expectancy
From MSGP4 data, different background life
expectancies were estimated for low and high-risk
patients, with a probability of survival much lower in
the latter case (Figure 2). Almost 10% of individuals
over the age of 65 were found to have an underlying
high-risk condition. The age specificpercentages that
were used in the model are reported in Table 2.
Burden of invasive pneumococcal disease
From the base-case analysis, around 3000 invasive
pneumococcal infections were estimated annually for
England and Wales in 65+ years of age, 34% have a
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discharge diagnosis indicative of being at high risk.
From the MSGP4 survey around 10% of the elderly
are high-risk, thus the incidence of IPD is roughly five
times higher in HRG compared to NHRG. The
overall average length of inpatient stay was estimated
to be II and 13 inpatient days for non- and high-risk
patients, respectively. Age specific figures are shown
in Table 2.
If the low estimate is assumed (Scenario 2), an
annual average of only around 50 deaths attributable
to IPD occurs in the elderly. Taking Scenario 1 gives
roughly 500 deaths per year due to IPD.
Cost-effectiveness results
Vaccinating all HR elderly is estimated to have a net
discounted cost to the health service of£215,002 (cost
of vaccination is estimated to be £302,291 and the
discounted medical care savings is £87,289), whereas
vaccination of all elderly individuals (65+) is esti-
mated to cost to the health service £2,485,65 (cost of
vaccinating the cohort is estimated to be £3,163,165
resulting in discounted medical care savings of
£677,510 over their lifetime).
Under Scenario 1 and holding all other parameters
at their base case values, the current UK recom-
mendations, which consist of vaccinating all HR el-
derly with PPV, gives a cost per life year gained of
£9477.Vaccinating all 65+ years old, with or without
high-risk conditions, results in being the dominating
option with a lower cost per life year gained of
(£8504) under base-case assumptions. Higher esti-
mates of cost per life year gained are reached when
using the lower CFR (Scenario 2): £17,065 and
£15,052 for, respectively, HRG and all 65+.
The optimum age at vaccination is determined
ranking the different options, from the least costly to
the most, and calculating the incremental expenditure
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
Age (years)
--- Overall (MSGP4) -- HRG (MSGP4)
••••••• Overall (Census) -- NHRG (MSGP4)
...M
O'l O'l
Figure 2. Survival curves for elderly at different risk of infection. Data taken from MSGP4 survey and compared with
survival curve published by the Census.
and the additional life years that are gained switching
from one option to the following (Table 4). Alter-
natives that are producing a loss in LYG with an
increased expenditure are considered dominated op-
tions. Assuming a maximum willingness to pay for an
extra LYG of approximately £30,000, then the opti-
mum age at vaccination when higher values of CFR
are considered is 70 years old for both NHRG and
HRG. 75 years appear to be the best option under
the low CFR Scenario, although both incremental
cost-effectiveness ratios are very close to what could
be considered the maximum willingness to pay for an
extra LYG. In Table 5 incremental cost-effectiveness
ratios are produced comparing one-off vaccination at
specific ages (65, 70, 75) to vaccination policies with
booster doses every 10 years, and the latter with the
option of revaccinating at shorter intervals (5 years).
Incremental cost-effectiveness ratios below the level
of £17,000 are estimated for both groups of elderly
when revaccinating every 10 years and under the high
CFR option. This value increases to £26,000 when
considering the lower estimates ofCFR. Much higher
levels of incremental cost-effectiveness ratios are
produced when looking at a revaccination policy
every 5 years (£23,000-£61,000).
In Table 6 the results of a univariate sensitivity
analysis are reported under the two different scenar-
ios. Apart from the CFR, the most influential
parameter is estimated incidence of IPD. Basing
incidence on the primary discharge diagnosis only
results in vaccination being unlikely to be deemed
cost effective, regardless of mortality assumptions
(£20,000-£54,000 per LYG). It is also apparent from
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Table 6 that if an extra GP consultation is necessary
to vaccinate the elderly (instead of vaccinating
opportunistically, presumably with influenza vaccine)
then vaccination appears much less cost-effective
(range £23,000-£52,000 per LYG). Slightly higher
levels of cost per life-year gained (range £10,000-
£22,700) are also reached when we assumed that the
vaccine was preventing only the additional inpatient
days caused by the bacteraemic episode (the average
length of stay is from 2 to 3 days longer when looking
at IPD compared to other non-invasive pneumococ-
cal disease). Other important parameters include the
discount rate: adopting the UK Treasury recom-
mended discount rates means that vaccination be-
comes slightly more economically attractive than is
shown in our base-case analysis (range £8000-
£16,800 per LYG).
Figure 3 shows the sensitivity of the results to the
different levels of protection of the vaccine in high
and low risk elderly. Taking a maximum willingness
to pay for a life-year gained of £30,000, for instance,
then the model predicts that provided vaccine efficacy
is at least 10-15% then vaccination of the high risk
would be cost-effective and 25-35% for vaccination
of the non-high risk elderly to be cost-effective
(holding other parameters at their base-case level).
The results of the multivariate sensitivity analysis,
in which all parameters except the discount rate (fixed
at 3%) are varied simultaneously, are shown in Fig-
ure 4.
The figure shows the probability of each pro-
gramme being deemed cost-effective (positive net
benefit) for different upper limits of society's will-
Table 4. Incremental cost-effectiveness ratios for one-off vaccination policies at different ages
Low CFR High CFR
Age at vaccination NHRG HRG NHRG HRG
85 £3362 £5418 £2077 £3350
80 £5140 £8493 £7110 £12,102
75 £27,911 £33,202 £11,633 £11,629
70 Dominated Dominated £13,168 £4101
65 Dominated Dominated Dominated Dominated
Table 5. Incremental cost-effectiveness ratios - comparisons of different vaccination policies
NHRG HRG
Age at vaccination 65 years 70 years 75 years 65 years 70 years 75 years
Scenario 1 - High CFR
Vaccination one off £8422 £6143 £5239 £9477 £7088 £7584
Revaccination every 10 years £14,602 £11,787 £10,438 £16,746 £13,897 £10,344
Revaccination every 5 years £37,380 £35,328 £26,309 £29,085 £28,771 £23,680
Scenario 2 - Low CFR
Vaccination one off £14,886 £11,048 £7589 £17,065 £13,930 £11,564
Revaccination every 10 years £21,811 £15,473 £16,892 £25,663 £17,216 £16,714
Revaccination every 5 years £61,310 £57,120 £32,188 £55,332 £46,459 £28,196
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Table 6. Univariate sensitivity analysis. Cost per life-year gained of vaccinating elderly (65+) with PPV
Scenario I (High CFR) Scenario 2 (Low CFR)
NHRG HRG ALL NHRG HRG All
Base-case values £8422 £9477 £8504 £14,886 £17,065 £15,052
Admission rate
Only first diagnosis admissions £19,616 £30,000 £20,277 £34,770 £53,999 £35,977
All diagnoses (SP codes + JI81) C.s. C.s. C.s. C.s. C.s. C.s.
Intensive care unit
Proportion to ICU = 20% £7437 £7744 £7461 £13,144 £13,945 £13,205
Proportion to ICU = 40% £6123 £5434 £6070 £10,822 £9785 £10,743
Vaccine parameters
Only protective against invasive part £10,354 £12,604 £10,528 £18,300 £22,695 £18,635
Protection in HRG = 3, NHRG = 4 years £12,522 £13,420 £12,596 £22,444 £24,007 £22,572
Protection in HRG = 7, NHRG = 9 years £6589 £7725 £6674 £1l,504 £13,917 £11,679
Costs
Costs per course of vaccination
Only vaccine cost (£9.94) £7031 £7730 £7085 £12,427 £13,919 £12,540
Vaccine cost + GP consultation £23,782 £28,764 £24,169 £42,034 £51,795 £42,779
Costs per inpatient day
Infectious disease ward (£348) £7654 £8126 £7690 £13,528 £14,632 £13,612
Geriatric ward (£144) £9132 £10,726 £9256 £16,141 £19,313 £16,383
Cost per GP cons & treat
-25% of the base case £8426 £9483 £8508 £14,892 £17,075 £15,059
+25% of the base case £8418 £9471 £8500 £14,879 £17,054 £15,045
Discount rate
Benefits 6%, costs 6% £14,786 £13,738 £14,690 £26,449 £24,658 £26,286
Benefits 0%, costs 3% £5215 £6976 £5333 £9143 £12,568 £9368
Benefits 1.5%, costs 6% £8264 £9342 £8347 £14,688 £16,808 £14,849
C.s. = cost saving.
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Figure 3. Cost per life-year gained by VE for high and low risk elderly and under the two different assumptions on CFR.
ingness to pay for an additional life-year gained.
Vaccination of high-risk groups has a relatively low
probability (no more than about 60%) of being cost-
effective regardless of which CFR is assumed and
regardless of the society's willingness to pay for a life-
year gained. This is because the programme has a
relatively low probability of being effective. On the
other hand, when considering low-risk elderly, a
higher proportion of simulations were cost-effective
compared to HRG, unless the upper value that
society places on a LYG is unrealistically low. The
two different scenarios of CFRs are, nevertheless,
influencing the rise of the curve and have a strong
impact on the probability of having a positive Net
Benefit in NHRG when the value of a LYG is around
£15,000.
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Figure 4. Results of the multivariate analysis. All the parameters are varied within their predefined distribution and the
proportion of cost-effective simulations is shown for different values of a life year gained and for high and low risk elderly.
CFR estimates are set to the lower or higher values.
Discussion
Invasive pneumococcal disease burden is high among
the elderly and, in particular, among those considered
to be at high-risk of pneumococcal infection. These
are the ones who experience the highest incidence
rates, and to whom the vaccine is currently recom-
mended. We presented here an economic evaluation
of the current 23-valent-polysaccharide vaccine
against IPD, looking at high-risk elderly and at the
general elderly population. Although other analyses
have been published for other European countries [6,
12]as well as for the US [13-18], this is the first study
that considers the UK setting and, in particular, the
possibility, which is currently under discussion, of
extending the current programme (only high-risk
groups) to the general elderly population.
The current UK recommendation does not appear
to be the most cost-effective strategy, due to the low
level of protection of the vaccine in these risk groups
and the shorter life expectancy of elderly patients
with chronic diseases. Routine vaccination of all el-
derly individuals appears to be more cost-effective.
Although the relative ranking of these alternatives are
unlikely to change, exact quantification of the cost-
effectivenessof either of the programmes is hampered
by considerable uncertainties in the degree of pro-
tection afforded by the vaccine and the number of
hospitalisations and deaths that are attributable to
IPD. Although many hospitalised patients have IPD
and a sizeable proportion of them die, their under-
lying cause of death was not necessarily IPD, nor
could this necessarily be prevented by vaccination.
We have attempted to account for some of these
problems in estimating the number of preventable
life-years being lost by IPD by taking average life
expectancy by risk group (rather than for the popu-
lation as a whole), and by testing the robustness of
our findings to very different assumptions regarding
CFR. Clearly further work could be performed in this
area; the most valid and relevant information would
be derived from a properly designed and imple-
mented randomised clinical trial that was appropri-
ately powered to investigate the effect of vaccination
on mortality. This is unlikely to happen in the fore-
seeable future. Therefore, do we have enough infor-
mation currently available to make a reasonably
sound judgement on the cost-effectiveness of vacci-
nation of the elderly with PPV? Provided the vaccine
is given opportunistically (at the same time as influ-
enza vaccination, for instance) then it seems likely
that vaccination of the non-high risk elderly popu-
lation would be cost-effectiveby most criteria, simply
because the vaccine is cheap, and the burden of dis-
ease is high. Vaccination of high-risk groups does not
have a high probability of being deemed cost-effec-
tive, because the vaccine may not be effectivein these
individuals. It seems unlikely, however, that vacci-
nation would be withdrawn from this group.
Moreover, the incremental analysis we performed
suggests that the optimal age to vaccinate is 70-
75 years depending on whether the, respectively, high
or low CFR assumptions are adopted. This produces
a lower gain in life expectancy as opposed to vacci-
nating at earlier ages (i.e. 65 years), but, at the same
time, keeps at a lower level the costs associated with
the programme. Our analysis also suggests that giving
a booster dose of the vaccine every ten years could be
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an economically sensible policy to adopt as its addi-
tional cost per life-year gained still lies within the
acceptable range.
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SUMMARY
This paper analyses Streptococcus pneumoniae transmission dynamics in households using
longitudinal data on pneumococcal (Pnc) carriage in the United Kingdom. Ten consecutive
swabs were taken at 4-week intervals from all members of 121 households. The family status is
derived from the observed Pnc carriage status of each family member. Transition matrices are
built for each family size and composition containing the observed frequency of transitions
between family statuses over a 28-day interval. A density-dependent transmission model is fitted
to derive maximum-likelihood estimates of the duration of carriage and acquisition rates from the
community and from infected individuals within the household. Parameter values are estimated
for children «5 years) and adults (5+ years). The duration of carriage is longer in children
<5 years of age than in older family members (51 vs. 19 days). Children are 3-4 times more
likely than adults to acquire Pnc infection from the community. Transmission rates within the
household suggest that adults are more infectious but less susceptible than children. Transmission
within the household is most important in large families. The proportion of household-acquired
infection ranges from 29 to 46% in households of three persons to 38-50 % in larger households.
Evidence of density-dependent within-household transmission is found, although the strength of
this relationship is not clear from the model estimates.
INTRODUCTION
Background
Streptococcus pneumoniae is one of the most import-
ant bacterial pathogens in respiratory tract infections,
affecting children and adults worldwide despite cur-
rent antibiotic therapies [1, 2]. It is responsible for
causing upper respiratory infections which may lead
to ear infections and sinusitis, as well as more serious
invasive disease such as pneumonia, septicaemia and
• Author for correspondence: A. Melegaro, Modelling and
Economics Unit, Communicable Disease Surveillance Centre,
Health Protection Agency, 61 Colindale Avenue, London
NW9SEQ, UK.
meningitis [3, 4]. Pneumococcus is the leading cause
of lobar pneumonia in children under 5 years of
age [5].
The bacterium gains entry into the host by col-
onizing the nasopharynx and the outcome of coloniz-
ation depends on both the virulence of the colonizing
serotype and the efficiency of the host immune system.
The interval between colonization and onset of dis-
ease, when it occurs, is variable, but there is some
evidence that disease is more likely to occur shortly
after colonization [6]. However, most of pneumo-
coccal (Pnc) infections remain asymptomatic and
S. pneumoniae is considered a common component of
the nasopharyngeal flora in healthy individuals.
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Transmission from a person infected with pneumo-
coccus is via droplets of respiratory secretions that
remain air-borne over a distance of a few feet. The
infecting organism may also be carried on hands
contaminated with secretions. As the majority of Pnc-
infected individuals remain asymptomatic, carriage
data are needed in order to gain an in-depth under-
standing of Pnc transmission dynamics.
A heptavalent protein-polysaccharide conjugate
vaccine has been licensed in the United Kingdom and
it is now recommended for children at high risk under
the age of 2 years. The vaccine has been proven to be
highly effective against invasive Pnc disease [7] and
moderately effective against non-invasive Pnc con-
ditions (otitis media, pneumonia) [8-10). Moreover,
some efficacy against Pnc carriage has been shown
[11], although there are still concerns about whether
serotype replacement will occur if vaccination is
widely introduced and what effects this will have on
the severity of the disease. Baseline information on
the transmission dynamics of Pnc carriage in the pre-
vaccination era is thus necessary to predict the effects
of interventions such as the introduction of the vac-
cine on disease burden.
Previous work
Longitudinal carriage studies have been performed
to gain insight into the pathogen's mechanism of
carriage and transmission within hosts. In this type
of study, individuals are swabbed at regular intervals,
their carriage status is assessed and inference on their
rate of acquisition and on the duration of carriage
can be obtained. Smith et al. [12] using longitudinal
carriage data collected in Papua New Guinea found
that Pnc serotypes vary widely in their acquisition
rates and in the length of time for which they persist.
An inverse relationship between duration of carriage
and age was shown by Ekdahl et al. [13] who studied
Pnc carriage using data from an intervention project
in Sweden. A similar relationship was found by
Auranen et al. [14] who analysed longitudinal data on
Pnc carriage in Finnish families taking into consider-
ation transmission within the family and from the
community and estimating acquisition rates and dur-
ation of carriage for children and adults.
The problem
The aim of this work is to analyse data from a longi-
tudinal carriage study in families in the United
Kingdom thereby gaining insights into Pnc trans-
mission dynamics in the pre-vaccination era. In par-
ticular, to estimate the duration of carriage for adults
and children, and the rate of acquisition of carriage
from the community and from infected family
members.
METHODS
Description of the data
The dynamics of Pnc transmission within families
were captured by a longitudinal study of Pnc car-
riage conducted in the United Kingdom from October
200 I to July 2002 as part of the European Pneumo-
coccal Project (PncEuro) [15]. The data consisted of
follow-up measurements of Pnc carriage of 132 pre-
school children «3 years) and their families, who
were enrolled through primary health-care registers
in Hertfordshire [15]. The size of the family varied
from 2 to 7, although in most of the families there
were 3 or 4 members.
From each family member, a nasopharyngeal
swab was obtained at initial home visit and followed
by 9 further swabs at 4-week intervals. As a pre-
vious study [13] suggested that duration of carriage
might be less than 28 days, especially in adults,
it is possible that not all episodes of carriage will
be observed from the data. Although serotyping was
performed when Pnc carriage was detected, this
analysis considers Pnc carriage in general and, thus,
is only looking at whether or not the individual is
carrying the bacteria. As there were only three cir-
cumstances in which two serotypes were found in
the same individual at the same time, the model
is based on the assumption that simultaneous car-
riage of different serotypes is rare enough to ignore
initially.
A total of 121 families comprising 489 individuals
were considered in this analysis. II families dropped
out from the study at the very beginning. For each
individual that took part in the study, the carriage
status at each monthly visit was obtained from the
data and then recoded as 0, if non-carrier, 1 if carrier
and 9 when either the swab was not taken or the
laboratory result not reported. The household state
at each visit is derived combining the carriage status
of all the family members and results in a sequence
of Os and Is if their information is complete. Missing
information on at least one family member results
in incomplete information at the household level
and, thus, a missing value code. Family sequences
are organized so that the last number represents the
status of the youngest member of the family. Due to
the strong association that has been shown in other
studies [13, 14] between Pnc carriage and age, with
younger children having a much higher prevalence
and longer duration of carriage, we set a cut-off at
5 years of age and stratified households by family
size and composition (number of adults and children
in the family). We derived strings of household re-
sults, which were then converted into a table show-
ing the number of transitions between each pair of
household states over a 28-day period for each
family size and structure. Two households of 2 in-
dividuals and one of 7 were excluded from the
analysis as their sequences were non-informative.
Ten distinct tables Nz•u were derived for the available
combinations of household size (z) and number of
adults (u) respectively in the family: (3, I), (3,2),
(4,2), (4,3), (5,2), (5,3), (5,4), (6,3), (6,4), (6,5).
Only complete family transitions, where the infection
state of all household members is known on two
consecutive observations, are used in the following
analysis.
The model
Following the work by Auranen and colleagues on
both Hib and Pnc infection [14, 16] the model con-
siders transmission of Pnc within the household.
We assumed that each individual can either be in a
non-infected state, i.e. susceptible to infection (S),
or they can already be infected (carriers) (C) and,
as a consequence, able to spread the infection to
uninfected individuals in their household. No Pnc-
specific disease was observed so this possibility is
not included. As in Auranen et al. [14] we set the
transition from C-tS to be dependent on a constant
recovery rate, and the transition from S-tC to be a
function of the potential exposure to the infective
agent both within the family (within-family acqui-
sition rate) and outside the family (community ac-
quisition rate).
The probabilities of transition from an infected to
an uninfected state and vice versa in a short time in-
terval ot are then defined for an individual in the age
class i= 1, 2 [where 1= child « 5 years) and 2= adult
(5+ years)]:
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P·(S C) _(k.+fJllh(t)+f3i2I2(t») ·ot (2)
I -t 01 - I (z -l)w ,
(1)
where fli and k, are the clearance and the community
acquisition rates respectively for age class i; and z
is the family size. I1(t) and Iz(t) are the number of
infected children and infected adults respectively in
the family. fJij is the transmission rate from an in-
fected to an uninfected individual and it reflects
both the infectiousness of an individual in age
class j and the susceptibility of an individual in age
class i. Thus the within-household probability of
being infected in ot is a function of the number
and age class of the other family members that are
carrying the bacteria at that particular time. Com-
munity acquisition rates and recovery rates are
similarly defined in vectors: (kl' kz) and (ftl> fl2)' The
term (z _1)W in eqn (2) represents a density correc-
tion factor; (z-I) being the number of other family
members in families of size z, and w the factor that
controls the extent of density dependence. When
w=O the model reflects density-independent trans-
mission: the probability of contracting infection
from another specific individual in the family does
not change with family size and, thus, the average
number of contacts increases linearly with family
size.When w = 1 the probability of getting in contact
with the same individual decreases in bigger families
although the average number of contacts remain
constant. If w> I the average number of contacts
decreases with family size. In total nine parameters
define the model.
Equations (I) and (2) are used to derive the prob-
ability Prs of transition between two different family
states rand s in a short time-interval ot. These
probabilities are calculated for each household size
and composition. It is assumed that in a short time-
interval ot, here chosen as 1 day, only one member
of the household will change status (either through
infection or recovery). The probability of transitions
where more than one individual changes status is
therefore set to zero. For example, in a family size of
three composed of two adults and one child, the
probabilities of going from state 001 (two susceptible
adults and one carrier child) to states 000, 101and 011
in one time-step, are derived using respectivelyeqn (I)
to become a fully susceptible household, and eqn (2)
to reach states 101or OIl. The T}(3,2) matrix [seeeqn
(3) below], contains all the probabilities of transitions
from the initial family status at the top of the matrix
to the consecutive status given on the left-hand side
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of the matrix when ot is 1 day:
000 100 010 110 001 101 011 III
000 qll f.1-2 f.1-2 0 f.1-1 0 0 0
100 kz q2Z 0 f.1-2 0 f.1-1 0 0
010 kz 0 qS3 f.1-1 0 0 f.1-1 0
110 0 [2-w.8u +k21 [2-W.8Z2 +kal q« 0 0 0 141 (3)
001 kl 0 0 0 q55 142 142 0
101 0 [2- W.8lZ +kd 0 0 [2-W.821 +kll q6ll 0 142
Oil 0 0 [2- W.812 +kd 0 [2- W.8Zl +kzl 0 qn 142
III 0 0 0 [21- W.812 + kll 0 [2- W<.Bzz+ .821) + kll [2- W<.Bu+ .821) + kll qsa
The sensitivity of the model to changes in the defi-
nition of ot (! day, 2 days) was checked. The daily
probability that the family does not change state is
given by qrr= l-'2:.s",rPrs' Similar formulations of the
transition matrix Tl are expressed for families with
3-6 members and different age structures.
The families transition probabilities for a 28-day
interval were then derived as T2s(3, 2) =T128(3, 2).
This allowed handling transitions in which more
than one individual in the family changes status.
Moreover, not having specified the pathway from one
state to the next, unobserved events were implicitly
included.
Parameter estimation
Maximum-likelihood techniques are adopted to esti-
mate the nine model parameters. The log likelihood
L(z, u) and saturated log likelihood L*(z, u) functions
are derived from each monthly transition matrix
T2s(z, u) and from the observed number of family
transitions between states nr.,(z, u). The deviance is
then calculated for each family size and composition
as follows:
Devz,u=
2' 2'
2· (L*-L)=2· LLnrs[1n(nrs)-ln(PrsNr)], (4)
r=1s=1
where nrs is the number of family transitions observed
in the data from state r to state sand Nr='2:.nrs. The
Prs is the element rs of matrix T2s(z, u) or, in other
words, is the model probability that a family of size
z and with u adults moves from state r to state s in a
28-day interval. The upper limit of the summations
represent the number of family states that are possible
for each family size.
The overall deviance [eqn (5)] is obtained as the sum
over all family sizes and compositions
6 z
Dev= LLDevz,u.
z=3u=1
(5)
Maximum-likelihood estimates for the parameters
are obtained by minimizing the deviance.
The profile-likelihood method [17] is used to derive
confidence intervals for the model parameters. The
analysis was conducted using Microsoft Excel.
Model fit
The overall fit of the model could not be formally
assessed using a Xl test on the residual deviance and
degrees of freedom. This was because the expected
count for each cell was too small and usually less
than 1.
However, after aggregating the states with the
same number of carriers, it was possible to assess
the goodness of fit visually for each family size by
plotting the number of family transitions between
states and comparing it to the number obtained
from the model after aggregating across cells. X2
tests comparing the observed and estimated number
of transitions on the aggregated data were per-
formed. Using the X2 test in this way only enables the
detection of fairly large aberrations in the model fit
because the fit is only being tested after the aggre-
gation of data and estimates from a more complex
model.
Prevalence of Pnc infection by household size and
composition
A steady-state vector v of dimension 2Z is calculated
from any of the family transition matrix [i.e. T1(z, u)]
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Fig. 1. Transition probabilities obtained from the model for completely susceptible families (--) and families with
one carrier (- - - -), compared to proportions of transition observed from carriage data (0, .).
by solving the following system of equations
T1(z, u) . v(z, u) =v(z, u),
where v gives the proportion of households that are in
each specific state at the equilibrium [18]. From this
the expected prevalence of infection in children and
adults in a household of given size and structure can
be calculated.
The proportion of community-acquired Pnc infec-
tion is calculated using the steady-state vector v and
deriving the expected number of new infections pro-
duced exclusively by household transmission (k = 0)
and comparing it to the expected number of those
acquired from the community (/3=0).
RESULTS
We had 560 (51 %) complete family transitions in the
data (Table 1), the majority of which are found in a
family size of 3 and 4. The overall deviance obtained
comparing the model log likelihood to the saturated
log likelihood is 645, with 180 D.F. (189 non-zero data-
points and nine parameters to estimate). In Figure I
the fit of the model is shown comparing the expected
number of transitions estimated by the model, for
uninfected families and families with one carrier, to
the number observed from the data for the same
(6)
Table 1. Number of complete transitions by family
size and number of adults in the family
No. of adults
Family
size 2 3 4 5 Total
3 8 226 234
4 146 54 200
5 8 27 45 80
6 14 I 31 46
Total 8 380 95 46 31 560
transitions. The Xi tests of the model fit (not shown)
did not show evidence of any significant difference
between the model and the data.
Estimates of the nine model parameters are shown
in Table 2. In children <5 years the mean duration
of Pnc carriage, derived using the inverse of the
estimated recovery rate, is 51 days (95 % CI 42-64).
The estimated mean duration of carriage in older
family members is close to 19 days (95 % CI 14--24).
The community acquisition rate for children (0'012
per day) is more than 3 times higher than that for
adults (0'004 per day), showing that children <5 years
are most likely to introduce the infection into the
household. On the other hand, estimates of the with-
in-family acquisition rates show that the highest
No. of No. of adults in household
children in
0'002-0'005 Prevalence household 2 3 4 5
0·008-0'016 Adults 0 0'06 0'10 0·11 0·12 0'12
1 0·09 0·10 0-11 0·11 0·12
2 0·10 0·11 0·11 0·11
0·010-0'180 3 0'10 0·11 0'11
0·020-0·450 Children 1 0·44 0·47 0·48 0-49 0'50
0-000-0-018 2 0-54 0-53 0-52 0-52
0'008-0·200 3 0'58 0'56 0-55
0-041-0'070
0,016-0,024 Table 4. Estimated proportion of pneumococcal
0,200-2-200 infection in adults and children acquired within the
family for different household size and composition
(w=l)
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Table 2. Maximum-likelihood parameter estimates
Description of
model parameters
Symbol
used 95% CI
Rates
(per day)
Community
acquisition rate
Adult
Child
Within-family
acquisition rate
Adult to adult
Adult to child
Child to adult
Child to child
Recovery rate
Adult
Child
Density factor
k2 0-004
kl 0·012
f32Z 0·048
f3n 0'106
f321 0'005
f3n 0'047
!iz 0'053
!il 0·020
W 1·184
CJ, Confidence interval.
650·5
648·5
.j 647·5
~
646·5
645·5
644·5+--t---.--.--....--.----....-..---.---.----.-..---,--
0·0 0·2 0-4 0·6 o.s 1·0 1·2 1-4 1·6 1·8 2·0 2·2 2-4
Density factor (w)
Fig. 2. Profile likelihood for the density factor w (the dotted
lines represent the 95 % confidence interval).
daily transmission rate is that from adults to children,
whereas the lowest is the one from children to adults.
These results are consistent with adults being less
susceptible to infection. A density coefficient signifi-
cantly greater than zero (w= 1'2,95 % CI 0'2-2'2) is
estimated from the model and suggests the import-
ance of considering density-dependent transmission.
However, due to the very wide confidence interval, no
clear indication is given on the strength of this effect
(Fig. 2). The sensitivity of the model to variation in
the time-interval (5t «(5t=! day, (5t=2 days) was as-
sessed and the parameters estimates were found to be
not significantly different from the base case results
«(5t= I day).
The expected prevalence of Pnc infection at equi-
librium in both adults and children is given in Table 3.
Table 3. Expected equilibrium prevalence of pneumo-
coccal carriage in household with different compositions
(children 0-5 years; adults 5+ years) (w=l)
No. of No. of adults in household
children in
household 2 3 4 5
Adult 0 0% 40% 47% 50% 52%
1 34% 41 % 45% 48% 50%
2 40% 42% 45% 47%
3 42% 43% 45%
Child 1 22% 29% 33% 36% 38%
2 46% 43% 43% 43%
3 54% 50% 49%
In order to have a baseline probability, the expected
Pnc carriage in adults is estimated also for families
with no children although no such families exist in our
data. The prevalence of Pnc carriage in adults does
not vary much when bigger families are considered
or when more children are present in the family. The
expected prevalence in children increases with the
number of children in the household. The prevalence
increases by 3-10% for each additional child.
The proportion of household-acquired Pnc infec-
tion increases in bigger families, reaching 50% for
both children and adults (Table 4). When only one
child is in the family the proportion in children
(22-38 %) is lower than in adults (34-50%).
DISCUSSION
Data from a UK Pnc longitudinal carriage study were
used and a transmission model fitted using maximum-
likelihood techniques to gain some insights into Pnc
transmission dynamics within the household, shed-
ding some light on its mechanism of acquisition and
on the duration of carriage. We used these estimates
to derive the individual equilibrium prevalence of Pnc
infection in households of given size and structure and
to assess the importance of household vs. community
acquisitions.
Although the study was carefully designed and
the swabbing interval was forced to its minimum, the
presence of unobserved events had to be considered
in the setting up of the model. In the past, Bayesian
data augmentation methods have been adopted in
order to tackle this issue and Markov Chain Monte
Carlo (MCMC) simulation has been used to explore
the joint posterior of the model parameters and the
augmented data [14]. Here we decided to deal with
unobserved events by setting up the model for a short
time-interval (1 day), during which we assume only
one event occurs, and then deriving the probabilities
of transitions for longer (i.e. 28 days) intervals. This
enabled us to describe the entire data-set with only
nine model parameters.
The model classifies individuals as Pnc carrier or
non-carrier and it does not consider which serotype
they were carrying. Acquisition and clearance rates
are thus estimated for carriage of any Pnc serotype.
Serotype-specific differences in Pnc acquisition and
clearance rates were shown in the past [12] and rep-
resent a very critical issue in terms of future disease
burden and impact of vaccination policies. Here some
baseline information on Pnc transmission dynamics
are derived and, although the model allows success-
ive positive tests to be attributed to recovery and
reacquisition, it does not exploit the information
provided by a change of the serotype carried. Further
work will be pursued on these matters.
In agreement with previous findings, the model
estimated that children carry Pnc for longer periods
than adult family members (51 vs. 19 days). Smith
et al. [12] estimated approximately 2 months of car-
riage in children for the most common serotypes
(6, 19,23) and Auranen et al. [14] published an esti-
mate of 2·3 months (95% CI 1'5-3'3), derived for
children aged <2 years. The difference between the
latter estimate and ours may be due to the younger
age group considered. Similarly, the estimated 1·5
months (95 % CI 1'0-2'0) duration of carriage derived
from the Finnish study [14] in children aged 2+ years
is higher than our estimate in the 5+ years group, and
this, again, is probably due to their being a younger
age group. Moreover, their study allowed for control
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of exposures but the estimates produced may be
imprecise as the study used long intervals between
observations (I month until 6 months of age, and
then 3 and 6 months). Slightly lower estimates of
the duration of carriage were found in the study of
Ekdahl et al. [13], where a clear relationship between
carriage and age was observed in individuals with
clinical diagnosis of pneumonia and otitis media
who were carrying penicillin-resistant Pnc strains. A
median of 30 days for children aged <1 year old;
21 days for children 1-2 years; 21 days for children
3-4 years; 12 days for children 5-6 years; 15 days for
persons 7-18 years and 14 days for adults 18+ years.
Estimates of Pnc acquisition rates from the com-
munity show a difference between children and adults.
The former appear 3-4 times more likely to acquire
Pnc infection from the community and to introduce
the bacteria in their household's environment. Pre-
vious work by Auranen et al. [14] showed a similar
pattern although the difference between children and
adults appears to be stronger in the Finnish data
and their rates are significantly lower than ours.
Although their model considers only three serotypes
that account for 30-60 % of infections, this does not
fully explain the lower community acquisition rates
that they obtain.
The within-family transmission rates incorporate
infectiousness of the carrier, susceptibility of the non-
carrier and contact between them. Although various
individual factors, such as age and immunity levels,
may contribute to this relationship, the model used
here is from the SIS class, and thus, it does not
explicitly account for immunity after infection.
Nevertheless, transmission rates within the family
were derived considering the age class to which both
the carrier and the non-carrier belong «5 years,
5+ years) and suggested a higher level of suscepti-
bility in children and infectiousness in adults.
The importance of density dependence when look-
ing at transmission dynamics of infection has been
discussed previously [19, 20]. We included a density-
dependent factor in our analysis and we found it to be
an important element of the model and necessary
to explain within-family transmission (w significantly
greater than 0). However, at this stage, no clear
judgement can be made on whether the transmission
increases (w < 1) or decreases (w > 1) as a consequence
of being in bigger families. More work is clearly
necessary to investigate this relationship and, thus, to
provide better estimates of within-family transmission
that takes into consideration changes in the contact
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patterns in households of different sizes, environment
and composition.
As expected, the prevalence of Pnc carriage for any
family size and structure is higher for children than for
adults. Moreover, we found that whereas the preva-
lence in adults does not vary much for different family
sizes and composition, the equilibrium prevalence in
children increases with the number of children and
adults in the family. This may again reflect the lower
level of susceptibility in older individuals and, thus,
the fact that they are not sensitive to changes in the
proportion of infectious contacts they may have
within the household.
Household-acquired infection makes a major con-
tribution to Pnc transmission in families both for
children and adults. The more siblings that are pres-
ent in the family the more the infection can circulate
among them and persist within the household. How-
ever, even in large families approximately 50-60 % of
children and adults' infections are acquired outside
the household.
Longitudinal data can be quite challenging to
analyse and many critical aspects have to be taken
into account in doing so. Nevertheless they can pro-
vide a great contribution to the understanding of a
pathogen's dynamics within the human host and on
the way individual properties can affect transmission
dynamics of the infectious agent. In this paper we
tried to draw some conclusions about Pnc trans-
mission dynamics, the contribution of community vs.
family transmission and the importance of family
structure when considering prevalence of Pnc infec-
tion within the household. Further analysis is clearly
needed in order to provide some specific understand-
ing of serotype-specific Pnc carriage and to be able
to give some baseline information on the links
between serotypes and transmission in the pre-
vaccination era.
ACKNOWLEDGEMENTS
We thank Drs Elisabeth Miller and Robert George
for providing us with pneumococcal carriage data and
for giving helpful advice. We also thank Drs Richard
Pebody and Mahein Hussain for organizing the study
and for giving us continuous updates on its progress.
Thanks are due to all the nurses for maintaining the
study and assisting the families involved throughout
the study. We are grateful to Drs John Edmunds,
Martin Eichner, Kari Auranen and Nick Andrews
for useful discussions on the manuscript. We thank
the EU for financial assistance (QLG4-CT-2000-
00640).
REFERENCES
I. Fedson DS, Scott JA, Scott G. The burden of pneumo-
coccal disease among adults in developed and develop-
ing countries: what is and is not known. Vaccine 1999;
17: SII-SI8.
2. Robinson K, Baughman W, Rothrock G, et al. Epi-
demiology of invasive Streptococcus pneumoniae infec-
tions in the United States, 1995-1998. Opportunities
for prevention in the conjugate vaccine era. JAMA
2001; 285: 1729-1735.
3. Miller E, Waight P, Efstratiou A, Brisson M,
Johnson A, George R. Epidemiology of invasive and
other pneumococcal disease in children in England
and Wales 1996-1998. Acta Paediatr Suppl 2000; 435:
11-16.
4. Lloyd-Evans N, O'Dempsey TJ, Baldeh I, et al. Naso-
pharyngeal carriage of pneumococci in Gambian
children and in their families. Pediatr Infect Dis J 1996;
15: 866-871.
5. Djuretic T, Ryan M, Miller E, Fairley CK, Goldblatt D.
Hospital admission in children due to pneumococcal
pneumonia in England. J Infect 1998; 37: 54-58.
6. Schaechter M, Engleberg N, Eisenstein BI, Medoff G.
Mechanisms of microbial disease. 3rd edn. Baltimore:
Lippincott Williams & Wilkins, 1998.
7. Black SB, Shinefield HR, Fireman B, et al. Efficacy,
safety and immunogenicity of heptavalent pneumo-
coccal conjugate vaccine in children. Pediatr Infect Dis
J 2000; 19: 187-195.
8. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E,
Ray P. Impact of the pneumococcal conjugate
vaccine on otitis media. Pediatr Infect Dis J 2003; 22:
10-16.
9. Black SB, Shinefield HR, Ling S, et al. Effectiveness
of heptavalent pneumococcal conjugate vaccine in
children younger than five years of age for preven-
tion of pneumonia. Pediatr Infect Dis J 2002; 21:
810-815.
10. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumo-
coccal conjugate vaccine against acute otitis media. N
Engl J Med 2001; 344: 403--409.
II. Dagan R, Givon-Lavi N, Zamir 0, et al. Reduction of
nasopharyngeal carriage of Streptococcus pneumoniae
after administration of a 9-valent pneumococcal conju-
gate vaccine to toddlers attending day care centers.
J Infect Dis 2002; 185: 927-936.
12. Smith T, Lehmann D, Montgomery J, Gratten M, Riley
ID, Alpers MP. Acquisition and invasiveness of differ-
ent serotypes of Streptococcus pneumoniae in young
children. Epidemiol Infect 1993; 111: 27-39.
13. Ekdahl K, Ahlinder I, Hansson HB, et al. Duration
of nasopharyngeal carriage of penicillin-resistant
Streptococcus Pneumoniae: experiences from the South
Swedish Pneumococcal Intervention Project. Clin Inf
Dis 1997; 25: 1113-1117.
14. Auranen K, Arjas E, Leino T, Takala AK. Trans-
mission of pneumococcal carriage in families: a latent
Markov Process Model for binary longitudinal data.
J Am Stat Assoc 2000; 95: 1044-1053.
15. Hussain M, Clark M, Tew A, Williams L, Miller E.
Upper respiratory tract carriage and transmission
of pneumococci in families in UK and possible intro-
duction of the new pneumococcal conjugate vaccine.
Nursing Times, in press.
16. Auranen K, Ranta J, Takala AK, Arjas E. A statistical
model of transmission of Hib bacteria in a family.
Estimating pneumococcalcarriage 441
Stat Med 1996; 15: 2235-2252.
17. Aitkin M. Profile likelihood. In: Armitage P, Colton T,
eds. Encyclopedia of biostatistics. New York: John
Wiley and Sons, 1998: 3534-3536.
18. Chin Long Chiang. An introduction to stochastic
processes and their applications. New York: Robert E.
Krieger, 1980.
19. Finkenstadt B, Bjornstad 0, Grenfell B. A stochastic
model for extinction and recurrence of epidemics: esti-
mation and inference for measles outbreaks. Biostat-
istics 2002; 3: 493-510.
20. McCallum H, BarlowN, Hone J. How should pathogen
transmission be modelled? Trends Ecol Evo12001; 16:
295-300.
Available online at www.sciencedirect.com
aC.BNCB@DI"BCT. '(acoine
ELSEVIER Vaccine 22 (2004) 4203-4214
www.elsevier.comllocatelvaccine
Cost-effectiveness analysis of pneumococcal conjugate
vaccination in England and Wales
A. Melegaro+'':", W.J. Edmunds's?
a Modelling and Economics Unit, Health Protection Agency, Communicable Disease Surveillance Centre,
61 Colindale Avenue, London NW9 5EQ, UK
b Department oj Biological Sciences, University oj Warwick, Coventry CV4 7AL, UK
C Department oj Economics, City University, London ECIV OHB, UK
Received II February 2004; accepted 4 May 2004
Abstract
Aim: To establish whether universal vaccination of infants with the pneumococcal conjugate vaccine is likely to be cost-effective from the
perspective of the health care provider (NHS). Method: Two hypothetical cohorts - one vaccinated and one unvaccinated - were followed over
their lifetime, and the expected net costs and benefits (measured in terms of life-years and quality adjusted life years (QALY) gained) were
compared in the two cohorts. The impact of indirect effects of the vaccine, such as herd immunity and serotype replacement, were investigated
and their relative importance was assessed by performing univariate sensitivity analysis and multivariate Monte Carlo simulations. Results:
Under base-case assumptions (no herd immunity and no serotype replacement) the programme is not expected to be cost-effective from the NHS
perspective at the current price of the vaccine (assumed £30 per dose, three-dose programme). A reduction of the cost of the vaccine to half of its
current level could bring the cost per QALY gained within normally acceptable ranges. If the burden of disease is significantly underestimated
by current surveillance systems, then the cost per QALY gained approaches acceptable levels at the current vaccine price. Herd immunity may
substantially reduce the burden of pneumococcal disease, particularly of pneumonia among the elderly, leading to a significant improvement
in the cost per life year and QALY gained. Serotype replacement would partly offset these benefits, although only with a complete substitution
of vaccine types with non-vaccine types and a low level of herd immunity, would pneumococcal vaccination programme would not be
cost-effective. Conclusions: Conclusions on the cost-effectiveness of pneumococcal conjugate vaccine are sensitive to assumptions regarding
the current burden of pneumococcal disease and the future impact that vaccination will have in the unvaccinated and on the future serotype
distribution. This study quantifies, for the first time, how these indirect effects may change the cost -effectiveness of pneumococcal vaccination.
© 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
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and deaths is difficult [4], it is well recognised that Pnc re-
lated diseases affect mainly children and the elderly and that
severe complications can be associated with pneumococcal
infection.
A seven-valent pneumococcal conjugate vaccine (PCV)
(Prevenar - Wyeth Pharmaceuticals) was licensed in the UK
in 2001 and is currently only recommended to infants aged
between 2 months and 2 years who are at special risk [5].
However, evidence of the direct effect of the seven-valent
vaccine on the incidence of Pnc disease (invasive pneumo-
coccal disease (IPD), pneumonia and AOM) among healthy
s.pneumoniae is a Gram-positive bacterium of the respira-
tory tract, responsible for a wide range of clinical conditions.
In the UK it is one of the major causes of meningitis and acute
otitis media (AOM) mainly in children [1], and septicaemia
and pneumonia largely among the elderly [2,3]. Although es-
timating the precise burden of pneumococcal (Pnc) disease
0264-41OXI$ - see front matter © 2004 Elsevier Ltd. All rights reserved.
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children has been shown in a large randomised controlled ef-
ficacy study that was conducted by the Northern California
Kaiser Permanente [6-8]. A Finnish study [9] estimated the
efficacy against AOM. Further studies have shown a reduc-
tion in carriage of vaccine serotypes as well as an increase
of non-vaccine serotypes among vaccinated individuals [10]
and also among their siblings [11]. These results are rais-
ing various questions related to the potential long-term ef-
fects of the vaccine in the population [12,13], such as will
serotype replacement and herd immunity effects occur and,
if so, what will be the effects on disease burden? Neverthe-
less, there is now the need to address questions related to
the economic acceptability of the programme with the cur-
rent knowledge on the vaccine efficacy and on the disease
burden.
This study addresses the issue of whether universal infant
vaccination with the seven-valent pneumococcal conjugate
vaccine (PCV) would be a cost-effective policy under the
health care provider perspective (NHS). The analysis takes
into consideration the various uncertainties related to the bur-
den of pneumococcal disease and the potential for indirect
protection (herd immunity) among unvaccinated individuals
as well as serotype replacement effects in the whole popu-
lation. Different UK vaccination schedules are considered in
the analysis as well as the sensitivity of the model results to
variations in the vaccine price.
2. Methods
2.1. Cohort model
Amodel was constructed to follow a vaccinated and an un-
vaccinated imaginary cohort of individuals from birth until
death. The number of life-years (LY) gained from the vac-
cination programme is taken as the primary measure of the
Table 1
outcome of the programme, and this is compared to its net
cost (the net cost being the additional cost of vaccination
minus the expected savings from the programme in terms
of reduced use of health care resources). Although pneu-
mococcal infection can result in a wide range of outcomes
such as invasive disease, pneumonia, ear infections, sinusitis,
bronchitis, arthritis, conjunctivitis, peritonitis, etc., the model
only considers the four major outcomes for which clinical
trial data are available regarding vaccine efficacy: pneumo-
coccal meningitis, pneumococcal bacteraemia, community-
acquired pneumonia (CAP) and AOM. Future benefits and
costs are discounted according to the current recommenda-
tions in the UK [14]: 3.5% per annum for costs and 1.5%
per annum for health benefits. Herd immunity, i.e. changes
in disease incidence among unvaccinated individuals, is in-
cluded as part of the scenario analyses as well as changes
in carriage and serotype distribution that may be expected
to occur after the introduction of pneumococcal vaccination.
These two scenarios are further investigated in the multivari-
ate sensitivity analysis.
2.2. Epidemiological data
The epidemiological parameters used in the base-case
analysis, are shown in Tables 1 and 2. For the base-case
analysis the average annual incidence of both pneumococ-
cal bacteraemia and meningitis was derived extracting the
number of invasive pneumococcal disease cases that was re-
ported to the reconciled CDSCIRSIL database [15,16] for
the period 1998-2000 and dividing it by the ONS popu-
lation estimates for England and Wales and for the same
time period. Age specific incidence rates were used in the
model, using 5-year age bands except in those under 1 year
of age, which were grouped in one age category. In the uni-
variate sensitivity analysis the effect of a further age stratifi-
cation «6 months, 6-11 months) is explored. CDSCIRSIL is
Estimated annual incidence of pneumococcal related diseases, hospitalisations, and GP consultations in England and Wales
Age group Incidence rate" Hospitalisations rate" GP consultation rate"
Pnc bacteraemia Pnc meningitis Pneumonia with + film AOM Pneumonia AOM
<I 27.3 14.6 221.2 173.2 467 23.636
1--4 10.6 1.6 131.2 203.2 272 24,856
5-9 1.9 0.2 41.7 123.9 62 7,698
10-14 0.7 0.2 17.2 34.3 62 7,698
15-19 1.2 0.1 16.3 13.1 51 2.250
20-24 1.8 0.2 18.1 7.5 51 2,250
25--44 3.1 0.3 26.0 9.1 152 1,741
45-64 6.5 0.5 55.4 11.7 268 1.175
65-74 18.7 0.9 193.6 11.0 508 994
75+ 42.5 0.6 697.7 7.5 1161 520
Overall 8.4 0.6 102.7 30.5 266 3.612
All rates are per 100.000 populations per year.
a National enhanced surveillance system of IPD cases (CDSCIRSIL).
b Hospital Episode Statistics. first diagnostic field (ICD-IO codes for pneumonia: II3. II 80. 1181. Jl88. 1189; any otitis media codes used for OM hospital-
isations).
C Royal College of General Practitioners [19].
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Table 2
Estimated case fatality ratios and length of stay in the hospital of admitted patients reporting Pnc bacteraemia (ICD-10 code: A403), Pnc meningitis (GOO1)or
pneumonia (codes as in Table I) in the first diagnostic field
Age group (years) Case-fatality ratio Length of stay (days)
Pnc septicaemia (%) Pnc meningitis (%) Pneumonia (%) Pnc septicaemia Pnc meningitis Pneumonia
<I 4 4 I 5.4 10.5 4.4
1-4 1 4 0 4.6 10.2 2.9
5-9 0 3 13.1 9.4 3.2
10-14 0 0 2 6.8 7.2 4.0
15-19 0 II 2 11.0 8.9 4.9
20-24 8 0 3 4.7 12.5 5.0
25-44 20 II 3 12.3 14.3 6.0
45-64 26 18 14 12.7 22.1 9.0
65-74 27 29 29 11.3 20.9 II.8
75+ 40 43 46 15.4 25.8 15.4
Overall 22 12 29 II.5 16.9 8.1
currently the most reliable data source on IPD in the UK, as
detailed information on the type of specimen (i.e. blood, CSF)
is provided together with a clinical description of the patient.
The case-fatality ratio (CFR) and the average length of stay
(LOS) in the hospital for IPD cases were derived from Hos-
pital Episodes Statistics (RES) [17], using number of deaths
and length of stay of all pneumococcal septicaemia (ICD-l 0
Code: A403) and pneumococcal meningitis (ICD-I0 Code:
GOOI)patients, as reported in the first diagnostic field for the
period April 1997-March 2000 (Table 2).
The number of hospitalisations for CAP was estimated
from RES, extracting all records that were reporting one of
the following ICD-l 0 pneumonia codes in the first diagnostic
field over the period April 1995-March 1998:
• Pneumococcal pneumonia: J13 (ICD-9: 481);
• Lobar pneumonia, organism unspecified: JI81 (ICD-9:
481);
• Bronchopneumonia, organism unspecified: 1180 (ICD-9:
485);
• Other pneumonia, organism unspecified: 1188 (ICD-9:
486);
• Pneumonia, organism unspecified: 1189 (ICD-9: 486).
Based on a study by Djuretic et al. [18], we assumed
that only 79% of these admissions presented with lobar/focal
changes and thus had to be considered in order to match
as closely as possible the case definition that was used in
the Kaiser Permanente trial [7] to estimate the level of vac-
cine efficacy. Base-case age specific hospitalisation rates
were thus derived dividing the number of hospital admis-
sions (first diagnosis) by ONS population estimates for Eng-
land (Table 1). CFR and the average LOS in hospital for
patients with pneumonia were calculated from the extracted
data. The annual GP consultation rates for pneumonia were
derived from the Royal College of General Practitioners
(RCGP) Weekly Returns Service [19], which is a sentinel
programme based on a representative sample of the prac-
tices (currently around 70) throughout England and Wales. It
publishes weekly data on diagnosis (recorded with the ICD-
9 coding system), age, and sex of the patient who consults
theGP.
Acute otitis media hospitalisation rates were derived from
RES extracting any hospitalisation with AOM ICD-lO codes
(H650-H678) in the first diagnostic field over the 1999-2000
RES financial year and dividing it by the corresponding ONS
population estimates for England. RCGP data were used to
derive GP consultation rates for AOM.
2.3. Vaccine efficacy
In the base-case analysis the vaccine was assumed to give
no protection against pneumococcal carriage and, thus, no
indirect effects such as herd immunity and serotype replace-
ment were considered. This scenario appears to be unrealistic,
as some protection against carriage and serotype replacement
has been observed. Quantifying the long-term impact of these
processes is, however, difficult, hence in the base-case we ig-
nore them. Vaccine efficacy (VE) against pneumococcal dis-
ease was based on intention to treat results of recent clinical
trials and for IPD this was adjusted to reflect the differing
serotype distribution in the UK compared with the popula-
tion in Northern California at the time of the study [6]. The
base-case VB against IPD was therefore 63-87% in the first
5 years of life. VE against all cause clinical pneumonia with
a positive film was assumed to be 17.7% (95% CI: 4.8-28.9)
[7]; and VE against any confirmed otitis media was 7% (95%
CI: -5 to 17%) [9]. Note also that due to the lack of data on
serotype distribution of otitis media and pneumonia cases, we
do not adjust the VB estimates for these conditions. It is as-
sumed, in the base-case, that children who respond to the vac-
cine become protected at 4 months of age after three doses of
vaccine have been given (accelerated infant schedule). Prior
to this age, they are unprotected. In addition, the following
alternative schedules were also considered: three doses with
the protection starting at 6 months of age (non-accelerated in-
fant schedule); two doses with the protection effective from
6 months of age; and one dose at 1 year of age. Note that
in the trials three doses plus a booster were used whereas in
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the above schedules 1-3 doses of vaccine are given, and we
have assumed that the reduced dosage does not reduce vac-
cine efficacy. Results of phase 2 trials with pneumococcal
conjugate vaccine in UK infants and toddlers demonstrated
that two doses of PCV given at 2 and 4 months of age pro-
vide satisfactory primary immunogenicity to the serotypes
contained in Prevenar [20]. Incremental cost-effectiveness
ratios were calculated for each successive alternative, from
the least costly to the most, examining the additional costs
that one programme imposes over another, compared with the
additional benefits it delivers [21]. Clearly, if vaccine efficacy
of the different schedules is the same, and protection starts
at the same age, then the schedule with the lower number of
doses will be preferred. Finally, in the base-case we assume
a lO-year period of vaccine-induced protection against dis-
ease although in the univariate sensitivity analysis the effect
of changes in the duration of protection on the model results
were assessed.
2.4. Health outcomes
The primary outcome measure was discounted life-years
gained. Pneumococcal specific case fatality ratios were calcu-
lated from hospitalisation data (see above). Fatal cases were
assumed to lose the average life expectancy for individuals
of that age. Life expectancy calculations were derived from
current all-cause mortality schedules, derived from ONS ta-
bles.
The secondary outcome measure was discounted quality
adjusted life-years (QALY) gained which can simultaneously
capture gains from reduced morbidity (quality gains) and re-
duced mortality (quantity gains) and integrates these into a
single measure [21]. Reductions in health related quality of
life due to pneumococcal disease (calculated on a 0-1 scale
where 1 is equivalent to perfect health) were derived from
the literature and are summarised in Table 3. A recent study
has suggested that the QALY's lost due to acute pneumococ-
cal disease are far greater than the values used here [22]. We
have not used these estimates, however, as they are orders of
magnitude greater than the other estimates available in the
literature. Note that due to the paucity of data we assume that
the proportion of !PD patients developing sequelae and the
QALY weights attached to these is not age-dependent. This
is unlikely to be the case. However, it will only affect the
results of the herd immunity scenario (see below), as direct
vaccine-induced protection is not assumed to be life-long.
As the elderly are more likely to have pre-existing morbid
conditions, the QALY loss from the herd-immunity scenario
is likely to be overestimated. Other outcome measures in-
clude GP consultations avoided, hospitalisations avoided and
deaths avoided.
2.5. Costs estimates
The perspective of the study was the health care provider
(NHS). Costs to the patient and their carers (i.e. absenteeism,
Table 3
Outcome from a meningitis episode and QALY lost of pneumococcal
diseases
Outcomes from meningitis % Children [25]
Severe bilateral hearing loss
Other sensorineural hearing loss
Conductive hearing loss
Seizures
14
16
19
16
Outcomes from Pnc diseases QALYloss
Bacteraemia
Meningitis
Bilateral hearing loss (first year)
Bilateral hearing loss (subsequent years)
Other hearing loss (all subsequent years)
Pneumonia
Outpatient
Inpatient
OM
0.0079 [41]b
0.0232 [41]b
0.460 [42]-
0.200 [42]"
0.100 [43]-
0.004 [44]b
0.006 [41,44]h
0.005 [45]b
a Per year.
b Per episode.
travel to clinics etc) were ignored because of a lack of data
on the wider (societal) costs of pneumococcal disease in the
UK. Average unit cost estimates of, for instance, an inpatient
day and GP consultation, were taken from standard sources
and are listed in Table 4. The cost per vaccine dose was set
to £30, assuming a volume based discount of approximately
£9 (list price of the vaccine is £39.25 per dose [23]). The
cost per course of vaccination was calculated multiplying the
cost of a vaccine dose by the number of doses and making an
additional allowance of £10 per child per dose (nurse consul-
tation cost [24]) for the administration of the schedule. All
costs were measured in pounds sterling at 2002 prices (aver-
age exchange rate for the time period 2001-2004 £ to US$
and £ to Euro = 1.55 and 1.54, respectively). The average
cost of a meningitis case was derived from a case notes re-
view of all meningitis cases <5 years of age from four regions
reported to CDSCIRSIL between 1996 and 1999 [25]. This
was calculated considering the proportion of patients that ex-
perienced different types of sequelae (Table 3) and estimating
their ~l~ted cost using standard sources [24,25]. Similarly,
an additional annual cost to the health service was estimated
for the subsequent years considering the additional visits and
therapies resulting from chronic sequelae of pneumococcal
meningitis. Hospitalisation cost for otitis media included the
cost of minor ear procedures (most would be tympanostomy)
and one ENT outpatient visit. All costs were varied in the
sensitivity analysis between ±25% of their base-case values.
2.6. Sensitivity and scenario analysis
The most likely parameters values were used in the base-
case scenario. However, a univariate sensitivity analysis was
also performed looking at the effect of changing one param-
eter at a time within its given range.
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Table 4
Unit costs of care and treatment parameters
Base value (range)Parameter
Cost per vaccine dose
Cost of vaccine (£)
Administration cost (£)
Number of doses
Cost per inpatient day
Mean cost of inpatient day
(general ward) (£)
Mean cost of inpatient day (paediatrics) (£)
Mean cost of intensive care
bed/day (£)
Mean cost of paediatric intensive care
bed/day (£)
Mean length of stay in hospital [17]
Bacteraemia (days)
Meningitis (days)
Pneumonia (days)
30 (22-37)
10 (7-12) [24]
3
273 (205-341) [24]
398 (298-497) [24]
1232 (924-1540) [46]
1384 (1038-1730) [46]
11 (variable by age)
17 (variable by age)
8 (variable by age)
Proportion of bed-days on intensive care (adult) [17]
Bacteraemia (%) 5 (3.7-6.2)
Meningitis (%) 10 (7.5-12.5)
Pneumonia (%) 1 (0.7-1.2)
Proportion of bed-days on intensive care (child) [17]
Bacteraemia (%) 3 (2.2-3.7)
Meningitis (%) 6 (4.5-7.5)
Pneumonia (%) 0
Other costs (acute stay)
Bacteraemia and pneumonia
X-ray (£)
Meningitis
CTscan(£)
Cranial ultra-sound (£)
Follow-up (exc, sequelae) (E)
MRI (£)
Otitis media
Ear procedures (E)
Outpatient ENT consultant visit (E)
Proportion undergoing different procedures [25]
CT scan (adult) (%)
CT scan (child) (%)
MRI(%)
Cranial ultrasound (child) (%)
General practice consultation and treatment costs
Cost per general practice consultation (E)
Mean cost of treatment per consultation -
IPD (£)
Mean cost of treatment per consultation -
pneumonia (£)
Mean cost of treatment per consultation -
OM(£)
Average cost of a meningitis case [25]
First year (£)
Subsequent years (£)
Discount rates [14]
Discount costs (%)
Discount benefits (%)
16 (12-20) [46]
89 (67-112) [46]
51 (38-64) [25]
103 (77-129) [46]
270 (203-338) [46]
517 (388-646) [46]
52 (39-65) [46]
100
46
9
30
19 (14-24) [24]
8 (6-10) [23]
4 (3-5) [23]
2 (1.5-2.5) [23]
4703 (3528-5880)
143 (113-189)
MRI = magnetic resonance imaging.
3.5
1.5
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In addition to the sensitivity analyses and due to the high
level of uncertainty that characterise the current and future
burden of pneumococcal disease, the following three scenar-
ios were also considered:
(a) High incidence scenario. A capture-recapture study [26],
estimated the sensitivity of CDSCIRSIL for the diagno-
sis of pneumococcal meningitis in adults (mean age 55,
range 16-97 years) to be 40% (95% CI: 37-44). Inci-
dence rates were thus inflated to take into account pos-
sible under ascertainment. For hospitalised pneumonia,
incidence rates were inflated by including the following
additional codes [ICD-I0: J158 (other bacterial pneumo-
nia) and J159 (bacterial pneumonia unspecified)]; any
code for pneumonia in any diagnostic field (i.e. not nec-
essarily primary diagnosis); and assuming that all admis-
sions for pneumonia resulted in a positive film (rather
than the estimated 79%). For AOM hospitalisations, any
AOM codes in any diagnostic fields were considered. An
upper estimate of both pneumonia and GP consultation
rates was obtained using MSGP4 data [27].
(b) Inclusion of herd immunity effects. Whitney et al. [28]
recently published estimates of the reduction in IPD inci-
dence in the US in unvaccinated age groups following the
introduction of the pneumococcal conjugate vaccine in
infants. They estimated the following reduction in IPD in-
cidence among unvaccinated individuals: 32% (95% CI:
23-39%) in the 20-39 years old, 8% (95% CI: 1-15%) in
the 40-64 years and 18% (95% CI: 11-24%) in the 65+
roughly 1 year after the introduction of infant vaccina-
tion. We allowed for these changes in invasive disease in-
cidence and assumed that a similar indirect effect occurs
on the proportion of pneumonia and otitis media cases
attributable to a pneumococcal infection (assumed, 48%
[3] and 30% [29,30], respectively). The effect of changes
in these proportions was considered in both the univari-
ate and multivariate sensitivity analyses. Since the period
of protection against carriage appears to be short [31] we
assumed that vaccination of one infant cohort will reduce
the carriage of pneumococci, and thus the incidence of
disease, in other age groups for 1 year.
(c) Serotype replacement. Serotype replacement of vaccine
types with non-vaccine types has been observed in both
pneumococcal carriage [10,32] and disease [9]. The po-
tential effect of a complete substitution of vaccine types
with non-vaccine ones on the cost-effectiveness of the
programme is explored in this scenario analysis reduc-
ing both the direct effect of the vaccine among vaccinated
individuals as well as the indirect effect (herd immunity
as in scenario (b) produced among unvaccinated ones
[28]. The percentage substitution of vaccine types with
non-vaccine types, which in this scenario is set to 100%
(i.e. complete substitution), is referred to in the follow-
ing text as the serotype replacement coefficient (SRC).
The severity of non-vaccine types in causing IPD is de-
rived from Brueggemenn et al. [33] study, calculating the
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non-vaccine versus vaccine types odds ratio (OR) af-
ter adjusting by the serotype-specific duration of car-
riage reported in Smith et al. [34] (OR = 0.16, 95%
CI: 0.10-0.25). Non-vaccine serotypes are assumed to
be equally severe in causing CAP and AOM (OR = 1).
Note that whereas scenario (a) still maintains the assump-
tion that the vaccine does not produce indirect effects, i.e. no
protection against pneumococcal carriage, and simply con-
siders a change in the incidence rates of pneumococcal dis-
ease, scenarios (b) and (c) allow the indirect effects of the vac-
cine at the population level to occur. In particular, scenario
(b) considers a reduction in pneumococcal disease among
unvaccinated individuals as a consequence of a reduction in
carriage. Scenario (c) includes both the herd immunity effect
as well as a change in the serotype distribution of pneumococ-
cal carriage, which also produces an effect on pneumococcal
disease.
A multivariate sensitivity analysis was also performed us-
ing Monte Carlo simulation with @Risk4.0 (palisade Corpo-
ration, NY, USA) and drawing input parameter values from
probability distributions using Latin Hypercube sampling.
Uniform distributions were assumed for age-specific inci-
dence rates, case-fatality ratios and length of stay in the hos-
pital as weJl as for all the parameters related to the cost of care
and treatment (Table 4). For incidence estimates the lower
limit was set to be the base-case and the upper limit was set
to the high incidence scenario (scenario a). CFRs and LOS
were varied between ±25% of their base-case values. The
SRC was assumed to follow a triangular distribution with a
mode of 1, and range of 0-1. A normal distribution was as-
signed to the log OR estimated from the vaccine trials [6,7,9]
and from which the levels of protection were derived (VE =
1 - OR). The proportion of CAP and AOM cases caused by
S. pneumoniae (48 and 30%, respectively in the base-case)
was assumed to follow a binomial distribution with variance
determined by the sample sizes of the original studies [3,29].
The herd immunity effect was kept constant at 5% in three
out of the five scenarios explored in the multivariate analysis.
The other two scenarios considered were the base-case, where
no herd immunity and no serotype replacement effect were
included, and the Whitney scenario where age-specific indi-
rect protection was assumed to vary within the reported 95%
confidence intervals [28]. A distribution of outcome values
was generated running the model 1000 times and the results
are presented for different levels of herd immunity and under
different assumptions on the level of serotype replacement.
3. Results
3.1. Current burden of disease
Table 5 gives the estimated current burden of IPD, all-
cause pneumonia and otitis media in England and Wales.
There are an estimated 2 million GP visits, almost 76,000
Thble 5
Estimated current burden of IPD, pneumonia (with lobar/focal change) and
otitis media in England and Wales'
All ages Under 15
GP visits 2,083,882 1,346,110
Pneumonia 142,017 14,547
OM 1,941,865 1,331,563
Admissions 75,720 19,989
Bacteraemia 4,407 544
Meningitis 324 148
Pneumonia 54,373 6,904
OM 16,616 12,394
Deaths 17,334 63
Bacteraemia 1,225 11
Meningitis 45 6
Pneumonia 16,064 46
a All cause pneumonia and AOM.
hospital admissions and over 17,000 deaths per year (most
of which are attributable to pneumonia in the elderly). The
health burden in children less than 15 years of age is large
with 46 and 75% of hospital admissions due to, respectively,
meningitis and otitis media falling in this age group as well
as 62% of GP visits. The estimated cost to the health service
related to these outcomes is given in Table 6. In children
an estimated 76% of the overall cost is due to treating otitis
media.
From these estimates and assuming that 48 and 30% are the
proportions of, respectively, pneumonia and AOM due to S.
pneumoniae [3,35], the burden of pneumococcal specific dis-
ease consists of over 650,000 GP consultations, 36,000 hos-
pital admissions (IPD and non-IPD) and around 9000 deaths
in England and Wales per year.
3.2. Base-case results
The estimated reduction in the burden of disease due to
the vaccination programme is shown in Table 7. The pro-
gramme with base-case parameters is estimated to prevent al-
most 63,000 GP consultations, 1890hospital admissions and
Thble6
Estimated cost (in £) of the current burden of pneumococcal related disease
from the health care payer perspective, England and Wales
All ages Under 15
GP visits (total) 44,021,605 28,306,271
Pneumonia 3,223,027 330,142
OM 40,798.578 27,976,129
Acute admissions (total) 212,275,776 16,552,586
Bacteraemia 18,645,033 1,424,670
Meningitis 3,873,214 1,415,882
Pneumonia (all cause) 180,303,253 6,660,063
OM (all cause) 9,454,276 7,051,971
Sequelae for meningitis 3,073,240 1,052,566
Total 259,370,621 45,911,423
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Table 7
Undiscounted health outcomes and estimated reduction of disease burden in the vaccinated cohort
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No vaccination With vaccination Difference
Deaths (total) 19,346 19,331 14
Deaths bacteraemia 1,307 1,301 6
Deaths meningitis 46 42 3
Deaths pneumonia 17,993 17,988 5
Hospital's (total) 77,492 75,602 1,890
Hospital bacteraemia 4,567 4,264 302
Hospital meningitis 318 239 79
Hospital pneumonia 57,527 56,632 894
HospOM 15,081 14,467 614
OP consult (total) 1,952,942 1,889,987 62,955
OP consult pneumonia 141,952 140,211 1,741
OP consult OM 1,810,990 1,749,776 61,215
14 deaths, resulting in a total of 1087 undiscounted life-years
and 1824 undiscounted QALYs gained in the vaccinated co-
hort over their life-span (at 1.5% discount rate these are 629
and 1188, respectively).
The base-case programme is estimated to have a net dis-
counted cost to the health service of £71 million, i.e. cost of
vaccinating the cohort is estimated to be £75 million (£56
and £19 million for, respectively, administration and vaccine
costs) resulting in discounted medical care savings of £4m
over their lifetime. The additional cost per life-year gained of
vaccination is therefore estimated to be £113,231 under base-
case assumptions. The equivalent cost per QALY gained is
estimated to be £59,945.
3.3. Sensitivity and scenario analyses
Univariate sensitivity and scenario analyses were per-
formed to assess the sensitivity of the results to changes in the
model parameters and assumptions (Table 8). This showed
that the most striking changes in the cost per life year or
QALY gained occurred when the upper estimates of the in-
cidence of IPD were used as well as when herd immunity
effects were included in the model. The vaccine price is also
an influential variable. Fig. 1 shows the estimated cost per
life-year and QALY gained for different costs of a vaccine
dose. At a maximum willingness to pay for a QALY gained
of £30,000 [36], the price of the vaccine would have to be
reduced to a third of its current value (under base-case as-
sumptions). Under the high-incidence scenario, and with all
other parameters at their base-case values, the cost per life
year gained drops to £48,257 and cost per QALY gained to
£23,800.
The cost per life-year and QALYs gained decreased dra-
matically if we included indirect protection in older age
groups from the introduction of infant vaccination. Using
the levels of indirect protection reported by Whitney et al.
for IPD and applying them to all relevant outcomes, this in-
direct effect alone is estimated to result in a reduction of
almost 46,000 GP visits, 4800 hospital admissions and 1551
deaths (204 bacteraemia, 6 meningitis, 1341 pneumonias),
Table 8
Cost per LY and QALY gained of pneumococcal conjugate vaccination pro-
gramme, results from univariate sensitivity analysis
Base-case
High incidence
High IPD incidence
High pneumonia incidence
High AOM incidence
Incidence in <1 year stratified in
0-6 and 6-11 months
High case-fatality ratio (CFR)
Among IPD cases
Among pneumonia hospitaliza-
tions
Herd immunity"
Proportion of Pnc pneumonia =
24%
Proportion ofPnc AOM = 15%
HI effect only on IPD
Herd immunity' and serotype
replacement"
Vaccine parameters
Duration of protection (5 years)
Duration of protection (15 years)
Cost per dose (£20)
Cost per dose (£40)
Cost of a meningits case
Increased by 50%
Increased by 100%
Alternative schedules
3 doses, protects from 6 months
2 doses protects form 6 months
1 dose, protects from 1 year
Discount rate
Benefits 3%, costs 3%
Benefits 6%, costs 6%
Benefits 0%, costs 3%
Benefits 1.5%, costs 6%
Cost per Cost per
LY gained QALY
(£) gained (£)
113,231 59.945
48,257 23,800
54,066 31,473
96,960 54,757
109,994 41,186
111.491 59,482
90,585 52,938
96,935 55,046
104,661 57.454
5,297 5.013
8,597 7,899
5,297 5,013
22,795 18,622
30,093 26,683
123,916
104,859
83,266
143,197
68,169
54,043
44,081
75,809
112,523
111,815
59,570
59,195
130,071
84,335
70,699
66,419
43,065
31,021
174,665
324,847
65,154
113,608
81,594
120,938
38,818
60,144
• Herd immunity as in Whitney et al. [28].
b Complete serotype replacement (100%).
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Fig. 1. Sensitivity analysis - cost per life-years gained (top graph) and
QALYs gained (bottom graph) for different cost per dose of the vaccine.
Herd immunity effect assumed as in Whitney et al. [28]. Complete serotype
replacement effect is considered (100%).
the majority of which falls in 65+ years of age (79, 67, 96%,
respectively). This generates an additional 12,814 life-years
gained (10,319 from pneumonia cases) and 13,017 QALY
gained, giving an overall cost per QALY gained of £5013. In
case herd immunity effects were only applicable to IPD pa-
tients (i.e, different serotype distribution for non-IPD cases),
the cost per QALY gained is higher (£ 18,625) though remain-
ing below what is considered the acceptable range. Moreover,
the inclusion of a complete serotype replacement mechanism
(i.e. carriage of non-vaccine serotypes completely substitutes
carriage of vaccine types) increases substantially the cost per
LY and QALY gained though remaining under £30,000. Note
that the herd immunity with complete serotype replacement
scenario is significantly more cost-effective than the base-
case (Table 8, Fig. 4).
3.4. Alternative schedules
Figs. 2 and 3 show the effect of adopting different sched-
ules on the cost per QALY gained of the programme for dif-
ferent levels of, respectively, the cost of the vaccine and the
duration of vaccine-induced protection. Note that these re-
sults are for the base-case model and neither herd immunity
nor serotype replacement mechanisms are included here.
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Fig. 2. Cost per QALY gained for different vaccination schedules and vary-
ing the cost of the vaccine.
At the base-case cost of the vaccine (£30), a cost per QALY
gained in the range of £31,000-66,000 is observed for dif-
ferent vaccination schedules (Fig. 2); the lowest estimate re-
sulting from a one dose schedule at 1 year of age. Although
more cost-effective, it should be noted that such a strategy is
expected to be less effective than the base-case resulting in
714 discounted QALYs gained in the cohort compared with
1188 in the base-case (Table 9). As expected, three doses and
a non-accelerated schedule is the least cost-effective option,
having the highest vaccine related costs (three doses) and
since vaccine-induced protection is delayed to 6 months of
age, after the child has experienced high level of disease rates
(30-55 per 100,000 per year in 0-6 months of age, CDSC-
RSIL 1996-2000). Results from the incremental analysis are
reported in Table 9, where the alternative strategies have been
ranked according to their net cost and the incremental cost-
effectiveness ratios have been calculated.
We assumed a 1O-yearvaccine induced protection against
disease in our base-case analysis. The cost per QALY gained
becomes approximately £79,000 when the duration ofprotec-
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Fig. 3. Cost per QALY gained for different vaccination schedules and vary-
ing the duration of vaccine-induced protection,
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tion is reduced to 4 years and when three doses are considered
in the schedule (Fig. 3). For the one and two doses schedules
the cost per QALY gained increases by, respectively, £10,500
and 8400 from their base-case values (£41,585 and 51,466).
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3.5. Multivariate sensitivity analysis
In the multivariate analysis (Fig. 4) the impact of differ-
ent herd immunity and serotype replacement scenarios is ex-
plored, keeping the discount rates fixed at their base-case
values (3.5 and 1.5%) and allowing the other parameters of
the model to change within their specified ranges. In the base-
case (no herd immunity and no serotype replacement) 29% of
the model simulations resulted in a cost per QALY gained of
less than £30,000. When assuming a 5% reduction ofPnc dis-
ease incidence among unvaccinated individuals (herd immu-
nity) then 100%of the model simulations are below this level
(Fig. 4b, extreme left curve) unless non-vaccine serotypes
completely substitute vaccine types (serotype replacement),
under which circumstances almost all simulations result in a
cost per QALY gained above £30,000. Ifmuch higher levels
of herd immunity were assumed, such as the ones estimated
by Whitney et al. [28], the reduction in disease incidence
would be so dramatic that even a complete serotype replace-
ment effect is unlikely to change the cost-effectiveness of
the programme (Fig. 4). When a less strong hypothesis is as-
sumed for serotype replacement (i.e. the level of serotype
replacement is uncertain and thus is assumed to vary be-
tween 0 and 1) and the level of herd immunity is fixed at
5%, then around 90% of the simulations are deemed to be
cost-effective at an upper limit of £30,000 per LY/QALY
gained. The programme is not cost-effective when looking
at the cost per LY gained under base-case assumptions and
also when the hypothesis of complete serotype replacement
is assumed (in both cases the proportion of simulations that
fall above £30,000 is 100%). However, when serotype re-
placement varies between 0 and 1 or when herd immunity
effects are as high as the ones recently published [28], then
the cost per LY gained is below £30,000 in, respectively, 85
and 100% of the simulations.
4. Discussion
This paper considers the possible health effects and costs
associated with a universal childhood vaccination programme
with the pneumococcal conjugate vaccine and establishes
baseline information on its cost-effectiveness under the pub-
lic health perspective. Due to the uncertainties that are related
to the current burden of disease and the long-term effects
of vaccination on the epidemiology of pneumococcal dis-
ease, deriving a precise estimate of the cost-effectiveness of
the programme was not possible. However, sensitivity anal-
yses were performed looking at the range within which the
cost per life-year gained lies for different prices of a vac-
cine dose and for different levels of disease incidence rates.
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In addition, to take into account the impact of pneumococ-
cal vaccine not only in terms of life-years saved but also
considering the effect of morbidity on survivors, the cost
per QALY gained was also estimated. The possible impacts
of herd immunity and serotype replacement were investi-
gated as scenario analyses and in the multivariate sensitivity
analysis.
Ignoring potential herd-immunity effects, universal vacci-
nation of children with the pneumococcal conjugate vaccine
is not likely to be deemed cost-effective from the NHS per-
spective at the current price of the vaccine. The latter should
be set at around £10-15 per dose in order to get a cost per
QALY gained of approximately £30,000. On the other hand,
if the current burden of pneumococcal diseases was greatly
under estimated by the national surveillance systems, then
the cost per QALY gained, at a £30 cost per vaccine dose,
could reach acceptable values.
Fig. 4. Cost per LY gained (top graph) and QALY gained (bottom graph) estimated from multivariate sensitivity analysis. Base-case scenario is compared to
alternative scenarios that include herd immunity (HI) effect = 5% (- - - -), HI = 5% together with serotype replacement coefficient (SRC) =100% (x x x), HI =
5% and SRC that varies between 0 and 100% (+++), ill as in Whitney and SRC = 100% (circles).
A two-dose non-accelerated programme is estimated to be
more cost-effective than a three dose accelerated programme,
assuming both result in similar vaccine efficacy. Neverthe-
less, at the current price of the vaccine, this is still not within
the generally accepted threshold unless herd immunity ef-
fects occur without significant serotype replacement. Further
work will clearly be needed when the results of the UK vac-
cine trials become available.
From the univariate sensitivity analysis the model esti-
mates that the infant vaccination is highly likely to be cost-
effective if the levels of indirect protection observed by Whit-
ney et al. [28] are attributable to the vaccine and apply equally
for each subsequent vaccinated cohort. Rates of pneumo-
coccal disease are very high in the elderly and the conse-
quent reduction of the number of cases in these age groups,
without additional costs, has a large effect on the overall
cost-effectiveness of the programme. It should be stressed,
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however, that these reductions are based on an ecological
analysis of the reduction in reported IPD incidence in the US
just after the introduction of the vaccine compared with the
period just before (1998-1999). These observed reductions
should be set in the context that the incidence of IPD was
falling before the introduction of the vaccine in all of these
age groups, and so may partly or in whole be due to other
factors. Finally, the reduction observed immediately after the
introduction of the vaccine may not reflect the long-term re-
duction in incidence as a honeymoon period may occur. Thus,
taken together, the level of indirect protection reported by
Whitney et al. [28] may well be an overestimate, hence in the
multivariate analysis the effect of having a lower indirect pro-
tection of the vaccine (5%) among unvaccinated individuals
is also investigated. However, even at this lower level of in-
direct protection, infant vaccination is still highly likely to be
cost-effective unless there is complete serotype replacement.
Serotype replacement has already been shown to occur
in both pneumococcal carriage studies [10,37,38] and oti-
tis media [9] following vaccine introduction. The effect of a
change in the serotype distribution on the economic analyses
of pneumococcal vaccination is to reduce the effectiveness of
the programme over time and, consequently, increase the cost
per LY and QALY gained. Whether this increase will change
conclusions on the overall economic evaluation of the pro-
gramme (making it not cost-effective) still remains an open
question, as little information is available on the magnitude
of the herd immunity effect and on the invasiveness of the
non-vaccine serotypes. From our analysis, the overall effect
depends firstly on the level of indirect protection conferred
to unvaccinated individuals by the vaccination programme.
Moreover, it also depends on whether the new types will com-
pletely substitute those which have been eliminated by the in-
troduction of the vaccine (in which case the programme is not
likely to be cost-effective) or else if this substitution will only
be partial and, in other words, carriage of pneumococci (any
serotype) will be reduced as a consequence of the introduction
of the vaccine. In this latter case, although serotype replace-
ment would increase the cost per LYIQALY gained in respect
to the situation in which only herd effects were present, infant
vaccination would be deemed cost-effective under most cir-
cumstances. Our conclusions on serotype replacement rely
heavily on a two-strain model by Lipstich [39,40] that shows
that carriage of the non-vaccine type increases up to the level
(but not beyond) that of the original vaccine-type. However,
it should be noted that Lipsitch also suggests that with more
than two strains it is possible to increase the prevalence of
carriage over the pre-vaccination level. We did not look at this
possibility in our analysis and, therefore, our estimates of the
negative effect of serotype replacement may be somewhat
underestimated.
Currently a higher proportion of vaccine types have de-
creased susceptibility to antibiotics than non-vaccine types.
Hence widespread immunisation should lead to a reduction
in the circulation of resistant organisms (at least in the short
term). If current trends continue, then the future prevalence
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of non-susceptible types is likely to increase and therefore
the average costs of treating pneumococcal cases will also
rise. This knock-on effect would render pneumococcal vac-
cination more attractive economically than is apparent in our
analysis.
In summary, the base-case analysis (excluding indirect ef-
fects) suggests that the use of the pneumococcal conjugate
vaccine in infants is not likely to be justified economically at
current vaccine prices. However, this conclusion is very sensi-
tive to assumptions regarding the current burden of pneumo-
coccal disease and the future impact that vaccination will have
in the unvaccinated, and on the future serotype distribution.
Herd immunity, even with a partial serotype replacement, is
likely to render infant vaccination cost-effective. This is the
first analysis to quantify the impact of these indirect effects
on the cost-effectiveness of pneumococcal conjugate vacci-
nation.
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